#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


#Text=Functional neural changes following behavioral therapies and disulfiram for cocaine dependence
#Text=A growing literature exists on neural correlates of treatment outcome.
1-1	0-10	Functional	_	
1-2	11-17	neural	_	
1-3	18-25	changes	_	
1-4	26-35	following	_	
1-5	36-46	behavioral	_	
1-6	47-56	therapies	_	
1-7	57-60	and	_	
1-8	61-71	disulfiram	_	
1-9	72-75	for	_	
1-10	76-83	cocaine	_	
1-11	84-94	dependence	_	
1-12	95-96	A	_	
1-13	97-104	growing	_	
1-14	105-115	literature	_	
1-15	116-122	exists	_	
1-16	123-125	on	_	
1-17	126-132	neural	_	
1-18	133-143	correlates	_	
1-19	144-146	of	_	
1-20	147-156	treatment	_	
1-21	157-164	outcome	_	
1-22	164-165	.	_	

#Text=However, different types - or components of - treatment have distinct theorized mechanisms of action.
2-1	166-173	However	_	
2-2	173-174	,	_	
2-3	175-184	different	_	
2-4	185-190	types	_	
2-5	191-192	-	_	
2-6	193-195	or	_	
2-7	196-206	components	_	
2-8	207-209	of	_	
2-9	210-211	-	_	
2-10	212-221	treatment	_	
2-11	222-226	have	_	
2-12	227-235	distinct	_	
2-13	236-245	theorized	_	
2-14	246-256	mechanisms	_	
2-15	257-259	of	_	
2-16	260-266	action	_	
2-17	266-267	.	_	

#Text=And, it is not yet known how changes in neural activity across treatment relate to engagement in different treatment components.
3-1	268-271	And	_	
3-2	271-272	,	_	
3-3	273-275	it	_	
3-4	276-278	is	_	
3-5	279-282	not	_	
3-6	283-286	yet	_	
3-7	287-292	known	_	
3-8	293-296	how	_	
3-9	297-304	changes	_	
3-10	305-307	in	_	
3-11	308-314	neural	_	
3-12	315-323	activity	_	
3-13	324-330	across	_	
3-14	331-340	treatment	_	
3-15	341-347	relate	_	
3-16	348-350	to	_	
3-17	351-361	engagement	_	
3-18	362-364	in	_	
3-19	365-374	different	_	
3-20	375-384	treatment	_	
3-21	385-395	components	_	
3-22	395-396	.	_	

#Text=Participants with cocaine-use disorders in a randomized clinical trial received cognitive behavioral therapy (CBT) plus, in a 2×2 design, contingency management (CM) or no-CM, and disulfiram or placebo.
4-1	397-409	Participants	_	
4-2	410-414	with	_	
4-3	415-426	cocaine-use	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[1]	
4-4	427-436	disorders	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[1]	
4-5	437-439	in	_	
4-6	440-441	a	_	
4-7	442-452	randomized	_	
4-8	453-461	clinical	_	
4-9	462-467	trial	_	
4-10	468-476	received	_	
4-11	477-486	cognitive	_	
4-12	487-497	behavioral	_	
4-13	498-505	therapy	_	
4-14	506-507	(	_	
4-15	507-510	CBT	_	
4-16	510-511	)	_	
4-17	512-516	plus	_	
4-18	516-517	,	_	
4-19	518-520	in	_	
4-20	521-522	a	_	
4-21	523-524	2	_	
4-22	524-525	×	_	
4-23	525-526	2	_	
4-24	527-533	design	_	
4-25	533-534	,	_	
4-26	535-546	contingency	_	
4-27	547-557	management	_	
4-28	558-559	(	_	
4-29	559-561	CM	_	
4-30	561-562	)	_	
4-31	563-565	or	_	
4-32	566-571	no-CM	_	
4-33	571-572	,	_	
4-34	573-576	and	_	
4-35	577-587	disulfiram	_	
4-36	588-590	or	_	
4-37	591-598	placebo	_	
4-38	598-599	.	_	

#Text=Participants performed an fMRI Stroop Task, a measure of cognitive-control, at the beginning of and after the 12-week treatment.
5-1	600-612	Participants	_	
5-2	613-622	performed	_	
5-3	623-625	an	_	
5-4	626-630	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging	
5-5	631-637	Stroop	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[2]	
5-6	638-642	Task	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[2]	
5-7	642-643	,	_	
5-8	644-645	a	_	
5-9	646-653	measure	_	
5-10	654-656	of	_	
5-11	657-674	cognitive-control	_	
5-12	674-675	,	_	
5-13	676-678	at	_	
5-14	679-682	the	_	
5-15	683-692	beginning	_	
5-16	693-695	of	_	
5-17	696-699	and	_	
5-18	700-705	after	_	
5-19	706-709	the	_	
5-20	710-712	12	_	
5-21	712-713	-	_	
5-22	713-717	week	_	
5-23	718-727	treatment	_	
5-24	727-728	.	_	

#Text=Analyses assessed changes in Stroop-related neural activity within the sample overall and assessed how changes in Stroop-related activity correlated with measures of treatment process specific to each form of treatment (i.e., participation in CBT sessions, receipt of CM prizes, administration of disulfiram pills).
6-1	729-737	Analyses	_	
6-2	738-746	assessed	_	
6-3	747-754	changes	_	
6-4	755-757	in	_	
6-5	758-772	Stroop-related	_	
6-6	773-779	neural	_	
6-7	780-788	activity	_	
6-8	789-795	within	_	
6-9	796-799	the	_	
6-10	800-806	sample	_	
6-11	807-814	overall	_	
6-12	815-818	and	_	
6-13	819-827	assessed	_	
6-14	828-831	how	_	
6-15	832-839	changes	_	
6-16	840-842	in	_	
6-17	843-857	Stroop-related	_	
6-18	858-866	activity	_	
6-19	867-877	correlated	_	
6-20	878-882	with	_	
6-21	883-891	measures	_	
6-22	892-894	of	_	
6-23	895-904	treatment	_	
6-24	905-912	process	_	
6-25	913-921	specific	_	
6-26	922-924	to	_	
6-27	925-929	each	_	
6-28	930-934	form	_	
6-29	935-937	of	_	
6-30	938-947	treatment	_	
6-31	948-949	(	_	
6-32	949-952	i.e	_	
6-33	952-953	.	_	
6-34	953-954	,	_	
6-35	955-968	participation	_	
6-36	969-971	in	_	
6-37	972-975	CBT	_	
6-38	976-984	sessions	_	
6-39	984-985	,	_	
6-40	986-993	receipt	_	
6-41	994-996	of	_	
6-42	997-999	CM	_	
6-43	1000-1006	prizes	_	
6-44	1006-1007	,	_	
6-45	1008-1022	administration	_	
6-46	1023-1025	of	_	
6-47	1026-1036	disulfiram	_	
6-48	1037-1042	pills	_	
6-49	1042-1043	)	_	
6-50	1043-1044	.	_	

#Text=Within the sample overall, compared to beginning-of-treatment, post-treatment Stroop-related neural activity was diminished in hippocampus, thalamus, cingulate, precentral, post/precentral gyrus, and precuneus and culmen regions (pFWE<.05).
7-1	1045-1051	Within	_	
7-2	1052-1055	the	_	
7-3	1056-1062	sample	_	
7-4	1063-1070	overall	_	
7-5	1070-1071	,	_	
7-6	1072-1080	compared	_	
7-7	1081-1083	to	_	
7-8	1084-1106	beginning-of-treatment	_	
7-9	1106-1107	,	_	
7-10	1108-1122	post-treatment	_	
7-11	1123-1137	Stroop-related	_	
7-12	1138-1144	neural	_	
7-13	1145-1153	activity	_	
7-14	1154-1157	was	_	
7-15	1158-1168	diminished	_	
7-16	1169-1171	in	_	
7-17	1172-1183	hippocampus	_	
7-18	1183-1184	,	_	
7-19	1185-1193	thalamus	_	
7-20	1193-1194	,	_	
7-21	1195-1204	cingulate	_	
7-22	1204-1205	,	_	
7-23	1206-1216	precentral	_	
7-24	1216-1217	,	_	
7-25	1218-1222	post	_	
7-26	1222-1223	/	_	
7-27	1223-1233	precentral	_	
7-28	1234-1239	gyrus	_	
7-29	1239-1240	,	_	
7-30	1241-1244	and	_	
7-31	1245-1254	precuneus	_	
7-32	1255-1258	and	_	
7-33	1259-1265	culmen	_	
7-34	1266-1273	regions	_	
7-35	1274-1275	(	_	
7-36	1275-1279	pFWE	_	
7-37	1279-1280	<	_	
7-38	1280-1283	.05	_	
7-39	1283-1284	)	_	
7-40	1284-1285	.	_	

#Text=In separate whole-brain correlation analyses, greater reductions in Stroop-related activity were associated with more treatment engagement: ‘CBT sessions’ with precentral gyrus, inferior parietal lobule, middle and medial frontal gyrus; ‘CM prizes’ with postcentral frontal gyrus.
8-1	1286-1288	In	_	
8-2	1289-1297	separate	_	
8-3	1298-1309	whole-brain	_	
8-4	1310-1321	correlation	_	
8-5	1322-1330	analyses	_	
8-6	1330-1331	,	_	
8-7	1332-1339	greater	_	
8-8	1340-1350	reductions	_	
8-9	1351-1353	in	_	
8-10	1354-1368	Stroop-related	_	
8-11	1369-1377	activity	_	
8-12	1378-1382	were	_	
8-13	1383-1393	associated	_	
8-14	1394-1398	with	_	
8-15	1399-1403	more	_	
8-16	1404-1413	treatment	_	
8-17	1414-1424	engagement	_	
8-18	1424-1425	:	_	
8-19	1426-1427	‘	_	
8-20	1427-1430	CBT	_	
8-21	1431-1439	sessions	_	
8-22	1439-1440	’	_	
8-23	1441-1445	with	_	
8-24	1446-1456	precentral	_	
8-25	1457-1462	gyrus	_	
8-26	1462-1463	,	_	
8-27	1464-1472	inferior	_	
8-28	1473-1481	parietal	_	
8-29	1482-1488	lobule	_	
8-30	1488-1489	,	_	
8-31	1490-1496	middle	_	
8-32	1497-1500	and	_	
8-33	1501-1507	medial	_	
8-34	1508-1515	frontal	_	
8-35	1516-1521	gyrus	_	
8-36	1521-1522	;	_	
8-37	1523-1524	‘	_	
8-38	1524-1526	CM	_	
8-39	1527-1533	prizes	_	
8-40	1533-1534	’	_	
8-41	1535-1539	with	_	
8-42	1540-1551	postcentral	_	
8-43	1552-1559	frontal	_	
8-44	1560-1565	gyrus	_	
8-45	1565-1566	.	_	

#Text=Disulfiram ‘medication days’ were not associated with changes in Stroop-related activity.
9-1	1567-1577	Disulfiram	_	
9-2	1578-1579	‘	_	
9-3	1579-1589	medication	_	
9-4	1590-1594	days	_	
9-5	1594-1595	’	_	
9-6	1596-1600	were	_	
9-7	1601-1604	not	_	
9-8	1605-1615	associated	_	
9-9	1616-1620	with	_	
9-10	1621-1628	changes	_	
9-11	1629-1631	in	_	
9-12	1632-1646	Stroop-related	_	
9-13	1647-1655	activity	_	
9-14	1655-1656	.	_	

#Text=Findings suggest key process indicators of CBT and CM may be associated with functional changes in cognitive-control-related neurocircuitry.
10-1	1657-1665	Findings	_	
10-2	1666-1673	suggest	_	
10-3	1674-1677	key	_	
10-4	1678-1685	process	_	
10-5	1686-1696	indicators	_	
10-6	1697-1699	of	_	
10-7	1700-1703	CBT	_	
10-8	1704-1707	and	_	
10-9	1708-1710	CM	_	
10-10	1711-1714	may	_	
10-11	1715-1717	be	_	
10-12	1718-1728	associated	_	
10-13	1729-1733	with	_	
10-14	1734-1744	functional	_	
10-15	1745-1752	changes	_	
10-16	1753-1755	in	_	
10-17	1756-1781	cognitive-control-related	_	
10-18	1782-1796	neurocircuitry	_	
10-19	1796-1797	.	_	

#Text=Introduction
#Text=Cocaine-use disorder (CUD) is associated with significant societal cost.
11-1	1798-1810	Introduction	_	
11-2	1811-1822	Cocaine-use	_	
11-3	1823-1831	disorder	_	
11-4	1832-1833	(	_	
11-5	1833-1836	CUD	_	
11-6	1836-1837	)	_	
11-7	1838-1840	is	_	
11-8	1841-1851	associated	_	
11-9	1852-1856	with	_	
11-10	1857-1868	significant	_	
11-11	1869-1877	societal	_	
11-12	1878-1882	cost	_	
11-13	1882-1883	.	_	

#Text=Even with the best available treatments, many individuals with CUD cannot achieve or maintain abstinence, highlighting the need for advancements in treatments.
12-1	1884-1888	Even	_	
12-2	1889-1893	with	_	
12-3	1894-1897	the	_	
12-4	1898-1902	best	_	
12-5	1903-1912	available	_	
12-6	1913-1923	treatments	_	
12-7	1923-1924	,	_	
12-8	1925-1929	many	_	
12-9	1930-1941	individuals	_	
12-10	1942-1946	with	_	
12-11	1947-1950	CUD	_	
12-12	1951-1957	cannot	_	
12-13	1958-1965	achieve	_	
12-14	1966-1968	or	_	
12-15	1969-1977	maintain	_	
12-16	1978-1988	abstinence	_	
12-17	1988-1989	,	_	
12-18	1990-2002	highlighting	_	
12-19	2003-2006	the	_	
12-20	2007-2011	need	_	
12-21	2012-2015	for	_	
12-22	2016-2028	advancements	_	
12-23	2029-2031	in	_	
12-24	2032-2042	treatments	_	
12-25	2042-2043	.	_	

#Text=An understanding of the mechanism of action of treatments, including neurocognitive mechanisms, could lead to improvements in existing treatments or development of new treatments.
13-1	2044-2046	An	_	
13-2	2047-2060	understanding	_	
13-3	2061-2063	of	_	
13-4	2064-2067	the	_	
13-5	2068-2077	mechanism	_	
13-6	2078-2080	of	_	
13-7	2081-2087	action	_	
13-8	2088-2090	of	_	
13-9	2091-2101	treatments	_	
13-10	2101-2102	,	_	
13-11	2103-2112	including	_	
13-12	2113-2127	neurocognitive	_	
13-13	2128-2138	mechanisms	_	
13-14	2138-2139	,	_	
13-15	2140-2145	could	_	
13-16	2146-2150	lead	_	
13-17	2151-2153	to	_	
13-18	2154-2166	improvements	_	
13-19	2167-2169	in	_	
13-20	2170-2178	existing	_	
13-21	2179-2189	treatments	_	
13-22	2190-2192	or	_	
13-23	2193-2204	development	_	
13-24	2205-2207	of	_	
13-25	2208-2211	new	_	
13-26	2212-2222	treatments	_	
13-27	2222-2223	.	_	

#Text=The aim of the current study is to make a preliminary attempt to relate changes in functional neural activity from beginning-of-treatment- to post-treatment to engagement with different components of treatment for cocaine use.
14-1	2224-2227	The	_	
14-2	2228-2231	aim	_	
14-3	2232-2234	of	_	
14-4	2235-2238	the	_	
14-5	2239-2246	current	_	
14-6	2247-2252	study	_	
14-7	2253-2255	is	_	
14-8	2256-2258	to	_	
14-9	2259-2263	make	_	
14-10	2264-2265	a	_	
14-11	2266-2277	preliminary	_	
14-12	2278-2285	attempt	_	
14-13	2286-2288	to	_	
14-14	2289-2295	relate	_	
14-15	2296-2303	changes	_	
14-16	2304-2306	in	_	
14-17	2307-2317	functional	_	
14-18	2318-2324	neural	_	
14-19	2325-2333	activity	_	
14-20	2334-2338	from	_	
14-21	2339-2361	beginning-of-treatment	_	
14-22	2361-2362	-	_	
14-23	2363-2365	to	_	
14-24	2366-2380	post-treatment	_	
14-25	2381-2383	to	_	
14-26	2384-2394	engagement	_	
14-27	2395-2399	with	_	
14-28	2400-2409	different	_	
14-29	2410-2420	components	_	
14-30	2421-2423	of	_	
14-31	2424-2433	treatment	_	
14-32	2434-2437	for	_	
14-33	2438-2445	cocaine	_	
14-34	2446-2449	use	_	
14-35	2449-2450	.	_	

#Text=The treatment offered in this study was a mix of cognitive behavioral therapy (CBT), contingency management (CM) and the medication disulfiram.
15-1	2451-2454	The	_	
15-2	2455-2464	treatment	_	
15-3	2465-2472	offered	_	
15-4	2473-2475	in	_	
15-5	2476-2480	this	_	
15-6	2481-2486	study	_	
15-7	2487-2490	was	_	
15-8	2491-2492	a	_	
15-9	2493-2496	mix	_	
15-10	2497-2499	of	_	
15-11	2500-2509	cognitive	_	
15-12	2510-2520	behavioral	_	
15-13	2521-2528	therapy	_	
15-14	2529-2530	(	_	
15-15	2530-2533	CBT	_	
15-16	2533-2534	)	_	
15-17	2534-2535	,	_	
15-18	2536-2547	contingency	_	
15-19	2548-2558	management	_	
15-20	2559-2560	(	_	
15-21	2560-2562	CM	_	
15-22	2562-2563	)	_	
15-23	2564-2567	and	_	
15-24	2568-2571	the	_	
15-25	2572-2582	medication	_	
15-26	2583-2593	disulfiram	_	
15-27	2593-2594	.	_	

#Text=The treatments offered in this study are thought to have complementary clinical strengths, to address different aspects of substance use disorders (SUDs) and are hypothesized to have different mechanisms of actions.
16-1	2595-2598	The	_	
16-2	2599-2609	treatments	_	
16-3	2610-2617	offered	_	
16-4	2618-2620	in	_	
16-5	2621-2625	this	_	
16-6	2626-2631	study	_	
16-7	2632-2635	are	_	
16-8	2636-2643	thought	_	
16-9	2644-2646	to	_	
16-10	2647-2651	have	_	
16-11	2652-2665	complementary	_	
16-12	2666-2674	clinical	_	
16-13	2675-2684	strengths	_	
16-14	2684-2685	,	_	
16-15	2686-2688	to	_	
16-16	2689-2696	address	_	
16-17	2697-2706	different	_	
16-18	2707-2714	aspects	_	
16-19	2715-2717	of	_	
16-20	2718-2727	substance	_	
16-21	2728-2731	use	_	
16-22	2732-2741	disorders	_	
16-23	2742-2743	(	_	
16-24	2743-2747	SUDs	_	
16-25	2747-2748	)	_	
16-26	2749-2752	and	_	
16-27	2753-2756	are	_	
16-28	2757-2769	hypothesized	_	
16-29	2770-2772	to	_	
16-30	2773-2777	have	_	
16-31	2778-2787	different	_	
16-32	2788-2798	mechanisms	_	
16-33	2799-2801	of	_	
16-34	2802-2809	actions	_	
16-35	2809-2810	.	_	

#Text=Combining several such treatments is widely accepted to improve clinical outcomes.
17-1	2811-2820	Combining	_	
17-2	2821-2828	several	_	
17-3	2829-2833	such	_	
17-4	2834-2844	treatments	_	
17-5	2845-2847	is	_	
17-6	2848-2854	widely	_	
17-7	2855-2863	accepted	_	
17-8	2864-2866	to	_	
17-9	2867-2874	improve	_	
17-10	2875-2883	clinical	_	
17-11	2884-2892	outcomes	_	
17-12	2892-2893	.	_	

#Text=For example, CBT, CM and disulfiram have each demonstrated enhancements in treatment efficacy relative to standard care alone, behavioral treatment controls, or placebo conditions in randomized clinical trials, and are thought to have complementary strengths and mechanisms.
18-1	2894-2897	For	_	
18-2	2898-2905	example	_	
18-3	2905-2906	,	_	
18-4	2907-2910	CBT	_	
18-5	2910-2911	,	_	
18-6	2912-2914	CM	_	
18-7	2915-2918	and	_	
18-8	2919-2929	disulfiram	_	
18-9	2930-2934	have	_	
18-10	2935-2939	each	_	
18-11	2940-2952	demonstrated	_	
18-12	2953-2965	enhancements	_	
18-13	2966-2968	in	_	
18-14	2969-2978	treatment	_	
18-15	2979-2987	efficacy	_	
18-16	2988-2996	relative	_	
18-17	2997-2999	to	_	
18-18	3000-3008	standard	_	
18-19	3009-3013	care	_	
18-20	3014-3019	alone	_	
18-21	3019-3020	,	_	
18-22	3021-3031	behavioral	_	
18-23	3032-3041	treatment	_	
18-24	3042-3050	controls	_	
18-25	3050-3051	,	_	
18-26	3052-3054	or	_	
18-27	3055-3062	placebo	_	
18-28	3063-3073	conditions	_	
18-29	3074-3076	in	_	
18-30	3077-3087	randomized	_	
18-31	3088-3096	clinical	_	
18-32	3097-3103	trials	_	
18-33	3103-3104	,	_	
18-34	3105-3108	and	_	
18-35	3109-3112	are	_	
18-36	3113-3120	thought	_	
18-37	3121-3123	to	_	
18-38	3124-3128	have	_	
18-39	3129-3142	complementary	_	
18-40	3143-3152	strengths	_	
18-41	3153-3156	and	_	
18-42	3157-3167	mechanisms	_	
18-43	3167-3168	.	_	

#Text=Specifically, CBT promotes abstinence by enhancing behavioral and cognitive coping skills as well as functional analyses of factors that contribute to continued drug use.
19-1	3169-3181	Specifically	_	
19-2	3181-3182	,	_	
19-3	3183-3186	CBT	_	
19-4	3187-3195	promotes	_	
19-5	3196-3206	abstinence	_	
19-6	3207-3209	by	_	
19-7	3210-3219	enhancing	_	
19-8	3220-3230	behavioral	_	
19-9	3231-3234	and	_	
19-10	3235-3244	cognitive	_	
19-11	3245-3251	coping	_	
19-12	3252-3258	skills	_	
19-13	3259-3261	as	_	
19-14	3262-3266	well	_	
19-15	3267-3269	as	_	
19-16	3270-3280	functional	_	
19-17	3281-3289	analyses	_	
19-18	3290-3292	of	_	
19-19	3293-3300	factors	_	
19-20	3301-3305	that	_	
19-21	3306-3316	contribute	_	
19-22	3317-3319	to	_	
19-23	3320-3329	continued	_	
19-24	3330-3334	drug	_	
19-25	3335-3338	use	_	
19-26	3338-3339	.	_	

#Text=A strength of CBT is its durability (i.e., persistent efficacy after treatment ceases), perhaps due to the focus on skill-building and greater cognitive-control over craving and drug-use behaviors.
20-1	3340-3341	A	_	
20-2	3342-3350	strength	_	
20-3	3351-3353	of	_	
20-4	3354-3357	CBT	_	
20-5	3358-3360	is	_	
20-6	3361-3364	its	_	
20-7	3365-3375	durability	_	
20-8	3376-3377	(	_	
20-9	3377-3380	i.e	_	
20-10	3380-3381	.	_	
20-11	3381-3382	,	_	
20-12	3383-3393	persistent	_	
20-13	3394-3402	efficacy	_	
20-14	3403-3408	after	_	
20-15	3409-3418	treatment	_	
20-16	3419-3425	ceases	_	
20-17	3425-3426	)	_	
20-18	3426-3427	,	_	
20-19	3428-3435	perhaps	_	
20-20	3436-3439	due	_	
20-21	3440-3442	to	_	
20-22	3443-3446	the	_	
20-23	3447-3452	focus	_	
20-24	3453-3455	on	_	
20-25	3456-3470	skill-building	_	
20-26	3471-3474	and	_	
20-27	3475-3482	greater	_	
20-28	3483-3500	cognitive-control	_	
20-29	3501-3505	over	_	
20-30	3506-3513	craving	_	
20-31	3514-3517	and	_	
20-32	3518-3526	drug-use	_	
20-33	3527-3536	behaviors	_	
20-34	3536-3537	.	_	

#Text=CM’s strengths and limitations are complementary to CBT’s.
21-1	3538-3540	CM	_	
21-2	3540-3541	’	_	
21-3	3541-3542	s	_	
21-4	3543-3552	strengths	_	
21-5	3553-3556	and	_	
21-6	3557-3568	limitations	_	
21-7	3569-3572	are	_	
21-8	3573-3586	complementary	_	
21-9	3587-3589	to	_	
21-10	3590-3593	CBT	_	
21-11	3593-3594	’	_	
21-12	3594-3595	s	_	
21-13	3595-3596	.	_	

#Text=CM promotes treatment adherence and abstinence initiation by reinforcing target behaviors (e.g., treatment attendance, medication administration, cocaine abstinence) with money or prizes.
22-1	3597-3599	CM	_	
22-2	3600-3608	promotes	_	
22-3	3609-3618	treatment	_	
22-4	3619-3628	adherence	_	
22-5	3629-3632	and	_	
22-6	3633-3643	abstinence	_	
22-7	3644-3654	initiation	_	
22-8	3655-3657	by	_	
22-9	3658-3669	reinforcing	_	
22-10	3670-3676	target	_	
22-11	3677-3686	behaviors	_	
22-12	3687-3688	(	_	
22-13	3688-3691	e.g	_	
22-14	3691-3692	.	_	
22-15	3692-3693	,	_	
22-16	3694-3703	treatment	_	
22-17	3704-3714	attendance	_	
22-18	3714-3715	,	_	
22-19	3716-3726	medication	_	
22-20	3727-3741	administration	_	
22-21	3741-3742	,	_	
22-22	3743-3750	cocaine	_	
22-23	3751-3761	abstinence	_	
22-24	3761-3762	)	_	
22-25	3763-3767	with	_	
22-26	3768-3773	money	_	
22-27	3774-3776	or	_	
22-28	3777-3783	prizes	_	
22-29	3783-3784	.	_	

#Text=As such, CM is a useful adjunct to enhance treatment adherence as well as initiate abstinence.
23-1	3785-3787	As	_	
23-2	3788-3792	such	_	
23-3	3792-3793	,	_	
23-4	3794-3796	CM	_	
23-5	3797-3799	is	_	
23-6	3800-3801	a	_	
23-7	3802-3808	useful	_	
23-8	3809-3816	adjunct	_	
23-9	3817-3819	to	_	
23-10	3820-3827	enhance	_	
23-11	3828-3837	treatment	_	
23-12	3838-3847	adherence	_	
23-13	3848-3850	as	_	
23-14	3851-3855	well	_	
23-15	3856-3858	as	_	
23-16	3859-3867	initiate	_	
23-17	3868-3878	abstinence	_	
23-18	3878-3879	.	_	

#Text=However, CM’s effects tend to weaken to some extent after the reinforcement schedule has ended.
24-1	3880-3887	However	_	
24-2	3887-3888	,	_	
24-3	3889-3891	CM	_	
24-4	3891-3892	’	_	
24-5	3892-3893	s	_	
24-6	3894-3901	effects	_	
24-7	3902-3906	tend	_	
24-8	3907-3909	to	_	
24-9	3910-3916	weaken	_	
24-10	3917-3919	to	_	
24-11	3920-3924	some	_	
24-12	3925-3931	extent	_	
24-13	3932-3937	after	_	
24-14	3938-3941	the	_	
24-15	3942-3955	reinforcement	_	
24-16	3956-3964	schedule	_	
24-17	3965-3968	has	_	
24-18	3969-3974	ended	_	
24-19	3974-3975	.	_	

#Text=While no pharmacotherapies have FDA-indication for the treatment of cocaine-use disorder, disulfiram has shown promise in some trials.
25-1	3976-3981	While	_	
25-2	3982-3984	no	_	
25-3	3985-4002	pharmacotherapies	_	
25-4	4003-4007	have	_	
25-5	4008-4022	FDA-indication	_	
25-6	4023-4026	for	_	
25-7	4027-4030	the	_	
25-8	4031-4040	treatment	_	
25-9	4041-4043	of	_	
25-10	4044-4055	cocaine-use	_	
25-11	4056-4064	disorder	_	
25-12	4064-4065	,	_	
25-13	4066-4076	disulfiram	_	
25-14	4077-4080	has	_	
25-15	4081-4086	shown	_	
25-16	4087-4094	promise	_	
25-17	4095-4097	in	_	
25-18	4098-4102	some	_	
25-19	4103-4109	trials	_	
25-20	4109-4110	.	_	

#Text=Although the mechanism underlying improved cocaine-use outcomes with disulfiram is unknown, several potential mechanisms have been proposed such as increasing plasma levels of dopamine by slowing the conversion of dopamine into noradrenaline via disulfiram’s inhibition of dopamine- β-hydroxylase (DβH), reducing alcohol-precipitated relapses by inducing aversive responses to alcohol and altering cocaine’s subjective reinforcing effects.
26-1	4111-4119	Although	_	
26-2	4120-4123	the	_	
26-3	4124-4133	mechanism	_	
26-4	4134-4144	underlying	_	
26-5	4145-4153	improved	_	
26-6	4154-4165	cocaine-use	_	
26-7	4166-4174	outcomes	_	
26-8	4175-4179	with	_	
26-9	4180-4190	disulfiram	_	
26-10	4191-4193	is	_	
26-11	4194-4201	unknown	_	
26-12	4201-4202	,	_	
26-13	4203-4210	several	_	
26-14	4211-4220	potential	_	
26-15	4221-4231	mechanisms	_	
26-16	4232-4236	have	_	
26-17	4237-4241	been	_	
26-18	4242-4250	proposed	_	
26-19	4251-4255	such	_	
26-20	4256-4258	as	_	
26-21	4259-4269	increasing	_	
26-22	4270-4276	plasma	_	
26-23	4277-4283	levels	_	
26-24	4284-4286	of	_	
26-25	4287-4295	dopamine	_	
26-26	4296-4298	by	_	
26-27	4299-4306	slowing	_	
26-28	4307-4310	the	_	
26-29	4311-4321	conversion	_	
26-30	4322-4324	of	_	
26-31	4325-4333	dopamine	_	
26-32	4334-4338	into	_	
26-33	4339-4352	noradrenaline	_	
26-34	4353-4356	via	_	
26-35	4357-4367	disulfiram	_	
26-36	4367-4368	’	_	
26-37	4368-4369	s	_	
26-38	4370-4380	inhibition	_	
26-39	4381-4383	of	_	
26-40	4384-4392	dopamine	_	
26-41	4392-4393	-	_	
26-42	4394-4407	β-hydroxylase	_	
26-43	4408-4409	(	_	
26-44	4409-4412	DβH	_	
26-45	4412-4413	)	_	
26-46	4413-4414	,	_	
26-47	4415-4423	reducing	_	
26-48	4424-4444	alcohol-precipitated	_	
26-49	4445-4453	relapses	_	
26-50	4454-4456	by	_	
26-51	4457-4465	inducing	_	
26-52	4466-4474	aversive	_	
26-53	4475-4484	responses	_	
26-54	4485-4487	to	_	
26-55	4488-4495	alcohol	_	
26-56	4496-4499	and	_	
26-57	4500-4508	altering	_	
26-58	4509-4516	cocaine	_	
26-59	4516-4517	’	_	
26-60	4517-4518	s	_	
26-61	4519-4529	subjective	_	
26-62	4530-4541	reinforcing	_	
26-63	4542-4549	effects	_	
26-64	4549-4550	.	_	

#Text=One step towards investigating neurocognitive mechanisms of treatments for cocaine use could be to incorporate functional magnetic resonance imaging (fMRI) measures into clinical trials for CUD.
27-1	4551-4554	One	_	
27-2	4555-4559	step	_	
27-3	4560-4567	towards	_	
27-4	4568-4581	investigating	_	
27-5	4582-4596	neurocognitive	_	
27-6	4597-4607	mechanisms	_	
27-7	4608-4610	of	_	
27-8	4611-4621	treatments	_	
27-9	4622-4625	for	_	
27-10	4626-4633	cocaine	_	
27-11	4634-4637	use	_	
27-12	4638-4643	could	_	
27-13	4644-4646	be	_	
27-14	4647-4649	to	_	
27-15	4650-4661	incorporate	_	
27-16	4662-4672	functional	_	
27-17	4673-4681	magnetic	_	
27-18	4682-4691	resonance	_	
27-19	4692-4699	imaging	_	
27-20	4700-4701	(	_	
27-21	4701-4705	fMRI	_	
27-22	4705-4706	)	_	
27-23	4707-4715	measures	_	
27-24	4716-4720	into	_	
27-25	4721-4729	clinical	_	
27-26	4730-4736	trials	_	
27-27	4737-4740	for	_	
27-28	4741-4744	CUD	_	
27-29	4744-4745	.	_	

#Text=The specific fMRI task chosen should tap a specific cognitive domain, such as cognitive control, related to CUD.
28-1	4746-4749	The	_	
28-2	4750-4758	specific	_	
28-3	4759-4763	fMRI	_	
28-4	4764-4768	task	_	
28-5	4769-4775	chosen	_	
28-6	4776-4782	should	_	
28-7	4783-4786	tap	_	
28-8	4787-4788	a	_	
28-9	4789-4797	specific	_	
28-10	4798-4807	cognitive	_	
28-11	4808-4814	domain	_	
28-12	4814-4815	,	_	
28-13	4816-4820	such	_	
28-14	4821-4823	as	_	
28-15	4824-4833	cognitive	_	
28-16	4834-4841	control	_	
28-17	4841-4842	,	_	
28-18	4843-4850	related	_	
28-19	4851-4853	to	_	
28-20	4854-4857	CUD	_	
28-21	4857-4858	.	_	

#Text=Disrupted cognitive-control has been proposed to contribute to initiation and maintenance of CUD through poor attentional control, attentional biases towards drug-related stimuli, impaired response inhibition, and reduced ability to regulate craving.
29-1	4859-4868	Disrupted	_	
29-2	4869-4886	cognitive-control	_	
29-3	4887-4890	has	_	
29-4	4891-4895	been	_	
29-5	4896-4904	proposed	_	
29-6	4905-4907	to	_	
29-7	4908-4918	contribute	_	
29-8	4919-4921	to	_	
29-9	4922-4932	initiation	_	
29-10	4933-4936	and	_	
29-11	4937-4948	maintenance	_	
29-12	4949-4951	of	_	
29-13	4952-4955	CUD	_	
29-14	4956-4963	through	_	
29-15	4964-4968	poor	_	
29-16	4969-4980	attentional	_	
29-17	4981-4988	control	_	
29-18	4988-4989	,	_	
29-19	4990-5001	attentional	_	
29-20	5002-5008	biases	_	
29-21	5009-5016	towards	_	
29-22	5017-5029	drug-related	_	
29-23	5030-5037	stimuli	_	
29-24	5037-5038	,	_	
29-25	5039-5047	impaired	_	
29-26	5048-5056	response	_	
29-27	5057-5067	inhibition	_	
29-28	5067-5068	,	_	
29-29	5069-5072	and	_	
29-30	5073-5080	reduced	_	
29-31	5081-5088	ability	_	
29-32	5089-5091	to	_	
29-33	5092-5100	regulate	_	
29-34	5101-5108	craving	_	
29-35	5108-5109	.	_	

#Text=However, the pattern of drug-induced alterations in cognitive-control-related-activity in SUDs is somewhat complex.
30-1	5110-5117	However	_	
30-2	5117-5118	,	_	
30-3	5119-5122	the	_	
30-4	5123-5130	pattern	_	
30-5	5131-5133	of	_	
30-6	5134-5146	drug-induced	_	
30-7	5147-5158	alterations	_	
30-8	5159-5161	in	_	
30-9	5162-5196	cognitive-control-related-activity	_	
30-10	5197-5199	in	_	
30-11	5200-5204	SUDs	_	
30-12	5205-5207	is	_	
30-13	5208-5216	somewhat	_	
30-14	5217-5224	complex	_	
30-15	5224-5225	.	_	

#Text=Specifically, individuals with stimulant-use disorders differ from non-substance-using individuals on task-related functional activity in a manner that is task- and process-specific; that is, the direction of difference (hypo- versus hyper-activation) and affected anatomical regions vary by task (for review).
31-1	5226-5238	Specifically	_	
31-2	5238-5239	,	_	
31-3	5240-5251	individuals	_	
31-4	5252-5256	with	_	
31-5	5257-5270	stimulant-use	_	
31-6	5271-5280	disorders	_	
31-7	5281-5287	differ	_	
31-8	5288-5292	from	_	
31-9	5293-5312	non-substance-using	_	
31-10	5313-5324	individuals	_	
31-11	5325-5327	on	_	
31-12	5328-5340	task-related	_	
31-13	5341-5351	functional	_	
31-14	5352-5360	activity	_	
31-15	5361-5363	in	_	
31-16	5364-5365	a	_	
31-17	5366-5372	manner	_	
31-18	5373-5377	that	_	
31-19	5378-5380	is	_	
31-20	5381-5385	task	_	
31-21	5385-5386	-	_	
31-22	5387-5390	and	_	
31-23	5391-5407	process-specific	_	
31-24	5407-5408	;	_	
31-25	5409-5413	that	_	
31-26	5414-5416	is	_	
31-27	5416-5417	,	_	
31-28	5418-5421	the	_	
31-29	5422-5431	direction	_	
31-30	5432-5434	of	_	
31-31	5435-5445	difference	_	
31-32	5446-5447	(	_	
31-33	5447-5451	hypo	_	
31-34	5451-5452	-	_	
31-35	5453-5459	versus	_	
31-36	5460-5476	hyper-activation	_	
31-37	5476-5477	)	_	
31-38	5478-5481	and	_	
31-39	5482-5490	affected	_	
31-40	5491-5501	anatomical	_	
31-41	5502-5509	regions	_	
31-42	5510-5514	vary	_	
31-43	5515-5517	by	_	
31-44	5518-5522	task	_	
31-45	5523-5524	(	_	
31-46	5524-5527	for	_	
31-47	5528-5534	review	_	
31-48	5534-5535	)	_	
31-49	5535-5536	.	_	

#Text=For example, cognitive-control-related neural activity differs between active cocaine users and healthy comparison groups.
32-1	5537-5540	For	_	
32-2	5541-5548	example	_	
32-3	5548-5549	,	_	
32-4	5550-5575	cognitive-control-related	_	
32-5	5576-5582	neural	_	
32-6	5583-5591	activity	_	
32-7	5592-5599	differs	_	
32-8	5600-5607	between	_	
32-9	5608-5614	active	_	
32-10	5615-5622	cocaine	_	
32-11	5623-5628	users	_	
32-12	5629-5632	and	_	
32-13	5633-5640	healthy	_	
32-14	5641-5651	comparison	_	
32-15	5652-5658	groups	_	
32-16	5658-5659	.	_	

#Text=Two separate studies comparing short-term abstinent (≤72 hrs.) cocaine users with healthy controls showed relatively decreased activity in cocaine users (N=15) in anterior cingulate and right prefrontal regions and relatively increased activity in cerebellar regions while performing a go/no-go task with a working memory component, while cocaine users (N=13) performed worse on a go/no-go task and showed relatively lower activity in the anterior cingulate and right insula during successful stops and greater recruitment of medial frontal gyrus, left insula and left inferior frontal gyrus (IFG) during errors.
33-1	5660-5663	Two	_	
33-2	5664-5672	separate	_	
33-3	5673-5680	studies	_	
33-4	5681-5690	comparing	_	
33-5	5691-5701	short-term	_	
33-6	5702-5711	abstinent	_	
33-7	5712-5713	(	_	
33-8	5713-5714	≤	_	
33-9	5714-5716	72	_	
33-10	5717-5720	hrs	_	
33-11	5720-5721	.	_	
33-12	5721-5722	)	_	
33-13	5723-5730	cocaine	_	
33-14	5731-5736	users	_	
33-15	5737-5741	with	_	
33-16	5742-5749	healthy	_	
33-17	5750-5758	controls	_	
33-18	5759-5765	showed	_	
33-19	5766-5776	relatively	_	
33-20	5777-5786	decreased	_	
33-21	5787-5795	activity	_	
33-22	5796-5798	in	_	
33-23	5799-5806	cocaine	_	
33-24	5807-5812	users	_	
33-25	5813-5814	(	_	
33-26	5814-5815	N	_	
33-27	5815-5816	=	_	
33-28	5816-5818	15	_	
33-29	5818-5819	)	_	
33-30	5820-5822	in	_	
33-31	5823-5831	anterior	_	
33-32	5832-5841	cingulate	_	
33-33	5842-5845	and	_	
33-34	5846-5851	right	_	
33-35	5852-5862	prefrontal	_	
33-36	5863-5870	regions	_	
33-37	5871-5874	and	_	
33-38	5875-5885	relatively	_	
33-39	5886-5895	increased	_	
33-40	5896-5904	activity	_	
33-41	5905-5907	in	_	
33-42	5908-5918	cerebellar	_	
33-43	5919-5926	regions	_	
33-44	5927-5932	while	_	
33-45	5933-5943	performing	_	
33-46	5944-5945	a	_	
33-47	5946-5948	go	_	
33-48	5948-5949	/	_	
33-49	5949-5954	no-go	_	
33-50	5955-5959	task	_	
33-51	5960-5964	with	_	
33-52	5965-5966	a	_	
33-53	5967-5974	working	_	
33-54	5975-5981	memory	_	
33-55	5982-5991	component	_	
33-56	5991-5992	,	_	
33-57	5993-5998	while	_	
33-58	5999-6006	cocaine	_	
33-59	6007-6012	users	_	
33-60	6013-6014	(	_	
33-61	6014-6015	N	_	
33-62	6015-6016	=	_	
33-63	6016-6018	13	_	
33-64	6018-6019	)	_	
33-65	6020-6029	performed	_	
33-66	6030-6035	worse	_	
33-67	6036-6038	on	_	
33-68	6039-6040	a	_	
33-69	6041-6043	go	_	
33-70	6043-6044	/	_	
33-71	6044-6049	no-go	_	
33-72	6050-6054	task	_	
33-73	6055-6058	and	_	
33-74	6059-6065	showed	_	
33-75	6066-6076	relatively	_	
33-76	6077-6082	lower	_	
33-77	6083-6091	activity	_	
33-78	6092-6094	in	_	
33-79	6095-6098	the	_	
33-80	6099-6107	anterior	_	
33-81	6108-6117	cingulate	_	
33-82	6118-6121	and	_	
33-83	6122-6127	right	_	
33-84	6128-6134	insula	_	
33-85	6135-6141	during	_	
33-86	6142-6152	successful	_	
33-87	6153-6158	stops	_	
33-88	6159-6162	and	_	
33-89	6163-6170	greater	_	
33-90	6171-6182	recruitment	_	
33-91	6183-6185	of	_	
33-92	6186-6192	medial	_	
33-93	6193-6200	frontal	_	
33-94	6201-6206	gyrus	_	
33-95	6206-6207	,	_	
33-96	6208-6212	left	_	
33-97	6213-6219	insula	_	
33-98	6220-6223	and	_	
33-99	6224-6228	left	_	
33-100	6229-6237	inferior	_	
33-101	6238-6245	frontal	_	
33-102	6246-6251	gyrus	_	
33-103	6252-6253	(	_	
33-104	6253-6256	IFG	_	
33-105	6256-6257	)	_	
33-106	6258-6264	during	_	
33-107	6265-6271	errors	_	
33-108	6271-6272	.	_	

#Text=Individuals with CUD (N=14) with confirmed short-term abstinence (>72 hrs.), performing a multi-sensory Stroop task, showed greater recruitment of left dorsolateral and ventrolateral PFC (dlPFC, vlPFC) and bilateral basal ganglia and less deactivation of bilateral ventromedial PFC (vmPFC), relative to non-users (N=16).
34-1	6273-6284	Individuals	_	
34-2	6285-6289	with	_	
34-3	6290-6293	CUD	_	
34-4	6294-6295	(	_	
34-5	6295-6296	N	_	
34-6	6296-6297	=	_	
34-7	6297-6299	14	_	
34-8	6299-6300	)	_	
34-9	6301-6305	with	_	
34-10	6306-6315	confirmed	_	
34-11	6316-6326	short-term	_	
34-12	6327-6337	abstinence	_	
34-13	6338-6339	(	_	
34-14	6339-6340	>	_	
34-15	6340-6342	72	_	
34-16	6343-6346	hrs	_	
34-17	6346-6347	.	_	
34-18	6347-6348	)	_	
34-19	6348-6349	,	_	
34-20	6350-6360	performing	_	
34-21	6361-6362	a	_	
34-22	6363-6376	multi-sensory	_	
34-23	6377-6383	Stroop	_	
34-24	6384-6388	task	_	
34-25	6388-6389	,	_	
34-26	6390-6396	showed	_	
34-27	6397-6404	greater	_	
34-28	6405-6416	recruitment	_	
34-29	6417-6419	of	_	
34-30	6420-6424	left	_	
34-31	6425-6437	dorsolateral	_	
34-32	6438-6441	and	_	
34-33	6442-6455	ventrolateral	_	
34-34	6456-6459	PFC	_	
34-35	6460-6461	(	_	
34-36	6461-6466	dlPFC	_	
34-37	6466-6467	,	_	
34-38	6468-6473	vlPFC	_	
34-39	6473-6474	)	_	
34-40	6475-6478	and	_	
34-41	6479-6488	bilateral	_	
34-42	6489-6494	basal	_	
34-43	6495-6502	ganglia	_	
34-44	6503-6506	and	_	
34-45	6507-6511	less	_	
34-46	6512-6524	deactivation	_	
34-47	6525-6527	of	_	
34-48	6528-6537	bilateral	_	
34-49	6538-6550	ventromedial	_	
34-50	6551-6554	PFC	_	
34-51	6555-6556	(	_	
34-52	6556-6561	vmPFC	_	
34-53	6561-6562	)	_	
34-54	6562-6563	,	_	
34-55	6564-6572	relative	_	
34-56	6573-6575	to	_	
34-57	6576-6585	non-users	_	
34-58	6586-6587	(	_	
34-59	6587-6588	N	_	
34-60	6588-6589	=	_	
34-61	6589-6591	16	_	
34-62	6591-6592	)	_	
34-63	6592-6593	.	_	

#Text=In addition, cognitive-control-related neural activity has been shown to be altered by acute cocaine administration (e.g.,) and may vary across abstinence duration (e.g.,).
35-1	6594-6596	In	_	
35-2	6597-6605	addition	_	
35-3	6605-6606	,	_	
35-4	6607-6632	cognitive-control-related	_	
35-5	6633-6639	neural	_	
35-6	6640-6648	activity	_	
35-7	6649-6652	has	_	
35-8	6653-6657	been	_	
35-9	6658-6663	shown	_	
35-10	6664-6666	to	_	
35-11	6667-6669	be	_	
35-12	6670-6677	altered	_	
35-13	6678-6680	by	_	
35-14	6681-6686	acute	_	
35-15	6687-6694	cocaine	_	
35-16	6695-6709	administration	_	
35-17	6710-6711	(	_	
35-18	6711-6714	e.g	_	
35-19	6714-6715	.	_	
35-20	6715-6716	,	_	
35-21	6716-6717	)	_	
35-22	6718-6721	and	_	
35-23	6722-6725	may	_	
35-24	6726-6730	vary	_	
35-25	6731-6737	across	_	
35-26	6738-6748	abstinence	_	
35-27	6749-6757	duration	_	
35-28	6758-6759	(	_	
35-29	6759-6762	e.g	_	
35-30	6762-6763	.	_	
35-31	6763-6764	,	_	
35-32	6764-6765	)	_	
35-33	6765-6766	.	_	

#Text=Finally, impairments on cognitive-control-related neuropsychological tasks may remain following abstinence.
36-1	6767-6774	Finally	_	
36-2	6774-6775	,	_	
36-3	6776-6787	impairments	_	
36-4	6788-6790	on	_	
36-5	6791-6816	cognitive-control-related	_	
36-6	6817-6835	neuropsychological	_	
36-7	6836-6841	tasks	_	
36-8	6842-6845	may	_	
36-9	6846-6852	remain	_	
36-10	6853-6862	following	_	
36-11	6863-6873	abstinence	_	
36-12	6873-6874	.	_	

#Text=This may be consistent with some irreversible substance-use-related neural insult, or with pre-morbid vulnerabilities in brain systems (which may have preceded substance use) remaining following prolonged cessation of substance use.
37-1	6875-6879	This	_	
37-2	6880-6883	may	_	
37-3	6884-6886	be	_	
37-4	6887-6897	consistent	_	
37-5	6898-6902	with	_	
37-6	6903-6907	some	_	
37-7	6908-6920	irreversible	_	
37-8	6921-6942	substance-use-related	_	
37-9	6943-6949	neural	_	
37-10	6950-6956	insult	_	
37-11	6956-6957	,	_	
37-12	6958-6960	or	_	
37-13	6961-6965	with	_	
37-14	6966-6976	pre-morbid	_	
37-15	6977-6992	vulnerabilities	_	
37-16	6993-6995	in	_	
37-17	6996-7001	brain	_	
37-18	7002-7009	systems	_	
37-19	7010-7011	(	_	
37-20	7011-7016	which	_	
37-21	7017-7020	may	_	
37-22	7021-7025	have	_	
37-23	7026-7034	preceded	_	
37-24	7035-7044	substance	_	
37-25	7045-7048	use	_	
37-26	7048-7049	)	_	
37-27	7050-7059	remaining	_	
37-28	7060-7069	following	_	
37-29	7070-7079	prolonged	_	
37-30	7080-7089	cessation	_	
37-31	7090-7092	of	_	
37-32	7093-7102	substance	_	
37-33	7103-7106	use	_	
37-34	7106-7107	.	_	

#Text=Taken together, these findings highlight the sensitivity of cognitive-control-related neural activity to CUD, cocaine use, and cocaine abstinence, but also illustrate the complexity of interpreting findings.
38-1	7108-7113	Taken	_	
38-2	7114-7122	together	_	
38-3	7122-7123	,	_	
38-4	7124-7129	these	_	
38-5	7130-7138	findings	_	
38-6	7139-7148	highlight	_	
38-7	7149-7152	the	_	
38-8	7153-7164	sensitivity	_	
38-9	7165-7167	of	_	
38-10	7168-7193	cognitive-control-related	_	
38-11	7194-7200	neural	_	
38-12	7201-7209	activity	_	
38-13	7210-7212	to	_	
38-14	7213-7216	CUD	_	
38-15	7216-7217	,	_	
38-16	7218-7225	cocaine	_	
38-17	7226-7229	use	_	
38-18	7229-7230	,	_	
38-19	7231-7234	and	_	
38-20	7235-7242	cocaine	_	
38-21	7243-7253	abstinence	_	
38-22	7253-7254	,	_	
38-23	7255-7258	but	_	
38-24	7259-7263	also	_	
38-25	7264-7274	illustrate	_	
38-26	7275-7278	the	_	
38-27	7279-7289	complexity	_	
38-28	7290-7292	of	_	
38-29	7293-7305	interpreting	_	
38-30	7306-7314	findings	_	
38-31	7314-7315	.	_	

#Text=In turn, this underscores the relevance of investigating these effects in the context of treatment.
39-1	7316-7318	In	_	
39-2	7319-7323	turn	_	
39-3	7323-7324	,	_	
39-4	7325-7329	this	_	
39-5	7330-7341	underscores	_	
39-6	7342-7345	the	_	
39-7	7346-7355	relevance	_	
39-8	7356-7358	of	_	
39-9	7359-7372	investigating	_	
39-10	7373-7378	these	_	
39-11	7379-7386	effects	_	
39-12	7387-7389	in	_	
39-13	7390-7393	the	_	
39-14	7394-7401	context	_	
39-15	7402-7404	of	_	
39-16	7405-7414	treatment	_	
39-17	7414-7415	.	_	

#Text=Few studies have applied neuroimaging in the context of treatment for SUDs (for review see), and several of those have demonstrated relationships between pre-treatment cognitive-control-task-related brain activations and clinical outcomes (e.g., substance use during treatment or follow-up).
40-1	7416-7419	Few	_	
40-2	7420-7427	studies	_	
40-3	7428-7432	have	_	
40-4	7433-7440	applied	_	
40-5	7441-7453	neuroimaging	_	
40-6	7454-7456	in	_	
40-7	7457-7460	the	_	
40-8	7461-7468	context	_	
40-9	7469-7471	of	_	
40-10	7472-7481	treatment	_	
40-11	7482-7485	for	_	
40-12	7486-7490	SUDs	_	
40-13	7491-7492	(	_	
40-14	7492-7495	for	_	
40-15	7496-7502	review	_	
40-16	7503-7506	see	_	
40-17	7506-7507	)	_	
40-18	7507-7508	,	_	
40-19	7509-7512	and	_	
40-20	7513-7520	several	_	
40-21	7521-7523	of	_	
40-22	7524-7529	those	_	
40-23	7530-7534	have	_	
40-24	7535-7547	demonstrated	_	
40-25	7548-7561	relationships	_	
40-26	7562-7569	between	_	
40-27	7570-7583	pre-treatment	_	
40-28	7584-7614	cognitive-control-task-related	_	
40-29	7615-7620	brain	_	
40-30	7621-7632	activations	_	
40-31	7633-7636	and	_	
40-32	7637-7645	clinical	_	
40-33	7646-7654	outcomes	_	
40-34	7655-7656	(	_	
40-35	7656-7659	e.g	_	
40-36	7659-7660	.	_	
40-37	7660-7661	,	_	
40-38	7662-7671	substance	_	
40-39	7672-7675	use	_	
40-40	7676-7682	during	_	
40-41	7683-7692	treatment	_	
40-42	7693-7695	or	_	
40-43	7696-7705	follow-up	_	
40-44	7705-7706	)	_	
40-45	7706-7707	.	_	

#Text=For example, Color-Word-Stroop-related activity in CUD individuals (N=20) initiating a range of treatments (sample combined from several randomized controlled trials (RCTs)) was associated with treatment outcome, such that greater pre-treatment Stroop-related activity in the vmPFC, left posterior cingulate cortex and right striatum correlated with longer duration of continuous abstinence during treatment.
41-1	7708-7711	For	_	
41-2	7712-7719	example	_	
41-3	7719-7720	,	_	
41-4	7721-7746	Color-Word-Stroop-related	_	
41-5	7747-7755	activity	_	
41-6	7756-7758	in	_	
41-7	7759-7762	CUD	_	
41-8	7763-7774	individuals	_	
41-9	7775-7776	(	_	
41-10	7776-7777	N	_	
41-11	7777-7778	=	_	
41-12	7778-7780	20	_	
41-13	7780-7781	)	_	
41-14	7782-7792	initiating	_	
41-15	7793-7794	a	_	
41-16	7795-7800	range	_	
41-17	7801-7803	of	_	
41-18	7804-7814	treatments	_	
41-19	7815-7816	(	_	
41-20	7816-7822	sample	_	
41-21	7823-7831	combined	_	
41-22	7832-7836	from	_	
41-23	7837-7844	several	_	
41-24	7845-7855	randomized	_	
41-25	7856-7866	controlled	_	
41-26	7867-7873	trials	_	
41-27	7874-7875	(	_	
41-28	7875-7879	RCTs	_	
41-29	7879-7880	)	_	
41-30	7880-7881	)	_	
41-31	7882-7885	was	_	
41-32	7886-7896	associated	_	
41-33	7897-7901	with	_	
41-34	7902-7911	treatment	_	
41-35	7912-7919	outcome	_	
41-36	7919-7920	,	_	
41-37	7921-7925	such	_	
41-38	7926-7930	that	_	
41-39	7931-7938	greater	_	
41-40	7939-7952	pre-treatment	_	
41-41	7953-7967	Stroop-related	_	
41-42	7968-7976	activity	_	
41-43	7977-7979	in	_	
41-44	7980-7983	the	_	
41-45	7984-7989	vmPFC	_	
41-46	7989-7990	,	_	
41-47	7991-7995	left	_	
41-48	7996-8005	posterior	_	
41-49	8006-8015	cingulate	_	
41-50	8016-8022	cortex	_	
41-51	8023-8026	and	_	
41-52	8027-8032	right	_	
41-53	8033-8041	striatum	_	
41-54	8042-8052	correlated	_	
41-55	8053-8057	with	_	
41-56	8058-8064	longer	_	
41-57	8065-8073	duration	_	
41-58	8074-8076	of	_	
41-59	8077-8087	continuous	_	
41-60	8088-8098	abstinence	_	
41-61	8099-8105	during	_	
41-62	8106-8115	treatment	_	
41-63	8115-8116	.	_	

#Text=In addition, higher pre-treatment Stroop-related activity in the striatum correlated with higher percent of drug-free urines during treatment, and lower pre-treatment Stroop-related activity in the dlPFC correlated with longer treatment retention.
42-1	8117-8119	In	_	
42-2	8120-8128	addition	_	
42-3	8128-8129	,	_	
42-4	8130-8136	higher	_	
42-5	8137-8150	pre-treatment	_	
42-6	8151-8165	Stroop-related	_	
42-7	8166-8174	activity	_	
42-8	8175-8177	in	_	
42-9	8178-8181	the	_	
42-10	8182-8190	striatum	_	
42-11	8191-8201	correlated	_	
42-12	8202-8206	with	_	
42-13	8207-8213	higher	_	
42-14	8214-8221	percent	_	
42-15	8222-8224	of	_	
42-16	8225-8234	drug-free	_	
42-17	8235-8241	urines	_	
42-18	8242-8248	during	_	
42-19	8249-8258	treatment	_	
42-20	8258-8259	,	_	
42-21	8260-8263	and	_	
42-22	8264-8269	lower	_	
42-23	8270-8283	pre-treatment	_	
42-24	8284-8298	Stroop-related	_	
42-25	8299-8307	activity	_	
42-26	8308-8310	in	_	
42-27	8311-8314	the	_	
42-28	8315-8320	dlPFC	_	
42-29	8321-8331	correlated	_	
42-30	8332-8336	with	_	
42-31	8337-8343	longer	_	
42-32	8344-8353	treatment	_	
42-33	8354-8363	retention	_	
42-34	8363-8364	.	_	

#Text=In another study, males with cannabis use disorder (N=20) scanned prior to CBT and/or CM treatment showed diminished Stroop-related activity in regions including dlPFC and ventral striatum relative to non-users (N=20).
43-1	8365-8367	In	_	
43-2	8368-8375	another	_	
43-3	8376-8381	study	_	
43-4	8381-8382	,	_	
43-5	8383-8388	males	_	
43-6	8389-8393	with	_	
43-7	8394-8402	cannabis	_	
43-8	8403-8406	use	_	
43-9	8407-8415	disorder	_	
43-10	8416-8417	(	_	
43-11	8417-8418	N	_	
43-12	8418-8419	=	_	
43-13	8419-8421	20	_	
43-14	8421-8422	)	_	
43-15	8423-8430	scanned	_	
43-16	8431-8436	prior	_	
43-17	8437-8439	to	_	
43-18	8440-8443	CBT	_	
43-19	8444-8447	and	_	
43-20	8447-8448	/	_	
43-21	8448-8450	or	_	
43-22	8451-8453	CM	_	
43-23	8454-8463	treatment	_	
43-24	8464-8470	showed	_	
43-25	8471-8481	diminished	_	
43-26	8482-8496	Stroop-related	_	
43-27	8497-8505	activity	_	
43-28	8506-8508	in	_	
43-29	8509-8516	regions	_	
43-30	8517-8526	including	_	
43-31	8527-8532	dlPFC	_	
43-32	8533-8536	and	_	
43-33	8537-8544	ventral	_	
43-34	8545-8553	striatum	_	
43-35	8554-8562	relative	_	
43-36	8563-8565	to	_	
43-37	8566-8575	non-users	_	
43-38	8576-8577	(	_	
43-39	8577-8578	N	_	
43-40	8578-8579	=	_	
43-41	8579-8581	20	_	
43-42	8581-8582	)	_	
43-43	8582-8583	.	_	

#Text=Furthermore, higher pre-treatment Stroop-related activity in dorsal anterior cingulate cortex (ACC) and ventral striatum was associated with less cannabis use during treatment and 1-year follow-up, respectively.
44-1	8584-8595	Furthermore	_	
44-2	8595-8596	,	_	
44-3	8597-8603	higher	_	
44-4	8604-8617	pre-treatment	_	
44-5	8618-8632	Stroop-related	_	
44-6	8633-8641	activity	_	
44-7	8642-8644	in	_	
44-8	8645-8651	dorsal	_	
44-9	8652-8660	anterior	_	
44-10	8661-8670	cingulate	_	
44-11	8671-8677	cortex	_	
44-12	8678-8679	(	_	
44-13	8679-8682	ACC	_	
44-14	8682-8683	)	_	
44-15	8684-8687	and	_	
44-16	8688-8695	ventral	_	
44-17	8696-8704	striatum	_	
44-18	8705-8708	was	_	
44-19	8709-8719	associated	_	
44-20	8720-8724	with	_	
44-21	8725-8729	less	_	
44-22	8730-8738	cannabis	_	
44-23	8739-8742	use	_	
44-24	8743-8749	during	_	
44-25	8750-8759	treatment	_	
44-26	8760-8763	and	_	
44-27	8764-8765	1	_	
44-28	8765-8766	-	_	
44-29	8766-8770	year	_	
44-30	8771-8780	follow-up	_	
44-31	8780-8781	,	_	
44-32	8782-8794	respectively	_	
44-33	8794-8795	.	_	

#Text=In individuals with CUD assessed at the beginning of inpatient detoxification treatment, higher right dorsal ACC activity during an attentional bias task (Drug Stroop; N=34;) and lower error-related negativity (an electrophysiological measure of cognitive control; N=49;) were each associated with more cocaine use at 3-month follow-up.
45-1	8796-8798	In	_	
45-2	8799-8810	individuals	_	
45-3	8811-8815	with	_	
45-4	8816-8819	CUD	_	
45-5	8820-8828	assessed	_	
45-6	8829-8831	at	_	
45-7	8832-8835	the	_	
45-8	8836-8845	beginning	_	
45-9	8846-8848	of	_	
45-10	8849-8858	inpatient	_	
45-11	8859-8873	detoxification	_	
45-12	8874-8883	treatment	_	
45-13	8883-8884	,	_	
45-14	8885-8891	higher	_	
45-15	8892-8897	right	_	
45-16	8898-8904	dorsal	_	
45-17	8905-8908	ACC	_	
45-18	8909-8917	activity	_	
45-19	8918-8924	during	_	
45-20	8925-8927	an	_	
45-21	8928-8939	attentional	_	
45-22	8940-8944	bias	_	
45-23	8945-8949	task	_	
45-24	8950-8951	(	_	
45-25	8951-8955	Drug	_	
45-26	8956-8962	Stroop	_	
45-27	8962-8963	;	_	
45-28	8964-8965	N	_	
45-29	8965-8966	=	_	
45-30	8966-8968	34	_	
45-31	8968-8969	;	_	
45-32	8969-8970	)	_	
45-33	8971-8974	and	_	
45-34	8975-8980	lower	_	
45-35	8981-8994	error-related	_	
45-36	8995-9005	negativity	_	
45-37	9006-9007	(	_	
45-38	9007-9009	an	_	
45-39	9010-9030	electrophysiological	_	
45-40	9031-9038	measure	_	
45-41	9039-9041	of	_	
45-42	9042-9051	cognitive	_	
45-43	9052-9059	control	_	
45-44	9059-9060	;	_	
45-45	9061-9062	N	_	
45-46	9062-9063	=	_	
45-47	9063-9065	49	_	
45-48	9065-9066	;	_	
45-49	9066-9067	)	_	
45-50	9068-9072	were	_	
45-51	9073-9077	each	_	
45-52	9078-9088	associated	_	
45-53	9089-9093	with	_	
45-54	9094-9098	more	_	
45-55	9099-9106	cocaine	_	
45-56	9107-9110	use	_	
45-57	9111-9113	at	_	
45-58	9114-9115	3	_	
45-59	9115-9116	-	_	
45-60	9116-9121	month	_	
45-61	9122-9131	follow-up	_	
45-62	9131-9132	.	_	

#Text=In sum, this research relating pre-treatment functional neural activity to drug use outcomes is important, but, it does not directly address changes across treatment or relationships between neural activity and exposure to different treatment components.
46-1	9133-9135	In	_	
46-2	9136-9139	sum	_	
46-3	9139-9140	,	_	
46-4	9141-9145	this	_	
46-5	9146-9154	research	_	
46-6	9155-9163	relating	_	
46-7	9164-9177	pre-treatment	_	
46-8	9178-9188	functional	_	
46-9	9189-9195	neural	_	
46-10	9196-9204	activity	_	
46-11	9205-9207	to	_	
46-12	9208-9212	drug	_	
46-13	9213-9216	use	_	
46-14	9217-9225	outcomes	_	
46-15	9226-9228	is	_	
46-16	9229-9238	important	_	
46-17	9238-9239	,	_	
46-18	9240-9243	but	_	
46-19	9243-9244	,	_	
46-20	9245-9247	it	_	
46-21	9248-9252	does	_	
46-22	9253-9256	not	_	
46-23	9257-9265	directly	_	
46-24	9266-9273	address	_	
46-25	9274-9281	changes	_	
46-26	9282-9288	across	_	
46-27	9289-9298	treatment	_	
46-28	9299-9301	or	_	
46-29	9302-9315	relationships	_	
46-30	9316-9323	between	_	
46-31	9324-9330	neural	_	
46-32	9331-9339	activity	_	
46-33	9340-9343	and	_	
46-34	9344-9352	exposure	_	
46-35	9353-9355	to	_	
46-36	9356-9365	different	_	
46-37	9366-9375	treatment	_	
46-38	9376-9386	components	_	
46-39	9386-9387	.	_	

#Text=A limited body of work has assessed changes in fMRI activity across treatment in substance users.
47-1	9388-9389	A	_	
47-2	9390-9397	limited	_	
47-3	9398-9402	body	_	
47-4	9403-9405	of	_	
47-5	9406-9410	work	_	
47-6	9411-9414	has	_	
47-7	9415-9423	assessed	_	
47-8	9424-9431	changes	_	
47-9	9432-9434	in	_	
47-10	9435-9439	fMRI	_	
47-11	9440-9448	activity	_	
47-12	9449-9455	across	_	
47-13	9456-9465	treatment	_	
47-14	9466-9468	in	_	
47-15	9469-9478	substance	_	
47-16	9479-9484	users	_	
47-17	9484-9485	.	_	

#Text=One prior study from our group assessed change across behavioral treatment in a mixed substance-using outpatient sample (N=12), receiving CBT or treatment as usual.
48-1	9486-9489	One	_	
48-2	9490-9495	prior	_	
48-3	9496-9501	study	_	
48-4	9502-9506	from	_	
48-5	9507-9510	our	_	
48-6	9511-9516	group	_	
48-7	9517-9525	assessed	_	
48-8	9526-9532	change	_	
48-9	9533-9539	across	_	
48-10	9540-9550	behavioral	_	
48-11	9551-9560	treatment	_	
48-12	9561-9563	in	_	
48-13	9564-9565	a	_	
48-14	9566-9571	mixed	_	
48-15	9572-9587	substance-using	_	
48-16	9588-9598	outpatient	_	
48-17	9599-9605	sample	_	
48-18	9606-9607	(	_	
48-19	9607-9608	N	_	
48-20	9608-9609	=	_	
48-21	9609-9611	12	_	
48-22	9611-9612	)	_	
48-23	9612-9613	,	_	
48-24	9614-9623	receiving	_	
48-25	9624-9627	CBT	_	
48-26	9628-9630	or	_	
48-27	9631-9640	treatment	_	
48-28	9641-9643	as	_	
48-29	9644-9649	usual	_	
48-30	9649-9650	.	_	

#Text=We found reduced Stroop-related activity after treatment relative to the beginning-of-treatment, in regions including the thalamus, midbrain, subthalamic nucleus, IFG, MFG and ACC.
49-1	9651-9653	We	_	
49-2	9654-9659	found	_	
49-3	9660-9667	reduced	_	
49-4	9668-9682	Stroop-related	_	
49-5	9683-9691	activity	_	
49-6	9692-9697	after	_	
49-7	9698-9707	treatment	_	
49-8	9708-9716	relative	_	
49-9	9717-9719	to	_	
49-10	9720-9723	the	_	
49-11	9724-9746	beginning-of-treatment	_	
49-12	9746-9747	,	_	
49-13	9748-9750	in	_	
49-14	9751-9758	regions	_	
49-15	9759-9768	including	_	
49-16	9769-9772	the	_	
49-17	9773-9781	thalamus	_	
49-18	9781-9782	,	_	
49-19	9783-9791	midbrain	_	
49-20	9791-9792	,	_	
49-21	9793-9804	subthalamic	_	
49-22	9805-9812	nucleus	_	
49-23	9812-9813	,	_	
49-24	9814-9817	IFG	_	
49-25	9817-9818	,	_	
49-26	9819-9822	MFG	_	
49-27	9823-9826	and	_	
49-28	9827-9830	ACC	_	
49-29	9830-9831	.	_	

#Text=In that study, the sample size and study design limited our ability to relate changes in neural activity to components of treatment received.
50-1	9832-9834	In	_	
50-2	9835-9839	that	_	
50-3	9840-9845	study	_	
50-4	9845-9846	,	_	
50-5	9847-9850	the	_	
50-6	9851-9857	sample	_	
50-7	9858-9862	size	_	
50-8	9863-9866	and	_	
50-9	9867-9872	study	_	
50-10	9873-9879	design	_	
50-11	9880-9887	limited	_	
50-12	9888-9891	our	_	
50-13	9892-9899	ability	_	
50-14	9900-9902	to	_	
50-15	9903-9909	relate	_	
50-16	9910-9917	changes	_	
50-17	9918-9920	in	_	
50-18	9921-9927	neural	_	
50-19	9928-9936	activity	_	
50-20	9937-9939	to	_	
50-21	9940-9950	components	_	
50-22	9951-9953	of	_	
50-23	9954-9963	treatment	_	
50-24	9964-9972	received	_	
50-25	9972-9973	.	_	

#Text=However, exploratory analyses within the ROIs showing significant Stroop-related change across treatment suggested associations between greater reductions in Stroop-related activity (in left middle temporal gyrus and right MFG ROIs) and more exposure to CBT sessions (Supplemental Materials in).
51-1	9974-9981	However	_	
51-2	9981-9982	,	_	
51-3	9983-9994	exploratory	_	
51-4	9995-10003	analyses	_	
51-5	10004-10010	within	_	
51-6	10011-10014	the	_	
51-7	10015-10019	ROIs	_	
51-8	10020-10027	showing	_	
51-9	10028-10039	significant	_	
51-10	10040-10054	Stroop-related	_	
51-11	10055-10061	change	_	
51-12	10062-10068	across	_	
51-13	10069-10078	treatment	_	
51-14	10079-10088	suggested	_	
51-15	10089-10101	associations	_	
51-16	10102-10109	between	_	
51-17	10110-10117	greater	_	
51-18	10118-10128	reductions	_	
51-19	10129-10131	in	_	
51-20	10132-10146	Stroop-related	_	
51-21	10147-10155	activity	_	
51-22	10156-10157	(	_	
51-23	10157-10159	in	_	
51-24	10160-10164	left	_	
51-25	10165-10171	middle	_	
51-26	10172-10180	temporal	_	
51-27	10181-10186	gyrus	_	
51-28	10187-10190	and	_	
51-29	10191-10196	right	_	
51-30	10197-10200	MFG	_	
51-31	10201-10205	ROIs	_	
51-32	10205-10206	)	_	
51-33	10207-10210	and	_	
51-34	10211-10215	more	_	
51-35	10216-10224	exposure	_	
51-36	10225-10227	to	_	
51-37	10228-10231	CBT	_	
51-38	10232-10240	sessions	_	
51-39	10241-10242	(	_	
51-40	10242-10254	Supplemental	_	
51-41	10255-10264	Materials	_	
51-42	10265-10267	in	_	
51-43	10267-10268	)	_	
51-44	10268-10269	.	_	

#Text=In another study in CUD, increases in Drug-Stroop-related activity (a measure of attentional bias to drug stimuli) in the midbrain from baseline to 6-month follow-up (N=15) was associated with fewer choices to view cocaine-related stimuli at follow-up; however, since subjects were recruited from a range of treatment programs, the relative contribution of differential treatment components or types were not assessed.
52-1	10270-10272	In	_	
52-2	10273-10280	another	_	
52-3	10281-10286	study	_	
52-4	10287-10289	in	_	
52-5	10290-10293	CUD	_	
52-6	10293-10294	,	_	
52-7	10295-10304	increases	_	
52-8	10305-10307	in	_	
52-9	10308-10327	Drug-Stroop-related	_	
52-10	10328-10336	activity	_	
52-11	10337-10338	(	_	
52-12	10338-10339	a	_	
52-13	10340-10347	measure	_	
52-14	10348-10350	of	_	
52-15	10351-10362	attentional	_	
52-16	10363-10367	bias	_	
52-17	10368-10370	to	_	
52-18	10371-10375	drug	_	
52-19	10376-10383	stimuli	_	
52-20	10383-10384	)	_	
52-21	10385-10387	in	_	
52-22	10388-10391	the	_	
52-23	10392-10400	midbrain	_	
52-24	10401-10405	from	_	
52-25	10406-10414	baseline	_	
52-26	10415-10417	to	_	
52-27	10418-10419	6	_	
52-28	10419-10420	-	_	
52-29	10420-10425	month	_	
52-30	10426-10435	follow-up	_	
52-31	10436-10437	(	_	
52-32	10437-10438	N	_	
52-33	10438-10439	=	_	
52-34	10439-10441	15	_	
52-35	10441-10442	)	_	
52-36	10443-10446	was	_	
52-37	10447-10457	associated	_	
52-38	10458-10462	with	_	
52-39	10463-10468	fewer	_	
52-40	10469-10476	choices	_	
52-41	10477-10479	to	_	
52-42	10480-10484	view	_	
52-43	10485-10500	cocaine-related	_	
52-44	10501-10508	stimuli	_	
52-45	10509-10511	at	_	
52-46	10512-10521	follow-up	_	
52-47	10521-10522	;	_	
52-48	10523-10530	however	_	
52-49	10530-10531	,	_	
52-50	10532-10537	since	_	
52-51	10538-10546	subjects	_	
52-52	10547-10551	were	_	
52-53	10552-10561	recruited	_	
52-54	10562-10566	from	_	
52-55	10567-10568	a	_	
52-56	10569-10574	range	_	
52-57	10575-10577	of	_	
52-58	10578-10587	treatment	_	
52-59	10588-10596	programs	_	
52-60	10596-10597	,	_	
52-61	10598-10601	the	_	
52-62	10602-10610	relative	_	
52-63	10611-10623	contribution	_	
52-64	10624-10626	of	_	
52-65	10627-10639	differential	_	
52-66	10640-10649	treatment	_	
52-67	10650-10660	components	_	
52-68	10661-10663	or	_	
52-69	10664-10669	types	_	
52-70	10670-10674	were	_	
52-71	10675-10678	not	_	
52-72	10679-10687	assessed	_	
52-73	10687-10688	.	_	

#Text=Studies that have linked functional changes in stimulant users with specific pharmacotherapy have included laboratory one-day trials of the medication, rather than full clinical courses.
53-1	10689-10696	Studies	_	
53-2	10697-10701	that	_	
53-3	10702-10706	have	_	
53-4	10707-10713	linked	_	
53-5	10714-10724	functional	_	
53-6	10725-10732	changes	_	
53-7	10733-10735	in	_	
53-8	10736-10745	stimulant	_	
53-9	10746-10751	users	_	
53-10	10752-10756	with	_	
53-11	10757-10765	specific	_	
53-12	10766-10781	pharmacotherapy	_	
53-13	10782-10786	have	_	
53-14	10787-10795	included	_	
53-15	10796-10806	laboratory	_	
53-16	10807-10814	one-day	_	
53-17	10815-10821	trials	_	
53-18	10822-10824	of	_	
53-19	10825-10828	the	_	
53-20	10829-10839	medication	_	
53-21	10839-10840	,	_	
53-22	10841-10847	rather	_	
53-23	10848-10852	than	_	
53-24	10853-10857	full	_	
53-25	10858-10866	clinical	_	
53-26	10867-10874	courses	_	
53-27	10874-10875	.	_	

#Text=For example, changes in Color-Word-Stroop-related activity were observed following administration of a single dose of methylphenidate (versus placebo).
54-1	10876-10879	For	_	
54-2	10880-10887	example	_	
54-3	10887-10888	,	_	
54-4	10889-10896	changes	_	
54-5	10897-10899	in	_	
54-6	10900-10925	Color-Word-Stroop-related	_	
54-7	10926-10934	activity	_	
54-8	10935-10939	were	_	
54-9	10940-10948	observed	_	
54-10	10949-10958	following	_	
54-11	10959-10973	administration	_	
54-12	10974-10976	of	_	
54-13	10977-10978	a	_	
54-14	10979-10985	single	_	
54-15	10986-10990	dose	_	
54-16	10991-10993	of	_	
54-17	10994-11009	methylphenidate	_	
54-18	11010-11011	(	_	
54-19	11011-11017	versus	_	
54-20	11018-11025	placebo	_	
54-21	11025-11026	)	_	
54-22	11026-11027	.	_	

#Text=In individuals with CUDs (N=16) and non-users (N=15), methylphenidate reduced Stroop-related activity in dorsal ACC and also reduced activity in dlPFC in the CUD group only.
55-1	11028-11030	In	_	
55-2	11031-11042	individuals	_	
55-3	11043-11047	with	_	
55-4	11048-11052	CUDs	_	
55-5	11053-11054	(	_	
55-6	11054-11055	N	_	
55-7	11055-11056	=	_	
55-8	11056-11058	16	_	
55-9	11058-11059	)	_	
55-10	11060-11063	and	_	
55-11	11064-11073	non-users	_	
55-12	11074-11075	(	_	
55-13	11075-11076	N	_	
55-14	11076-11077	=	_	
55-15	11077-11079	15	_	
55-16	11079-11080	)	_	
55-17	11080-11081	,	_	
55-18	11082-11097	methylphenidate	_	
55-19	11098-11105	reduced	_	
55-20	11106-11120	Stroop-related	_	
55-21	11121-11129	activity	_	
55-22	11130-11132	in	_	
55-23	11133-11139	dorsal	_	
55-24	11140-11143	ACC	_	
55-25	11144-11147	and	_	
55-26	11148-11152	also	_	
55-27	11153-11160	reduced	_	
55-28	11161-11169	activity	_	
55-29	11170-11172	in	_	
55-30	11173-11178	dlPFC	_	
55-31	11179-11181	in	_	
55-32	11182-11185	the	_	
55-33	11186-11189	CUD	_	
55-34	11190-11195	group	_	
55-35	11196-11200	only	_	
55-36	11200-11201	.	_	

#Text=Individuals with methamphetamine use disorders (N=15) exhibited increased Stroop-related activity, including in dlPFC, parietal and occipital regions relative to non-users (N=18), and methylphenidate further increased already hyperactive (relative to controls) Stroop-related activity in dlPFC, but reduced activity in parietal and occipital regions.
56-1	11202-11213	Individuals	_	
56-2	11214-11218	with	_	
56-3	11219-11234	methamphetamine	_	
56-4	11235-11238	use	_	
56-5	11239-11248	disorders	_	
56-6	11249-11250	(	_	
56-7	11250-11251	N	_	
56-8	11251-11252	=	_	
56-9	11252-11254	15	_	
56-10	11254-11255	)	_	
56-11	11256-11265	exhibited	_	
56-12	11266-11275	increased	_	
56-13	11276-11290	Stroop-related	_	
56-14	11291-11299	activity	_	
56-15	11299-11300	,	_	
56-16	11301-11310	including	_	
56-17	11311-11313	in	_	
56-18	11314-11319	dlPFC	_	
56-19	11319-11320	,	_	
56-20	11321-11329	parietal	_	
56-21	11330-11333	and	_	
56-22	11334-11343	occipital	_	
56-23	11344-11351	regions	_	
56-24	11352-11360	relative	_	
56-25	11361-11363	to	_	
56-26	11364-11373	non-users	_	
56-27	11374-11375	(	_	
56-28	11375-11376	N	_	
56-29	11376-11377	=	_	
56-30	11377-11379	18	_	
56-31	11379-11380	)	_	
56-32	11380-11381	,	_	
56-33	11382-11385	and	_	
56-34	11386-11401	methylphenidate	_	
56-35	11402-11409	further	_	
56-36	11410-11419	increased	_	
56-37	11420-11427	already	_	
56-38	11428-11439	hyperactive	_	
56-39	11440-11441	(	_	
56-40	11441-11449	relative	_	
56-41	11450-11452	to	_	
56-42	11453-11461	controls	_	
56-43	11461-11462	)	_	
56-44	11463-11477	Stroop-related	_	
56-45	11478-11486	activity	_	
56-46	11487-11489	in	_	
56-47	11490-11495	dlPFC	_	
56-48	11495-11496	,	_	
56-49	11497-11500	but	_	
56-50	11501-11508	reduced	_	
56-51	11509-11517	activity	_	
56-52	11518-11520	in	_	
56-53	11521-11529	parietal	_	
56-54	11530-11533	and	_	
56-55	11534-11543	occipital	_	
56-56	11544-11551	regions	_	
56-57	11551-11552	.	_	

#Text=These findings suggest that the impact of treatment on Stroop-related activity may vary across different substance using and healthy comparison groups.
57-1	11553-11558	These	_	
57-2	11559-11567	findings	_	
57-3	11568-11575	suggest	_	
57-4	11576-11580	that	_	
57-5	11581-11584	the	_	
57-6	11585-11591	impact	_	
57-7	11592-11594	of	_	
57-8	11595-11604	treatment	_	
57-9	11605-11607	on	_	
57-10	11608-11622	Stroop-related	_	
57-11	11623-11631	activity	_	
57-12	11632-11635	may	_	
57-13	11636-11640	vary	_	
57-14	11641-11647	across	_	
57-15	11648-11657	different	_	
57-16	11658-11667	substance	_	
57-17	11668-11673	using	_	
57-18	11674-11677	and	_	
57-19	11678-11685	healthy	_	
57-20	11686-11696	comparison	_	
57-21	11697-11703	groups	_	
57-22	11703-11704	.	_	

#Text=Taken together the existing research supports the clinical relevance of cognitive-control-related functional activity by demonstrating its associations with treatment outcome and ability to change in response to treatment for SUDs.
58-1	11705-11710	Taken	_	
58-2	11711-11719	together	_	
58-3	11720-11723	the	_	
58-4	11724-11732	existing	_	
58-5	11733-11741	research	_	
58-6	11742-11750	supports	_	
58-7	11751-11754	the	_	
58-8	11755-11763	clinical	_	
58-9	11764-11773	relevance	_	
58-10	11774-11776	of	_	
58-11	11777-11802	cognitive-control-related	_	
58-12	11803-11813	functional	_	
58-13	11814-11822	activity	_	
58-14	11823-11825	by	_	
58-15	11826-11839	demonstrating	_	
58-16	11840-11843	its	_	
58-17	11844-11856	associations	_	
58-18	11857-11861	with	_	
58-19	11862-11871	treatment	_	
58-20	11872-11879	outcome	_	
58-21	11880-11883	and	_	
58-22	11884-11891	ability	_	
58-23	11892-11894	to	_	
58-24	11895-11901	change	_	
58-25	11902-11904	in	_	
58-26	11905-11913	response	_	
58-27	11914-11916	to	_	
58-28	11917-11926	treatment	_	
58-29	11927-11930	for	_	
58-30	11931-11935	SUDs	_	
58-31	11935-11936	.	_	

#Text=Focusing on changes over the treatment course that relate to exposure to components of specific treatments is a novel approach to understanding mechanisms of action.
59-1	11937-11945	Focusing	_	
59-2	11946-11948	on	_	
59-3	11949-11956	changes	_	
59-4	11957-11961	over	_	
59-5	11962-11965	the	_	
59-6	11966-11975	treatment	_	
59-7	11976-11982	course	_	
59-8	11983-11987	that	_	
59-9	11988-11994	relate	_	
59-10	11995-11997	to	_	
59-11	11998-12006	exposure	_	
59-12	12007-12009	to	_	
59-13	12010-12020	components	_	
59-14	12021-12023	of	_	
59-15	12024-12032	specific	_	
59-16	12033-12043	treatments	_	
59-17	12044-12046	is	_	
59-18	12047-12048	a	_	
59-19	12049-12054	novel	_	
59-20	12055-12063	approach	_	
59-21	12064-12066	to	_	
59-22	12067-12080	understanding	_	
59-23	12081-12091	mechanisms	_	
59-24	12092-12094	of	_	
59-25	12095-12101	action	_	
59-26	12101-12102	.	_	

#Text=This is important because effective therapies are hypothesized to change substance use by first changing brain-based cognitive processes related to substance use, including cognitive control.
60-1	12103-12107	This	_	
60-2	12108-12110	is	_	
60-3	12111-12120	important	_	
60-4	12121-12128	because	_	
60-5	12129-12138	effective	_	
60-6	12139-12148	therapies	_	
60-7	12149-12152	are	_	
60-8	12153-12165	hypothesized	_	
60-9	12166-12168	to	_	
60-10	12169-12175	change	_	
60-11	12176-12185	substance	_	
60-12	12186-12189	use	_	
60-13	12190-12192	by	_	
60-14	12193-12198	first	_	
60-15	12199-12207	changing	_	
60-16	12208-12219	brain-based	_	
60-17	12220-12229	cognitive	_	
60-18	12230-12239	processes	_	
60-19	12240-12247	related	_	
60-20	12248-12250	to	_	
60-21	12251-12260	substance	_	
60-22	12261-12264	use	_	
60-23	12264-12265	,	_	
60-24	12266-12275	including	_	
60-25	12276-12285	cognitive	_	
60-26	12286-12293	control	_	
60-27	12293-12294	.	_	

#Text=Prior work has demonstrated the efficacies of CBT, CM, disulfiram or combinations of these treatments on reducing cocaine use in some individuals.
61-1	12295-12300	Prior	_	
61-2	12301-12305	work	_	
61-3	12306-12309	has	_	
61-4	12310-12322	demonstrated	_	
61-5	12323-12326	the	_	
61-6	12327-12337	efficacies	_	
61-7	12338-12340	of	_	
61-8	12341-12344	CBT	_	
61-9	12344-12345	,	_	
61-10	12346-12348	CM	_	
61-11	12348-12349	,	_	
61-12	12350-12360	disulfiram	_	
61-13	12361-12363	or	_	
61-14	12364-12376	combinations	_	
61-15	12377-12379	of	_	
61-16	12380-12385	these	_	
61-17	12386-12396	treatments	_	
61-18	12397-12399	on	_	
61-19	12400-12408	reducing	_	
61-20	12409-12416	cocaine	_	
61-21	12417-12420	use	_	
61-22	12421-12423	in	_	
61-23	12424-12428	some	_	
61-24	12429-12440	individuals	_	
61-25	12440-12441	.	_	

#Text=However, no studies have directly investigated i) how changes in cognitive-control-related neural functioning over treatment may be associated with exposure to different treatment components; and, ii) whether these treatment-component-related changes are distinct from functional brain changes associated with cocaine use outcomes.
62-1	12442-12449	However	_	
62-2	12449-12450	,	_	
62-3	12451-12453	no	_	
62-4	12454-12461	studies	_	
62-5	12462-12466	have	_	
62-6	12467-12475	directly	_	
62-7	12476-12488	investigated	_	
62-8	12489-12490	i	_	
62-9	12490-12491	)	_	
62-10	12492-12495	how	_	
62-11	12496-12503	changes	_	
62-12	12504-12506	in	_	
62-13	12507-12532	cognitive-control-related	_	
62-14	12533-12539	neural	_	
62-15	12540-12551	functioning	_	
62-16	12552-12556	over	_	
62-17	12557-12566	treatment	_	
62-18	12567-12570	may	_	
62-19	12571-12573	be	_	
62-20	12574-12584	associated	_	
62-21	12585-12589	with	_	
62-22	12590-12598	exposure	_	
62-23	12599-12601	to	_	
62-24	12602-12611	different	_	
62-25	12612-12621	treatment	_	
62-26	12622-12632	components	_	
62-27	12632-12633	;	_	
62-28	12634-12637	and	_	
62-29	12637-12638	,	_	
62-30	12639-12641	ii	_	
62-31	12641-12642	)	_	
62-32	12643-12650	whether	_	
62-33	12651-12656	these	_	
62-34	12657-12684	treatment-component-related	_	
62-35	12685-12692	changes	_	
62-36	12693-12696	are	_	
62-37	12697-12705	distinct	_	
62-38	12706-12710	from	_	
62-39	12711-12721	functional	_	
62-40	12722-12727	brain	_	
62-41	12728-12735	changes	_	
62-42	12736-12746	associated	_	
62-43	12747-12751	with	_	
62-44	12752-12759	cocaine	_	
62-45	12760-12763	use	_	
62-46	12764-12772	outcomes	_	
62-47	12772-12773	.	_	

#Text=The current study’s goal was to extend prior work and relate exposure to different components of treatment to changes in cognitive-control-related fMRI activity from beginning-of-treatment to post-treatment, in individuals with CUD.
63-1	12774-12777	The	_	
63-2	12778-12785	current	_	
63-3	12786-12791	study	_	
63-4	12791-12792	’	_	
63-5	12792-12793	s	_	
63-6	12794-12798	goal	_	
63-7	12799-12802	was	_	
63-8	12803-12805	to	_	
63-9	12806-12812	extend	_	
63-10	12813-12818	prior	_	
63-11	12819-12823	work	_	
63-12	12824-12827	and	_	
63-13	12828-12834	relate	_	
63-14	12835-12843	exposure	_	
63-15	12844-12846	to	_	
63-16	12847-12856	different	_	
63-17	12857-12867	components	_	
63-18	12868-12870	of	_	
63-19	12871-12880	treatment	_	
63-20	12881-12883	to	_	
63-21	12884-12891	changes	_	
63-22	12892-12894	in	_	
63-23	12895-12920	cognitive-control-related	_	
63-24	12921-12925	fMRI	_	
63-25	12926-12934	activity	_	
63-26	12935-12939	from	_	
63-27	12940-12962	beginning-of-treatment	_	
63-28	12963-12965	to	_	
63-29	12966-12980	post-treatment	_	
63-30	12980-12981	,	_	
63-31	12982-12984	in	_	
63-32	12985-12996	individuals	_	
63-33	12997-13001	with	_	
63-34	13002-13005	CUD	_	
63-35	13005-13006	.	_	

#Text=The Color-Word Stroop color-word task, a measure of cognitive control, was chosen based on the proposed centrality of this cognitive construct to SUDs and abstinence.
64-1	13007-13010	The	_	
64-2	13011-13021	Color-Word	_	
64-3	13022-13028	Stroop	_	
64-4	13029-13039	color-word	_	
64-5	13040-13044	task	_	
64-6	13044-13045	,	_	
64-7	13046-13047	a	_	
64-8	13048-13055	measure	_	
64-9	13056-13058	of	_	
64-10	13059-13068	cognitive	_	
64-11	13069-13076	control	_	
64-12	13076-13077	,	_	
64-13	13078-13081	was	_	
64-14	13082-13088	chosen	_	
64-15	13089-13094	based	_	
64-16	13095-13097	on	_	
64-17	13098-13101	the	_	
64-18	13102-13110	proposed	_	
64-19	13111-13121	centrality	_	
64-20	13122-13124	of	_	
64-21	13125-13129	this	_	
64-22	13130-13139	cognitive	_	
64-23	13140-13149	construct	_	
64-24	13150-13152	to	_	
64-25	13153-13157	SUDs	_	
64-26	13158-13161	and	_	
64-27	13162-13172	abstinence	_	
64-28	13172-13173	.	_	

#Text=Data were drawn from participants in an RCT, all of whom received CBT as a platform treatment.
65-1	13174-13178	Data	_	
65-2	13179-13183	were	_	
65-3	13184-13189	drawn	_	
65-4	13190-13194	from	_	
65-5	13195-13207	participants	_	
65-6	13208-13210	in	_	
65-7	13211-13213	an	_	
65-8	13214-13217	RCT	_	
65-9	13217-13218	,	_	
65-10	13219-13222	all	_	
65-11	13223-13225	of	_	
65-12	13226-13230	whom	_	
65-13	13231-13239	received	_	
65-14	13240-13243	CBT	_	
65-15	13244-13246	as	_	
65-16	13247-13248	a	_	
65-17	13249-13257	platform	_	
65-18	13258-13267	treatment	_	
65-19	13267-13268	.	_	

#Text=Participants were also randomized to CM vs. no-CM and to disulfiram vs. placebo.
66-1	13269-13281	Participants	_	
66-2	13282-13286	were	_	
66-3	13287-13291	also	_	
66-4	13292-13302	randomized	_	
66-5	13303-13305	to	_	
66-6	13306-13308	CM	_	
66-7	13309-13311	vs	_	
66-8	13311-13312	.	_	
66-9	13313-13318	no-CM	_	
66-10	13319-13322	and	_	
66-11	13323-13325	to	_	
66-12	13326-13336	disulfiram	_	
66-13	13337-13339	vs	_	
66-14	13339-13340	.	_	
66-15	13341-13348	placebo	_	
66-16	13348-13349	.	_	

#Text=The primary goal of the analyses was to identify how exposure to components of treatment was associated with changes in cognitive-control-related brain activity across treatment.
67-1	13350-13353	The	_	
67-2	13354-13361	primary	_	
67-3	13362-13366	goal	_	
67-4	13367-13369	of	_	
67-5	13370-13373	the	_	
67-6	13374-13382	analyses	_	
67-7	13383-13386	was	_	
67-8	13387-13389	to	_	
67-9	13390-13398	identify	_	
67-10	13399-13402	how	_	
67-11	13403-13411	exposure	_	
67-12	13412-13414	to	_	
67-13	13415-13425	components	_	
67-14	13426-13428	of	_	
67-15	13429-13438	treatment	_	
67-16	13439-13442	was	_	
67-17	13443-13453	associated	_	
67-18	13454-13458	with	_	
67-19	13459-13466	changes	_	
67-20	13467-13469	in	_	
67-21	13470-13495	cognitive-control-related	_	
67-22	13496-13501	brain	_	
67-23	13502-13510	activity	_	
67-24	13511-13517	across	_	
67-25	13518-13527	treatment	_	
67-26	13527-13528	.	_	

#Text=First, we used a whole-brain analysis to assessed how Stroop-related brain activity changed at post-treatment versus beginning-of-treatment in the sample overall.
68-1	13529-13534	First	_	
68-2	13534-13535	,	_	
68-3	13536-13538	we	_	
68-4	13539-13543	used	_	
68-5	13544-13545	a	_	
68-6	13546-13557	whole-brain	_	
68-7	13558-13566	analysis	_	
68-8	13567-13569	to	_	
68-9	13570-13578	assessed	_	
68-10	13579-13582	how	_	
68-11	13583-13597	Stroop-related	_	
68-12	13598-13603	brain	_	
68-13	13604-13612	activity	_	
68-14	13613-13620	changed	_	
68-15	13621-13623	at	_	
68-16	13624-13638	post-treatment	_	
68-17	13639-13645	versus	_	
68-18	13646-13668	beginning-of-treatment	_	
68-19	13669-13671	in	_	
68-20	13672-13675	the	_	
68-21	13676-13682	sample	_	
68-22	13683-13690	overall	_	
68-23	13690-13691	.	_	

#Text=Second, we used separate whole brain correlation analyses to assess how changes in Stroop-related brain activity at post-treatment versus beginning-of-treatment related to specific treatment components (number of CBT sessions, CM prizes or days of disulfiram medication) and cocaine-use measures (percent days cocaine abstinence during treatment; percent cocaine-negative urines during treatment).
69-1	13692-13698	Second	_	
69-2	13698-13699	,	_	
69-3	13700-13702	we	_	
69-4	13703-13707	used	_	
69-5	13708-13716	separate	_	
69-6	13717-13722	whole	_	
69-7	13723-13728	brain	_	
69-8	13729-13740	correlation	_	
69-9	13741-13749	analyses	_	
69-10	13750-13752	to	_	
69-11	13753-13759	assess	_	
69-12	13760-13763	how	_	
69-13	13764-13771	changes	_	
69-14	13772-13774	in	_	
69-15	13775-13789	Stroop-related	_	
69-16	13790-13795	brain	_	
69-17	13796-13804	activity	_	
69-18	13805-13807	at	_	
69-19	13808-13822	post-treatment	_	
69-20	13823-13829	versus	_	
69-21	13830-13852	beginning-of-treatment	_	
69-22	13853-13860	related	_	
69-23	13861-13863	to	_	
69-24	13864-13872	specific	_	
69-25	13873-13882	treatment	_	
69-26	13883-13893	components	_	
69-27	13894-13895	(	_	
69-28	13895-13901	number	_	
69-29	13902-13904	of	_	
69-30	13905-13908	CBT	_	
69-31	13909-13917	sessions	_	
69-32	13917-13918	,	_	
69-33	13919-13921	CM	_	
69-34	13922-13928	prizes	_	
69-35	13929-13931	or	_	
69-36	13932-13936	days	_	
69-37	13937-13939	of	_	
69-38	13940-13950	disulfiram	_	
69-39	13951-13961	medication	_	
69-40	13961-13962	)	_	
69-41	13963-13966	and	_	
69-42	13967-13978	cocaine-use	_	
69-43	13979-13987	measures	_	
69-44	13988-13989	(	_	
69-45	13989-13996	percent	_	
69-46	13997-14001	days	_	
69-47	14002-14009	cocaine	_	
69-48	14010-14020	abstinence	_	
69-49	14021-14027	during	_	
69-50	14028-14037	treatment	_	
69-51	14037-14038	;	_	
69-52	14039-14046	percent	_	
69-53	14047-14063	cocaine-negative	_	
69-54	14064-14070	urines	_	
69-55	14071-14077	during	_	
69-56	14078-14087	treatment	_	
69-57	14087-14088	)	_	
69-58	14088-14089	.	_	

#Text=Based on our prior work reviewed above in a mixed substance-using sample receiving CBT or treatment as usual which showed reduced Stroop-related activity at post- relative to pre-treatment in the thalamus, midbrain, subthalamic nucleus, IFG, MFG and ACC, we hypothesized that patients would show diminished Stroop-related brain activity at post-treatment relative to beginning-of-treatment in these regions.
70-1	14090-14095	Based	_	
70-2	14096-14098	on	_	
70-3	14099-14102	our	_	
70-4	14103-14108	prior	_	
70-5	14109-14113	work	_	
70-6	14114-14122	reviewed	_	
70-7	14123-14128	above	_	
70-8	14129-14131	in	_	
70-9	14132-14133	a	_	
70-10	14134-14139	mixed	_	
70-11	14140-14155	substance-using	_	
70-12	14156-14162	sample	_	
70-13	14163-14172	receiving	_	
70-14	14173-14176	CBT	_	
70-15	14177-14179	or	_	
70-16	14180-14189	treatment	_	
70-17	14190-14192	as	_	
70-18	14193-14198	usual	_	
70-19	14199-14204	which	_	
70-20	14205-14211	showed	_	
70-21	14212-14219	reduced	_	
70-22	14220-14234	Stroop-related	_	
70-23	14235-14243	activity	_	
70-24	14244-14246	at	_	
70-25	14247-14251	post	_	
70-26	14251-14252	-	_	
70-27	14253-14261	relative	_	
70-28	14262-14264	to	_	
70-29	14265-14278	pre-treatment	_	
70-30	14279-14281	in	_	
70-31	14282-14285	the	_	
70-32	14286-14294	thalamus	_	
70-33	14294-14295	,	_	
70-34	14296-14304	midbrain	_	
70-35	14304-14305	,	_	
70-36	14306-14317	subthalamic	_	
70-37	14318-14325	nucleus	_	
70-38	14325-14326	,	_	
70-39	14327-14330	IFG	_	
70-40	14330-14331	,	_	
70-41	14332-14335	MFG	_	
70-42	14336-14339	and	_	
70-43	14340-14343	ACC	_	
70-44	14343-14344	,	_	
70-45	14345-14347	we	_	
70-46	14348-14360	hypothesized	_	
70-47	14361-14365	that	_	
70-48	14366-14374	patients	_	
70-49	14375-14380	would	_	
70-50	14381-14385	show	_	
70-51	14386-14396	diminished	_	
70-52	14397-14411	Stroop-related	_	
70-53	14412-14417	brain	_	
70-54	14418-14426	activity	_	
70-55	14427-14429	at	_	
70-56	14430-14444	post-treatment	_	
70-57	14445-14453	relative	_	
70-58	14454-14456	to	_	
70-59	14457-14479	beginning-of-treatment	_	
70-60	14480-14482	in	_	
70-61	14483-14488	these	_	
70-62	14489-14496	regions	_	
70-63	14496-14497	.	_	

#Text=We hypothesized that greater reductions in Stroop-related activity would be observed in association with exposure to active ingredients of each treatment type as operationalized by process indicators as follows (see Table 1): (1) exposure to CBT skills training (CBT sessions attended), (2) access to reinforcement through CM (CM prizes drawn for abstinence or adherence to medication) and (3) exposure to disulfiram (total days of medication doses taken).
71-1	14498-14500	We	_	
71-2	14501-14513	hypothesized	_	
71-3	14514-14518	that	_	
71-4	14519-14526	greater	_	
71-5	14527-14537	reductions	_	
71-6	14538-14540	in	_	
71-7	14541-14555	Stroop-related	_	
71-8	14556-14564	activity	_	
71-9	14565-14570	would	_	
71-10	14571-14573	be	_	
71-11	14574-14582	observed	_	
71-12	14583-14585	in	_	
71-13	14586-14597	association	_	
71-14	14598-14602	with	_	
71-15	14603-14611	exposure	_	
71-16	14612-14614	to	_	
71-17	14615-14621	active	_	
71-18	14622-14633	ingredients	_	
71-19	14634-14636	of	_	
71-20	14637-14641	each	_	
71-21	14642-14651	treatment	_	
71-22	14652-14656	type	_	
71-23	14657-14659	as	_	
71-24	14660-14675	operationalized	_	
71-25	14676-14678	by	_	
71-26	14679-14686	process	_	
71-27	14687-14697	indicators	_	
71-28	14698-14700	as	_	
71-29	14701-14708	follows	_	
71-30	14709-14710	(	_	
71-31	14710-14713	see	_	
71-32	14714-14719	Table	_	
71-33	14720-14721	1	_	
71-34	14721-14722	)	_	
71-35	14722-14723	:	_	
71-36	14724-14725	(	_	
71-37	14725-14726	1	_	
71-38	14726-14727	)	_	
71-39	14728-14736	exposure	_	
71-40	14737-14739	to	_	
71-41	14740-14743	CBT	_	
71-42	14744-14750	skills	_	
71-43	14751-14759	training	_	
71-44	14760-14761	(	_	
71-45	14761-14764	CBT	_	
71-46	14765-14773	sessions	_	
71-47	14774-14782	attended	_	
71-48	14782-14783	)	_	
71-49	14783-14784	,	_	
71-50	14785-14786	(	_	
71-51	14786-14787	2	_	
71-52	14787-14788	)	_	
71-53	14789-14795	access	_	
71-54	14796-14798	to	_	
71-55	14799-14812	reinforcement	_	
71-56	14813-14820	through	_	
71-57	14821-14823	CM	_	
71-58	14824-14825	(	_	
71-59	14825-14827	CM	_	
71-60	14828-14834	prizes	_	
71-61	14835-14840	drawn	_	
71-62	14841-14844	for	_	
71-63	14845-14855	abstinence	_	
71-64	14856-14858	or	_	
71-65	14859-14868	adherence	_	
71-66	14869-14871	to	_	
71-67	14872-14882	medication	_	
71-68	14882-14883	)	_	
71-69	14884-14887	and	_	
71-70	14888-14889	(	_	
71-71	14889-14890	3	_	
71-72	14890-14891	)	_	
71-73	14892-14900	exposure	_	
71-74	14901-14903	to	_	
71-75	14904-14914	disulfiram	_	
71-76	14915-14916	(	_	
71-77	14916-14921	total	_	
71-78	14922-14926	days	_	
71-79	14927-14929	of	_	
71-80	14930-14940	medication	_	
71-81	14941-14946	doses	_	
71-82	14947-14952	taken	_	
71-83	14952-14953	)	_	
71-84	14953-14954	.	_	

#Text=Finally, we hypothesized, based on the structure and goals of the respective treatments, that CBT engagement specifically would be associated with greater efficiency (as indicated by lower Stroop-related activity at post-treatment vs. beginning-of-treatment) in regions associated with ‘top-down’ regulatory control (e.g., ACC, IFG, MFG), and that CM engagement (i.e., randomization to CM group; more CM prizes drawn) would be associated with greater efficiency in regions which are involved in ‘bottom-up’ circuitry (i.e., regions implicated in reward-processing and valuation, including striatum, ventromedial prefrontal cortex) which are also engaged by Stroop and other cognitive-control tasks.
72-1	14955-14962	Finally	_	
72-2	14962-14963	,	_	
72-3	14964-14966	we	_	
72-4	14967-14979	hypothesized	_	
72-5	14979-14980	,	_	
72-6	14981-14986	based	_	
72-7	14987-14989	on	_	
72-8	14990-14993	the	_	
72-9	14994-15003	structure	_	
72-10	15004-15007	and	_	
72-11	15008-15013	goals	_	
72-12	15014-15016	of	_	
72-13	15017-15020	the	_	
72-14	15021-15031	respective	_	
72-15	15032-15042	treatments	_	
72-16	15042-15043	,	_	
72-17	15044-15048	that	_	
72-18	15049-15052	CBT	_	
72-19	15053-15063	engagement	_	
72-20	15064-15076	specifically	_	
72-21	15077-15082	would	_	
72-22	15083-15085	be	_	
72-23	15086-15096	associated	_	
72-24	15097-15101	with	_	
72-25	15102-15109	greater	_	
72-26	15110-15120	efficiency	_	
72-27	15121-15122	(	_	
72-28	15122-15124	as	_	
72-29	15125-15134	indicated	_	
72-30	15135-15137	by	_	
72-31	15138-15143	lower	_	
72-32	15144-15158	Stroop-related	_	
72-33	15159-15167	activity	_	
72-34	15168-15170	at	_	
72-35	15171-15185	post-treatment	_	
72-36	15186-15188	vs	_	
72-37	15188-15189	.	_	
72-38	15190-15212	beginning-of-treatment	_	
72-39	15212-15213	)	_	
72-40	15214-15216	in	_	
72-41	15217-15224	regions	_	
72-42	15225-15235	associated	_	
72-43	15236-15240	with	_	
72-44	15241-15242	‘	_	
72-45	15242-15250	top-down	_	
72-46	15250-15251	’	_	
72-47	15252-15262	regulatory	_	
72-48	15263-15270	control	_	
72-49	15271-15272	(	_	
72-50	15272-15275	e.g	_	
72-51	15275-15276	.	_	
72-52	15276-15277	,	_	
72-53	15278-15281	ACC	_	
72-54	15281-15282	,	_	
72-55	15283-15286	IFG	_	
72-56	15286-15287	,	_	
72-57	15288-15291	MFG	_	
72-58	15291-15292	)	_	
72-59	15292-15293	,	_	
72-60	15294-15297	and	_	
72-61	15298-15302	that	_	
72-62	15303-15305	CM	_	
72-63	15306-15316	engagement	_	
72-64	15317-15318	(	_	
72-65	15318-15321	i.e	_	
72-66	15321-15322	.	_	
72-67	15322-15323	,	_	
72-68	15324-15337	randomization	_	
72-69	15338-15340	to	_	
72-70	15341-15343	CM	_	
72-71	15344-15349	group	_	
72-72	15349-15350	;	_	
72-73	15351-15355	more	_	
72-74	15356-15358	CM	_	
72-75	15359-15365	prizes	_	
72-76	15366-15371	drawn	_	
72-77	15371-15372	)	_	
72-78	15373-15378	would	_	
72-79	15379-15381	be	_	
72-80	15382-15392	associated	_	
72-81	15393-15397	with	_	
72-82	15398-15405	greater	_	
72-83	15406-15416	efficiency	_	
72-84	15417-15419	in	_	
72-85	15420-15427	regions	_	
72-86	15428-15433	which	_	
72-87	15434-15437	are	_	
72-88	15438-15446	involved	_	
72-89	15447-15449	in	_	
72-90	15450-15451	‘	_	
72-91	15451-15460	bottom-up	_	
72-92	15460-15461	’	_	
72-93	15462-15471	circuitry	_	
72-94	15472-15473	(	_	
72-95	15473-15476	i.e	_	
72-96	15476-15477	.	_	
72-97	15477-15478	,	_	
72-98	15479-15486	regions	_	
72-99	15487-15497	implicated	_	
72-100	15498-15500	in	_	
72-101	15501-15518	reward-processing	_	
72-102	15519-15522	and	_	
72-103	15523-15532	valuation	_	
72-104	15532-15533	,	_	
72-105	15534-15543	including	_	
72-106	15544-15552	striatum	_	
72-107	15552-15553	,	_	
72-108	15554-15566	ventromedial	_	
72-109	15567-15577	prefrontal	_	
72-110	15578-15584	cortex	_	
72-111	15584-15585	)	_	
72-112	15586-15591	which	_	
72-113	15592-15595	are	_	
72-114	15596-15600	also	_	
72-115	15601-15608	engaged	_	
72-116	15609-15611	by	_	
72-117	15612-15618	Stroop	_	
72-118	15619-15622	and	_	
72-119	15623-15628	other	_	
72-120	15629-15646	cognitive-control	_	
72-121	15647-15652	tasks	_	
72-122	15652-15653	.	_	

#Text=Materials and Methods
#Text=Participants
#Text=Treatment-seeking participants were recruited to the fMRI study prior to treatment randomization in an RCT for CUD.
73-1	15654-15663	Materials	http://www.case.edu/ProvCaRe/provcare#StudyMethod[3]	
73-2	15664-15667	and	http://www.case.edu/ProvCaRe/provcare#StudyMethod[3]	
73-3	15668-15675	Methods	http://www.case.edu/ProvCaRe/provcare#StudyMethod[3]	
73-4	15676-15688	Participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
73-5	15689-15706	Treatment-seeking	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
73-6	15707-15719	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
73-7	15720-15724	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
73-8	15725-15734	recruited	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
73-9	15735-15737	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
73-10	15738-15741	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
73-11	15742-15746	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]|http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[5]	
73-12	15747-15752	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
73-13	15753-15758	prior	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
73-14	15759-15761	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
73-15	15762-15771	treatment	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
73-16	15772-15785	randomization	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
73-17	15786-15788	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
73-18	15789-15791	an	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
73-19	15792-15795	RCT	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
73-20	15796-15799	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
73-21	15800-15803	CUD	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]|http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[6]	
73-22	15803-15804	.	_	

#Text=Participants were 18 years or older, recruited from a community-based outpatient treatment center, met DSM-IV criteria for current cocaine dependence and did not meet current dependence criteria for other illicit drugs.
74-1	15805-15817	Participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
74-2	15818-15822	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
74-3	15823-15825	18	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
74-4	15826-15831	years	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
74-5	15832-15834	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
74-6	15835-15840	older	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
74-7	15840-15841	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
74-8	15842-15851	recruited	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
74-9	15852-15856	from	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
74-10	15857-15858	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
74-11	15859-15874	community-based	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
74-12	15875-15885	outpatient	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
74-13	15886-15895	treatment	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
74-14	15896-15902	center	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
74-15	15902-15903	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
74-16	15904-15907	met	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
74-17	15908-15914	DSM-IV	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
74-18	15915-15923	criteria	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
74-19	15924-15927	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
74-20	15928-15935	current	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
74-21	15936-15943	cocaine	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]|http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[8]	
74-22	15944-15954	dependence	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]|http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[8]	
74-23	15955-15958	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
74-24	15959-15962	did	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
74-25	15963-15966	not	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
74-26	15967-15971	meet	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
74-27	15972-15979	current	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
74-28	15980-15990	dependence	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
74-29	15991-15999	criteria	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
74-30	16000-16003	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
74-31	16004-16009	other	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
74-32	16010-16017	illicit	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
74-33	16018-16023	drugs	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
74-34	16023-16024	.	_	

#Text=Other exclusion criteria included lifetime psychotic or bipolar disorder, current suicidal or homicidal ideation or current medical condition that would contraindicate disulfiram treatment (e.g. hepatic or cardiac problems, hypertension, pregnancy).
75-1	16025-16030	Other	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
75-2	16031-16040	exclusion	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
75-3	16041-16049	criteria	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
75-4	16050-16058	included	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
75-5	16059-16067	lifetime	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
75-6	16068-16077	psychotic	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
75-7	16078-16080	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
75-8	16081-16088	bipolar	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
75-9	16089-16097	disorder	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
75-10	16097-16098	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
75-11	16099-16106	current	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
75-12	16107-16115	suicidal	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
75-13	16116-16118	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
75-14	16119-16128	homicidal	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
75-15	16129-16137	ideation	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
75-16	16138-16140	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
75-17	16141-16148	current	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
75-18	16149-16156	medical	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
75-19	16157-16166	condition	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
75-20	16167-16171	that	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
75-21	16172-16177	would	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
75-22	16178-16192	contraindicate	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
75-23	16193-16203	disulfiram	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
75-24	16204-16213	treatment	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
75-25	16214-16215	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
75-26	16215-16218	e.g	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
75-27	16218-16219	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
75-28	16220-16227	hepatic	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
75-29	16228-16230	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
75-30	16231-16238	cardiac	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
75-31	16239-16247	problems	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
75-32	16247-16248	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
75-33	16249-16261	hypertension	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
75-34	16261-16262	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
75-35	16263-16272	pregnancy	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
75-36	16272-16273	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
75-37	16273-16274	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	

#Text=RCT participants were offered participation in the fMRI component if they did not report claustrophobia, colorblindness, history of severe head trauma with loss of consciousness, or metallic implants contraindicated in MRI.
76-1	16275-16278	RCT	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
76-2	16279-16291	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
76-3	16292-16296	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
76-4	16297-16304	offered	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
76-5	16305-16318	participation	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
76-6	16319-16321	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
76-7	16322-16325	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
76-8	16326-16330	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]|http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[11]	
76-9	16331-16340	component	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
76-10	16341-16343	if	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
76-11	16344-16348	they	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
76-12	16349-16352	did	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
76-13	16353-16356	not	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
76-14	16357-16363	report	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
76-15	16364-16378	claustrophobia	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
76-16	16378-16379	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
76-17	16380-16394	colorblindness	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
76-18	16394-16395	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
76-19	16396-16403	history	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
76-20	16404-16406	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
76-21	16407-16413	severe	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
76-22	16414-16418	head	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
76-23	16419-16425	trauma	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
76-24	16426-16430	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
76-25	16431-16435	loss	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
76-26	16436-16438	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
76-27	16439-16452	consciousness	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
76-28	16452-16453	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
76-29	16454-16456	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
76-30	16457-16465	metallic	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
76-31	16466-16474	implants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
76-32	16475-16490	contraindicated	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
76-33	16491-16493	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
76-34	16494-16497	MRI	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]|http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging[12]	
76-35	16497-16498	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	

#Text=Of 99 RCT participants, 35 completed fMRI scans at in the beginning-of-treatment and following treatment. 26 of whom were included in the current fMRI analyses (N=9 excluded due to delayed timing of scans relative to beginning-of-treatment or post-treatment, or to insufficient treatment exposure; for details see Supplementary Materials).
77-1	16499-16501	Of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
77-2	16502-16504	99	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
77-3	16505-16508	RCT	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
77-4	16509-16521	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
77-5	16521-16522	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
77-6	16523-16525	35	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
77-7	16526-16535	completed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
77-8	16536-16540	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]|http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[14]	
77-9	16541-16546	scans	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
77-10	16547-16549	at	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
77-11	16550-16552	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
77-12	16553-16556	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
77-13	16557-16579	beginning-of-treatment	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
77-14	16580-16583	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
77-15	16584-16593	following	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
77-16	16594-16603	treatment	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
77-17	16603-16604	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
77-18	16605-16607	26	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
77-19	16608-16610	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
77-20	16611-16615	whom	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
77-21	16616-16620	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
77-22	16621-16629	included	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
77-23	16630-16632	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
77-24	16633-16636	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
77-25	16637-16644	current	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
77-26	16645-16649	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]|http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[15]	
77-27	16650-16658	analyses	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
77-28	16659-16660	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
77-29	16660-16661	N	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
77-30	16661-16662	=	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
77-31	16662-16663	9	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
77-32	16664-16672	excluded	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
77-33	16673-16676	due	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
77-34	16677-16679	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
77-35	16680-16687	delayed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
77-36	16688-16694	timing	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
77-37	16695-16697	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
77-38	16698-16703	scans	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
77-39	16704-16712	relative	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
77-40	16713-16715	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
77-41	16716-16738	beginning-of-treatment	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
77-42	16739-16741	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
77-43	16742-16756	post-treatment	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
77-44	16756-16757	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
77-45	16758-16760	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
77-46	16761-16763	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
77-47	16764-16776	insufficient	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
77-48	16777-16786	treatment	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
77-49	16787-16795	exposure	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
77-50	16795-16796	;	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
77-51	16797-16800	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
77-52	16801-16808	details	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
77-53	16809-16812	see	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
77-54	16813-16826	Supplementary	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
77-55	16827-16836	Materials	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
77-56	16836-16837	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
77-57	16837-16838	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	

#Text=This study was approved by a human subjects Institutional Review Board and participants provided written informed consent prior to participation.
78-1	16839-16843	This	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
78-2	16844-16849	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
78-3	16850-16853	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
78-4	16854-16862	approved	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
78-5	16863-16865	by	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
78-6	16866-16867	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
78-7	16868-16873	human	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
78-8	16874-16882	subjects	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
78-9	16883-16896	Institutional	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
78-10	16897-16903	Review	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
78-11	16904-16909	Board	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
78-12	16910-16913	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
78-13	16914-16926	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
78-14	16927-16935	provided	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
78-15	16936-16943	written	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
78-16	16944-16952	informed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
78-17	16953-16960	consent	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
78-18	16961-16966	prior	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
78-19	16967-16969	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
78-20	16970-16983	participation	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
78-21	16983-16984	.	_	

#Text=Treatment and Clinical Assessments
#Text=RCT methods are reported in full elsewhere.
79-1	16985-16994	Treatment	_	
79-2	16995-16998	and	_	
79-3	16999-17007	Clinical	_	
79-4	17008-17019	Assessments	_	
79-5	17020-17023	RCT	_	
79-6	17024-17031	methods	_	
79-7	17032-17035	are	_	
79-8	17036-17044	reported	_	
79-9	17045-17047	in	_	
79-10	17048-17052	full	_	
79-11	17053-17062	elsewhere	_	
79-12	17062-17063	.	_	

#Text=Briefly, treatment lasted 12 weeks, and all participants were offered CBT.
80-1	17064-17071	Briefly	_	
80-2	17071-17072	,	_	
80-3	17073-17082	treatment	_	
80-4	17083-17089	lasted	_	
80-5	17090-17092	12	_	
80-6	17093-17098	weeks	_	
80-7	17098-17099	,	_	
80-8	17100-17103	and	_	
80-9	17104-17107	all	_	
80-10	17108-17120	participants	_	
80-11	17121-17125	were	_	
80-12	17126-17133	offered	_	
80-13	17134-17137	CBT	_	
80-14	17137-17138	.	_	

#Text=In addition, all participants included in the fMRI analyses were randomized to either disulfiram (N=10) or placebo (N=16) and CM (N=14) or no-CM (N=12) in a factorial design, resulting in four treatment conditions: 1) CBT+ CM + disulfiram (N=4), 2) CBT + CM + placebo (N=10), 3) CBT + disulfiram (N=6), 4) CBT + placebo (N=6).
81-1	17139-17141	In	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
81-2	17142-17150	addition	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
81-3	17150-17151	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
81-4	17152-17155	all	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
81-5	17156-17168	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
81-6	17169-17177	included	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
81-7	17178-17180	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
81-8	17181-17184	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
81-9	17185-17189	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]|http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[18]	
81-10	17190-17198	analyses	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
81-11	17199-17203	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
81-12	17204-17214	randomized	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
81-13	17215-17217	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
81-14	17218-17224	either	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
81-15	17225-17235	disulfiram	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
81-16	17236-17237	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
81-17	17237-17238	N	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
81-18	17238-17239	=	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
81-19	17239-17241	10	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
81-20	17241-17242	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
81-21	17243-17245	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
81-22	17246-17253	placebo	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
81-23	17254-17255	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
81-24	17255-17256	N	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
81-25	17256-17257	=	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
81-26	17257-17259	16	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
81-27	17259-17260	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
81-28	17261-17264	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
81-29	17265-17267	CM	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
81-30	17268-17269	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
81-31	17269-17270	N	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
81-32	17270-17271	=	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
81-33	17271-17273	14	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
81-34	17273-17274	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
81-35	17275-17277	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
81-36	17278-17283	no-CM	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
81-37	17284-17285	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
81-38	17285-17286	N	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
81-39	17286-17287	=	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
81-40	17287-17289	12	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
81-41	17289-17290	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
81-42	17291-17293	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
81-43	17294-17295	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
81-44	17296-17305	factorial	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
81-45	17306-17312	design	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
81-46	17312-17313	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
81-47	17314-17323	resulting	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
81-48	17324-17326	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
81-49	17327-17331	four	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
81-50	17332-17341	treatment	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
81-51	17342-17352	conditions	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
81-52	17352-17353	:	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
81-53	17354-17355	1	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
81-54	17355-17356	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
81-55	17357-17360	CBT	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
81-56	17360-17361	+	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
81-57	17362-17364	CM	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
81-58	17365-17366	+	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
81-59	17367-17377	disulfiram	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
81-60	17378-17379	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
81-61	17379-17380	N	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
81-62	17380-17381	=	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
81-63	17381-17382	4	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
81-64	17382-17383	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
81-65	17383-17384	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
81-66	17385-17386	2	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
81-67	17386-17387	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
81-68	17388-17391	CBT	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
81-69	17392-17393	+	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
81-70	17394-17396	CM	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
81-71	17397-17398	+	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
81-72	17399-17406	placebo	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
81-73	17407-17408	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
81-74	17408-17409	N	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
81-75	17409-17410	=	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
81-76	17410-17412	10	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
81-77	17412-17413	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
81-78	17413-17414	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
81-79	17415-17416	3	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
81-80	17416-17417	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
81-81	17418-17421	CBT	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
81-82	17422-17423	+	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
81-83	17424-17434	disulfiram	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
81-84	17435-17436	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
81-85	17436-17437	N	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
81-86	17437-17438	=	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
81-87	17438-17439	6	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
81-88	17439-17440	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
81-89	17440-17441	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
81-90	17442-17443	4	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
81-91	17443-17444	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
81-92	17445-17448	CBT	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
81-93	17449-17450	+	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
81-94	17451-17458	placebo	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
81-95	17459-17460	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
81-96	17460-17461	N	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
81-97	17461-17462	=	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
81-98	17462-17463	6	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
81-99	17463-17464	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
81-100	17464-17465	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	

#Text=Participants were asked to attend the clinic three times per week during the 12-week protocol; medication was dispensed and urine specimens were collected at each clinic visit.
82-1	17466-17478	Participants	_	
82-2	17479-17483	were	_	
82-3	17484-17489	asked	_	
82-4	17490-17492	to	_	
82-5	17493-17499	attend	_	
82-6	17500-17503	the	_	
82-7	17504-17510	clinic	_	
82-8	17511-17516	three	_	
82-9	17517-17522	times	_	
82-10	17523-17526	per	_	
82-11	17527-17531	week	_	
82-12	17532-17538	during	_	
82-13	17539-17542	the	_	
82-14	17543-17545	12	_	
82-15	17545-17546	-	_	
82-16	17546-17550	week	_	
82-17	17551-17559	protocol	_	
82-18	17559-17560	;	_	
82-19	17561-17571	medication	_	
82-20	17572-17575	was	_	
82-21	17576-17585	dispensed	_	
82-22	17586-17589	and	_	
82-23	17590-17595	urine	_	
82-24	17596-17605	specimens	_	
82-25	17606-17610	were	_	
82-26	17611-17620	collected	_	
82-27	17621-17623	at	_	
82-28	17624-17628	each	_	
82-29	17629-17635	clinic	_	
82-30	17636-17641	visit	_	
82-31	17641-17642	.	_	

#Text=All in-person treatment delivery, tracking of treatment adherence and tracking monitoring of substance use occurred in those thrice-weekly visits.
83-1	17643-17646	All	_	
83-2	17647-17656	in-person	_	
83-3	17657-17666	treatment	_	
83-4	17667-17675	delivery	_	
83-5	17675-17676	,	_	
83-6	17677-17685	tracking	_	
83-7	17686-17688	of	_	
83-8	17689-17698	treatment	_	
83-9	17699-17708	adherence	_	
83-10	17709-17712	and	_	
83-11	17713-17721	tracking	_	
83-12	17722-17732	monitoring	_	
83-13	17733-17735	of	_	
83-14	17736-17745	substance	_	
83-15	17746-17749	use	_	
83-16	17750-17758	occurred	_	
83-17	17759-17761	in	_	
83-18	17762-17767	those	_	
83-19	17768-17781	thrice-weekly	_	
83-20	17782-17788	visits	_	
83-21	17788-17789	.	_	

#Text=Due to the limited sample sizes for the four treatment cells within the fMRI sample, analyses focused on the entire sample or comparing disulfiram versus placebo, or CM versus no-CM.
84-1	17790-17793	Due	_	
84-2	17794-17796	to	_	
84-3	17797-17800	the	_	
84-4	17801-17808	limited	_	
84-5	17809-17815	sample	_	
84-6	17816-17821	sizes	_	
84-7	17822-17825	for	_	
84-8	17826-17829	the	_	
84-9	17830-17834	four	_	
84-10	17835-17844	treatment	_	
84-11	17845-17850	cells	_	
84-12	17851-17857	within	_	
84-13	17858-17861	the	_	
84-14	17862-17866	fMRI	_	
84-15	17867-17873	sample	_	
84-16	17873-17874	,	_	
84-17	17875-17883	analyses	_	
84-18	17884-17891	focused	_	
84-19	17892-17894	on	_	
84-20	17895-17898	the	_	
84-21	17899-17905	entire	_	
84-22	17906-17912	sample	_	
84-23	17913-17915	or	_	
84-24	17916-17925	comparing	_	
84-25	17926-17936	disulfiram	_	
84-26	17937-17943	versus	_	
84-27	17944-17951	placebo	_	
84-28	17951-17952	,	_	
84-29	17953-17955	or	_	
84-30	17956-17958	CM	_	
84-31	17959-17965	versus	_	
84-32	17966-17971	no-CM	_	
84-33	17971-17972	.	_	

#Text=Cognitive Behavioral Therapy (CBT)
#Text=Weekly 50-minute individual CBT sessions were offered as per the CBT manual, delivered by doctoral-level clinicians with CBT experience and demonstrated competence.
85-1	17973-17982	Cognitive	_	
85-2	17983-17993	Behavioral	_	
85-3	17994-18001	Therapy	_	
85-4	18002-18003	(	_	
85-5	18003-18006	CBT	_	
85-6	18006-18007	)	_	
85-7	18008-18014	Weekly	_	
85-8	18015-18017	50	_	
85-9	18017-18018	-	_	
85-10	18018-18024	minute	_	
85-11	18025-18035	individual	_	
85-12	18036-18039	CBT	_	
85-13	18040-18048	sessions	_	
85-14	18049-18053	were	_	
85-15	18054-18061	offered	_	
85-16	18062-18064	as	_	
85-17	18065-18068	per	_	
85-18	18069-18072	the	_	
85-19	18073-18076	CBT	_	
85-20	18077-18083	manual	_	
85-21	18083-18084	,	_	
85-22	18085-18094	delivered	_	
85-23	18095-18097	by	_	
85-24	18098-18112	doctoral-level	_	
85-25	18113-18123	clinicians	_	
85-26	18124-18128	with	_	
85-27	18129-18132	CBT	_	
85-28	18133-18143	experience	_	
85-29	18144-18147	and	_	
85-30	18148-18160	demonstrated	_	
85-31	18161-18171	competence	_	
85-32	18171-18172	.	_	

#Text=The primary process indicator for CBT was number of CBT sessions attended (see Table 1).
86-1	18173-18176	The	_	
86-2	18177-18184	primary	_	
86-3	18185-18192	process	_	
86-4	18193-18202	indicator	_	
86-5	18203-18206	for	_	
86-6	18207-18210	CBT	_	
86-7	18211-18214	was	_	
86-8	18215-18221	number	_	
86-9	18222-18224	of	_	
86-10	18225-18228	CBT	_	
86-11	18229-18237	sessions	_	
86-12	18238-18246	attended	_	
86-13	18247-18248	(	_	
86-14	18248-18251	see	_	
86-15	18252-18257	Table	_	
86-16	18258-18259	1	_	
86-17	18259-18260	)	_	
86-18	18260-18261	.	_	

#Text=CBT aims to promote abstinence by teaching and promoting practice of behavioral and cognitive control strategies (e.g., coping with craving, improving decision making skills).
87-1	18262-18265	CBT	_	
87-2	18266-18270	aims	_	
87-3	18271-18273	to	_	
87-4	18274-18281	promote	_	
87-5	18282-18292	abstinence	_	
87-6	18293-18295	by	_	
87-7	18296-18304	teaching	_	
87-8	18305-18308	and	_	
87-9	18309-18318	promoting	_	
87-10	18319-18327	practice	_	
87-11	18328-18330	of	_	
87-12	18331-18341	behavioral	_	
87-13	18342-18345	and	_	
87-14	18346-18355	cognitive	_	
87-15	18356-18363	control	_	
87-16	18364-18374	strategies	_	
87-17	18375-18376	(	_	
87-18	18376-18379	e.g	_	
87-19	18379-18380	.	_	
87-20	18380-18381	,	_	
87-21	18382-18388	coping	_	
87-22	18389-18393	with	_	
87-23	18394-18401	craving	_	
87-24	18401-18402	,	_	
87-25	18403-18412	improving	_	
87-26	18413-18421	decision	_	
87-27	18422-18428	making	_	
87-28	18429-18435	skills	_	
87-29	18435-18436	)	_	
87-30	18436-18437	.	_	

#Text=CBT homework, assigned at each session, offers the opportunity to practice applying the skills discussed in CBT sessions.
88-1	18438-18441	CBT	_	
88-2	18442-18450	homework	_	
88-3	18450-18451	,	_	
88-4	18452-18460	assigned	_	
88-5	18461-18463	at	_	
88-6	18464-18468	each	_	
88-7	18469-18476	session	_	
88-8	18476-18477	,	_	
88-9	18478-18484	offers	_	
88-10	18485-18488	the	_	
88-11	18489-18500	opportunity	_	
88-12	18501-18503	to	_	
88-13	18504-18512	practice	_	
88-14	18513-18521	applying	_	
88-15	18522-18525	the	_	
88-16	18526-18532	skills	_	
88-17	18533-18542	discussed	_	
88-18	18543-18545	in	_	
88-19	18546-18549	CBT	_	
88-20	18550-18558	sessions	_	
88-21	18558-18559	.	_	

#Text=Contingency Management (CM)
#Text=All participants were randomly assigned to receive contingency management (CM group) or not (no-CM group).
89-1	18560-18571	Contingency	_	
89-2	18572-18582	Management	_	
89-3	18583-18584	(	_	
89-4	18584-18586	CM	_	
89-5	18586-18587	)	_	
89-6	18588-18591	All	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
89-7	18592-18604	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
89-8	18605-18609	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
89-9	18610-18618	randomly	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
89-10	18619-18627	assigned	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
89-11	18628-18630	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
89-12	18631-18638	receive	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
89-13	18639-18650	contingency	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
89-14	18651-18661	management	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
89-15	18662-18663	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
89-16	18663-18665	CM	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
89-17	18666-18671	group	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
89-18	18671-18672	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
89-19	18673-18675	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
89-20	18676-18679	not	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
89-21	18680-18681	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
89-22	18681-18686	no-CM	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
89-23	18687-18692	group	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
89-24	18692-18693	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
89-25	18693-18694	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	

#Text=Those assigned to CM could draw at least one prize chance from a bowl each time they demonstrated abstinence (submitted a cocaine-free urine specimen) or pill adherence (staff witnessed ingestion of study capsule).
90-1	18695-18700	Those	_	
90-2	18701-18709	assigned	_	
90-3	18710-18712	to	_	
90-4	18713-18715	CM	_	
90-5	18716-18721	could	_	
90-6	18722-18726	draw	_	
90-7	18727-18729	at	_	
90-8	18730-18735	least	_	
90-9	18736-18739	one	_	
90-10	18740-18745	prize	_	
90-11	18746-18752	chance	_	
90-12	18753-18757	from	_	
90-13	18758-18759	a	_	
90-14	18760-18764	bowl	_	
90-15	18765-18769	each	_	
90-16	18770-18774	time	_	
90-17	18775-18779	they	_	
90-18	18780-18792	demonstrated	_	
90-19	18793-18803	abstinence	_	
90-20	18804-18805	(	_	
90-21	18805-18814	submitted	_	
90-22	18815-18816	a	_	
90-23	18817-18829	cocaine-free	_	
90-24	18830-18835	urine	_	
90-25	18836-18844	specimen	_	
90-26	18844-18845	)	_	
90-27	18846-18848	or	_	
90-28	18849-18853	pill	_	
90-29	18854-18863	adherence	_	
90-30	18864-18865	(	_	
90-31	18865-18870	staff	_	
90-32	18871-18880	witnessed	_	
90-33	18881-18890	ingestion	_	
90-34	18891-18893	of	_	
90-35	18894-18899	study	_	
90-36	18900-18907	capsule	_	
90-37	18907-18908	)	_	
90-38	18908-18909	.	_	

#Text=Consistent with previously established procedures, the number of CM draws per reinforced behavior (abstinence, pill adherence) escalated (up to a maximum of 7 draws) with each consecutive demonstration of abstinence or adherence.
91-1	18910-18920	Consistent	_	
91-2	18921-18925	with	_	
91-3	18926-18936	previously	_	
91-4	18937-18948	established	_	
91-5	18949-18959	procedures	_	
91-6	18959-18960	,	_	
91-7	18961-18964	the	_	
91-8	18965-18971	number	_	
91-9	18972-18974	of	_	
91-10	18975-18977	CM	_	
91-11	18978-18983	draws	_	
91-12	18984-18987	per	_	
91-13	18988-18998	reinforced	_	
91-14	18999-19007	behavior	_	
91-15	19008-19009	(	_	
91-16	19009-19019	abstinence	_	
91-17	19019-19020	,	_	
91-18	19021-19025	pill	_	
91-19	19026-19035	adherence	_	
91-20	19035-19036	)	_	
91-21	19037-19046	escalated	_	
91-22	19047-19048	(	_	
91-23	19048-19050	up	_	
91-24	19051-19053	to	_	
91-25	19054-19055	a	_	
91-26	19056-19063	maximum	_	
91-27	19064-19066	of	_	
91-28	19067-19068	7	_	
91-29	19069-19074	draws	_	
91-30	19074-19075	)	_	
91-31	19076-19080	with	_	
91-32	19081-19085	each	_	
91-33	19086-19097	consecutive	_	
91-34	19098-19111	demonstration	_	
91-35	19112-19114	of	_	
91-36	19115-19125	abstinence	_	
91-37	19126-19128	or	_	
91-38	19129-19138	adherence	_	
91-39	19138-19139	.	_	

#Text=If patients missed a scheduled visit or failed to submit a cocaine-negative urine, the number of prize draws for subsequent reinforced behaviors would drop back down to one (for CM methods details, see Supplementary Methods and.
92-1	19140-19142	If	_	
92-2	19143-19151	patients	_	
92-3	19152-19158	missed	_	
92-4	19159-19160	a	_	
92-5	19161-19170	scheduled	_	
92-6	19171-19176	visit	_	
92-7	19177-19179	or	_	
92-8	19180-19186	failed	_	
92-9	19187-19189	to	_	
92-10	19190-19196	submit	_	
92-11	19197-19198	a	_	
92-12	19199-19215	cocaine-negative	_	
92-13	19216-19221	urine	_	
92-14	19221-19222	,	_	
92-15	19223-19226	the	_	
92-16	19227-19233	number	_	
92-17	19234-19236	of	_	
92-18	19237-19242	prize	_	
92-19	19243-19248	draws	_	
92-20	19249-19252	for	_	
92-21	19253-19263	subsequent	_	
92-22	19264-19274	reinforced	_	
92-23	19275-19284	behaviors	_	
92-24	19285-19290	would	_	
92-25	19291-19295	drop	_	
92-26	19296-19300	back	_	
92-27	19301-19305	down	_	
92-28	19306-19308	to	_	
92-29	19309-19312	one	_	
92-30	19313-19314	(	_	
92-31	19314-19317	for	_	
92-32	19318-19320	CM	_	
92-33	19321-19328	methods	_	
92-34	19329-19336	details	_	
92-35	19336-19337	,	_	
92-36	19338-19341	see	_	
92-37	19342-19355	Supplementary	_	
92-38	19356-19363	Methods	_	
92-39	19364-19367	and	_	
92-40	19367-19368	.	_	

#Text=The primary process indicator for exposure to CM in these analyses was the sum of total prizes drawn across treatment (‘number of CM prizes’; Table 1).
93-1	19369-19372	The	_	
93-2	19373-19380	primary	_	
93-3	19381-19388	process	_	
93-4	19389-19398	indicator	_	
93-5	19399-19402	for	_	
93-6	19403-19411	exposure	_	
93-7	19412-19414	to	_	
93-8	19415-19417	CM	_	
93-9	19418-19420	in	_	
93-10	19421-19426	these	_	
93-11	19427-19435	analyses	_	
93-12	19436-19439	was	_	
93-13	19440-19443	the	_	
93-14	19444-19447	sum	_	
93-15	19448-19450	of	_	
93-16	19451-19456	total	_	
93-17	19457-19463	prizes	_	
93-18	19464-19469	drawn	_	
93-19	19470-19476	across	_	
93-20	19477-19486	treatment	_	
93-21	19487-19488	(	_	
93-22	19488-19489	‘	_	
93-23	19489-19495	number	_	
93-24	19496-19498	of	_	
93-25	19499-19501	CM	_	
93-26	19502-19508	prizes	_	
93-27	19508-19509	’	_	
93-28	19509-19510	;	_	
93-29	19511-19516	Table	_	
93-30	19517-19518	1	_	
93-31	19518-19519	)	_	
93-32	19519-19520	.	_	

#Text=Disulfiram
#Text=All participants were randomly assigned to either disulfiram (250 mg daily) or identical placebo capsules, administered in a double-blind manner.
94-1	19521-19531	Disulfiram	_	
94-2	19532-19535	All	_	
94-3	19536-19548	participants	_	
94-4	19549-19553	were	_	
94-5	19554-19562	randomly	_	
94-6	19563-19571	assigned	_	
94-7	19572-19574	to	_	
94-8	19575-19581	either	_	
94-9	19582-19592	disulfiram	_	
94-10	19593-19594	(	_	
94-11	19594-19597	250	_	
94-12	19598-19600	mg	_	
94-13	19601-19606	daily	_	
94-14	19606-19607	)	_	
94-15	19608-19610	or	_	
94-16	19611-19620	identical	_	
94-17	19621-19628	placebo	_	
94-18	19629-19637	capsules	_	
94-19	19637-19638	,	_	
94-20	19639-19651	administered	_	
94-21	19652-19654	in	_	
94-22	19655-19656	a	_	
94-23	19657-19669	double-blind	_	
94-24	19670-19676	manner	_	
94-25	19676-19677	.	_	

#Text=This disulfiram dose was associated with reduced cocaine use in previous trials.
95-1	19678-19682	This	_	
95-2	19683-19693	disulfiram	_	
95-3	19694-19698	dose	_	
95-4	19699-19702	was	_	
95-5	19703-19713	associated	_	
95-6	19714-19718	with	_	
95-7	19719-19726	reduced	_	
95-8	19727-19734	cocaine	_	
95-9	19735-19738	use	_	
95-10	19739-19741	in	_	
95-11	19742-19750	previous	_	
95-12	19751-19757	trials	_	
95-13	19757-19758	.	_	

#Text=Medication or placebo pill adherence was tracked by observed medication administration at thrice-weekly visits, plus patient self-report for take-home doses.
96-1	19759-19769	Medication	_	
96-2	19770-19772	or	_	
96-3	19773-19780	placebo	_	
96-4	19781-19785	pill	_	
96-5	19786-19795	adherence	_	
96-6	19796-19799	was	_	
96-7	19800-19807	tracked	_	
96-8	19808-19810	by	_	
96-9	19811-19819	observed	_	
96-10	19820-19830	medication	_	
96-11	19831-19845	administration	_	
96-12	19846-19848	at	_	
96-13	19849-19862	thrice-weekly	_	
96-14	19863-19869	visits	_	
96-15	19869-19870	,	_	
96-16	19871-19875	plus	_	
96-17	19876-19883	patient	_	
96-18	19884-19895	self-report	_	
96-19	19896-19899	for	_	
96-20	19900-19909	take-home	_	
96-21	19910-19915	doses	_	
96-22	19915-19916	.	_	

#Text=This combination of observed and self-reported adherence was used as the primary process indicator (‘days of medication’; Table 1) for disulfiram treatment within the group randomized to disulfiram.
97-1	19917-19921	This	_	
97-2	19922-19933	combination	_	
97-3	19934-19936	of	_	
97-4	19937-19945	observed	_	
97-5	19946-19949	and	_	
97-6	19950-19963	self-reported	_	
97-7	19964-19973	adherence	_	
97-8	19974-19977	was	_	
97-9	19978-19982	used	_	
97-10	19983-19985	as	_	
97-11	19986-19989	the	_	
97-12	19990-19997	primary	_	
97-13	19998-20005	process	_	
97-14	20006-20015	indicator	_	
97-15	20016-20017	(	_	
97-16	20017-20018	‘	_	
97-17	20018-20022	days	_	
97-18	20023-20025	of	_	
97-19	20026-20036	medication	_	
97-20	20036-20037	’	_	
97-21	20037-20038	;	_	
97-22	20039-20044	Table	_	
97-23	20045-20046	1	_	
97-24	20046-20047	)	_	
97-25	20048-20051	for	_	
97-26	20052-20062	disulfiram	_	
97-27	20063-20072	treatment	_	
97-28	20073-20079	within	_	
97-29	20080-20083	the	_	
97-30	20084-20089	group	_	
97-31	20090-20100	randomized	_	
97-32	20101-20103	to	_	
97-33	20104-20114	disulfiram	_	
97-34	20114-20115	.	_	

#Text=A riboflavin tracer in the pills indicated high consistency with self-report.
98-1	20116-20117	A	_	
98-2	20118-20128	riboflavin	_	
98-3	20129-20135	tracer	_	
98-4	20136-20138	in	_	
98-5	20139-20142	the	_	
98-6	20143-20148	pills	_	
98-7	20149-20158	indicated	_	
98-8	20159-20163	high	_	
98-9	20164-20175	consistency	_	
98-10	20176-20180	with	_	
98-11	20181-20192	self-report	_	
98-12	20192-20193	.	_	

#Text=All participants were warned of negative consequences of drinking alcohol on disulfiram, strongly discouraged from drinking alcohol during the study, and told that their capsules would be withheld if their breath samples tested positive for alcohol.
99-1	20194-20197	All	_	
99-2	20198-20210	participants	_	
99-3	20211-20215	were	_	
99-4	20216-20222	warned	_	
99-5	20223-20225	of	_	
99-6	20226-20234	negative	_	
99-7	20235-20247	consequences	_	
99-8	20248-20250	of	_	
99-9	20251-20259	drinking	_	
99-10	20260-20267	alcohol	_	
99-11	20268-20270	on	_	
99-12	20271-20281	disulfiram	_	
99-13	20281-20282	,	_	
99-14	20283-20291	strongly	_	
99-15	20292-20303	discouraged	_	
99-16	20304-20308	from	_	
99-17	20309-20317	drinking	_	
99-18	20318-20325	alcohol	_	
99-19	20326-20332	during	_	
99-20	20333-20336	the	_	
99-21	20337-20342	study	_	
99-22	20342-20343	,	_	
99-23	20344-20347	and	_	
99-24	20348-20352	told	_	
99-25	20353-20357	that	_	
99-26	20358-20363	their	_	
99-27	20364-20372	capsules	_	
99-28	20373-20378	would	_	
99-29	20379-20381	be	_	
99-30	20382-20390	withheld	_	
99-31	20391-20393	if	_	
99-32	20394-20399	their	_	
99-33	20400-20406	breath	_	
99-34	20407-20414	samples	_	
99-35	20415-20421	tested	_	
99-36	20422-20430	positive	_	
99-37	20431-20434	for	_	
99-38	20435-20442	alcohol	_	
99-39	20442-20443	.	_	

#Text=Substance-use assessments
#Text=Baseline assessments included the Addiction Severity Index (ASI.
100-1	20444-20457	Substance-use	_	
100-2	20458-20469	assessments	_	
100-3	20470-20478	Baseline	_	
100-4	20479-20490	assessments	_	
100-5	20491-20499	included	_	
100-6	20500-20503	the	_	
100-7	20504-20513	Addiction	_	
100-8	20514-20522	Severity	_	
100-9	20523-20528	Index	_	
100-10	20529-20530	(	_	
100-11	20530-20533	ASI	_	
100-12	20533-20534	.	_	

#Text=Thrice weekly during treatment, participants were assessed with urine toxicology and alcohol-breath screens, had study capsules dispensed (disulfiram or placebo) and clinical symptoms monitored.
101-1	20535-20541	Thrice	_	
101-2	20542-20548	weekly	_	
101-3	20549-20555	during	_	
101-4	20556-20565	treatment	_	
101-5	20565-20566	,	_	
101-6	20567-20579	participants	_	
101-7	20580-20584	were	_	
101-8	20585-20593	assessed	_	
101-9	20594-20598	with	_	
101-10	20599-20604	urine	_	
101-11	20605-20615	toxicology	_	
101-12	20616-20619	and	_	
101-13	20620-20634	alcohol-breath	_	
101-14	20635-20642	screens	_	
101-15	20642-20643	,	_	
101-16	20644-20647	had	_	
101-17	20648-20653	study	_	
101-18	20654-20662	capsules	_	
101-19	20663-20672	dispensed	_	
101-20	20673-20674	(	_	
101-21	20674-20684	disulfiram	_	
101-22	20685-20687	or	_	
101-23	20688-20695	placebo	_	
101-24	20695-20696	)	_	
101-25	20697-20700	and	_	
101-26	20701-20709	clinical	_	
101-27	20710-20718	symptoms	_	
101-28	20719-20728	monitored	_	
101-29	20728-20729	.	_	

#Text=Self-reports of day-by-day use of cocaine, alcohol, and other drugs were collected weekly during treatment, using the Timeline Followback method.
102-1	20730-20742	Self-reports	_	
102-2	20743-20745	of	_	
102-3	20746-20756	day-by-day	_	
102-4	20757-20760	use	_	
102-5	20761-20763	of	_	
102-6	20764-20771	cocaine	_	
102-7	20771-20772	,	_	
102-8	20773-20780	alcohol	_	
102-9	20780-20781	,	_	
102-10	20782-20785	and	_	
102-11	20786-20791	other	_	
102-12	20792-20797	drugs	_	
102-13	20798-20802	were	_	
102-14	20803-20812	collected	_	
102-15	20813-20819	weekly	_	
102-16	20820-20826	during	_	
102-17	20827-20836	treatment	_	
102-18	20836-20837	,	_	
102-19	20838-20843	using	_	
102-20	20844-20847	the	_	
102-21	20848-20856	Timeline	_	
102-22	20857-20867	Followback	_	
102-23	20868-20874	method	_	
102-24	20874-20875	.	_	

#Text=When sessions were missed or the participant did not complete treatment, self-report data were collected for the missed data-collection days at subsequent sessions.
103-1	20876-20880	When	_	
103-2	20881-20889	sessions	_	
103-3	20890-20894	were	_	
103-4	20895-20901	missed	_	
103-5	20902-20904	or	_	
103-6	20905-20908	the	_	
103-7	20909-20920	participant	_	
103-8	20921-20924	did	_	
103-9	20925-20928	not	_	
103-10	20929-20937	complete	_	
103-11	20938-20947	treatment	_	
103-12	20947-20948	,	_	
103-13	20949-20960	self-report	_	
103-14	20961-20965	data	_	
103-15	20966-20970	were	_	
103-16	20971-20980	collected	_	
103-17	20981-20984	for	_	
103-18	20985-20988	the	_	
103-19	20989-20995	missed	_	
103-20	20996-21011	data-collection	_	
103-21	21012-21016	days	_	
103-22	21017-21019	at	_	
103-23	21020-21030	subsequent	_	
103-24	21031-21039	sessions	_	
103-25	21039-21040	.	_	

#Text=Adverse events and blood pressure were tracked weekly during treatment.
104-1	21041-21048	Adverse	_	
104-2	21049-21055	events	_	
104-3	21056-21059	and	_	
104-4	21060-21065	blood	_	
104-5	21066-21074	pressure	_	
104-6	21075-21079	were	_	
104-7	21080-21087	tracked	_	
104-8	21088-21094	weekly	_	
104-9	21095-21101	during	_	
104-10	21102-21111	treatment	_	
104-11	21111-21112	.	_	

#Text=Consistent with our prior work, primary clinical outcome variables were percent of cocaine-negative urines and self-reported days of abstinence during treatment.
105-1	21113-21123	Consistent	_	
105-2	21124-21128	with	_	
105-3	21129-21132	our	_	
105-4	21133-21138	prior	_	
105-5	21139-21143	work	_	
105-6	21143-21144	,	_	
105-7	21145-21152	primary	_	
105-8	21153-21161	clinical	_	
105-9	21162-21169	outcome	_	
105-10	21170-21179	variables	_	
105-11	21180-21184	were	_	
105-12	21185-21192	percent	_	
105-13	21193-21195	of	_	
105-14	21196-21212	cocaine-negative	_	
105-15	21213-21219	urines	_	
105-16	21220-21223	and	_	
105-17	21224-21237	self-reported	_	
105-18	21238-21242	days	_	
105-19	21243-21245	of	_	
105-20	21246-21256	abstinence	_	
105-21	21257-21263	during	_	
105-22	21264-21273	treatment	_	
105-23	21273-21274	.	_	

#Text=Clinical Data Analyses
#Text=Indicators of cocaine use within-treatment were assessed with ANOVAs including medication (disulfiram, placebo) and CM (CM, no-CM) as between-subject factors (see Table 2).
106-1	21275-21283	Clinical	_	
106-2	21284-21288	Data	_	
106-3	21289-21297	Analyses	_	
106-4	21298-21308	Indicators	_	
106-5	21309-21311	of	_	
106-6	21312-21319	cocaine	_	
106-7	21320-21323	use	_	
106-8	21324-21340	within-treatment	_	
106-9	21341-21345	were	_	
106-10	21346-21354	assessed	_	
106-11	21355-21359	with	_	
106-12	21360-21366	ANOVAs	_	
106-13	21367-21376	including	_	
106-14	21377-21387	medication	_	
106-15	21388-21389	(	_	
106-16	21389-21399	disulfiram	_	
106-17	21399-21400	,	_	
106-18	21401-21408	placebo	_	
106-19	21408-21409	)	_	
106-20	21410-21413	and	_	
106-21	21414-21416	CM	_	
106-22	21417-21418	(	_	
106-23	21418-21420	CM	_	
106-24	21420-21421	,	_	
106-25	21422-21427	no-CM	_	
106-26	21427-21428	)	_	
106-27	21429-21431	as	_	
106-28	21432-21447	between-subject	_	
106-29	21448-21455	factors	_	
106-30	21456-21457	(	_	
106-31	21457-21460	see	_	
106-32	21461-21466	Table	_	
106-33	21467-21468	2	_	
106-34	21468-21469	)	_	
106-35	21469-21470	.	_	

#Text=Clinical outcomes for the parent RCT sample are reported elsewhere.
107-1	21471-21479	Clinical	_	
107-2	21480-21488	outcomes	_	
107-3	21489-21492	for	_	
107-4	21493-21496	the	_	
107-5	21497-21503	parent	_	
107-6	21504-21507	RCT	_	
107-7	21508-21514	sample	_	
107-8	21515-21518	are	_	
107-9	21519-21527	reported	_	
107-10	21528-21537	elsewhere	_	
107-11	21537-21538	.	_	

#Text=Briefly, there were consistent effects favoring CM over no-CM, with mixed findings for disulfiram.
#Text=fMRI Methods
#Text=Participants were administered a measure of cognitive-control, the event-related fMRI Color-Word Stroop task, on two occasions: prior to or in the beginning-of-treatment (days between start of study treatment and ‘beginning-of-treatment’ scan: M=3 days, SD=5, range= 6 days prior to treatment start −12 days into treatment) and following the end of the 12-week treatment (i.e., post-treatment and prior to 3-month follow-up (days between end of treatment and post-treatment scan: M=20 days, SD=20, range=1–61 days).
108-1	21539-21546	Briefly	_	
108-2	21546-21547	,	_	
108-3	21548-21553	there	_	
108-4	21554-21558	were	_	
108-5	21559-21569	consistent	_	
108-6	21570-21577	effects	_	
108-7	21578-21586	favoring	_	
108-8	21587-21589	CM	_	
108-9	21590-21594	over	_	
108-10	21595-21600	no-CM	_	
108-11	21600-21601	,	_	
108-12	21602-21606	with	_	
108-13	21607-21612	mixed	_	
108-14	21613-21621	findings	_	
108-15	21622-21625	for	_	
108-16	21626-21636	disulfiram	_	
108-17	21636-21637	.	_	
108-18	21638-21642	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging	
108-19	21643-21650	Methods	_	
108-20	21651-21663	Participants	_	
108-21	21664-21668	were	_	
108-22	21669-21681	administered	_	
108-23	21682-21683	a	_	
108-24	21684-21691	measure	_	
108-25	21692-21694	of	_	
108-26	21695-21712	cognitive-control	_	
108-27	21712-21713	,	_	
108-28	21714-21717	the	_	
108-29	21718-21731	event-related	_	
108-30	21732-21736	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging	
108-31	21737-21747	Color-Word	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[20]	
108-32	21748-21754	Stroop	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[20]	
108-33	21755-21759	task	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[20]	
108-34	21759-21760	,	_	
108-35	21761-21763	on	_	
108-36	21764-21767	two	_	
108-37	21768-21777	occasions	_	
108-38	21777-21778	:	_	
108-39	21779-21784	prior	_	
108-40	21785-21787	to	_	
108-41	21788-21790	or	_	
108-42	21791-21793	in	_	
108-43	21794-21797	the	_	
108-44	21798-21820	beginning-of-treatment	_	
108-45	21821-21822	(	_	
108-46	21822-21826	days	_	
108-47	21827-21834	between	_	
108-48	21835-21840	start	_	
108-49	21841-21843	of	_	
108-50	21844-21849	study	_	
108-51	21850-21859	treatment	_	
108-52	21860-21863	and	_	
108-53	21864-21865	‘	_	
108-54	21865-21887	beginning-of-treatment	_	
108-55	21887-21888	’	_	
108-56	21889-21893	scan	_	
108-57	21893-21894	:	_	
108-58	21895-21896	M	_	
108-59	21896-21897	=	_	
108-60	21897-21898	3	_	
108-61	21899-21903	days	_	
108-62	21903-21904	,	_	
108-63	21905-21907	SD	_	
108-64	21907-21908	=	_	
108-65	21908-21909	5	_	
108-66	21909-21910	,	_	
108-67	21911-21916	range	_	
108-68	21916-21917	=	_	
108-69	21918-21919	6	_	
108-70	21920-21924	days	_	
108-71	21925-21930	prior	_	
108-72	21931-21933	to	_	
108-73	21934-21943	treatment	_	
108-74	21944-21949	start	_	
108-75	21950-21951	−	_	
108-76	21951-21953	12	_	
108-77	21954-21958	days	_	
108-78	21959-21963	into	_	
108-79	21964-21973	treatment	_	
108-80	21973-21974	)	_	
108-81	21975-21978	and	_	
108-82	21979-21988	following	_	
108-83	21989-21992	the	_	
108-84	21993-21996	end	_	
108-85	21997-21999	of	_	
108-86	22000-22003	the	_	
108-87	22004-22006	12	_	
108-88	22006-22007	-	_	
108-89	22007-22011	week	_	
108-90	22012-22021	treatment	_	
108-91	22022-22023	(	_	
108-92	22023-22026	i.e	_	
108-93	22026-22027	.	_	
108-94	22027-22028	,	_	
108-95	22029-22043	post-treatment	_	
108-96	22044-22047	and	_	
108-97	22048-22053	prior	_	
108-98	22054-22056	to	_	
108-99	22057-22058	3	_	
108-100	22058-22059	-	_	
108-101	22059-22064	month	_	
108-102	22065-22074	follow-up	_	
108-103	22075-22076	(	_	
108-104	22076-22080	days	_	
108-105	22081-22088	between	_	
108-106	22089-22092	end	_	
108-107	22093-22095	of	_	
108-108	22096-22105	treatment	_	
108-109	22106-22109	and	_	
108-110	22110-22124	post-treatment	_	
108-111	22125-22129	scan	_	
108-112	22129-22130	:	_	
108-113	22131-22132	M	_	
108-114	22132-22133	=	_	
108-115	22133-22135	20	_	
108-116	22136-22140	days	_	
108-117	22140-22141	,	_	
108-118	22142-22144	SD	_	
108-119	22144-22145	=	_	
108-120	22145-22147	20	_	
108-121	22147-22148	,	_	
108-122	22149-22154	range	_	
108-123	22154-22155	=	_	
108-124	22155-22156	1	_	
108-125	22156-22157	–	_	
108-126	22157-22159	61	_	
108-127	22160-22164	days	_	
108-128	22164-22165	)	_	
108-129	22165-22166	.	_	

#Text=On each trial, participants were asked to name the ink color of color-words presented in congruent (e.g., “RED” in red ink) or incongruent colors (e.g., “RED” in blue ink; see Supplemental Methods for task details).
109-1	22167-22169	On	_	
109-2	22170-22174	each	_	
109-3	22175-22180	trial	_	
109-4	22180-22181	,	_	
109-5	22182-22194	participants	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[21]	
109-6	22195-22199	were	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[21]	
109-7	22200-22205	asked	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[21]	
109-8	22206-22208	to	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[21]	
109-9	22209-22213	name	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[21]	
109-10	22214-22217	the	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[21]	
109-11	22218-22221	ink	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[21]	
109-12	22222-22227	color	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[21]	
109-13	22228-22230	of	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[21]	
109-14	22231-22242	color-words	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[21]	
109-15	22243-22252	presented	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[21]	
109-16	22253-22255	in	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[21]	
109-17	22256-22265	congruent	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[21]	
109-18	22266-22267	(	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[21]	
109-19	22267-22270	e.g	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[21]	
109-20	22270-22271	.	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[21]	
109-21	22271-22272	,	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[21]	
109-22	22273-22274	“	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[21]	
109-23	22274-22277	RED	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[21]	
109-24	22277-22278	”	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[21]	
109-25	22279-22281	in	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[21]	
109-26	22282-22285	red	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[21]	
109-27	22286-22289	ink	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[21]	
109-28	22289-22290	)	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[21]	
109-29	22291-22293	or	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[21]	
109-30	22294-22305	incongruent	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[21]	
109-31	22306-22312	colors	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[21]	
109-32	22313-22314	(	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[21]	
109-33	22314-22317	e.g	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[21]	
109-34	22317-22318	.	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[21]	
109-35	22318-22319	,	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[21]	
109-36	22320-22321	“	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[21]	
109-37	22321-22324	RED	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[21]	
109-38	22324-22325	”	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[21]	
109-39	22326-22328	in	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[21]	
109-40	22329-22333	blue	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[21]	
109-41	22334-22337	ink	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[21]	
109-42	22337-22338	;	_	
109-43	22339-22342	see	_	
109-44	22343-22355	Supplemental	_	
109-45	22356-22363	Methods	_	
109-46	22364-22367	for	_	
109-47	22368-22372	task	_	
109-48	22373-22380	details	_	
109-49	22380-22381	)	_	
109-50	22381-22382	.	_	

#Text=Stroop mean response times, collected out-of-scanner at time of scanning, were analyzed in SPSS with mixed model ANOVAs including session (beginning-of-treatment, post-treatment) and trial type (incongruent, congruent) as within-subject factors and medication (disulfiram, placebo) and CM (CM, no-CM) conditions as between-subject factors.
110-1	22383-22389	Stroop	_	
110-2	22390-22394	mean	_	
110-3	22395-22403	response	_	
110-4	22404-22409	times	_	
110-5	22409-22410	,	_	
110-6	22411-22420	collected	_	
110-7	22421-22435	out-of-scanner	_	
110-8	22436-22438	at	_	
110-9	22439-22443	time	_	
110-10	22444-22446	of	_	
110-11	22447-22455	scanning	_	
110-12	22455-22456	,	_	
110-13	22457-22461	were	_	
110-14	22462-22470	analyzed	_	
110-15	22471-22473	in	_	
110-16	22474-22478	SPSS	_	
110-17	22479-22483	with	_	
110-18	22484-22489	mixed	_	
110-19	22490-22495	model	_	
110-20	22496-22502	ANOVAs	_	
110-21	22503-22512	including	_	
110-22	22513-22520	session	_	
110-23	22521-22522	(	_	
110-24	22522-22544	beginning-of-treatment	_	
110-25	22544-22545	,	_	
110-26	22546-22560	post-treatment	_	
110-27	22560-22561	)	_	
110-28	22562-22565	and	_	
110-29	22566-22571	trial	_	
110-30	22572-22576	type	_	
110-31	22577-22578	(	_	
110-32	22578-22589	incongruent	_	
110-33	22589-22590	,	_	
110-34	22591-22600	congruent	_	
110-35	22600-22601	)	_	
110-36	22602-22604	as	_	
110-37	22605-22619	within-subject	_	
110-38	22620-22627	factors	_	
110-39	22628-22631	and	_	
110-40	22632-22642	medication	_	
110-41	22643-22644	(	_	
110-42	22644-22654	disulfiram	_	
110-43	22654-22655	,	_	
110-44	22656-22663	placebo	_	
110-45	22663-22664	)	_	
110-46	22665-22668	and	_	
110-47	22669-22671	CM	_	
110-48	22672-22673	(	_	
110-49	22673-22675	CM	_	
110-50	22675-22676	,	_	
110-51	22677-22682	no-CM	_	
110-52	22682-22683	)	_	
110-53	22684-22694	conditions	_	
110-54	22695-22697	as	_	
110-55	22698-22713	between-subject	_	
110-56	22714-22721	factors	_	
110-57	22721-22722	.	_	

#Text=Stroop errors on incongruent trials were analyzed with mixed-model ANOVAs including session as a within-subject factor and medication and CM conditions as between-subject factors.
#Text=fMRI data acquisition and pre-processing steps were consistent with our prior work (e.g.,; see Supplemental Methods for details).
111-1	22723-22729	Stroop	_	
111-2	22730-22736	errors	_	
111-3	22737-22739	on	_	
111-4	22740-22751	incongruent	_	
111-5	22752-22758	trials	_	
111-6	22759-22763	were	_	
111-7	22764-22772	analyzed	_	
111-8	22773-22777	with	_	
111-9	22778-22789	mixed-model	_	
111-10	22790-22796	ANOVAs	_	
111-11	22797-22806	including	_	
111-12	22807-22814	session	_	
111-13	22815-22817	as	_	
111-14	22818-22819	a	_	
111-15	22820-22834	within-subject	_	
111-16	22835-22841	factor	_	
111-17	22842-22845	and	_	
111-18	22846-22856	medication	_	
111-19	22857-22860	and	_	
111-20	22861-22863	CM	_	
111-21	22864-22874	conditions	_	
111-22	22875-22877	as	_	
111-23	22878-22893	between-subject	_	
111-24	22894-22901	factors	_	
111-25	22901-22902	.	_	
111-26	22903-22907	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging	
111-27	22908-22912	data	_	
111-28	22913-22924	acquisition	_	
111-29	22925-22928	and	_	
111-30	22929-22943	pre-processing	_	
111-31	22944-22949	steps	_	
111-32	22950-22954	were	_	
111-33	22955-22965	consistent	_	
111-34	22966-22970	with	_	
111-35	22971-22974	our	_	
111-36	22975-22980	prior	_	
111-37	22981-22985	work	_	
111-38	22986-22987	(	_	
111-39	22987-22990	e.g	_	
111-40	22990-22991	.	_	
111-41	22991-22992	,	_	
111-42	22992-22993	;	_	
111-43	22994-22997	see	_	
111-44	22998-23010	Supplemental	_	
111-45	23011-23018	Methods	_	
111-46	23019-23022	for	_	
111-47	23023-23030	details	_	
111-48	23030-23031	)	_	
111-49	23031-23032	.	_	

#Text=For second-level random-effects analyses, the contrast of interest was the ‘change in Stroop-effect’ calculated as [(Incongruentpost>Congruentpost)>(Incongruentpre>Congruentpre)], which assessed changes in Stroop-effect-related activity at post-treatment versus beginning-of-treatment. fMRI results were family-wise-error-corrected at two-tailed pFWE<0.05.
112-1	23033-23036	For	_	
112-2	23037-23049	second-level	_	
112-3	23050-23064	random-effects	_	
112-4	23065-23073	analyses	_	
112-5	23073-23074	,	_	
112-6	23075-23078	the	_	
112-7	23079-23087	contrast	_	
112-8	23088-23090	of	_	
112-9	23091-23099	interest	_	
112-10	23100-23103	was	_	
112-11	23104-23107	the	_	
112-12	23108-23109	‘	_	
112-13	23109-23115	change	_	
112-14	23116-23118	in	_	
112-15	23119-23132	Stroop-effect	_	
112-16	23132-23133	’	_	
112-17	23134-23144	calculated	_	
112-18	23145-23147	as	_	
112-19	23148-23149	[	_	
112-20	23149-23150	(	_	
112-21	23150-23165	Incongruentpost	_	
112-22	23165-23166	>	_	
112-23	23166-23179	Congruentpost	_	
112-24	23179-23180	)	_	
112-25	23180-23181	>	_	
112-26	23181-23182	(	_	
112-27	23182-23196	Incongruentpre	_	
112-28	23196-23197	>	_	
112-29	23197-23209	Congruentpre	_	
112-30	23209-23210	)	_	
112-31	23210-23211	]	_	
112-32	23211-23212	,	_	
112-33	23213-23218	which	_	
112-34	23219-23227	assessed	_	
112-35	23228-23235	changes	_	
112-36	23236-23238	in	_	
112-37	23239-23260	Stroop-effect-related	_	
112-38	23261-23269	activity	_	
112-39	23270-23272	at	_	
112-40	23273-23287	post-treatment	_	
112-41	23288-23294	versus	_	
112-42	23295-23317	beginning-of-treatment	_	
112-43	23317-23318	.	_	
112-44	23319-23323	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging	
112-45	23324-23331	results	_	
112-46	23332-23336	were	_	
112-47	23337-23364	family-wise-error-corrected	_	
112-48	23365-23367	at	_	
112-49	23368-23378	two-tailed	_	
112-50	23379-23383	pFWE	_	
112-51	23383-23384	<	_	
112-52	23384-23388	0.05	_	
112-53	23388-23389	.	_	

#Text=To address the primary research question regarding how neural correlates of cognitive-control change across treatment and how these changes relate to engagement with different treatment components, the following approach was taken.
113-1	23390-23392	To	_	
113-2	23393-23400	address	_	
113-3	23401-23404	the	_	
113-4	23405-23412	primary	_	
113-5	23413-23421	research	_	
113-6	23422-23430	question	_	
113-7	23431-23440	regarding	_	
113-8	23441-23444	how	_	
113-9	23445-23451	neural	_	
113-10	23452-23462	correlates	_	
113-11	23463-23465	of	_	
113-12	23466-23483	cognitive-control	_	
113-13	23484-23490	change	_	
113-14	23491-23497	across	_	
113-15	23498-23507	treatment	_	
113-16	23508-23511	and	_	
113-17	23512-23515	how	_	
113-18	23516-23521	these	_	
113-19	23522-23529	changes	_	
113-20	23530-23536	relate	_	
113-21	23537-23539	to	_	
113-22	23540-23550	engagement	_	
113-23	23551-23555	with	_	
113-24	23556-23565	different	_	
113-25	23566-23575	treatment	_	
113-26	23576-23586	components	_	
113-27	23586-23587	,	_	
113-28	23588-23591	the	_	
113-29	23592-23601	following	_	
113-30	23602-23610	approach	_	
113-31	23611-23614	was	_	
113-32	23615-23620	taken	_	
113-33	23620-23621	.	_	

#Text=First, changes in fMRI Stroop effect were assessed at the whole brain level (Table 3A).
114-1	23622-23627	First	_	
114-2	23627-23628	,	_	
114-3	23629-23636	changes	_	
114-4	23637-23639	in	_	
114-5	23640-23644	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging	
114-6	23645-23651	Stroop	_	
114-7	23652-23658	effect	_	
114-8	23659-23663	were	_	
114-9	23664-23672	assessed	_	
114-10	23673-23675	at	_	
114-11	23676-23679	the	_	
114-12	23680-23685	whole	_	
114-13	23686-23691	brain	_	
114-14	23692-23697	level	_	
114-15	23698-23699	(	_	
114-16	23699-23704	Table	_	
114-17	23705-23707	3A	_	
114-18	23707-23708	)	_	
114-19	23708-23709	.	_	

#Text=Second, separate whole-brain correlation analyses were carried out between the ‘change in Stroop effect’ contrast and the following indicators of treatment engagement: a) CBT sessions (entire sample, N=26); b) CM prizes drawn (subsample randomized to CM, N=14); and c) days of study medication taken (subsample randomized to disulfiram, N=10) (description of variables Table 1; results Table 3B).
115-1	23710-23716	Second	_	
115-2	23716-23717	,	_	
115-3	23718-23726	separate	_	
115-4	23727-23738	whole-brain	_	
115-5	23739-23750	correlation	_	
115-6	23751-23759	analyses	_	
115-7	23760-23764	were	_	
115-8	23765-23772	carried	_	
115-9	23773-23776	out	_	
115-10	23777-23784	between	_	
115-11	23785-23788	the	_	
115-12	23789-23790	‘	_	
115-13	23790-23796	change	_	
115-14	23797-23799	in	_	
115-15	23800-23806	Stroop	_	
115-16	23807-23813	effect	_	
115-17	23813-23814	’	_	
115-18	23815-23823	contrast	_	
115-19	23824-23827	and	_	
115-20	23828-23831	the	_	
115-21	23832-23841	following	_	
115-22	23842-23852	indicators	_	
115-23	23853-23855	of	_	
115-24	23856-23865	treatment	_	
115-25	23866-23876	engagement	_	
115-26	23876-23877	:	_	
115-27	23878-23879	a	_	
115-28	23879-23880	)	_	
115-29	23881-23884	CBT	_	
115-30	23885-23893	sessions	_	
115-31	23894-23895	(	_	
115-32	23895-23901	entire	_	
115-33	23902-23908	sample	_	
115-34	23908-23909	,	_	
115-35	23910-23911	N	_	
115-36	23911-23912	=	_	
115-37	23912-23914	26	_	
115-38	23914-23915	)	_	
115-39	23915-23916	;	_	
115-40	23917-23918	b	_	
115-41	23918-23919	)	_	
115-42	23920-23922	CM	_	
115-43	23923-23929	prizes	_	
115-44	23930-23935	drawn	_	
115-45	23936-23937	(	_	
115-46	23937-23946	subsample	_	
115-47	23947-23957	randomized	_	
115-48	23958-23960	to	_	
115-49	23961-23963	CM	_	
115-50	23963-23964	,	_	
115-51	23965-23966	N	_	
115-52	23966-23967	=	_	
115-53	23967-23969	14	_	
115-54	23969-23970	)	_	
115-55	23970-23971	;	_	
115-56	23972-23975	and	_	
115-57	23976-23977	c	_	
115-58	23977-23978	)	_	
115-59	23979-23983	days	_	
115-60	23984-23986	of	_	
115-61	23987-23992	study	_	
115-62	23993-24003	medication	_	
115-63	24004-24009	taken	_	
115-64	24010-24011	(	_	
115-65	24011-24020	subsample	_	
115-66	24021-24031	randomized	_	
115-67	24032-24034	to	_	
115-68	24035-24045	disulfiram	_	
115-69	24045-24046	,	_	
115-70	24047-24048	N	_	
115-71	24048-24049	=	_	
115-72	24049-24051	10	_	
115-73	24051-24052	)	_	
115-74	24053-24054	(	_	
115-75	24054-24065	description	_	
115-76	24066-24068	of	_	
115-77	24069-24078	variables	_	
115-78	24079-24084	Table	_	
115-79	24085-24086	1	_	
115-80	24086-24087	;	_	
115-81	24088-24095	results	_	
115-82	24096-24101	Table	_	
115-83	24102-24104	3B	_	
115-84	24104-24105	)	_	
115-85	24105-24106	.	_	

#Text=All analyses were familywise error corrected for multiple comparisons (pFWE = .05)
#Text=Since level of cocaine abstinence during treatment could affect ‘change in Stroop-effect’ across treatment, a separate whole-brain correlation was run between the ‘change in Stroop effect’ contrast and cocaine use within-treatment (i.e., percent days self-reported abstinence during treatment; percent cocaine-negative urines during treatment) (Table 3B).
116-1	24107-24110	All	_	
116-2	24111-24119	analyses	_	
116-3	24120-24124	were	_	
116-4	24125-24135	familywise	_	
116-5	24136-24141	error	_	
116-6	24142-24151	corrected	_	
116-7	24152-24155	for	_	
116-8	24156-24164	multiple	_	
116-9	24165-24176	comparisons	_	
116-10	24177-24178	(	_	
116-11	24178-24182	pFWE	_	
116-12	24183-24184	=	_	
116-13	24185-24188	.05	_	
116-14	24188-24189	)	_	
116-15	24190-24195	Since	_	
116-16	24196-24201	level	_	
116-17	24202-24204	of	_	
116-18	24205-24212	cocaine	_	
116-19	24213-24223	abstinence	_	
116-20	24224-24230	during	_	
116-21	24231-24240	treatment	_	
116-22	24241-24246	could	_	
116-23	24247-24253	affect	_	
116-24	24254-24255	‘	_	
116-25	24255-24261	change	_	
116-26	24262-24264	in	_	
116-27	24265-24278	Stroop-effect	_	
116-28	24278-24279	’	_	
116-29	24280-24286	across	_	
116-30	24287-24296	treatment	_	
116-31	24296-24297	,	_	
116-32	24298-24299	a	_	
116-33	24300-24308	separate	_	
116-34	24309-24320	whole-brain	_	
116-35	24321-24332	correlation	_	
116-36	24333-24336	was	_	
116-37	24337-24340	run	_	
116-38	24341-24348	between	_	
116-39	24349-24352	the	_	
116-40	24353-24354	‘	_	
116-41	24354-24360	change	_	
116-42	24361-24363	in	_	
116-43	24364-24370	Stroop	_	
116-44	24371-24377	effect	_	
116-45	24377-24378	’	_	
116-46	24379-24387	contrast	_	
116-47	24388-24391	and	_	
116-48	24392-24399	cocaine	_	
116-49	24400-24403	use	_	
116-50	24404-24420	within-treatment	_	
116-51	24421-24422	(	_	
116-52	24422-24425	i.e	_	
116-53	24425-24426	.	_	
116-54	24426-24427	,	_	
116-55	24428-24435	percent	_	
116-56	24436-24440	days	_	
116-57	24441-24454	self-reported	_	
116-58	24455-24465	abstinence	_	
116-59	24466-24472	during	_	
116-60	24473-24482	treatment	_	
116-61	24482-24483	;	_	
116-62	24484-24491	percent	_	
116-63	24492-24508	cocaine-negative	_	
116-64	24509-24515	urines	_	
116-65	24516-24522	during	_	
116-66	24523-24532	treatment	_	
116-67	24532-24533	)	_	
116-68	24534-24535	(	_	
116-69	24535-24540	Table	_	
116-70	24541-24543	3B	_	
116-71	24543-24544	)	_	
116-72	24544-24545	.	_	

#Text=To check whether the regions associated with engagement in different aspects of treatment overlapped or were simply reflections of the same regions associated with cocaine abstinence during treatment, the separate correlation analyses were entered into formal conjunction analyses (see Supplemental Material for detailed methods).
117-1	24546-24548	To	_	
117-2	24549-24554	check	_	
117-3	24555-24562	whether	_	
117-4	24563-24566	the	_	
117-5	24567-24574	regions	_	
117-6	24575-24585	associated	_	
117-7	24586-24590	with	_	
117-8	24591-24601	engagement	_	
117-9	24602-24604	in	_	
117-10	24605-24614	different	_	
117-11	24615-24622	aspects	_	
117-12	24623-24625	of	_	
117-13	24626-24635	treatment	_	
117-14	24636-24646	overlapped	_	
117-15	24647-24649	or	_	
117-16	24650-24654	were	_	
117-17	24655-24661	simply	_	
117-18	24662-24673	reflections	_	
117-19	24674-24676	of	_	
117-20	24677-24680	the	_	
117-21	24681-24685	same	_	
117-22	24686-24693	regions	_	
117-23	24694-24704	associated	_	
117-24	24705-24709	with	_	
117-25	24710-24717	cocaine	_	
117-26	24718-24728	abstinence	_	
117-27	24729-24735	during	_	
117-28	24736-24745	treatment	_	
117-29	24745-24746	,	_	
117-30	24747-24750	the	_	
117-31	24751-24759	separate	_	
117-32	24760-24771	correlation	_	
117-33	24772-24780	analyses	_	
117-34	24781-24785	were	_	
117-35	24786-24793	entered	_	
117-36	24794-24798	into	_	
117-37	24799-24805	formal	_	
117-38	24806-24817	conjunction	_	
117-39	24818-24826	analyses	_	
117-40	24827-24828	(	_	
117-41	24828-24831	see	_	
117-42	24832-24844	Supplemental	_	
117-43	24845-24853	Material	_	
117-44	24854-24857	for	_	
117-45	24858-24866	detailed	_	
117-46	24867-24874	methods	_	
117-47	24874-24875	)	_	
117-48	24875-24876	.	_	

#Text=For all fMRI correlation analyses, if variables were not normally distributed, rank-order correlations were used as a non-parametric alternative.
118-1	24877-24880	For	_	
118-2	24881-24884	all	_	
118-3	24885-24889	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging	
118-4	24890-24901	correlation	_	
118-5	24902-24910	analyses	_	
118-6	24910-24911	,	_	
118-7	24912-24914	if	_	
118-8	24915-24924	variables	_	
118-9	24925-24929	were	_	
118-10	24930-24933	not	_	
118-11	24934-24942	normally	_	
118-12	24943-24954	distributed	_	
118-13	24954-24955	,	_	
118-14	24956-24966	rank-order	_	
118-15	24967-24979	correlations	_	
118-16	24980-24984	were	_	
118-17	24985-24989	used	_	
118-18	24990-24992	as	_	
118-19	24993-24994	a	_	
118-20	24995-25009	non-parametric	_	
118-21	25010-25021	alternative	_	
118-22	25021-25022	.	_	

#Text=Additional analyses addressed whether ‘change in Stroop-effect’ differed by randomly assigned treatment condition in separate analyses: a) CM versus no-CM groups, b) disulfiram versus placebo groups.
119-1	25023-25033	Additional	_	
119-2	25034-25042	analyses	_	
119-3	25043-25052	addressed	_	
119-4	25053-25060	whether	_	
119-5	25061-25062	‘	_	
119-6	25062-25068	change	_	
119-7	25069-25071	in	_	
119-8	25072-25085	Stroop-effect	_	
119-9	25085-25086	’	_	
119-10	25087-25095	differed	_	
119-11	25096-25098	by	_	
119-12	25099-25107	randomly	_	
119-13	25108-25116	assigned	_	
119-14	25117-25126	treatment	_	
119-15	25127-25136	condition	_	
119-16	25137-25139	in	_	
119-17	25140-25148	separate	_	
119-18	25149-25157	analyses	_	
119-19	25157-25158	:	_	
119-20	25159-25160	a	_	
119-21	25160-25161	)	_	
119-22	25162-25164	CM	_	
119-23	25165-25171	versus	_	
119-24	25172-25177	no-CM	_	
119-25	25178-25184	groups	_	
119-26	25184-25185	,	_	
119-27	25186-25187	b	_	
119-28	25187-25188	)	_	
119-29	25189-25199	disulfiram	_	
119-30	25200-25206	versus	_	
119-31	25207-25214	placebo	_	
119-32	25215-25221	groups	_	
119-33	25221-25222	.	_	

#Text=Since treatment group differences in ‘change in Stroop-effect’ could be influenced by beginning-of-treatment group differences, potentially confounding beginning-of-treatment differences between treatment groups were assessed by comparing beginning-of-treatment Stroop-effect (Incongruentpre >Congruentpre trials) by CM (CM>no-CM) and medication (disulfiram>placebo) randomization status.
120-1	25223-25228	Since	_	
120-2	25229-25238	treatment	_	
120-3	25239-25244	group	_	
120-4	25245-25256	differences	_	
120-5	25257-25259	in	_	
120-6	25260-25261	‘	_	
120-7	25261-25267	change	_	
120-8	25268-25270	in	_	
120-9	25271-25284	Stroop-effect	_	
120-10	25284-25285	’	_	
120-11	25286-25291	could	_	
120-12	25292-25294	be	_	
120-13	25295-25305	influenced	_	
120-14	25306-25308	by	_	
120-15	25309-25331	beginning-of-treatment	_	
120-16	25332-25337	group	_	
120-17	25338-25349	differences	_	
120-18	25349-25350	,	_	
120-19	25351-25362	potentially	_	
120-20	25363-25374	confounding	_	
120-21	25375-25397	beginning-of-treatment	_	
120-22	25398-25409	differences	_	
120-23	25410-25417	between	_	
120-24	25418-25427	treatment	_	
120-25	25428-25434	groups	_	
120-26	25435-25439	were	_	
120-27	25440-25448	assessed	_	
120-28	25449-25451	by	_	
120-29	25452-25461	comparing	_	
120-30	25462-25484	beginning-of-treatment	_	
120-31	25485-25498	Stroop-effect	_	
120-32	25499-25500	(	_	
120-33	25500-25514	Incongruentpre	_	
120-34	25515-25516	>	_	
120-35	25516-25528	Congruentpre	_	
120-36	25529-25535	trials	_	
120-37	25535-25536	)	_	
120-38	25537-25539	by	_	
120-39	25540-25542	CM	_	
120-40	25543-25544	(	_	
120-41	25544-25546	CM	_	
120-42	25546-25547	>	_	
120-43	25547-25552	no-CM	_	
120-44	25552-25553	)	_	
120-45	25554-25557	and	_	
120-46	25558-25568	medication	_	
120-47	25569-25570	(	_	
120-48	25570-25580	disulfiram	_	
120-49	25580-25581	>	_	
120-50	25581-25588	placebo	_	
120-51	25588-25589	)	_	
120-52	25590-25603	randomization	_	
120-53	25604-25610	status	_	
120-54	25610-25611	.	_	

#Text=Results
#Text=Beginning-of-Treatment Clinical Characteristics, Treatment Engagement and Cocaine-Use Outcomes
#Text=There were no significant treatment group differences on demographic, baseline clinical or treatment engagement measures, with two exceptions: there were more years of cannabis use in no-CM vs.
121-1	25612-25619	Results	_	
121-2	25620-25642	Beginning-of-Treatment	_	
121-3	25643-25651	Clinical	_	
121-4	25652-25667	Characteristics	_	
121-5	25667-25668	,	_	
121-6	25669-25678	Treatment	_	
121-7	25679-25689	Engagement	_	
121-8	25690-25693	and	_	
121-9	25694-25705	Cocaine-Use	_	
121-10	25706-25714	Outcomes	_	
121-11	25715-25720	There	_	
121-12	25721-25725	were	_	
121-13	25726-25728	no	_	
121-14	25729-25740	significant	_	
121-15	25741-25750	treatment	_	
121-16	25751-25756	group	_	
121-17	25757-25768	differences	_	
121-18	25769-25771	on	_	
121-19	25772-25783	demographic	_	
121-20	25783-25784	,	_	
121-21	25785-25793	baseline	_	
121-22	25794-25802	clinical	_	
121-23	25803-25805	or	_	
121-24	25806-25815	treatment	_	
121-25	25816-25826	engagement	_	
121-26	25827-25835	measures	_	
121-27	25835-25836	,	_	
121-28	25837-25841	with	_	
121-29	25842-25845	two	_	
121-30	25846-25856	exceptions	_	
121-31	25856-25857	:	_	
121-32	25858-25863	there	_	
121-33	25864-25868	were	_	
121-34	25869-25873	more	_	
121-35	25874-25879	years	_	
121-36	25880-25882	of	_	
121-37	25883-25891	cannabis	_	
121-38	25892-25895	use	_	
121-39	25896-25898	in	_	
121-40	25899-25904	no-CM	_	
121-41	25905-25907	vs	_	
121-42	25907-25908	.	_	

#Text=CM groups, and more days in treatment in the disulfiram versus placebo groups (see Table 2).
122-1	25909-25911	CM	_	
122-2	25912-25918	groups	_	
122-3	25918-25919	,	_	
122-4	25920-25923	and	_	
122-5	25924-25928	more	_	
122-6	25929-25933	days	_	
122-7	25934-25936	in	_	
122-8	25937-25946	treatment	_	
122-9	25947-25949	in	_	
122-10	25950-25953	the	_	
122-11	25954-25964	disulfiram	_	
122-12	25965-25971	versus	_	
122-13	25972-25979	placebo	_	
122-14	25980-25986	groups	_	
122-15	25987-25988	(	_	
122-16	25988-25991	see	_	
122-17	25992-25997	Table	_	
122-18	25998-25999	2	_	
122-19	25999-26000	)	_	
122-20	26000-26001	.	_	

#Text=Despite no main effects of group on cocaine-use outcomes in this fMRI subsample, a significant CM by medication condition interaction on ‘percent days self-reported cocaine abstinence’ during treatment indicated best cocaine use outcomes in the CM/placebo group, worst outcomes in the CM/disulfiram group and intermediate outcomes in the no-CM groups (see Table 2).
123-1	26002-26009	Despite	_	
123-2	26010-26012	no	_	
123-3	26013-26017	main	_	
123-4	26018-26025	effects	_	
123-5	26026-26028	of	_	
123-6	26029-26034	group	_	
123-7	26035-26037	on	_	
123-8	26038-26049	cocaine-use	_	
123-9	26050-26058	outcomes	_	
123-10	26059-26061	in	_	
123-11	26062-26066	this	_	
123-12	26067-26071	fMRI	_	
123-13	26072-26081	subsample	_	
123-14	26081-26082	,	_	
123-15	26083-26084	a	_	
123-16	26085-26096	significant	_	
123-17	26097-26099	CM	_	
123-18	26100-26102	by	_	
123-19	26103-26113	medication	_	
123-20	26114-26123	condition	_	
123-21	26124-26135	interaction	_	
123-22	26136-26138	on	_	
123-23	26139-26140	‘	_	
123-24	26140-26147	percent	_	
123-25	26148-26152	days	_	
123-26	26153-26166	self-reported	_	
123-27	26167-26174	cocaine	_	
123-28	26175-26185	abstinence	_	
123-29	26185-26186	’	_	
123-30	26187-26193	during	_	
123-31	26194-26203	treatment	_	
123-32	26204-26213	indicated	_	
123-33	26214-26218	best	_	
123-34	26219-26226	cocaine	_	
123-35	26227-26230	use	_	
123-36	26231-26239	outcomes	_	
123-37	26240-26242	in	_	
123-38	26243-26246	the	_	
123-39	26247-26249	CM	_	
123-40	26249-26250	/	_	
123-41	26250-26257	placebo	_	
123-42	26258-26263	group	_	
123-43	26263-26264	,	_	
123-44	26265-26270	worst	_	
123-45	26271-26279	outcomes	_	
123-46	26280-26282	in	_	
123-47	26283-26286	the	_	
123-48	26287-26289	CM	_	
123-49	26289-26290	/	_	
123-50	26290-26300	disulfiram	_	
123-51	26301-26306	group	_	
123-52	26307-26310	and	_	
123-53	26311-26323	intermediate	_	
123-54	26324-26332	outcomes	_	
123-55	26333-26335	in	_	
123-56	26336-26339	the	_	
123-57	26340-26345	no-CM	_	
123-58	26346-26352	groups	_	
123-59	26353-26354	(	_	
123-60	26354-26357	see	_	
123-61	26358-26363	Table	_	
123-62	26364-26365	2	_	
123-63	26365-26366	)	_	
123-64	26366-26367	.	_	

#Text=This pattern is slightly different than that of the full RCT sample wherein cocaine-use outcomes were best in the CM/placebo group, worst in the no-CM/placebo group and intermediate in the disulfiram groups.
124-1	26368-26372	This	_	
124-2	26373-26380	pattern	_	
124-3	26381-26383	is	_	
124-4	26384-26392	slightly	_	
124-5	26393-26402	different	_	
124-6	26403-26407	than	_	
124-7	26408-26412	that	_	
124-8	26413-26415	of	_	
124-9	26416-26419	the	_	
124-10	26420-26424	full	_	
124-11	26425-26428	RCT	_	
124-12	26429-26435	sample	_	
124-13	26436-26443	wherein	_	
124-14	26444-26455	cocaine-use	_	
124-15	26456-26464	outcomes	_	
124-16	26465-26469	were	_	
124-17	26470-26474	best	_	
124-18	26475-26477	in	_	
124-19	26478-26481	the	_	
124-20	26482-26484	CM	_	
124-21	26484-26485	/	_	
124-22	26485-26492	placebo	_	
124-23	26493-26498	group	_	
124-24	26498-26499	,	_	
124-25	26500-26505	worst	_	
124-26	26506-26508	in	_	
124-27	26509-26512	the	_	
124-28	26513-26518	no-CM	_	
124-29	26518-26519	/	_	
124-30	26519-26526	placebo	_	
124-31	26527-26532	group	_	
124-32	26533-26536	and	_	
124-33	26537-26549	intermediate	_	
124-34	26550-26552	in	_	
124-35	26553-26556	the	_	
124-36	26557-26567	disulfiram	_	
124-37	26568-26574	groups	_	
124-38	26574-26575	.	_	

#Text=Stroop Behavior
#Text=The expected behavioral Stroop-effect was indicated by a main effect of trial type on response times, reflecting slower correct response times for incongruent versus congruent trials (trial type: F(1,15)= 58.99, p<.001).
125-1	26576-26582	Stroop	_	
125-2	26583-26591	Behavior	_	
125-3	26592-26595	The	_	
125-4	26596-26604	expected	_	
125-5	26605-26615	behavioral	_	
125-6	26616-26629	Stroop-effect	_	
125-7	26630-26633	was	_	
125-8	26634-26643	indicated	_	
125-9	26644-26646	by	_	
125-10	26647-26648	a	_	
125-11	26649-26653	main	_	
125-12	26654-26660	effect	_	
125-13	26661-26663	of	_	
125-14	26664-26669	trial	_	
125-15	26670-26674	type	_	
125-16	26675-26677	on	_	
125-17	26678-26686	response	_	
125-18	26687-26692	times	_	
125-19	26692-26693	,	_	
125-20	26694-26704	reflecting	_	
125-21	26705-26711	slower	_	
125-22	26712-26719	correct	_	
125-23	26720-26728	response	_	
125-24	26729-26734	times	_	
125-25	26735-26738	for	_	
125-26	26739-26750	incongruent	_	
125-27	26751-26757	versus	_	
125-28	26758-26767	congruent	_	
125-29	26768-26774	trials	_	
125-30	26775-26776	(	_	
125-31	26776-26781	trial	_	
125-32	26782-26786	type	_	
125-33	26786-26787	:	_	
125-34	26788-26789	F	_	
125-35	26789-26790	(	_	
125-36	26790-26794	1,15	_	
125-37	26794-26795	)	_	
125-38	26795-26796	=	_	
125-39	26797-26802	58.99	_	
125-40	26802-26803	,	_	
125-41	26804-26805	p	_	
125-42	26805-26806	<	_	
125-43	26806-26810	.001	_	
125-44	26810-26811	)	_	
125-45	26811-26812	.	_	

#Text=There were no main or interactive effects of group (CM, No CM; disulfiram, placebo) or session (post-treatment, beginning-of-treatment) on response times errors during incongruent trials (see Table 2).
126-1	26813-26818	There	_	
126-2	26819-26823	were	_	
126-3	26824-26826	no	_	
126-4	26827-26831	main	_	
126-5	26832-26834	or	_	
126-6	26835-26846	interactive	_	
126-7	26847-26854	effects	_	
126-8	26855-26857	of	_	
126-9	26858-26863	group	_	
126-10	26864-26865	(	_	
126-11	26865-26867	CM	_	
126-12	26867-26868	,	_	
126-13	26869-26871	No	_	
126-14	26872-26874	CM	_	
126-15	26874-26875	;	_	
126-16	26876-26886	disulfiram	_	
126-17	26886-26887	,	_	
126-18	26888-26895	placebo	_	
126-19	26895-26896	)	_	
126-20	26897-26899	or	_	
126-21	26900-26907	session	_	
126-22	26908-26909	(	_	
126-23	26909-26923	post-treatment	_	
126-24	26923-26924	,	_	
126-25	26925-26947	beginning-of-treatment	_	
126-26	26947-26948	)	_	
126-27	26949-26951	on	_	
126-28	26952-26960	response	_	
126-29	26961-26966	times	_	
126-30	26967-26973	errors	_	
126-31	26974-26980	during	_	
126-32	26981-26992	incongruent	_	
126-33	26993-26999	trials	_	
126-34	27000-27001	(	_	
126-35	27001-27004	see	_	
126-36	27005-27010	Table	_	
126-37	27011-27012	2	_	
126-38	27012-27013	)	_	
126-39	27013-27014	.	_	

#Text=Changes in fMRI Stroop and Relationship to Treatment Engagement and Outcome
#Text=Within the whole sample (across treatment groups; N=26), there were significant reductions in Stroop-related neural activity from beginning-of-treatment to post-treatment in: hippocampus, thalamus, cingulate, precentral gyrus, postcentral gyrus, precuneus and culmen clusters (see Table 3A, Figure 1A–B; Supplementary Figure 2 for additional views; and Supplementary Figure 1 for Stroop-related activity at beginning-of-treatment and post-treatment).
127-1	27015-27022	Changes	_	
127-2	27023-27025	in	_	
127-3	27026-27030	fMRI	_	
127-4	27031-27037	Stroop	_	
127-5	27038-27041	and	_	
127-6	27042-27054	Relationship	_	
127-7	27055-27057	to	_	
127-8	27058-27067	Treatment	_	
127-9	27068-27078	Engagement	_	
127-10	27079-27082	and	_	
127-11	27083-27090	Outcome	_	
127-12	27091-27097	Within	_	
127-13	27098-27101	the	_	
127-14	27102-27107	whole	_	
127-15	27108-27114	sample	_	
127-16	27115-27116	(	_	
127-17	27116-27122	across	_	
127-18	27123-27132	treatment	_	
127-19	27133-27139	groups	_	
127-20	27139-27140	;	_	
127-21	27141-27142	N	_	
127-22	27142-27143	=	_	
127-23	27143-27145	26	_	
127-24	27145-27146	)	_	
127-25	27146-27147	,	_	
127-26	27148-27153	there	_	
127-27	27154-27158	were	_	
127-28	27159-27170	significant	_	
127-29	27171-27181	reductions	_	
127-30	27182-27184	in	_	
127-31	27185-27199	Stroop-related	_	
127-32	27200-27206	neural	_	
127-33	27207-27215	activity	_	
127-34	27216-27220	from	_	
127-35	27221-27243	beginning-of-treatment	_	
127-36	27244-27246	to	_	
127-37	27247-27261	post-treatment	_	
127-38	27262-27264	in	_	
127-39	27264-27265	:	_	
127-40	27266-27277	hippocampus	_	
127-41	27277-27278	,	_	
127-42	27279-27287	thalamus	_	
127-43	27287-27288	,	_	
127-44	27289-27298	cingulate	_	
127-45	27298-27299	,	_	
127-46	27300-27310	precentral	_	
127-47	27311-27316	gyrus	_	
127-48	27316-27317	,	_	
127-49	27318-27329	postcentral	_	
127-50	27330-27335	gyrus	_	
127-51	27335-27336	,	_	
127-52	27337-27346	precuneus	_	
127-53	27347-27350	and	_	
127-54	27351-27357	culmen	_	
127-55	27358-27366	clusters	_	
127-56	27367-27368	(	_	
127-57	27368-27371	see	_	
127-58	27372-27377	Table	_	
127-59	27378-27380	3A	_	
127-60	27380-27381	,	_	
127-61	27382-27388	Figure	_	
127-62	27389-27393	1A–B	_	
127-63	27393-27394	;	_	
127-64	27395-27408	Supplementary	_	
127-65	27409-27415	Figure	_	
127-66	27416-27417	2	_	
127-67	27418-27421	for	_	
127-68	27422-27432	additional	_	
127-69	27433-27438	views	_	
127-70	27438-27439	;	_	
127-71	27440-27443	and	_	
127-72	27444-27457	Supplementary	_	
127-73	27458-27464	Figure	_	
127-74	27465-27466	1	_	
127-75	27467-27470	for	_	
127-76	27471-27485	Stroop-related	_	
127-77	27486-27494	activity	_	
127-78	27495-27497	at	_	
127-79	27498-27520	beginning-of-treatment	_	
127-80	27521-27524	and	_	
127-81	27525-27539	post-treatment	_	
127-82	27539-27540	)	_	
127-83	27540-27541	.	_	

#Text=This is consistent with our prior work.
128-1	27542-27546	This	_	
128-2	27547-27549	is	_	
128-3	27550-27560	consistent	_	
128-4	27561-27565	with	_	
128-5	27566-27569	our	_	
128-6	27570-27575	prior	_	
128-7	27576-27580	work	_	
128-8	27580-27581	.	_	

#Text=Whole-brain correlations between ‘change in Stroop effect’ and treatment engagement revealed negative correlations, showing that greater reductions in Stroop-related activity at post-treatment (relative to beginning-of-treatment), were associated with greater treatment engagement.
129-1	27582-27593	Whole-brain	_	
129-2	27594-27606	correlations	_	
129-3	27607-27614	between	_	
129-4	27615-27616	‘	_	
129-5	27616-27622	change	_	
129-6	27623-27625	in	_	
129-7	27626-27632	Stroop	_	
129-8	27633-27639	effect	_	
129-9	27639-27640	’	_	
129-10	27641-27644	and	_	
129-11	27645-27654	treatment	_	
129-12	27655-27665	engagement	_	
129-13	27666-27674	revealed	_	
129-14	27675-27683	negative	_	
129-15	27684-27696	correlations	_	
129-16	27696-27697	,	_	
129-17	27698-27705	showing	_	
129-18	27706-27710	that	_	
129-19	27711-27718	greater	_	
129-20	27719-27729	reductions	_	
129-21	27730-27732	in	_	
129-22	27733-27747	Stroop-related	_	
129-23	27748-27756	activity	_	
129-24	27757-27759	at	_	
129-25	27760-27774	post-treatment	_	
129-26	27775-27776	(	_	
129-27	27776-27784	relative	_	
129-28	27785-27787	to	_	
129-29	27788-27810	beginning-of-treatment	_	
129-30	27810-27811	)	_	
129-31	27811-27812	,	_	
129-32	27813-27817	were	_	
129-33	27818-27828	associated	_	
129-34	27829-27833	with	_	
129-35	27834-27841	greater	_	
129-36	27842-27851	treatment	_	
129-37	27852-27862	engagement	_	
129-38	27862-27863	.	_	

#Text=Importantly, this pattern was apparent in different regions, depending on the specific treatment engagement measure (Table 3B).
130-1	27864-27875	Importantly	_	
130-2	27875-27876	,	_	
130-3	27877-27881	this	_	
130-4	27882-27889	pattern	_	
130-5	27890-27893	was	_	
130-6	27894-27902	apparent	_	
130-7	27903-27905	in	_	
130-8	27906-27915	different	_	
130-9	27916-27923	regions	_	
130-10	27923-27924	,	_	
130-11	27925-27934	depending	_	
130-12	27935-27937	on	_	
130-13	27938-27941	the	_	
130-14	27942-27950	specific	_	
130-15	27951-27960	treatment	_	
130-16	27961-27971	engagement	_	
130-17	27972-27979	measure	_	
130-18	27980-27981	(	_	
130-19	27981-27986	Table	_	
130-20	27987-27989	3B	_	
130-21	27989-27990	)	_	
130-22	27990-27991	.	_	

#Text=Specifically, attendance at more CBT sessions was associated with a greater reduction in Stroop-related activity in the precentral gyrus, IPL, MFG and medial frontal gyrus and more earned CM prizes were associated with greater reduction in postcentral gyrus.
131-1	27992-28004	Specifically	_	
131-2	28004-28005	,	_	
131-3	28006-28016	attendance	_	
131-4	28017-28019	at	_	
131-5	28020-28024	more	_	
131-6	28025-28028	CBT	_	
131-7	28029-28037	sessions	_	
131-8	28038-28041	was	_	
131-9	28042-28052	associated	_	
131-10	28053-28057	with	_	
131-11	28058-28059	a	_	
131-12	28060-28067	greater	_	
131-13	28068-28077	reduction	_	
131-14	28078-28080	in	_	
131-15	28081-28095	Stroop-related	_	
131-16	28096-28104	activity	_	
131-17	28105-28107	in	_	
131-18	28108-28111	the	_	
131-19	28112-28122	precentral	_	
131-20	28123-28128	gyrus	_	
131-21	28128-28129	,	_	
131-22	28130-28133	IPL	_	
131-23	28133-28134	,	_	
131-24	28135-28138	MFG	_	
131-25	28139-28142	and	_	
131-26	28143-28149	medial	_	
131-27	28150-28157	frontal	_	
131-28	28158-28163	gyrus	_	
131-29	28164-28167	and	_	
131-30	28168-28172	more	_	
131-31	28173-28179	earned	_	
131-32	28180-28182	CM	_	
131-33	28183-28189	prizes	_	
131-34	28190-28194	were	_	
131-35	28195-28205	associated	_	
131-36	28206-28210	with	_	
131-37	28211-28218	greater	_	
131-38	28219-28228	reduction	_	
131-39	28229-28231	in	_	
131-40	28232-28243	postcentral	_	
131-41	28244-28249	gyrus	_	
131-42	28249-28250	.	_	

#Text=In contrast, days of disulfiram medication taken was not significantly associated with changes in Stroop fMRI.
132-1	28251-28253	In	_	
132-2	28254-28262	contrast	_	
132-3	28262-28263	,	_	
132-4	28264-28268	days	_	
132-5	28269-28271	of	_	
132-6	28272-28282	disulfiram	_	
132-7	28283-28293	medication	_	
132-8	28294-28299	taken	_	
132-9	28300-28303	was	_	
132-10	28304-28307	not	_	
132-11	28308-28321	significantly	_	
132-12	28322-28332	associated	_	
132-13	28333-28337	with	_	
132-14	28338-28345	changes	_	
132-15	28346-28348	in	_	
132-16	28349-28355	Stroop	_	
132-17	28356-28360	fMRI	_	
132-18	28360-28361	.	_	

#Text=Better cocaine use outcomes during treatment (higher percent days of cocaine abstinence during treatment) was positively associated with increases in Stroop-related activity in the superior temporal gyrus.
133-1	28362-28368	Better	_	
133-2	28369-28376	cocaine	_	
133-3	28377-28380	use	_	
133-4	28381-28389	outcomes	_	
133-5	28390-28396	during	_	
133-6	28397-28406	treatment	_	
133-7	28407-28408	(	_	
133-8	28408-28414	higher	_	
133-9	28415-28422	percent	_	
133-10	28423-28427	days	_	
133-11	28428-28430	of	_	
133-12	28431-28438	cocaine	_	
133-13	28439-28449	abstinence	_	
133-14	28450-28456	during	_	
133-15	28457-28466	treatment	_	
133-16	28466-28467	)	_	
133-17	28468-28471	was	_	
133-18	28472-28482	positively	_	
133-19	28483-28493	associated	_	
133-20	28494-28498	with	_	
133-21	28499-28508	increases	_	
133-22	28509-28511	in	_	
133-23	28512-28526	Stroop-related	_	
133-24	28527-28535	activity	_	
133-25	28536-28538	in	_	
133-26	28539-28542	the	_	
133-27	28543-28551	superior	_	
133-28	28552-28560	temporal	_	
133-29	28561-28566	gyrus	_	
133-30	28566-28567	.	_	

#Text=There were no significant correlations between changes in Stroop fMRI and cocaine negative urines.
134-1	28568-28573	There	_	
134-2	28574-28578	were	_	
134-3	28579-28581	no	_	
134-4	28582-28593	significant	_	
134-5	28594-28606	correlations	_	
134-6	28607-28614	between	_	
134-7	28615-28622	changes	_	
134-8	28623-28625	in	_	
134-9	28626-28632	Stroop	_	
134-10	28633-28637	fMRI	_	
134-11	28638-28641	and	_	
134-12	28642-28649	cocaine	_	
134-13	28650-28658	negative	_	
134-14	28659-28665	urines	_	
134-15	28665-28666	.	_	

#Text=Conjunction analyses revealed that the regions associated with cocaine-use outcomes did not overlap with regions associated with treatment engagement measures and regions associated with different aspects of treatment engagement (CBT, CM or disulfiram) did not overlap (see Supplementary Materials for detailed results).
135-1	28667-28678	Conjunction	_	
135-2	28679-28687	analyses	_	
135-3	28688-28696	revealed	_	
135-4	28697-28701	that	_	
135-5	28702-28705	the	_	
135-6	28706-28713	regions	_	
135-7	28714-28724	associated	_	
135-8	28725-28729	with	_	
135-9	28730-28741	cocaine-use	_	
135-10	28742-28750	outcomes	_	
135-11	28751-28754	did	_	
135-12	28755-28758	not	_	
135-13	28759-28766	overlap	_	
135-14	28767-28771	with	_	
135-15	28772-28779	regions	_	
135-16	28780-28790	associated	_	
135-17	28791-28795	with	_	
135-18	28796-28805	treatment	_	
135-19	28806-28816	engagement	_	
135-20	28817-28825	measures	_	
135-21	28826-28829	and	_	
135-22	28830-28837	regions	_	
135-23	28838-28848	associated	_	
135-24	28849-28853	with	_	
135-25	28854-28863	different	_	
135-26	28864-28871	aspects	_	
135-27	28872-28874	of	_	
135-28	28875-28884	treatment	_	
135-29	28885-28895	engagement	_	
135-30	28896-28897	(	_	
135-31	28897-28900	CBT	_	
135-32	28900-28901	,	_	
135-33	28902-28904	CM	_	
135-34	28905-28907	or	_	
135-35	28908-28918	disulfiram	_	
135-36	28918-28919	)	_	
135-37	28920-28923	did	_	
135-38	28924-28927	not	_	
135-39	28928-28935	overlap	_	
135-40	28936-28937	(	_	
135-41	28937-28940	see	_	
135-42	28941-28954	Supplementary	_	
135-43	28955-28964	Materials	_	
135-44	28965-28968	for	_	
135-45	28969-28977	detailed	_	
135-46	28978-28985	results	_	
135-47	28985-28986	)	_	
135-48	28986-28987	.	_	

#Text=Analyses comparing changes in Stroop effect from beginning-of-treatment to post-treatment by treatment group did not reveal any significant differences between CM vs. no-CM or disulfiram vs. placebo groups.
136-1	28988-28996	Analyses	_	
136-2	28997-29006	comparing	_	
136-3	29007-29014	changes	_	
136-4	29015-29017	in	_	
136-5	29018-29024	Stroop	_	
136-6	29025-29031	effect	_	
136-7	29032-29036	from	_	
136-8	29037-29059	beginning-of-treatment	_	
136-9	29060-29062	to	_	
136-10	29063-29077	post-treatment	_	
136-11	29078-29080	by	_	
136-12	29081-29090	treatment	_	
136-13	29091-29096	group	_	
136-14	29097-29100	did	_	
136-15	29101-29104	not	_	
136-16	29105-29111	reveal	_	
136-17	29112-29115	any	_	
136-18	29116-29127	significant	_	
136-19	29128-29139	differences	_	
136-20	29140-29147	between	_	
136-21	29148-29150	CM	_	
136-22	29151-29153	vs	_	
136-23	29153-29154	.	_	
136-24	29155-29160	no-CM	_	
136-25	29161-29163	or	_	
136-26	29164-29174	disulfiram	_	
136-27	29175-29177	vs	_	
136-28	29177-29178	.	_	
136-29	29179-29186	placebo	_	
136-30	29187-29193	groups	_	
136-31	29193-29194	.	_	

#Text=Further, there were no significant differences in fMRI Stroop-related neural activity at beginning-of-treatment by CM or disulfiram group status, which was investigated as a potentially confounding factor.
137-1	29195-29202	Further	_	
137-2	29202-29203	,	_	
137-3	29204-29209	there	_	
137-4	29210-29214	were	_	
137-5	29215-29217	no	_	
137-6	29218-29229	significant	_	
137-7	29230-29241	differences	_	
137-8	29242-29244	in	_	
137-9	29245-29249	fMRI	_	
137-10	29250-29264	Stroop-related	_	
137-11	29265-29271	neural	_	
137-12	29272-29280	activity	_	
137-13	29281-29283	at	_	
137-14	29284-29306	beginning-of-treatment	_	
137-15	29307-29309	by	_	
137-16	29310-29312	CM	_	
137-17	29313-29315	or	_	
137-18	29316-29326	disulfiram	_	
137-19	29327-29332	group	_	
137-20	29333-29339	status	_	
137-21	29339-29340	,	_	
137-22	29341-29346	which	_	
137-23	29347-29350	was	_	
137-24	29351-29363	investigated	_	
137-25	29364-29366	as	_	
137-26	29367-29368	a	_	
137-27	29369-29380	potentially	_	
137-28	29381-29392	confounding	_	
137-29	29393-29399	factor	_	
137-30	29399-29400	.	_	

#Text=Discussion
#Text=Cognitive-control is considered a key process in SUDs.
138-1	29401-29411	Discussion	_	
138-2	29412-29429	Cognitive-control	_	
138-3	29430-29432	is	_	
138-4	29433-29443	considered	_	
138-5	29444-29445	a	_	
138-6	29446-29449	key	_	
138-7	29450-29457	process	_	
138-8	29458-29460	in	_	
138-9	29461-29465	SUDs	_	
138-10	29465-29466	.	_	

#Text=This study is the first to investigate relationships between cognitive-control-related neural activity and indicators of exposure to putative active ingredients of treatment in individuals with CUDs.
139-1	29467-29471	This	_	
139-2	29472-29477	study	_	
139-3	29478-29480	is	_	
139-4	29481-29484	the	_	
139-5	29485-29490	first	_	
139-6	29491-29493	to	_	
139-7	29494-29505	investigate	_	
139-8	29506-29519	relationships	_	
139-9	29520-29527	between	_	
139-10	29528-29553	cognitive-control-related	_	
139-11	29554-29560	neural	_	
139-12	29561-29569	activity	_	
139-13	29570-29573	and	_	
139-14	29574-29584	indicators	_	
139-15	29585-29587	of	_	
139-16	29588-29596	exposure	_	
139-17	29597-29599	to	_	
139-18	29600-29608	putative	_	
139-19	29609-29615	active	_	
139-20	29616-29627	ingredients	_	
139-21	29628-29630	of	_	
139-22	29631-29640	treatment	_	
139-23	29641-29643	in	_	
139-24	29644-29655	individuals	_	
139-25	29656-29660	with	_	
139-26	29661-29665	CUDs	_	
139-27	29665-29666	.	_	

#Text=Findings partially supported our hypotheses.
140-1	29667-29675	Findings	_	
140-2	29676-29685	partially	_	
140-3	29686-29695	supported	_	
140-4	29696-29699	our	_	
140-5	29700-29710	hypotheses	_	
140-6	29710-29711	.	_	

#Text=Consistent with our hypotheses for the first analytic approach, greater treatment engagement was associated with greater reduction in Stroop-related activity.
141-1	29712-29722	Consistent	_	
141-2	29723-29727	with	_	
141-3	29728-29731	our	_	
141-4	29732-29742	hypotheses	_	
141-5	29743-29746	for	_	
141-6	29747-29750	the	_	
141-7	29751-29756	first	_	
141-8	29757-29765	analytic	_	
141-9	29766-29774	approach	_	
141-10	29774-29775	,	_	
141-11	29776-29783	greater	_	
141-12	29784-29793	treatment	_	
141-13	29794-29804	engagement	_	
141-14	29805-29808	was	_	
141-15	29809-29819	associated	_	
141-16	29820-29824	with	_	
141-17	29825-29832	greater	_	
141-18	29833-29842	reduction	_	
141-19	29843-29845	in	_	
141-20	29846-29860	Stroop-related	_	
141-21	29861-29869	activity	_	
141-22	29869-29870	.	_	

#Text=Importantly, engagement with different treatment components (e.g., exposure to CBT or CM components) was correlated with reductions in Stroop-related activity across different cognitive-control-related regions - consistent with the conceptualization of these components as theoretically and mechanistically distinct.
142-1	29871-29882	Importantly	_	
142-2	29882-29883	,	_	
142-3	29884-29894	engagement	_	
142-4	29895-29899	with	_	
142-5	29900-29909	different	_	
142-6	29910-29919	treatment	_	
142-7	29920-29930	components	_	
142-8	29931-29932	(	_	
142-9	29932-29935	e.g	_	
142-10	29935-29936	.	_	
142-11	29936-29937	,	_	
142-12	29938-29946	exposure	_	
142-13	29947-29949	to	_	
142-14	29950-29953	CBT	_	
142-15	29954-29956	or	_	
142-16	29957-29959	CM	_	
142-17	29960-29970	components	_	
142-18	29970-29971	)	_	
142-19	29972-29975	was	_	
142-20	29976-29986	correlated	_	
142-21	29987-29991	with	_	
142-22	29992-30002	reductions	_	
142-23	30003-30005	in	_	
142-24	30006-30020	Stroop-related	_	
142-25	30021-30029	activity	_	
142-26	30030-30036	across	_	
142-27	30037-30046	different	_	
142-28	30047-30072	cognitive-control-related	_	
142-29	30073-30080	regions	_	
142-30	30081-30082	-	_	
142-31	30083-30093	consistent	_	
142-32	30094-30098	with	_	
142-33	30099-30102	the	_	
142-34	30103-30120	conceptualization	_	
142-35	30121-30123	of	_	
142-36	30124-30129	these	_	
142-37	30130-30140	components	_	
142-38	30141-30143	as	_	
142-39	30144-30157	theoretically	_	
142-40	30158-30161	and	_	
142-41	30162-30177	mechanistically	_	
142-42	30178-30186	distinct	_	
142-43	30186-30187	.	_	

#Text=However, engagement with disulfiram was not associated with change in Stroop-related activity in these regions.
143-1	30188-30195	However	_	
143-2	30195-30196	,	_	
143-3	30197-30207	engagement	_	
143-4	30208-30212	with	_	
143-5	30213-30223	disulfiram	_	
143-6	30224-30227	was	_	
143-7	30228-30231	not	_	
143-8	30232-30242	associated	_	
143-9	30243-30247	with	_	
143-10	30248-30254	change	_	
143-11	30255-30257	in	_	
143-12	30258-30272	Stroop-related	_	
143-13	30273-30281	activity	_	
143-14	30282-30284	in	_	
143-15	30285-30290	these	_	
143-16	30291-30298	regions	_	
143-17	30298-30299	.	_	

#Text=The patterns of associations between treatment engagement and changes in Stroop-related activity were in distinct regions from those associated with cocaine use during treatment, suggesting these associations were not simply a reflection of cocaine-use outcomes.
144-1	30300-30303	The	_	
144-2	30304-30312	patterns	_	
144-3	30313-30315	of	_	
144-4	30316-30328	associations	_	
144-5	30329-30336	between	_	
144-6	30337-30346	treatment	_	
144-7	30347-30357	engagement	_	
144-8	30358-30361	and	_	
144-9	30362-30369	changes	_	
144-10	30370-30372	in	_	
144-11	30373-30387	Stroop-related	_	
144-12	30388-30396	activity	_	
144-13	30397-30401	were	_	
144-14	30402-30404	in	_	
144-15	30405-30413	distinct	_	
144-16	30414-30421	regions	_	
144-17	30422-30426	from	_	
144-18	30427-30432	those	_	
144-19	30433-30443	associated	_	
144-20	30444-30448	with	_	
144-21	30449-30456	cocaine	_	
144-22	30457-30460	use	_	
144-23	30461-30467	during	_	
144-24	30468-30477	treatment	_	
144-25	30477-30478	,	_	
144-26	30479-30489	suggesting	_	
144-27	30490-30495	these	_	
144-28	30496-30508	associations	_	
144-29	30509-30513	were	_	
144-30	30514-30517	not	_	
144-31	30518-30524	simply	_	
144-32	30525-30526	a	_	
144-33	30527-30537	reflection	_	
144-34	30538-30540	of	_	
144-35	30541-30552	cocaine-use	_	
144-36	30553-30561	outcomes	_	
144-37	30561-30562	.	_	

#Text=In contrast with our hypotheses for the second analytic approach, no treatment group (CM vs. no-CM; disulfiram vs. placebo) differences in ‘change in Stroop effect’ survived corrections for multiple comparisons at the whole brain level.
145-1	30563-30565	In	_	
145-2	30566-30574	contrast	_	
145-3	30575-30579	with	_	
145-4	30580-30583	our	_	
145-5	30584-30594	hypotheses	_	
145-6	30595-30598	for	_	
145-7	30599-30602	the	_	
145-8	30603-30609	second	_	
145-9	30610-30618	analytic	_	
145-10	30619-30627	approach	_	
145-11	30627-30628	,	_	
145-12	30629-30631	no	_	
145-13	30632-30641	treatment	_	
145-14	30642-30647	group	_	
145-15	30648-30649	(	_	
145-16	30649-30651	CM	_	
145-17	30652-30654	vs	_	
145-18	30654-30655	.	_	
145-19	30656-30661	no-CM	_	
145-20	30661-30662	;	_	
145-21	30663-30673	disulfiram	_	
145-22	30674-30676	vs	_	
145-23	30676-30677	.	_	
145-24	30678-30685	placebo	_	
145-25	30685-30686	)	_	
145-26	30687-30698	differences	_	
145-27	30699-30701	in	_	
145-28	30702-30703	‘	_	
145-29	30703-30709	change	_	
145-30	30710-30712	in	_	
145-31	30713-30719	Stroop	_	
145-32	30720-30726	effect	_	
145-33	30726-30727	’	_	
145-34	30728-30736	survived	_	
145-35	30737-30748	corrections	_	
145-36	30749-30752	for	_	
145-37	30753-30761	multiple	_	
145-38	30762-30773	comparisons	_	
145-39	30774-30776	at	_	
145-40	30777-30780	the	_	
145-41	30781-30786	whole	_	
145-42	30787-30792	brain	_	
145-43	30793-30798	level	_	
145-44	30798-30799	.	_	

#Text=Out-of-scanner behavioral Stroop performance did not significantly change across treatment.
146-1	30800-30814	Out-of-scanner	_	
146-2	30815-30825	behavioral	_	
146-3	30826-30832	Stroop	_	
146-4	30833-30844	performance	_	
146-5	30845-30848	did	_	
146-6	30849-30852	not	_	
146-7	30853-30866	significantly	_	
146-8	30867-30873	change	_	
146-9	30874-30880	across	_	
146-10	30881-30890	treatment	_	
146-11	30890-30891	.	_	

#Text=Although this lack of significant improvement could be seen as a limitation, it is also a strength in allowing interpretation of improved neural efficiency in the context of relatively stable behavioral performance.
147-1	30892-30900	Although	_	
147-2	30901-30905	this	_	
147-3	30906-30910	lack	_	
147-4	30911-30913	of	_	
147-5	30914-30925	significant	_	
147-6	30926-30937	improvement	_	
147-7	30938-30943	could	_	
147-8	30944-30946	be	_	
147-9	30947-30951	seen	_	
147-10	30952-30954	as	_	
147-11	30955-30956	a	_	
147-12	30957-30967	limitation	_	
147-13	30967-30968	,	_	
147-14	30969-30971	it	_	
147-15	30972-30974	is	_	
147-16	30975-30979	also	_	
147-17	30980-30981	a	_	
147-18	30982-30990	strength	_	
147-19	30991-30993	in	_	
147-20	30994-31002	allowing	_	
147-21	31003-31017	interpretation	_	
147-22	31018-31020	of	_	
147-23	31021-31029	improved	_	
147-24	31030-31036	neural	_	
147-25	31037-31047	efficiency	_	
147-26	31048-31050	in	_	
147-27	31051-31054	the	_	
147-28	31055-31062	context	_	
147-29	31063-31065	of	_	
147-30	31066-31076	relatively	_	
147-31	31077-31083	stable	_	
147-32	31084-31094	behavioral	_	
147-33	31095-31106	performance	_	
147-34	31106-31107	.	_	

#Text=Designing fMRI studies to match groups behaviorally such that the neural activity can be directly compared is a well-established method when cognitive impairment is expected in one group (e.g.,).
148-1	31108-31117	Designing	_	
148-2	31118-31122	fMRI	_	
148-3	31123-31130	studies	_	
148-4	31131-31133	to	_	
148-5	31134-31139	match	_	
148-6	31140-31146	groups	_	
148-7	31147-31159	behaviorally	_	
148-8	31160-31164	such	_	
148-9	31165-31169	that	_	
148-10	31170-31173	the	_	
148-11	31174-31180	neural	_	
148-12	31181-31189	activity	_	
148-13	31190-31193	can	_	
148-14	31194-31196	be	_	
148-15	31197-31205	directly	_	
148-16	31206-31214	compared	_	
148-17	31215-31217	is	_	
148-18	31218-31219	a	_	
148-19	31220-31236	well-established	_	
148-20	31237-31243	method	_	
148-21	31244-31248	when	_	
148-22	31249-31258	cognitive	_	
148-23	31259-31269	impairment	_	
148-24	31270-31272	is	_	
148-25	31273-31281	expected	_	
148-26	31282-31284	in	_	
148-27	31285-31288	one	_	
148-28	31289-31294	group	_	
148-29	31295-31296	(	_	
148-30	31296-31299	e.g	_	
148-31	31299-31300	.	_	
148-32	31300-31301	,	_	
148-33	31301-31302	)	_	
148-34	31302-31303	.	_	

#Text=In the sample overall, we found diminished Stroop-related activity post treatment compared to beginning-of-treatment.
149-1	31304-31306	In	_	
149-2	31307-31310	the	_	
149-3	31311-31317	sample	_	
149-4	31318-31325	overall	_	
149-5	31325-31326	,	_	
149-6	31327-31329	we	_	
149-7	31330-31335	found	_	
149-8	31336-31346	diminished	_	
149-9	31347-31361	Stroop-related	_	
149-10	31362-31370	activity	_	
149-11	31371-31375	post	_	
149-12	31376-31385	treatment	_	
149-13	31386-31394	compared	_	
149-14	31395-31397	to	_	
149-15	31398-31420	beginning-of-treatment	_	
149-16	31420-31421	.	_	

#Text=This pattern of change is consistent with our prior findings in a mixed substance-abusing sample receiving CBT or treatment as usual.
150-1	31422-31426	This	_	
150-2	31427-31434	pattern	_	
150-3	31435-31437	of	_	
150-4	31438-31444	change	_	
150-5	31445-31447	is	_	
150-6	31448-31458	consistent	_	
150-7	31459-31463	with	_	
150-8	31464-31467	our	_	
150-9	31468-31473	prior	_	
150-10	31474-31482	findings	_	
150-11	31483-31485	in	_	
150-12	31486-31487	a	_	
150-13	31488-31493	mixed	_	
150-14	31494-31511	substance-abusing	_	
150-15	31512-31518	sample	_	
150-16	31519-31528	receiving	_	
150-17	31529-31532	CBT	_	
150-18	31533-31535	or	_	
150-19	31536-31545	treatment	_	
150-20	31546-31548	as	_	
150-21	31549-31554	usual	_	
150-22	31554-31555	.	_	

#Text=Regions showing reduced Stroop-related activity in the overall sample have previously been shown to exhibit task-related functional differences between individuals with CUD and non-substance-using comparisons, using tasks tapping similar cognitive constructs as the Stroop.
151-1	31556-31563	Regions	_	
151-2	31564-31571	showing	_	
151-3	31572-31579	reduced	_	
151-4	31580-31594	Stroop-related	_	
151-5	31595-31603	activity	_	
151-6	31604-31606	in	_	
151-7	31607-31610	the	_	
151-8	31611-31618	overall	_	
151-9	31619-31625	sample	_	
151-10	31626-31630	have	_	
151-11	31631-31641	previously	_	
151-12	31642-31646	been	_	
151-13	31647-31652	shown	_	
151-14	31653-31655	to	_	
151-15	31656-31663	exhibit	_	
151-16	31664-31676	task-related	_	
151-17	31677-31687	functional	_	
151-18	31688-31699	differences	_	
151-19	31700-31707	between	_	
151-20	31708-31719	individuals	_	
151-21	31720-31724	with	_	
151-22	31725-31728	CUD	_	
151-23	31729-31732	and	_	
151-24	31733-31752	non-substance-using	_	
151-25	31753-31764	comparisons	_	
151-26	31764-31765	,	_	
151-27	31766-31771	using	_	
151-28	31772-31777	tasks	_	
151-29	31778-31785	tapping	_	
151-30	31786-31793	similar	_	
151-31	31794-31803	cognitive	_	
151-32	31804-31814	constructs	_	
151-33	31815-31817	as	_	
151-34	31818-31821	the	_	
151-35	31822-31828	Stroop	_	
151-36	31828-31829	.	_	

#Text=Prior research provides context for interpreting such diminished activity following treatment.
152-1	31830-31835	Prior	_	
152-2	31836-31844	research	_	
152-3	31845-31853	provides	_	
152-4	31854-31861	context	_	
152-5	31862-31865	for	_	
152-6	31866-31878	interpreting	_	
152-7	31879-31883	such	_	
152-8	31884-31894	diminished	_	
152-9	31895-31903	activity	_	
152-10	31904-31913	following	_	
152-11	31914-31923	treatment	_	
152-12	31923-31924	.	_	

#Text=Decreased task-related activity following treatment may reflect improved efficiency.
153-1	31925-31934	Decreased	_	
153-2	31935-31947	task-related	_	
153-3	31948-31956	activity	_	
153-4	31957-31966	following	_	
153-5	31967-31976	treatment	_	
153-6	31977-31980	may	_	
153-7	31981-31988	reflect	_	
153-8	31989-31997	improved	_	
153-9	31998-32008	efficiency	_	
153-10	32008-32009	.	_	

#Text=For example, while increased task difficulty and attentional load have been associated with increased task-related activity, practice is known to reduce task-related activity, which suggests improved efficiency (e.g.,.
154-1	32010-32013	For	_	
154-2	32014-32021	example	_	
154-3	32021-32022	,	_	
154-4	32023-32028	while	_	
154-5	32029-32038	increased	_	
154-6	32039-32043	task	_	
154-7	32044-32054	difficulty	_	
154-8	32055-32058	and	_	
154-9	32059-32070	attentional	_	
154-10	32071-32075	load	_	
154-11	32076-32080	have	_	
154-12	32081-32085	been	_	
154-13	32086-32096	associated	_	
154-14	32097-32101	with	_	
154-15	32102-32111	increased	_	
154-16	32112-32124	task-related	_	
154-17	32125-32133	activity	_	
154-18	32133-32134	,	_	
154-19	32135-32143	practice	_	
154-20	32144-32146	is	_	
154-21	32147-32152	known	_	
154-22	32153-32155	to	_	
154-23	32156-32162	reduce	_	
154-24	32163-32175	task-related	_	
154-25	32176-32184	activity	_	
154-26	32184-32185	,	_	
154-27	32186-32191	which	_	
154-28	32192-32200	suggests	_	
154-29	32201-32209	improved	_	
154-30	32210-32220	efficiency	_	
154-31	32221-32222	(	_	
154-32	32222-32225	e.g	_	
154-33	32225-32226	.	_	
154-34	32226-32227	,	_	
154-35	32227-32228	.	_	

#Text=Furthermore, practice effects are associated with decreased precuneus activation, and individuals with CUD show less practice-effect-related deactivation than healthy-comparison subjects, suggesting greater practice-related decreases in functional activity may be more optimal.
155-1	32229-32240	Furthermore	_	
155-2	32240-32241	,	_	
155-3	32242-32250	practice	_	
155-4	32251-32258	effects	_	
155-5	32259-32262	are	_	
155-6	32263-32273	associated	_	
155-7	32274-32278	with	_	
155-8	32279-32288	decreased	_	
155-9	32289-32298	precuneus	_	
155-10	32299-32309	activation	_	
155-11	32309-32310	,	_	
155-12	32311-32314	and	_	
155-13	32315-32326	individuals	_	
155-14	32327-32331	with	_	
155-15	32332-32335	CUD	_	
155-16	32336-32340	show	_	
155-17	32341-32345	less	_	
155-18	32346-32369	practice-effect-related	_	
155-19	32370-32382	deactivation	_	
155-20	32383-32387	than	_	
155-21	32388-32406	healthy-comparison	_	
155-22	32407-32415	subjects	_	
155-23	32415-32416	,	_	
155-24	32417-32427	suggesting	_	
155-25	32428-32435	greater	_	
155-26	32436-32452	practice-related	_	
155-27	32453-32462	decreases	_	
155-28	32463-32465	in	_	
155-29	32466-32476	functional	_	
155-30	32477-32485	activity	_	
155-31	32486-32489	may	_	
155-32	32490-32492	be	_	
155-33	32493-32497	more	_	
155-34	32498-32505	optimal	_	
155-35	32505-32506	.	_	

#Text=Changes in task-related activity following treatment may also relate to changes in cocaine use since cognitive-control-related functional activity is altered by acute cocaine administration and across cocaine abstinence.
156-1	32507-32514	Changes	_	
156-2	32515-32517	in	_	
156-3	32518-32530	task-related	_	
156-4	32531-32539	activity	_	
156-5	32540-32549	following	_	
156-6	32550-32559	treatment	_	
156-7	32560-32563	may	_	
156-8	32564-32568	also	_	
156-9	32569-32575	relate	_	
156-10	32576-32578	to	_	
156-11	32579-32586	changes	_	
156-12	32587-32589	in	_	
156-13	32590-32597	cocaine	_	
156-14	32598-32601	use	_	
156-15	32602-32607	since	_	
156-16	32608-32633	cognitive-control-related	_	
156-17	32634-32644	functional	_	
156-18	32645-32653	activity	_	
156-19	32654-32656	is	_	
156-20	32657-32664	altered	_	
156-21	32665-32667	by	_	
156-22	32668-32673	acute	_	
156-23	32674-32681	cocaine	_	
156-24	32682-32696	administration	_	
156-25	32697-32700	and	_	
156-26	32701-32707	across	_	
156-27	32708-32715	cocaine	_	
156-28	32716-32726	abstinence	_	
156-29	32726-32727	.	_	

#Text=For example, acute intravenous administration of cocaine prior to Go/No-Go increased fMRI task-related neural activity in a manner that partially ‘normalized’ functional activity in active cocaine users.
157-1	32728-32731	For	_	
157-2	32732-32739	example	_	
157-3	32739-32740	,	_	
157-4	32741-32746	acute	_	
157-5	32747-32758	intravenous	_	
157-6	32759-32773	administration	_	
157-7	32774-32776	of	_	
157-8	32777-32784	cocaine	_	
157-9	32785-32790	prior	_	
157-10	32791-32793	to	_	
157-11	32794-32796	Go	_	
157-12	32796-32797	/	_	
157-13	32797-32802	No-Go	_	
157-14	32803-32812	increased	_	
157-15	32813-32817	fMRI	_	
157-16	32818-32830	task-related	_	
157-17	32831-32837	neural	_	
157-18	32838-32846	activity	_	
157-19	32847-32849	in	_	
157-20	32850-32851	a	_	
157-21	32852-32858	manner	_	
157-22	32859-32863	that	_	
157-23	32864-32873	partially	_	
157-24	32874-32875	‘	_	
157-25	32875-32885	normalized	_	
157-26	32885-32886	’	_	
157-27	32887-32897	functional	_	
157-28	32898-32906	activity	_	
157-29	32907-32909	in	_	
157-30	32910-32916	active	_	
157-31	32917-32924	cocaine	_	
157-32	32925-32930	users	_	
157-33	32930-32931	.	_	

#Text=More specifically, following intravenous injection of cocaine (relative to intravenous saline) active cocaine users had higher successful-inhibition-related activity in right insula/IFG and right middle frontal gyrus (MFG) and higher error-related activity in right posterior cingulate/lingual gyrus, culmen of vermis/left lingual gyrus, left inferior parietal lobule (IPL) and right middle frontal gyrus, and decreased activity in left posterior cingulate on a Go/No-Go task.
158-1	32932-32936	More	_	
158-2	32937-32949	specifically	_	
158-3	32949-32950	,	_	
158-4	32951-32960	following	_	
158-5	32961-32972	intravenous	_	
158-6	32973-32982	injection	_	
158-7	32983-32985	of	_	
158-8	32986-32993	cocaine	_	
158-9	32994-32995	(	_	
158-10	32995-33003	relative	_	
158-11	33004-33006	to	_	
158-12	33007-33018	intravenous	_	
158-13	33019-33025	saline	_	
158-14	33025-33026	)	_	
158-15	33027-33033	active	_	
158-16	33034-33041	cocaine	_	
158-17	33042-33047	users	_	
158-18	33048-33051	had	_	
158-19	33052-33058	higher	_	
158-20	33059-33088	successful-inhibition-related	_	
158-21	33089-33097	activity	_	
158-22	33098-33100	in	_	
158-23	33101-33106	right	_	
158-24	33107-33113	insula	_	
158-25	33113-33114	/	_	
158-26	33114-33117	IFG	_	
158-27	33118-33121	and	_	
158-28	33122-33127	right	_	
158-29	33128-33134	middle	_	
158-30	33135-33142	frontal	_	
158-31	33143-33148	gyrus	_	
158-32	33149-33150	(	_	
158-33	33150-33153	MFG	_	
158-34	33153-33154	)	_	
158-35	33155-33158	and	_	
158-36	33159-33165	higher	_	
158-37	33166-33179	error-related	_	
158-38	33180-33188	activity	_	
158-39	33189-33191	in	_	
158-40	33192-33197	right	_	
158-41	33198-33207	posterior	_	
158-42	33208-33217	cingulate	_	
158-43	33217-33218	/	_	
158-44	33218-33225	lingual	_	
158-45	33226-33231	gyrus	_	
158-46	33231-33232	,	_	
158-47	33233-33239	culmen	_	
158-48	33240-33242	of	_	
158-49	33243-33249	vermis	_	
158-50	33249-33250	/	_	
158-51	33250-33254	left	_	
158-52	33255-33262	lingual	_	
158-53	33263-33268	gyrus	_	
158-54	33268-33269	,	_	
158-55	33270-33274	left	_	
158-56	33275-33283	inferior	_	
158-57	33284-33292	parietal	_	
158-58	33293-33299	lobule	_	
158-59	33300-33301	(	_	
158-60	33301-33304	IPL	_	
158-61	33304-33305	)	_	
158-62	33306-33309	and	_	
158-63	33310-33315	right	_	
158-64	33316-33322	middle	_	
158-65	33323-33330	frontal	_	
158-66	33331-33336	gyrus	_	
158-67	33336-33337	,	_	
158-68	33338-33341	and	_	
158-69	33342-33351	decreased	_	
158-70	33352-33360	activity	_	
158-71	33361-33363	in	_	
158-72	33364-33368	left	_	
158-73	33369-33378	posterior	_	
158-74	33379-33388	cingulate	_	
158-75	33389-33391	on	_	
158-76	33392-33393	a	_	
158-77	33394-33396	Go	_	
158-78	33396-33397	/	_	
158-79	33397-33402	No-Go	_	
158-80	33403-33407	task	_	
158-81	33407-33408	.	_	

#Text=When compared with healthy participants from a prior study and using the same ROIs that had previously shown reduced activity in cocaine users, the findings were replicated in this group of cocaine users on saline indicating that cocaine users showed Go/No-Go-related hypo-activation following IV saline, relative to healthy controls, and that IV cocaine increased task-related activity in overlapping regions and abolished the significant hypoactive differences (relative to healthy controls).
159-1	33409-33413	When	_	
159-2	33414-33422	compared	_	
159-3	33423-33427	with	_	
159-4	33428-33435	healthy	_	
159-5	33436-33448	participants	_	
159-6	33449-33453	from	_	
159-7	33454-33455	a	_	
159-8	33456-33461	prior	_	
159-9	33462-33467	study	_	
159-10	33468-33471	and	_	
159-11	33472-33477	using	_	
159-12	33478-33481	the	_	
159-13	33482-33486	same	_	
159-14	33487-33491	ROIs	_	
159-15	33492-33496	that	_	
159-16	33497-33500	had	_	
159-17	33501-33511	previously	_	
159-18	33512-33517	shown	_	
159-19	33518-33525	reduced	_	
159-20	33526-33534	activity	_	
159-21	33535-33537	in	_	
159-22	33538-33545	cocaine	_	
159-23	33546-33551	users	_	
159-24	33551-33552	,	_	
159-25	33553-33556	the	_	
159-26	33557-33565	findings	_	
159-27	33566-33570	were	_	
159-28	33571-33581	replicated	_	
159-29	33582-33584	in	_	
159-30	33585-33589	this	_	
159-31	33590-33595	group	_	
159-32	33596-33598	of	_	
159-33	33599-33606	cocaine	_	
159-34	33607-33612	users	_	
159-35	33613-33615	on	_	
159-36	33616-33622	saline	_	
159-37	33623-33633	indicating	_	
159-38	33634-33638	that	_	
159-39	33639-33646	cocaine	_	
159-40	33647-33652	users	_	
159-41	33653-33659	showed	_	
159-42	33660-33662	Go	_	
159-43	33662-33663	/	_	
159-44	33663-33676	No-Go-related	_	
159-45	33677-33692	hypo-activation	_	
159-46	33693-33702	following	_	
159-47	33703-33705	IV	_	
159-48	33706-33712	saline	_	
159-49	33712-33713	,	_	
159-50	33714-33722	relative	_	
159-51	33723-33725	to	_	
159-52	33726-33733	healthy	_	
159-53	33734-33742	controls	_	
159-54	33742-33743	,	_	
159-55	33744-33747	and	_	
159-56	33748-33752	that	_	
159-57	33753-33755	IV	_	
159-58	33756-33763	cocaine	_	
159-59	33764-33773	increased	_	
159-60	33774-33786	task-related	_	
159-61	33787-33795	activity	_	
159-62	33796-33798	in	_	
159-63	33799-33810	overlapping	_	
159-64	33811-33818	regions	_	
159-65	33819-33822	and	_	
159-66	33823-33832	abolished	_	
159-67	33833-33836	the	_	
159-68	33837-33848	significant	_	
159-69	33849-33859	hypoactive	_	
159-70	33860-33871	differences	_	
159-71	33872-33873	(	_	
159-72	33873-33881	relative	_	
159-73	33882-33884	to	_	
159-74	33885-33892	healthy	_	
159-75	33893-33901	controls	_	
159-76	33901-33902	)	_	
159-77	33902-33903	.	_	

#Text=Furthermore, response-inhibition-related activity is altered non-uniformly throughout abstinence and prior findings from cross-sectional studies remain somewhat mixed.
160-1	33904-33915	Furthermore	_	
160-2	33915-33916	,	_	
160-3	33917-33944	response-inhibition-related	_	
160-4	33945-33953	activity	_	
160-5	33954-33956	is	_	
160-6	33957-33964	altered	_	
160-7	33965-33978	non-uniformly	_	
160-8	33979-33989	throughout	_	
160-9	33990-34000	abstinence	_	
160-10	34001-34004	and	_	
160-11	34005-34010	prior	_	
160-12	34011-34019	findings	_	
160-13	34020-34024	from	_	
160-14	34025-34040	cross-sectional	_	
160-15	34041-34048	studies	_	
160-16	34049-34055	remain	_	
160-17	34056-34064	somewhat	_	
160-18	34065-34070	mixed	_	
160-19	34070-34071	.	_	

#Text=For example, in a cross-sectional study comparing healthy non-users, shorter-term abstinent (1–5weeks) and longer-term abstinent (40–120 weeks) cocaine users, fMRI Go/No-Go task-related activity differed across groups in several brain regions.
161-1	34072-34075	For	_	
161-2	34076-34083	example	_	
161-3	34083-34084	,	_	
161-4	34085-34087	in	_	
161-5	34088-34089	a	_	
161-6	34090-34105	cross-sectional	_	
161-7	34106-34111	study	_	
161-8	34112-34121	comparing	_	
161-9	34122-34129	healthy	_	
161-10	34130-34139	non-users	_	
161-11	34139-34140	,	_	
161-12	34141-34153	shorter-term	_	
161-13	34154-34163	abstinent	_	
161-14	34164-34165	(	_	
161-15	34165-34166	1	_	
161-16	34166-34167	–	_	
161-17	34167-34173	5weeks	_	
161-18	34173-34174	)	_	
161-19	34175-34178	and	_	
161-20	34179-34190	longer-term	_	
161-21	34191-34200	abstinent	_	
161-22	34201-34202	(	_	
161-23	34202-34204	40	_	
161-24	34204-34205	–	_	
161-25	34205-34208	120	_	
161-26	34209-34214	weeks	_	
161-27	34214-34215	)	_	
161-28	34216-34223	cocaine	_	
161-29	34224-34229	users	_	
161-30	34229-34230	,	_	
161-31	34231-34235	fMRI	_	
161-32	34236-34238	Go	_	
161-33	34238-34239	/	_	
161-34	34239-34244	No-Go	_	
161-35	34245-34257	task-related	_	
161-36	34258-34266	activity	_	
161-37	34267-34275	differed	_	
161-38	34276-34282	across	_	
161-39	34283-34289	groups	_	
161-40	34290-34292	in	_	
161-41	34293-34300	several	_	
161-42	34301-34306	brain	_	
161-43	34307-34314	regions	_	
161-44	34314-34315	.	_	

#Text=However, longer duration of abstinence was not necessarily associated with a change towards normalization (i.e., becoming closer to the healthy control group); rather, neural activity in some regions was more ‘abnormal’ in the longer-term abstinence group, which might reflect compensation.
162-1	34316-34323	However	_	
162-2	34323-34324	,	_	
162-3	34325-34331	longer	_	
162-4	34332-34340	duration	_	
162-5	34341-34343	of	_	
162-6	34344-34354	abstinence	_	
162-7	34355-34358	was	_	
162-8	34359-34362	not	_	
162-9	34363-34374	necessarily	_	
162-10	34375-34385	associated	_	
162-11	34386-34390	with	_	
162-12	34391-34392	a	_	
162-13	34393-34399	change	_	
162-14	34400-34407	towards	_	
162-15	34408-34421	normalization	_	
162-16	34422-34423	(	_	
162-17	34423-34426	i.e	_	
162-18	34426-34427	.	_	
162-19	34427-34428	,	_	
162-20	34429-34437	becoming	_	
162-21	34438-34444	closer	_	
162-22	34445-34447	to	_	
162-23	34448-34451	the	_	
162-24	34452-34459	healthy	_	
162-25	34460-34467	control	_	
162-26	34468-34473	group	_	
162-27	34473-34474	)	_	
162-28	34474-34475	;	_	
162-29	34476-34482	rather	_	
162-30	34482-34483	,	_	
162-31	34484-34490	neural	_	
162-32	34491-34499	activity	_	
162-33	34500-34502	in	_	
162-34	34503-34507	some	_	
162-35	34508-34515	regions	_	
162-36	34516-34519	was	_	
162-37	34520-34524	more	_	
162-38	34525-34526	‘	_	
162-39	34526-34534	abnormal	_	
162-40	34534-34535	’	_	
162-41	34536-34538	in	_	
162-42	34539-34542	the	_	
162-43	34543-34554	longer-term	_	
162-44	34555-34565	abstinence	_	
162-45	34566-34571	group	_	
162-46	34571-34572	,	_	
162-47	34573-34578	which	_	
162-48	34579-34584	might	_	
162-49	34585-34592	reflect	_	
162-50	34593-34605	compensation	_	
162-51	34605-34606	.	_	

#Text=Furthermore, one study found no statistically significant group differences in fMRI Go/No-Go between healthy controls (N=45) and cocaine-abstinent individuals (average abstinence 32.3 weeks; range <1 −100 weeks) who were recruited from intensive inpatient treatment for cocaine-use disorder (N=27).
163-1	34607-34618	Furthermore	_	
163-2	34618-34619	,	_	
163-3	34620-34623	one	_	
163-4	34624-34629	study	_	
163-5	34630-34635	found	_	
163-6	34636-34638	no	_	
163-7	34639-34652	statistically	_	
163-8	34653-34664	significant	_	
163-9	34665-34670	group	_	
163-10	34671-34682	differences	_	
163-11	34683-34685	in	_	
163-12	34686-34690	fMRI	_	
163-13	34691-34693	Go	_	
163-14	34693-34694	/	_	
163-15	34694-34699	No-Go	_	
163-16	34700-34707	between	_	
163-17	34708-34715	healthy	_	
163-18	34716-34724	controls	_	
163-19	34725-34726	(	_	
163-20	34726-34727	N	_	
163-21	34727-34728	=	_	
163-22	34728-34730	45	_	
163-23	34730-34731	)	_	
163-24	34732-34735	and	_	
163-25	34736-34753	cocaine-abstinent	_	
163-26	34754-34765	individuals	_	
163-27	34766-34767	(	_	
163-28	34767-34774	average	_	
163-29	34775-34785	abstinence	_	
163-30	34786-34790	32.3	_	
163-31	34791-34796	weeks	_	
163-32	34796-34797	;	_	
163-33	34798-34803	range	_	
163-34	34804-34805	<	_	
163-35	34805-34806	1	_	
163-36	34807-34808	−	_	
163-37	34808-34811	100	_	
163-38	34812-34817	weeks	_	
163-39	34817-34818	)	_	
163-40	34819-34822	who	_	
163-41	34823-34827	were	_	
163-42	34828-34837	recruited	_	
163-43	34838-34842	from	_	
163-44	34843-34852	intensive	_	
163-45	34853-34862	inpatient	_	
163-46	34863-34872	treatment	_	
163-47	34873-34876	for	_	
163-48	34877-34888	cocaine-use	_	
163-49	34889-34897	disorder	_	
163-50	34898-34899	(	_	
163-51	34899-34900	N	_	
163-52	34900-34901	=	_	
163-53	34901-34903	27	_	
163-54	34903-34904	)	_	
163-55	34904-34905	.	_	

#Text=In contrast, a separate Go/No-Go fMRI study found no group differences during successful inhibitions, but during commission errors found that both current (N=30) and former cocaine users (N=29; average duration of abstinence 51.2 weeks) differed from healthy controls (N=35), with former cocaine users showing differences from healthy controls in more a priori regions of interest than current cocaine users.
164-1	34906-34908	In	_	
164-2	34909-34917	contrast	_	
164-3	34917-34918	,	_	
164-4	34919-34920	a	_	
164-5	34921-34929	separate	_	
164-6	34930-34932	Go	_	
164-7	34932-34933	/	_	
164-8	34933-34938	No-Go	_	
164-9	34939-34943	fMRI	_	
164-10	34944-34949	study	_	
164-11	34950-34955	found	_	
164-12	34956-34958	no	_	
164-13	34959-34964	group	_	
164-14	34965-34976	differences	_	
164-15	34977-34983	during	_	
164-16	34984-34994	successful	_	
164-17	34995-35006	inhibitions	_	
164-18	35006-35007	,	_	
164-19	35008-35011	but	_	
164-20	35012-35018	during	_	
164-21	35019-35029	commission	_	
164-22	35030-35036	errors	_	
164-23	35037-35042	found	_	
164-24	35043-35047	that	_	
164-25	35048-35052	both	_	
164-26	35053-35060	current	_	
164-27	35061-35062	(	_	
164-28	35062-35063	N	_	
164-29	35063-35064	=	_	
164-30	35064-35066	30	_	
164-31	35066-35067	)	_	
164-32	35068-35071	and	_	
164-33	35072-35078	former	_	
164-34	35079-35086	cocaine	_	
164-35	35087-35092	users	_	
164-36	35093-35094	(	_	
164-37	35094-35095	N	_	
164-38	35095-35096	=	_	
164-39	35096-35098	29	_	
164-40	35098-35099	;	_	
164-41	35100-35107	average	_	
164-42	35108-35116	duration	_	
164-43	35117-35119	of	_	
164-44	35120-35130	abstinence	_	
164-45	35131-35135	51.2	_	
164-46	35136-35141	weeks	_	
164-47	35141-35142	)	_	
164-48	35143-35151	differed	_	
164-49	35152-35156	from	_	
164-50	35157-35164	healthy	_	
164-51	35165-35173	controls	_	
164-52	35174-35175	(	_	
164-53	35175-35176	N	_	
164-54	35176-35177	=	_	
164-55	35177-35179	35	_	
164-56	35179-35180	)	_	
164-57	35180-35181	,	_	
164-58	35182-35186	with	_	
164-59	35187-35193	former	_	
164-60	35194-35201	cocaine	_	
164-61	35202-35207	users	_	
164-62	35208-35215	showing	_	
164-63	35216-35227	differences	_	
164-64	35228-35232	from	_	
164-65	35233-35240	healthy	_	
164-66	35241-35249	controls	_	
164-67	35250-35252	in	_	
164-68	35253-35257	more	_	
164-69	35258-35259	a	_	
164-70	35260-35266	priori	_	
164-71	35267-35274	regions	_	
164-72	35275-35277	of	_	
164-73	35278-35286	interest	_	
164-74	35287-35291	than	_	
164-75	35292-35299	current	_	
164-76	35300-35307	cocaine	_	
164-77	35308-35313	users	_	
164-78	35313-35314	.	_	

#Text=However, cocaine use or abstinence did not appear to be substantial factors driving the current findings since changes in Stroop-related BOLD-signal measures within treatment did not correlate with activity in the same regions as did measures of cocaine abstinence during treatment.
165-1	35315-35322	However	_	
165-2	35322-35323	,	_	
165-3	35324-35331	cocaine	_	
165-4	35332-35335	use	_	
165-5	35336-35338	or	_	
165-6	35339-35349	abstinence	_	
165-7	35350-35353	did	_	
165-8	35354-35357	not	_	
165-9	35358-35364	appear	_	
165-10	35365-35367	to	_	
165-11	35368-35370	be	_	
165-12	35371-35382	substantial	_	
165-13	35383-35390	factors	_	
165-14	35391-35398	driving	_	
165-15	35399-35402	the	_	
165-16	35403-35410	current	_	
165-17	35411-35419	findings	_	
165-18	35420-35425	since	_	
165-19	35426-35433	changes	_	
165-20	35434-35436	in	_	
165-21	35437-35451	Stroop-related	_	
165-22	35452-35463	BOLD-signal	_	
165-23	35464-35472	measures	_	
165-24	35473-35479	within	_	
165-25	35480-35489	treatment	_	
165-26	35490-35493	did	_	
165-27	35494-35497	not	_	
165-28	35498-35507	correlate	_	
165-29	35508-35512	with	_	
165-30	35513-35521	activity	_	
165-31	35522-35524	in	_	
165-32	35525-35528	the	_	
165-33	35529-35533	same	_	
165-34	35534-35541	regions	_	
165-35	35542-35544	as	_	
165-36	35545-35548	did	_	
165-37	35549-35557	measures	_	
165-38	35558-35560	of	_	
165-39	35561-35568	cocaine	_	
165-40	35569-35579	abstinence	_	
165-41	35580-35586	during	_	
165-42	35587-35596	treatment	_	
165-43	35596-35597	.	_	

#Text=When interpreting the pattern of change in task-related activity following treatment, it may be important to note that clinical improvements may not always be accompanied by functional changes in the direction of ‘normalization’.
166-1	35598-35602	When	_	
166-2	35603-35615	interpreting	_	
166-3	35616-35619	the	_	
166-4	35620-35627	pattern	_	
166-5	35628-35630	of	_	
166-6	35631-35637	change	_	
166-7	35638-35640	in	_	
166-8	35641-35653	task-related	_	
166-9	35654-35662	activity	_	
166-10	35663-35672	following	_	
166-11	35673-35682	treatment	_	
166-12	35682-35683	,	_	
166-13	35684-35686	it	_	
166-14	35687-35690	may	_	
166-15	35691-35693	be	_	
166-16	35694-35703	important	_	
166-17	35704-35706	to	_	
166-18	35707-35711	note	_	
166-19	35712-35716	that	_	
166-20	35717-35725	clinical	_	
166-21	35726-35738	improvements	_	
166-22	35739-35742	may	_	
166-23	35743-35746	not	_	
166-24	35747-35753	always	_	
166-25	35754-35756	be	_	
166-26	35757-35768	accompanied	_	
166-27	35769-35771	by	_	
166-28	35772-35782	functional	_	
166-29	35783-35790	changes	_	
166-30	35791-35793	in	_	
166-31	35794-35797	the	_	
166-32	35798-35807	direction	_	
166-33	35808-35810	of	_	
166-34	35811-35812	‘	_	
166-35	35812-35825	normalization	_	
166-36	35825-35826	’	_	
166-37	35826-35827	.	_	

#Text=Rather, substance-use treatments may act through both adaptation and ‘normalization’ of functional activity.
167-1	35828-35834	Rather	_	
167-2	35834-35835	,	_	
167-3	35836-35849	substance-use	_	
167-4	35850-35860	treatments	_	
167-5	35861-35864	may	_	
167-6	35865-35868	act	_	
167-7	35869-35876	through	_	
167-8	35877-35881	both	_	
167-9	35882-35892	adaptation	_	
167-10	35893-35896	and	_	
167-11	35897-35898	‘	_	
167-12	35898-35911	normalization	_	
167-13	35911-35912	’	_	
167-14	35913-35915	of	_	
167-15	35916-35926	functional	_	
167-16	35927-35935	activity	_	
167-17	35935-35936	.	_	

#Text=For example, modafinil further increased hyperactive task-related functional activity in the ACC in cocaine users, relative to non-substance-using comparisons, and this increased activity was associated with diminished cocaine-craving.
168-1	35937-35940	For	_	
168-2	35941-35948	example	_	
168-3	35948-35949	,	_	
168-4	35950-35959	modafinil	_	
168-5	35960-35967	further	_	
168-6	35968-35977	increased	_	
168-7	35978-35989	hyperactive	_	
168-8	35990-36002	task-related	_	
168-9	36003-36013	functional	_	
168-10	36014-36022	activity	_	
168-11	36023-36025	in	_	
168-12	36026-36029	the	_	
168-13	36030-36033	ACC	_	
168-14	36034-36036	in	_	
168-15	36037-36044	cocaine	_	
168-16	36045-36050	users	_	
168-17	36050-36051	,	_	
168-18	36052-36060	relative	_	
168-19	36061-36063	to	_	
168-20	36064-36083	non-substance-using	_	
168-21	36084-36095	comparisons	_	
168-22	36095-36096	,	_	
168-23	36097-36100	and	_	
168-24	36101-36105	this	_	
168-25	36106-36115	increased	_	
168-26	36116-36124	activity	_	
168-27	36125-36128	was	_	
168-28	36129-36139	associated	_	
168-29	36140-36144	with	_	
168-30	36145-36155	diminished	_	
168-31	36156-36171	cocaine-craving	_	
168-32	36171-36172	.	_	

#Text=Furthermore, duration of abstinence is not necessarily associated with a change towards normalization (i.e., becoming closer to the healthy control group). , This may reflect the complex interplay between pre-existing vulnerabilities and drug-induced neuroadaptation in substance users.
169-1	36173-36184	Furthermore	_	
169-2	36184-36185	,	_	
169-3	36186-36194	duration	_	
169-4	36195-36197	of	_	
169-5	36198-36208	abstinence	_	
169-6	36209-36211	is	_	
169-7	36212-36215	not	_	
169-8	36216-36227	necessarily	_	
169-9	36228-36238	associated	_	
169-10	36239-36243	with	_	
169-11	36244-36245	a	_	
169-12	36246-36252	change	_	
169-13	36253-36260	towards	_	
169-14	36261-36274	normalization	_	
169-15	36275-36276	(	_	
169-16	36276-36279	i.e	_	
169-17	36279-36280	.	_	
169-18	36280-36281	,	_	
169-19	36282-36290	becoming	_	
169-20	36291-36297	closer	_	
169-21	36298-36300	to	_	
169-22	36301-36304	the	_	
169-23	36305-36312	healthy	_	
169-24	36313-36320	control	_	
169-25	36321-36326	group	_	
169-26	36326-36327	)	_	
169-27	36327-36328	.	_	
169-28	36329-36330	,	_	
169-29	36331-36335	This	_	
169-30	36336-36339	may	_	
169-31	36340-36347	reflect	_	
169-32	36348-36351	the	_	
169-33	36352-36359	complex	_	
169-34	36360-36369	interplay	_	
169-35	36370-36377	between	_	
169-36	36378-36390	pre-existing	_	
169-37	36391-36406	vulnerabilities	_	
169-38	36407-36410	and	_	
169-39	36411-36423	drug-induced	_	
169-40	36424-36439	neuroadaptation	_	
169-41	36440-36442	in	_	
169-42	36443-36452	substance	_	
169-43	36453-36458	users	_	
169-44	36458-36459	.	_	

#Text=Namely, pre-morbid functional abnormalities may confer vulnerability to SUDs and drugs may have acute and prolonged effects on brain function, and some drug-induced abnormalities may persist through prolonged abstinence.
170-1	36460-36466	Namely	_	
170-2	36466-36467	,	_	
170-3	36468-36478	pre-morbid	_	
170-4	36479-36489	functional	_	
170-5	36490-36503	abnormalities	_	
170-6	36504-36507	may	_	
170-7	36508-36514	confer	_	
170-8	36515-36528	vulnerability	_	
170-9	36529-36531	to	_	
170-10	36532-36536	SUDs	_	
170-11	36537-36540	and	_	
170-12	36541-36546	drugs	_	
170-13	36547-36550	may	_	
170-14	36551-36555	have	_	
170-15	36556-36561	acute	_	
170-16	36562-36565	and	_	
170-17	36566-36575	prolonged	_	
170-18	36576-36583	effects	_	
170-19	36584-36586	on	_	
170-20	36587-36592	brain	_	
170-21	36593-36601	function	_	
170-22	36601-36602	,	_	
170-23	36603-36606	and	_	
170-24	36607-36611	some	_	
170-25	36612-36624	drug-induced	_	
170-26	36625-36638	abnormalities	_	
170-27	36639-36642	may	_	
170-28	36643-36650	persist	_	
170-29	36651-36658	through	_	
170-30	36659-36668	prolonged	_	
170-31	36669-36679	abstinence	_	
170-32	36679-36680	.	_	

#Text=Therefore, abstinence may not return individuals to pre-substance-use-disorder baselines, and pre-morbid baselines may be suboptimal treatment targets as they may not represent ‘normalizations’ of functional activity relative to healthy non-drug-users with low SUD-vulnerability (see for review of changes with substance-use onset and predictors of treatment outcome).
171-1	36681-36690	Therefore	_	
171-2	36690-36691	,	_	
171-3	36692-36702	abstinence	_	
171-4	36703-36706	may	_	
171-5	36707-36710	not	_	
171-6	36711-36717	return	_	
171-7	36718-36729	individuals	_	
171-8	36730-36732	to	_	
171-9	36733-36759	pre-substance-use-disorder	_	
171-10	36760-36769	baselines	_	
171-11	36769-36770	,	_	
171-12	36771-36774	and	_	
171-13	36775-36785	pre-morbid	_	
171-14	36786-36795	baselines	_	
171-15	36796-36799	may	_	
171-16	36800-36802	be	_	
171-17	36803-36813	suboptimal	_	
171-18	36814-36823	treatment	_	
171-19	36824-36831	targets	_	
171-20	36832-36834	as	_	
171-21	36835-36839	they	_	
171-22	36840-36843	may	_	
171-23	36844-36847	not	_	
171-24	36848-36857	represent	_	
171-25	36858-36859	‘	_	
171-26	36859-36873	normalizations	_	
171-27	36873-36874	’	_	
171-28	36875-36877	of	_	
171-29	36878-36888	functional	_	
171-30	36889-36897	activity	_	
171-31	36898-36906	relative	_	
171-32	36907-36909	to	_	
171-33	36910-36917	healthy	_	
171-34	36918-36932	non-drug-users	_	
171-35	36933-36937	with	_	
171-36	36938-36941	low	_	
171-37	36942-36959	SUD-vulnerability	_	
171-38	36960-36961	(	_	
171-39	36961-36964	see	_	
171-40	36965-36968	for	_	
171-41	36969-36975	review	_	
171-42	36976-36978	of	_	
171-43	36979-36986	changes	_	
171-44	36987-36991	with	_	
171-45	36992-37005	substance-use	_	
171-46	37006-37011	onset	_	
171-47	37012-37015	and	_	
171-48	37016-37026	predictors	_	
171-49	37027-37029	of	_	
171-50	37030-37039	treatment	_	
171-51	37040-37047	outcome	_	
171-52	37047-37048	)	_	
171-53	37048-37049	.	_	

#Text=These complexities underline the limits of using healthy case-comparisons to derive treatment targets and reinforce the importance of testing treatment-related change within substance abusers and relating these changes to treatment mechanisms.
172-1	37050-37055	These	_	
172-2	37056-37068	complexities	_	
172-3	37069-37078	underline	_	
172-4	37079-37082	the	_	
172-5	37083-37089	limits	_	
172-6	37090-37092	of	_	
172-7	37093-37098	using	_	
172-8	37099-37106	healthy	_	
172-9	37107-37123	case-comparisons	_	
172-10	37124-37126	to	_	
172-11	37127-37133	derive	_	
172-12	37134-37143	treatment	_	
172-13	37144-37151	targets	_	
172-14	37152-37155	and	_	
172-15	37156-37165	reinforce	_	
172-16	37166-37169	the	_	
172-17	37170-37180	importance	_	
172-18	37181-37183	of	_	
172-19	37184-37191	testing	_	
172-20	37192-37209	treatment-related	_	
172-21	37210-37216	change	_	
172-22	37217-37223	within	_	
172-23	37224-37233	substance	_	
172-24	37234-37241	abusers	_	
172-25	37242-37245	and	_	
172-26	37246-37254	relating	_	
172-27	37255-37260	these	_	
172-28	37261-37268	changes	_	
172-29	37269-37271	to	_	
172-30	37272-37281	treatment	_	
172-31	37282-37292	mechanisms	_	
172-32	37292-37293	.	_	

#Text=However, taken together, greater diminishment of Stroop-related activity across treatment and its association with exposure to treatment components could be consistent with greater improvements in efficiency with more treatment exposure.
173-1	37294-37301	However	_	
173-2	37301-37302	,	_	
173-3	37303-37308	taken	_	
173-4	37309-37317	together	_	
173-5	37317-37318	,	_	
173-6	37319-37326	greater	_	
173-7	37327-37339	diminishment	_	
173-8	37340-37342	of	_	
173-9	37343-37357	Stroop-related	_	
173-10	37358-37366	activity	_	
173-11	37367-37373	across	_	
173-12	37374-37383	treatment	_	
173-13	37384-37387	and	_	
173-14	37388-37391	its	_	
173-15	37392-37403	association	_	
173-16	37404-37408	with	_	
173-17	37409-37417	exposure	_	
173-18	37418-37420	to	_	
173-19	37421-37430	treatment	_	
173-20	37431-37441	components	_	
173-21	37442-37447	could	_	
173-22	37448-37450	be	_	
173-23	37451-37461	consistent	_	
173-24	37462-37466	with	_	
173-25	37467-37474	greater	_	
173-26	37475-37487	improvements	_	
173-27	37488-37490	in	_	
173-28	37491-37501	efficiency	_	
173-29	37502-37506	with	_	
173-30	37507-37511	more	_	
173-31	37512-37521	treatment	_	
173-32	37522-37530	exposure	_	
173-33	37530-37531	.	_	

#Text=Clinical Implications and Mechanisms of Action
#Text=Within the thalamus, failed-inhibition-related activity is greater in individuals with CUD in earlier versus later stages of abstinence and positively associated with subjective feelings of loss of control.
174-1	37532-37540	Clinical	_	
174-2	37541-37553	Implications	_	
174-3	37554-37557	and	_	
174-4	37558-37568	Mechanisms	_	
174-5	37569-37571	of	_	
174-6	37572-37578	Action	_	
174-7	37579-37585	Within	_	
174-8	37586-37589	the	_	
174-9	37590-37598	thalamus	_	
174-10	37598-37599	,	_	
174-11	37600-37625	failed-inhibition-related	_	
174-12	37626-37634	activity	_	
174-13	37635-37637	is	_	
174-14	37638-37645	greater	_	
174-15	37646-37648	in	_	
174-16	37649-37660	individuals	_	
174-17	37661-37665	with	_	
174-18	37666-37669	CUD	_	
174-19	37670-37672	in	_	
174-20	37673-37680	earlier	_	
174-21	37681-37687	versus	_	
174-22	37688-37693	later	_	
174-23	37694-37700	stages	_	
174-24	37701-37703	of	_	
174-25	37704-37714	abstinence	_	
174-26	37715-37718	and	_	
174-27	37719-37729	positively	_	
174-28	37730-37740	associated	_	
174-29	37741-37745	with	_	
174-30	37746-37756	subjective	_	
174-31	37757-37765	feelings	_	
174-32	37766-37768	of	_	
174-33	37769-37773	loss	_	
174-34	37774-37776	of	_	
174-35	37777-37784	control	_	
174-36	37784-37785	.	_	

#Text=Thalamo-cortical connectivity is important in ‘bottom-up’ cognitive-control in CUD.
175-1	37786-37802	Thalamo-cortical	_	
175-2	37803-37815	connectivity	_	
175-3	37816-37818	is	_	
175-4	37819-37828	important	_	
175-5	37829-37831	in	_	
175-6	37832-37833	‘	_	
175-7	37833-37842	bottom-up	_	
175-8	37842-37843	’	_	
175-9	37844-37861	cognitive-control	_	
175-10	37862-37864	in	_	
175-11	37865-37868	CUD	_	
175-12	37868-37869	.	_	

#Text=Performance-monitoring, including error-processing and behavioral adjustment, is crucial to successful cognitive-control and impaired in cocaine-dependent individuals.
176-1	37870-37892	Performance-monitoring	_	
176-2	37892-37893	,	_	
176-3	37894-37903	including	_	
176-4	37904-37920	error-processing	_	
176-5	37921-37924	and	_	
176-6	37925-37935	behavioral	_	
176-7	37936-37946	adjustment	_	
176-8	37946-37947	,	_	
176-9	37948-37950	is	_	
176-10	37951-37958	crucial	_	
176-11	37959-37961	to	_	
176-12	37962-37972	successful	_	
176-13	37973-37990	cognitive-control	_	
176-14	37991-37994	and	_	
176-15	37995-38003	impaired	_	
176-16	38004-38006	in	_	
176-17	38007-38024	cocaine-dependent	_	
176-18	38025-38036	individuals	_	
176-19	38036-38037	.	_	

#Text=The ACC has been implicated in cocaine craving and has a well-established role in response conflict monitoring.
177-1	38038-38041	The	_	
177-2	38042-38045	ACC	_	
177-3	38046-38049	has	_	
177-4	38050-38054	been	_	
177-5	38055-38065	implicated	_	
177-6	38066-38068	in	_	
177-7	38069-38076	cocaine	_	
177-8	38077-38084	craving	_	
177-9	38085-38088	and	_	
177-10	38089-38092	has	_	
177-11	38093-38094	a	_	
177-12	38095-38111	well-established	_	
177-13	38112-38116	role	_	
177-14	38117-38119	in	_	
177-15	38120-38128	response	_	
177-16	38129-38137	conflict	_	
177-17	38138-38148	monitoring	_	
177-18	38148-38149	.	_	

#Text=Thus, our findings of reduced Stroop-effect-related thalamic and cingulate activity at post-treatment relative to beginning-of-treatment in the sample overall may be consistent with greater efficiency of cognitive-control and performance-monitoring following treatment.
178-1	38150-38154	Thus	_	
178-2	38154-38155	,	_	
178-3	38156-38159	our	_	
178-4	38160-38168	findings	_	
178-5	38169-38171	of	_	
178-6	38172-38179	reduced	_	
178-7	38180-38201	Stroop-effect-related	_	
178-8	38202-38210	thalamic	_	
178-9	38211-38214	and	_	
178-10	38215-38224	cingulate	_	
178-11	38225-38233	activity	_	
178-12	38234-38236	at	_	
178-13	38237-38251	post-treatment	_	
178-14	38252-38260	relative	_	
178-15	38261-38263	to	_	
178-16	38264-38286	beginning-of-treatment	_	
178-17	38287-38289	in	_	
178-18	38290-38293	the	_	
178-19	38294-38300	sample	_	
178-20	38301-38308	overall	_	
178-21	38309-38312	may	_	
178-22	38313-38315	be	_	
178-23	38316-38326	consistent	_	
178-24	38327-38331	with	_	
178-25	38332-38339	greater	_	
178-26	38340-38350	efficiency	_	
178-27	38351-38353	of	_	
178-28	38354-38371	cognitive-control	_	
178-29	38372-38375	and	_	
178-30	38376-38398	performance-monitoring	_	
178-31	38399-38408	following	_	
178-32	38409-38418	treatment	_	
178-33	38418-38419	.	_	

#Text=The medial frontal gyrus has been implicated in the cognitive regulation of craving.
179-1	38420-38423	The	_	
179-2	38424-38430	medial	_	
179-3	38431-38438	frontal	_	
179-4	38439-38444	gyrus	_	
179-5	38445-38448	has	_	
179-6	38449-38453	been	_	
179-7	38454-38464	implicated	_	
179-8	38465-38467	in	_	
179-9	38468-38471	the	_	
179-10	38472-38481	cognitive	_	
179-11	38482-38492	regulation	_	
179-12	38493-38495	of	_	
179-13	38496-38503	craving	_	
179-14	38503-38504	.	_	

#Text=Training in recognizing and coping with craving is central to CBT.
180-1	38505-38513	Training	_	
180-2	38514-38516	in	_	
180-3	38517-38528	recognizing	_	
180-4	38529-38532	and	_	
180-5	38533-38539	coping	_	
180-6	38540-38544	with	_	
180-7	38545-38552	craving	_	
180-8	38553-38555	is	_	
180-9	38556-38563	central	_	
180-10	38564-38566	to	_	
180-11	38567-38570	CBT	_	
180-12	38570-38571	.	_	

#Text=Therefore, correlations between greater reductions in Stroop-related activity in the medial frontal gyrus and more CBT sessions attended, but not other treatment components, may be consistent with ‘top-down’ regulation of attention-related processes as a treatment mechanism of CBT 
#Text=Disulfiram doses did not correlate with change in cognitive-control-related activity in any clusters.
181-1	38572-38581	Therefore	_	
181-2	38581-38582	,	_	
181-3	38583-38595	correlations	_	
181-4	38596-38603	between	_	
181-5	38604-38611	greater	_	
181-6	38612-38622	reductions	_	
181-7	38623-38625	in	_	
181-8	38626-38640	Stroop-related	_	
181-9	38641-38649	activity	_	
181-10	38650-38652	in	_	
181-11	38653-38656	the	_	
181-12	38657-38663	medial	_	
181-13	38664-38671	frontal	_	
181-14	38672-38677	gyrus	_	
181-15	38678-38681	and	_	
181-16	38682-38686	more	_	
181-17	38687-38690	CBT	_	
181-18	38691-38699	sessions	_	
181-19	38700-38708	attended	_	
181-20	38708-38709	,	_	
181-21	38710-38713	but	_	
181-22	38714-38717	not	_	
181-23	38718-38723	other	_	
181-24	38724-38733	treatment	_	
181-25	38734-38744	components	_	
181-26	38744-38745	,	_	
181-27	38746-38749	may	_	
181-28	38750-38752	be	_	
181-29	38753-38763	consistent	_	
181-30	38764-38768	with	_	
181-31	38769-38770	‘	_	
181-32	38770-38778	top-down	_	
181-33	38778-38779	’	_	
181-34	38780-38790	regulation	_	
181-35	38791-38793	of	_	
181-36	38794-38811	attention-related	_	
181-37	38812-38821	processes	_	
181-38	38822-38824	as	_	
181-39	38825-38826	a	_	
181-40	38827-38836	treatment	_	
181-41	38837-38846	mechanism	_	
181-42	38847-38849	of	_	
181-43	38850-38853	CBT	_	
181-44	38855-38865	Disulfiram	_	
181-45	38866-38871	doses	_	
181-46	38872-38875	did	_	
181-47	38876-38879	not	_	
181-48	38880-38889	correlate	_	
181-49	38890-38894	with	_	
181-50	38895-38901	change	_	
181-51	38902-38904	in	_	
181-52	38905-38930	cognitive-control-related	_	
181-53	38931-38939	activity	_	
181-54	38940-38942	in	_	
181-55	38943-38946	any	_	
181-56	38947-38955	clusters	_	
181-57	38955-38956	.	_	

#Text=This may reflect the weak therapeutic efficacy of disulfiram in this RCT and moderate efficacy in prior trials and may suggest that disulfiram’s therapeutic mechanism of action is not likely related to cognitive-control, although a larger sample of individuals receiving disulfiram is needed to make more definitive statements.
182-1	38957-38961	This	_	
182-2	38962-38965	may	_	
182-3	38966-38973	reflect	_	
182-4	38974-38977	the	_	
182-5	38978-38982	weak	_	
182-6	38983-38994	therapeutic	_	
182-7	38995-39003	efficacy	_	
182-8	39004-39006	of	_	
182-9	39007-39017	disulfiram	_	
182-10	39018-39020	in	_	
182-11	39021-39025	this	_	
182-12	39026-39029	RCT	_	
182-13	39030-39033	and	_	
182-14	39034-39042	moderate	_	
182-15	39043-39051	efficacy	_	
182-16	39052-39054	in	_	
182-17	39055-39060	prior	_	
182-18	39061-39067	trials	_	
182-19	39068-39071	and	_	
182-20	39072-39075	may	_	
182-21	39076-39083	suggest	_	
182-22	39084-39088	that	_	
182-23	39089-39099	disulfiram	_	
182-24	39099-39100	’	_	
182-25	39100-39101	s	_	
182-26	39102-39113	therapeutic	_	
182-27	39114-39123	mechanism	_	
182-28	39124-39126	of	_	
182-29	39127-39133	action	_	
182-30	39134-39136	is	_	
182-31	39137-39140	not	_	
182-32	39141-39147	likely	_	
182-33	39148-39155	related	_	
182-34	39156-39158	to	_	
182-35	39159-39176	cognitive-control	_	
182-36	39176-39177	,	_	
182-37	39178-39186	although	_	
182-38	39187-39188	a	_	
182-39	39189-39195	larger	_	
182-40	39196-39202	sample	_	
182-41	39203-39205	of	_	
182-42	39206-39217	individuals	_	
182-43	39218-39227	receiving	_	
182-44	39228-39238	disulfiram	_	
182-45	39239-39241	is	_	
182-46	39242-39248	needed	_	
182-47	39249-39251	to	_	
182-48	39252-39256	make	_	
182-49	39257-39261	more	_	
182-50	39262-39272	definitive	_	
182-51	39273-39283	statements	_	
182-52	39283-39284	.	_	

#Text=Limitations
#Text=Strengths of this manuscript included availability of beginning of and post-treatment fMRI data from a factorial RCTs testing three well-systematized evidence-based therapies, which also included objective indices of treatment process.
183-1	39285-39296	Limitations	_	
183-2	39297-39306	Strengths	_	
183-3	39307-39309	of	_	
183-4	39310-39314	this	_	
183-5	39315-39325	manuscript	_	
183-6	39326-39334	included	_	
183-7	39335-39347	availability	_	
183-8	39348-39350	of	_	
183-9	39351-39360	beginning	_	
183-10	39361-39363	of	_	
183-11	39364-39367	and	_	
183-12	39368-39382	post-treatment	_	
183-13	39383-39387	fMRI	_	
183-14	39388-39392	data	_	
183-15	39393-39397	from	_	
183-16	39398-39399	a	_	
183-17	39400-39409	factorial	_	
183-18	39410-39414	RCTs	_	
183-19	39415-39422	testing	_	
183-20	39423-39428	three	_	
183-21	39429-39446	well-systematized	_	
183-22	39447-39461	evidence-based	_	
183-23	39462-39471	therapies	_	
183-24	39471-39472	,	_	
183-25	39473-39478	which	_	
183-26	39479-39483	also	_	
183-27	39484-39492	included	_	
183-28	39493-39502	objective	_	
183-29	39503-39510	indices	_	
183-30	39511-39513	of	_	
183-31	39514-39523	treatment	_	
183-32	39524-39531	process	_	
183-33	39531-39532	.	_	

#Text=The principal limitation is the small sample size, which limited power and precluded a full mediational analysis linking beginning-of-treatment to post-treatment changes in neural activity to exposure to treatment components and cocaine-use outcomes.
184-1	39533-39536	The	_	
184-2	39537-39546	principal	_	
184-3	39547-39557	limitation	_	
184-4	39558-39560	is	_	
184-5	39561-39564	the	_	
184-6	39565-39570	small	_	
184-7	39571-39577	sample	_	
184-8	39578-39582	size	_	
184-9	39582-39583	,	_	
184-10	39584-39589	which	_	
184-11	39590-39597	limited	_	
184-12	39598-39603	power	_	
184-13	39604-39607	and	_	
184-14	39608-39617	precluded	_	
184-15	39618-39619	a	_	
184-16	39620-39624	full	_	
184-17	39625-39636	mediational	_	
184-18	39637-39645	analysis	_	
184-19	39646-39653	linking	_	
184-20	39654-39676	beginning-of-treatment	_	
184-21	39677-39679	to	_	
184-22	39680-39694	post-treatment	_	
184-23	39695-39702	changes	_	
184-24	39703-39705	in	_	
184-25	39706-39712	neural	_	
184-26	39713-39721	activity	_	
184-27	39722-39724	to	_	
184-28	39725-39733	exposure	_	
184-29	39734-39736	to	_	
184-30	39737-39746	treatment	_	
184-31	39747-39757	components	_	
184-32	39758-39761	and	_	
184-33	39762-39773	cocaine-use	_	
184-34	39774-39782	outcomes	_	
184-35	39782-39783	.	_	

#Text=In addition, only a subset of RCT participants participated in the optional fMRI component of the RCT.
185-1	39784-39786	In	_	
185-2	39787-39795	addition	_	
185-3	39795-39796	,	_	
185-4	39797-39801	only	_	
185-5	39802-39803	a	_	
185-6	39804-39810	subset	_	
185-7	39811-39813	of	_	
185-8	39814-39817	RCT	_	
185-9	39818-39830	participants	_	
185-10	39831-39843	participated	_	
185-11	39844-39846	in	_	
185-12	39847-39850	the	_	
185-13	39851-39859	optional	_	
185-14	39860-39864	fMRI	_	
185-15	39865-39874	component	_	
185-16	39875-39877	of	_	
185-17	39878-39881	the	_	
185-18	39882-39885	RCT	_	
185-19	39885-39886	.	_	

#Text=This limitation is mitigated by matching of groups on important baseline variables in the RCT and fMRI samples.
186-1	39887-39891	This	_	
186-2	39892-39902	limitation	_	
186-3	39903-39905	is	_	
186-4	39906-39915	mitigated	_	
186-5	39916-39918	by	_	
186-6	39919-39927	matching	_	
186-7	39928-39930	of	_	
186-8	39931-39937	groups	_	
186-9	39938-39940	on	_	
186-10	39941-39950	important	_	
186-11	39951-39959	baseline	_	
186-12	39960-39969	variables	_	
186-13	39970-39972	in	_	
186-14	39973-39976	the	_	
186-15	39977-39980	RCT	_	
186-16	39981-39984	and	_	
186-17	39985-39989	fMRI	_	
186-18	39990-39997	samples	_	
186-19	39997-39998	.	_	

#Text=Although the RCT included a full-factorial design, fMRI subgroup sample sizes prohibited analysis of CM-by-disulfiram or sex/gender-by-treatment type interactions.
187-1	39999-40007	Although	_	
187-2	40008-40011	the	_	
187-3	40012-40015	RCT	_	
187-4	40016-40024	included	_	
187-5	40025-40026	a	_	
187-6	40027-40041	full-factorial	_	
187-7	40042-40048	design	_	
187-8	40048-40049	,	_	
187-9	40050-40054	fMRI	_	
187-10	40055-40063	subgroup	_	
187-11	40064-40070	sample	_	
187-12	40071-40076	sizes	_	
187-13	40077-40087	prohibited	_	
187-14	40088-40096	analysis	_	
187-15	40097-40099	of	_	
187-16	40100-40116	CM-by-disulfiram	_	
187-17	40117-40119	or	_	
187-18	40120-40123	sex	_	
187-19	40123-40124	/	_	
187-20	40124-40143	gender-by-treatment	_	
187-21	40144-40148	type	_	
187-22	40149-40161	interactions	_	
187-23	40161-40162	.	_	

#Text=Future research is needed since disulfiram may less effectively treat cocaine-use in women than men and cognitive-control-related neural activity may differentially relate to treatment outcomes across sex/gender.
188-1	40163-40169	Future	_	
188-2	40170-40178	research	_	
188-3	40179-40181	is	_	
188-4	40182-40188	needed	_	
188-5	40189-40194	since	_	
188-6	40195-40205	disulfiram	_	
188-7	40206-40209	may	_	
188-8	40210-40214	less	_	
188-9	40215-40226	effectively	_	
188-10	40227-40232	treat	_	
188-11	40233-40244	cocaine-use	_	
188-12	40245-40247	in	_	
188-13	40248-40253	women	_	
188-14	40254-40258	than	_	
188-15	40259-40262	men	_	
188-16	40263-40266	and	_	
188-17	40267-40292	cognitive-control-related	_	
188-18	40293-40299	neural	_	
188-19	40300-40308	activity	_	
188-20	40309-40312	may	_	
188-21	40313-40327	differentially	_	
188-22	40328-40334	relate	_	
188-23	40335-40337	to	_	
188-24	40338-40347	treatment	_	
188-25	40348-40356	outcomes	_	
188-26	40357-40363	across	_	
188-27	40364-40367	sex	_	
188-28	40367-40368	/	_	
188-29	40368-40374	gender	_	
188-30	40374-40375	.	_	

#Text=The current study focused on cognitive-control-related brain function and was therefore only sensitive to treatment-related changes associated with this construct.
189-1	40376-40379	The	_	
189-2	40380-40387	current	_	
189-3	40388-40393	study	_	
189-4	40394-40401	focused	_	
189-5	40402-40404	on	_	
189-6	40405-40430	cognitive-control-related	_	
189-7	40431-40436	brain	_	
189-8	40437-40445	function	_	
189-9	40446-40449	and	_	
189-10	40450-40453	was	_	
189-11	40454-40463	therefore	_	
189-12	40464-40468	only	_	
189-13	40469-40478	sensitive	_	
189-14	40479-40481	to	_	
189-15	40482-40499	treatment-related	_	
189-16	40500-40507	changes	_	
189-17	40508-40518	associated	_	
189-18	40519-40523	with	_	
189-19	40524-40528	this	_	
189-20	40529-40538	construct	_	
189-21	40538-40539	.	_	

#Text=Future research should investigate relationship between treatment components and non-cognitive-control-related mechanisms, using tasks tapping other cognitive constructs with relevance to SUDs (e.g., reward sensitivity, craving).
190-1	40540-40546	Future	_	
190-2	40547-40555	research	_	
190-3	40556-40562	should	_	
190-4	40563-40574	investigate	_	
190-5	40575-40587	relationship	_	
190-6	40588-40595	between	_	
190-7	40596-40605	treatment	_	
190-8	40606-40616	components	_	
190-9	40617-40620	and	_	
190-10	40621-40650	non-cognitive-control-related	_	
190-11	40651-40661	mechanisms	_	
190-12	40661-40662	,	_	
190-13	40663-40668	using	_	
190-14	40669-40674	tasks	_	
190-15	40675-40682	tapping	_	
190-16	40683-40688	other	_	
190-17	40689-40698	cognitive	_	
190-18	40699-40709	constructs	_	
190-19	40710-40714	with	_	
190-20	40715-40724	relevance	_	
190-21	40725-40727	to	_	
190-22	40728-40732	SUDs	_	
190-23	40733-40734	(	_	
190-24	40734-40737	e.g	_	
190-25	40737-40738	.	_	
190-26	40738-40739	,	_	
190-27	40740-40746	reward	_	
190-28	40747-40758	sensitivity	_	
190-29	40758-40759	,	_	
190-30	40760-40767	craving	_	
190-31	40767-40768	)	_	
190-32	40768-40769	.	_	

#Text=As with all treatment trials, it is not possible to control for all potential sources of variance and other measures (e.g., motivation, self-efficacy, social factors) which may fluctuate across treatment and may also theoretically impact changes in fMRI Stroop effects.
191-1	40770-40772	As	_	
191-2	40773-40777	with	_	
191-3	40778-40781	all	_	
191-4	40782-40791	treatment	_	
191-5	40792-40798	trials	_	
191-6	40798-40799	,	_	
191-7	40800-40802	it	_	
191-8	40803-40805	is	_	
191-9	40806-40809	not	_	
191-10	40810-40818	possible	_	
191-11	40819-40821	to	_	
191-12	40822-40829	control	_	
191-13	40830-40833	for	_	
191-14	40834-40837	all	_	
191-15	40838-40847	potential	_	
191-16	40848-40855	sources	_	
191-17	40856-40858	of	_	
191-18	40859-40867	variance	_	
191-19	40868-40871	and	_	
191-20	40872-40877	other	_	
191-21	40878-40886	measures	_	
191-22	40887-40888	(	_	
191-23	40888-40891	e.g	_	
191-24	40891-40892	.	_	
191-25	40892-40893	,	_	
191-26	40894-40904	motivation	_	
191-27	40904-40905	,	_	
191-28	40906-40919	self-efficacy	_	
191-29	40919-40920	,	_	
191-30	40921-40927	social	_	
191-31	40928-40935	factors	_	
191-32	40935-40936	)	_	
191-33	40937-40942	which	_	
191-34	40943-40946	may	_	
191-35	40947-40956	fluctuate	_	
191-36	40957-40963	across	_	
191-37	40964-40973	treatment	_	
191-38	40974-40977	and	_	
191-39	40978-40981	may	_	
191-40	40982-40986	also	_	
191-41	40987-41000	theoretically	_	
191-42	41001-41007	impact	_	
191-43	41008-41015	changes	_	
191-44	41016-41018	in	_	
191-45	41019-41023	fMRI	_	
191-46	41024-41030	Stroop	_	
191-47	41031-41038	effects	_	
191-48	41038-41039	.	_	

#Text=While inclusion of a healthy control test-retest group would allow for some control of time and practice effects, these effects cannot be presumed to be identical between SUD and healthy samples for reasons discussed above.
192-1	41040-41045	While	_	
192-2	41046-41055	inclusion	_	
192-3	41056-41058	of	_	
192-4	41059-41060	a	_	
192-5	41061-41068	healthy	_	
192-6	41069-41076	control	_	
192-7	41077-41088	test-retest	_	
192-8	41089-41094	group	_	
192-9	41095-41100	would	_	
192-10	41101-41106	allow	_	
192-11	41107-41110	for	_	
192-12	41111-41115	some	_	
192-13	41116-41123	control	_	
192-14	41124-41126	of	_	
192-15	41127-41131	time	_	
192-16	41132-41135	and	_	
192-17	41136-41144	practice	_	
192-18	41145-41152	effects	_	
192-19	41152-41153	,	_	
192-20	41154-41159	these	_	
192-21	41160-41167	effects	_	
192-22	41168-41174	cannot	_	
192-23	41175-41177	be	_	
192-24	41178-41186	presumed	_	
192-25	41187-41189	to	_	
192-26	41190-41192	be	_	
192-27	41193-41202	identical	_	
192-28	41203-41210	between	_	
192-29	41211-41214	SUD	_	
192-30	41215-41218	and	_	
192-31	41219-41226	healthy	_	
192-32	41227-41234	samples	_	
192-33	41235-41238	for	_	
192-34	41239-41246	reasons	_	
192-35	41247-41256	discussed	_	
192-36	41257-41262	above	_	
192-37	41262-41263	.	_	

#Text=Conclusions
#Text=This study is the first to assess indicators of treatment process and exposure in relation to changes in fMRI during treatment for CUD.
193-1	41264-41275	Conclusions	_	
193-2	41276-41280	This	_	
193-3	41281-41286	study	_	
193-4	41287-41289	is	_	
193-5	41290-41293	the	_	
193-6	41294-41299	first	_	
193-7	41300-41302	to	_	
193-8	41303-41309	assess	_	
193-9	41310-41320	indicators	_	
193-10	41321-41323	of	_	
193-11	41324-41333	treatment	_	
193-12	41334-41341	process	_	
193-13	41342-41345	and	_	
193-14	41346-41354	exposure	_	
193-15	41355-41357	in	_	
193-16	41358-41366	relation	_	
193-17	41367-41369	to	_	
193-18	41370-41377	changes	_	
193-19	41378-41380	in	_	
193-20	41381-41385	fMRI	_	
193-21	41386-41392	during	_	
193-22	41393-41402	treatment	_	
193-23	41403-41406	for	_	
193-24	41407-41410	CUD	_	
193-25	41410-41411	.	_	

#Text=It represents an important, albeit preliminary, step in understanding neurocognitive mechanisms of action for well-established treatments for CUD, particularly CM.
194-1	41412-41414	It	_	
194-2	41415-41425	represents	_	
194-3	41426-41428	an	_	
194-4	41429-41438	important	_	
194-5	41438-41439	,	_	
194-6	41440-41446	albeit	_	
194-7	41447-41458	preliminary	_	
194-8	41458-41459	,	_	
194-9	41460-41464	step	_	
194-10	41465-41467	in	_	
194-11	41468-41481	understanding	_	
194-12	41482-41496	neurocognitive	_	
194-13	41497-41507	mechanisms	_	
194-14	41508-41510	of	_	
194-15	41511-41517	action	_	
194-16	41518-41521	for	_	
194-17	41522-41538	well-established	_	
194-18	41539-41549	treatments	_	
194-19	41550-41553	for	_	
194-20	41554-41557	CUD	_	
194-21	41557-41558	,	_	
194-22	41559-41571	particularly	_	
194-23	41572-41574	CM	_	
194-24	41574-41575	.	_	

#Text=Specifically, enhanced cognitive control may be an important treatment target for SUD treatments, as indicated by the relationships seen here between exposure to components of effective therapies (CM and CBT) and post-treatment versus beginning-of-treatment changes in areas related to cognitive-control as assessed by Stroop.
195-1	41576-41588	Specifically	_	
195-2	41588-41589	,	_	
195-3	41590-41598	enhanced	_	
195-4	41599-41608	cognitive	_	
195-5	41609-41616	control	_	
195-6	41617-41620	may	_	
195-7	41621-41623	be	_	
195-8	41624-41626	an	_	
195-9	41627-41636	important	_	
195-10	41637-41646	treatment	_	
195-11	41647-41653	target	_	
195-12	41654-41657	for	_	
195-13	41658-41661	SUD	_	
195-14	41662-41672	treatments	_	
195-15	41672-41673	,	_	
195-16	41674-41676	as	_	
195-17	41677-41686	indicated	_	
195-18	41687-41689	by	_	
195-19	41690-41693	the	_	
195-20	41694-41707	relationships	_	
195-21	41708-41712	seen	_	
195-22	41713-41717	here	_	
195-23	41718-41725	between	_	
195-24	41726-41734	exposure	_	
195-25	41735-41737	to	_	
195-26	41738-41748	components	_	
195-27	41749-41751	of	_	
195-28	41752-41761	effective	_	
195-29	41762-41771	therapies	_	
195-30	41772-41773	(	_	
195-31	41773-41775	CM	_	
195-32	41776-41779	and	_	
195-33	41780-41783	CBT	_	
195-34	41783-41784	)	_	
195-35	41785-41788	and	_	
195-36	41789-41803	post-treatment	_	
195-37	41804-41810	versus	_	
195-38	41811-41833	beginning-of-treatment	_	
195-39	41834-41841	changes	_	
195-40	41842-41844	in	_	
195-41	41845-41850	areas	_	
195-42	41851-41858	related	_	
195-43	41859-41861	to	_	
195-44	41862-41879	cognitive-control	_	
195-45	41880-41882	as	_	
195-46	41883-41891	assessed	_	
195-47	41892-41894	by	_	
195-48	41895-41901	Stroop	_	
195-49	41901-41902	.	_	

#Text=Our approach to these analyses may also prove a step forward in utilizing fMRI to understand how empirically-validated therapies may exert their effects.
196-1	41903-41906	Our	_	
196-2	41907-41915	approach	_	
196-3	41916-41918	to	_	
196-4	41919-41924	these	_	
196-5	41925-41933	analyses	_	
196-6	41934-41937	may	_	
196-7	41938-41942	also	_	
196-8	41943-41948	prove	_	
196-9	41949-41950	a	_	
196-10	41951-41955	step	_	
196-11	41956-41963	forward	_	
196-12	41964-41966	in	_	
196-13	41967-41976	utilizing	_	
196-14	41977-41981	fMRI	_	
196-15	41982-41984	to	_	
196-16	41985-41995	understand	_	
196-17	41996-41999	how	_	
196-18	42000-42021	empirically-validated	_	
196-19	42022-42031	therapies	_	
196-20	42032-42035	may	_	
196-21	42036-42041	exert	_	
196-22	42042-42047	their	_	
196-23	42048-42055	effects	_	
196-24	42055-42056	.	_	

#Text=That is, we attempted to go beyond analyses of whether specific patterns of neural activity are associated with post-treatment drug use outcomes, which have yielded inconsistent findings across studies and have limited ability to parse out effects of specific treatment, time, or chronic or acute effects of drug use on those relationships.
197-1	42057-42061	That	_	
197-2	42062-42064	is	_	
197-3	42064-42065	,	_	
197-4	42066-42068	we	_	
197-5	42069-42078	attempted	_	
197-6	42079-42081	to	_	
197-7	42082-42084	go	_	
197-8	42085-42091	beyond	_	
197-9	42092-42100	analyses	_	
197-10	42101-42103	of	_	
197-11	42104-42111	whether	_	
197-12	42112-42120	specific	_	
197-13	42121-42129	patterns	_	
197-14	42130-42132	of	_	
197-15	42133-42139	neural	_	
197-16	42140-42148	activity	_	
197-17	42149-42152	are	_	
197-18	42153-42163	associated	_	
197-19	42164-42168	with	_	
197-20	42169-42183	post-treatment	_	
197-21	42184-42188	drug	_	
197-22	42189-42192	use	_	
197-23	42193-42201	outcomes	_	
197-24	42201-42202	,	_	
197-25	42203-42208	which	_	
197-26	42209-42213	have	_	
197-27	42214-42221	yielded	_	
197-28	42222-42234	inconsistent	_	
197-29	42235-42243	findings	_	
197-30	42244-42250	across	_	
197-31	42251-42258	studies	_	
197-32	42259-42262	and	_	
197-33	42263-42267	have	_	
197-34	42268-42275	limited	_	
197-35	42276-42283	ability	_	
197-36	42284-42286	to	_	
197-37	42287-42292	parse	_	
197-38	42293-42296	out	_	
197-39	42297-42304	effects	_	
197-40	42305-42307	of	_	
197-41	42308-42316	specific	_	
197-42	42317-42326	treatment	_	
197-43	42326-42327	,	_	
197-44	42328-42332	time	_	
197-45	42332-42333	,	_	
197-46	42334-42336	or	_	
197-47	42337-42344	chronic	_	
197-48	42345-42347	or	_	
197-49	42348-42353	acute	_	
197-50	42354-42361	effects	_	
197-51	42362-42364	of	_	
197-52	42365-42369	drug	_	
197-53	42370-42373	use	_	
197-54	42374-42376	on	_	
197-55	42377-42382	those	_	
197-56	42383-42396	relationships	_	
197-57	42396-42397	.	_	

#Text=Rather, in these analyses we linked changes in neural activity associated with cognitive-control to putative indicators of treatment exposure for three specific treatment conditions, while separately assessing associations with drug use during the trial.
198-1	42398-42404	Rather	_	
198-2	42404-42405	,	_	
198-3	42406-42408	in	_	
198-4	42409-42414	these	_	
198-5	42415-42423	analyses	_	
198-6	42424-42426	we	_	
198-7	42427-42433	linked	_	
198-8	42434-42441	changes	_	
198-9	42442-42444	in	_	
198-10	42445-42451	neural	_	
198-11	42452-42460	activity	_	
198-12	42461-42471	associated	_	
198-13	42472-42476	with	_	
198-14	42477-42494	cognitive-control	_	
198-15	42495-42497	to	_	
198-16	42498-42506	putative	_	
198-17	42507-42517	indicators	_	
198-18	42518-42520	of	_	
198-19	42521-42530	treatment	_	
198-20	42531-42539	exposure	_	
198-21	42540-42543	for	_	
198-22	42544-42549	three	_	
198-23	42550-42558	specific	_	
198-24	42559-42568	treatment	_	
198-25	42569-42579	conditions	_	
198-26	42579-42580	,	_	
198-27	42581-42586	while	_	
198-28	42587-42597	separately	_	
198-29	42598-42607	assessing	_	
198-30	42608-42620	associations	_	
198-31	42621-42625	with	_	
198-32	42626-42630	drug	_	
198-33	42631-42634	use	_	
198-34	42635-42641	during	_	
198-35	42642-42645	the	_	
198-36	42646-42651	trial	_	
198-37	42651-42652	.	_	

#Text=This approach, which focuses on comparing effects of multiple treatments with known efficacy, reliable indicators of treatment exposure, and a well-established cognitive task (Stroop) associated with a likely common mechanism of treatment response in addicted populations, may be a path toward understanding how effective therapies affect complex conditions such as SUDs.
199-1	42653-42657	This	_	
199-2	42658-42666	approach	_	
199-3	42666-42667	,	_	
199-4	42668-42673	which	_	
199-5	42674-42681	focuses	_	
199-6	42682-42684	on	_	
199-7	42685-42694	comparing	_	
199-8	42695-42702	effects	_	
199-9	42703-42705	of	_	
199-10	42706-42714	multiple	_	
199-11	42715-42725	treatments	_	
199-12	42726-42730	with	_	
199-13	42731-42736	known	_	
199-14	42737-42745	efficacy	_	
199-15	42745-42746	,	_	
199-16	42747-42755	reliable	_	
199-17	42756-42766	indicators	_	
199-18	42767-42769	of	_	
199-19	42770-42779	treatment	_	
199-20	42780-42788	exposure	_	
199-21	42788-42789	,	_	
199-22	42790-42793	and	_	
199-23	42794-42795	a	_	
199-24	42796-42812	well-established	_	
199-25	42813-42822	cognitive	_	
199-26	42823-42827	task	_	
199-27	42828-42829	(	_	
199-28	42829-42835	Stroop	_	
199-29	42835-42836	)	_	
199-30	42837-42847	associated	_	
199-31	42848-42852	with	_	
199-32	42853-42854	a	_	
199-33	42855-42861	likely	_	
199-34	42862-42868	common	_	
199-35	42869-42878	mechanism	_	
199-36	42879-42881	of	_	
199-37	42882-42891	treatment	_	
199-38	42892-42900	response	_	
199-39	42901-42903	in	_	
199-40	42904-42912	addicted	_	
199-41	42913-42924	populations	_	
199-42	42924-42925	,	_	
199-43	42926-42929	may	_	
199-44	42930-42932	be	_	
199-45	42933-42934	a	_	
199-46	42935-42939	path	_	
199-47	42940-42946	toward	_	
199-48	42947-42960	understanding	_	
199-49	42961-42964	how	_	
199-50	42965-42974	effective	_	
199-51	42975-42984	therapies	_	
199-52	42985-42991	affect	_	
199-53	42992-42999	complex	_	
199-54	43000-43010	conditions	_	
199-55	43011-43015	such	_	
199-56	43016-43018	as	_	
199-57	43019-43023	SUDs	_	
199-58	43023-43024	.	_	

#Text=Supplementary Material
#Text=Aspects of the data included in this manuscript were presented in a poster at the Annual Meeting of The College on Problems of Drug Dependence (CPDD) (Palm Springs, California, 13 June 2016), and in a talk as part of the Yale Division of Substance Abuse Seminar series (West Haven, Connecticut, 16 March 2016).
200-1	43025-43038	Supplementary	_	
200-2	43039-43047	Material	_	
200-3	43048-43055	Aspects	_	
200-4	43056-43058	of	_	
200-5	43059-43062	the	_	
200-6	43063-43067	data	_	
200-7	43068-43076	included	_	
200-8	43077-43079	in	_	
200-9	43080-43084	this	_	
200-10	43085-43095	manuscript	_	
200-11	43096-43100	were	_	
200-12	43101-43110	presented	_	
200-13	43111-43113	in	_	
200-14	43114-43115	a	_	
200-15	43116-43122	poster	_	
200-16	43123-43125	at	_	
200-17	43126-43129	the	_	
200-18	43130-43136	Annual	_	
200-19	43137-43144	Meeting	_	
200-20	43145-43147	of	_	
200-21	43148-43151	The	_	
200-22	43152-43159	College	_	
200-23	43160-43162	on	_	
200-24	43163-43171	Problems	_	
200-25	43172-43174	of	_	
200-26	43175-43179	Drug	_	
200-27	43180-43190	Dependence	_	
200-28	43191-43192	(	_	
200-29	43192-43196	CPDD	_	
200-30	43196-43197	)	_	
200-31	43198-43199	(	_	
200-32	43199-43203	Palm	_	
200-33	43204-43211	Springs	_	
200-34	43211-43212	,	_	
200-35	43213-43223	California	_	
200-36	43223-43224	,	_	
200-37	43225-43227	13	_	
200-38	43228-43232	June	_	
200-39	43233-43237	2016	_	
200-40	43237-43238	)	_	
200-41	43238-43239	,	_	
200-42	43240-43243	and	_	
200-43	43244-43246	in	_	
200-44	43247-43248	a	_	
200-45	43249-43253	talk	_	
200-46	43254-43256	as	_	
200-47	43257-43261	part	_	
200-48	43262-43264	of	_	
200-49	43265-43268	the	_	
200-50	43269-43273	Yale	_	
200-51	43274-43282	Division	_	
200-52	43283-43285	of	_	
200-53	43286-43295	Substance	_	
200-54	43296-43301	Abuse	_	
200-55	43302-43309	Seminar	_	
200-56	43310-43316	series	_	
200-57	43317-43318	(	_	
200-58	43318-43322	West	_	
200-59	43323-43328	Haven	_	
200-60	43328-43329	,	_	
200-61	43330-43341	Connecticut	_	
200-62	43341-43342	,	_	
200-63	43343-43345	16	_	
200-64	43346-43351	March	_	
200-65	43352-43356	2016	_	
200-66	43356-43357	)	_	
200-67	43357-43358	.	_	

#Text=Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial
#Text=Location, location: using functional magnetic resonance imaging to pinpoint brain differences relevant to stimulant use
#Text=Unified segmentation
#Text=Disulfiram effects on responses to intravenous cocaine administration
#Text=Anterior cingulate cortex and response conflict: effects of response modality and processing domain
#Text=Disulfiram: an old therapeutic with new applications
#Text=Intact inhibitory control processes in abstinent drug abusers (I): a functional neuroimaging study in former cocaine addicts
#Text=Prize-based contingency management for the treatment of substance abusers: a meta-analysis
#Text=Pretreatment brain activation during stroop task is associated with outcomes in cocaine-dependent patients
#Text=
#Text=
#Text=Efficacy of disulfiram and cognitive behavior therapy in cocaine-dependent outpatients: a randomized placebo-controlled trial
#Text=Toward empirical identification of a clinically meaningful indicator of treatment outcome: features of candidate indicators and evaluation of sensitivity to treatment effects and relationship to one year follow up cocaine use outcomes
#Text=One-year follow-up of disulfiram and psychotherapy for cocaine-alcohol users: sustained effects of treatment
#Text=Treatment of cocaine and alcohol dependence with psychotherapy and disulfiram
#Text=A randomized factorial trial of disulfiram and contingency management to enhance cognitive behavioral therapy for cocaine dependence
#Text=Efficacy of disulfiram and Twelve Step Facilitation in cocaine-dependent individuals maintained on methadone: a randomized placebo-controlled trial
#Text=A general system for evaluating therapist adherence and competence in psychotherapy research in the addictions
#Text=Imaging the developing brain: what have we learned about cognitive development?
201-1	43359-43367	Combined	_	
201-2	43368-43385	pharmacotherapies	_	
201-3	43386-43389	and	_	
201-4	43390-43400	behavioral	_	
201-5	43401-43414	interventions	_	
201-6	43415-43418	for	_	
201-7	43419-43426	alcohol	_	
201-8	43427-43437	dependence	_	
201-9	43437-43438	:	_	
201-10	43439-43442	the	_	
201-11	43443-43450	COMBINE	_	
201-12	43451-43456	study	_	
201-13	43456-43457	:	_	
201-14	43458-43459	a	_	
201-15	43460-43470	randomized	_	
201-16	43471-43481	controlled	_	
201-17	43482-43487	trial	_	
201-18	43488-43496	Location	_	
201-19	43496-43497	,	_	
201-20	43498-43506	location	_	
201-21	43506-43507	:	_	
201-22	43508-43513	using	_	
201-23	43514-43524	functional	_	
201-24	43525-43533	magnetic	_	
201-25	43534-43543	resonance	_	
201-26	43544-43551	imaging	_	
201-27	43552-43554	to	_	
201-28	43555-43563	pinpoint	_	
201-29	43564-43569	brain	_	
201-30	43570-43581	differences	_	
201-31	43582-43590	relevant	_	
201-32	43591-43593	to	_	
201-33	43594-43603	stimulant	_	
201-34	43604-43607	use	_	
201-35	43608-43615	Unified	_	
201-36	43616-43628	segmentation	_	
201-37	43629-43639	Disulfiram	_	
201-38	43640-43647	effects	_	
201-39	43648-43650	on	_	
201-40	43651-43660	responses	_	
201-41	43661-43663	to	_	
201-42	43664-43675	intravenous	_	
201-43	43676-43683	cocaine	_	
201-44	43684-43698	administration	_	
201-45	43699-43707	Anterior	_	
201-46	43708-43717	cingulate	_	
201-47	43718-43724	cortex	_	
201-48	43725-43728	and	_	
201-49	43729-43737	response	_	
201-50	43738-43746	conflict	_	
201-51	43746-43747	:	_	
201-52	43748-43755	effects	_	
201-53	43756-43758	of	_	
201-54	43759-43767	response	_	
201-55	43768-43776	modality	_	
201-56	43777-43780	and	_	
201-57	43781-43791	processing	_	
201-58	43792-43798	domain	_	
201-59	43799-43809	Disulfiram	_	
201-60	43809-43810	:	_	
201-61	43811-43813	an	_	
201-62	43814-43817	old	_	
201-63	43818-43829	therapeutic	_	
201-64	43830-43834	with	_	
201-65	43835-43838	new	_	
201-66	43839-43851	applications	_	
201-67	43852-43858	Intact	_	
201-68	43859-43869	inhibitory	_	
201-69	43870-43877	control	_	
201-70	43878-43887	processes	_	
201-71	43888-43890	in	_	
201-72	43891-43900	abstinent	_	
201-73	43901-43905	drug	_	
201-74	43906-43913	abusers	_	
201-75	43914-43915	(	_	
201-76	43915-43916	I	_	
201-77	43916-43917	)	_	
201-78	43917-43918	:	_	
201-79	43919-43920	a	_	
201-80	43921-43931	functional	_	
201-81	43932-43944	neuroimaging	_	
201-82	43945-43950	study	_	
201-83	43951-43953	in	_	
201-84	43954-43960	former	_	
201-85	43961-43968	cocaine	_	
201-86	43969-43976	addicts	_	
201-87	43977-43988	Prize-based	_	
201-88	43989-44000	contingency	_	
201-89	44001-44011	management	_	
201-90	44012-44015	for	_	
201-91	44016-44019	the	_	
201-92	44020-44029	treatment	_	
201-93	44030-44032	of	_	
201-94	44033-44042	substance	_	
201-95	44043-44050	abusers	_	
201-96	44050-44051	:	_	
201-97	44052-44053	a	_	
201-98	44054-44067	meta-analysis	_	
201-99	44068-44080	Pretreatment	_	
201-100	44081-44086	brain	_	
201-101	44087-44097	activation	_	
201-102	44098-44104	during	_	
201-103	44105-44111	stroop	_	
201-104	44112-44116	task	_	
201-105	44117-44119	is	_	
201-106	44120-44130	associated	_	
201-107	44131-44135	with	_	
201-108	44136-44144	outcomes	_	
201-109	44145-44147	in	_	
201-110	44148-44165	cocaine-dependent	_	
201-111	44166-44174	patients	_	
201-112	44177-44185	Efficacy	_	
201-113	44186-44188	of	_	
201-114	44189-44199	disulfiram	_	
201-115	44200-44203	and	_	
201-116	44204-44213	cognitive	_	
201-117	44214-44222	behavior	_	
201-118	44223-44230	therapy	_	
201-119	44231-44233	in	_	
201-120	44234-44251	cocaine-dependent	_	
201-121	44252-44263	outpatients	_	
201-122	44263-44264	:	_	
201-123	44265-44266	a	_	
201-124	44267-44277	randomized	_	
201-125	44278-44296	placebo-controlled	_	
201-126	44297-44302	trial	_	
201-127	44303-44309	Toward	_	
201-128	44310-44319	empirical	_	
201-129	44320-44334	identification	_	
201-130	44335-44337	of	_	
201-131	44338-44339	a	_	
201-132	44340-44350	clinically	_	
201-133	44351-44361	meaningful	_	
201-134	44362-44371	indicator	_	
201-135	44372-44374	of	_	
201-136	44375-44384	treatment	_	
201-137	44385-44392	outcome	_	
201-138	44392-44393	:	_	
201-139	44394-44402	features	_	
201-140	44403-44405	of	_	
201-141	44406-44415	candidate	_	
201-142	44416-44426	indicators	_	
201-143	44427-44430	and	_	
201-144	44431-44441	evaluation	_	
201-145	44442-44444	of	_	
201-146	44445-44456	sensitivity	_	
201-147	44457-44459	to	_	
201-148	44460-44469	treatment	_	
201-149	44470-44477	effects	_	
201-150	44478-44481	and	_	
201-151	44482-44494	relationship	_	
201-152	44495-44497	to	_	
201-153	44498-44501	one	_	
201-154	44502-44506	year	_	
201-155	44507-44513	follow	_	
201-156	44514-44516	up	_	
201-157	44517-44524	cocaine	_	
201-158	44525-44528	use	_	
201-159	44529-44537	outcomes	_	
201-160	44538-44546	One-year	_	
201-161	44547-44556	follow-up	_	
201-162	44557-44559	of	_	
201-163	44560-44570	disulfiram	_	
201-164	44571-44574	and	_	
201-165	44575-44588	psychotherapy	_	
201-166	44589-44592	for	_	
201-167	44593-44608	cocaine-alcohol	_	
201-168	44609-44614	users	_	
201-169	44614-44615	:	_	
201-170	44616-44625	sustained	_	
201-171	44626-44633	effects	_	
201-172	44634-44636	of	_	
201-173	44637-44646	treatment	_	
201-174	44647-44656	Treatment	_	
201-175	44657-44659	of	_	
201-176	44660-44667	cocaine	_	
201-177	44668-44671	and	_	
201-178	44672-44679	alcohol	_	
201-179	44680-44690	dependence	_	
201-180	44691-44695	with	_	
201-181	44696-44709	psychotherapy	_	
201-182	44710-44713	and	_	
201-183	44714-44724	disulfiram	_	
201-184	44725-44726	A	_	
201-185	44727-44737	randomized	_	
201-186	44738-44747	factorial	_	
201-187	44748-44753	trial	_	
201-188	44754-44756	of	_	
201-189	44757-44767	disulfiram	_	
201-190	44768-44771	and	_	
201-191	44772-44783	contingency	_	
201-192	44784-44794	management	_	
201-193	44795-44797	to	_	
201-194	44798-44805	enhance	_	
201-195	44806-44815	cognitive	_	
201-196	44816-44826	behavioral	_	
201-197	44827-44834	therapy	_	
201-198	44835-44838	for	_	
201-199	44839-44846	cocaine	_	
201-200	44847-44857	dependence	_	
201-201	44858-44866	Efficacy	_	
201-202	44867-44869	of	_	
201-203	44870-44880	disulfiram	_	
201-204	44881-44884	and	_	
201-205	44885-44891	Twelve	_	
201-206	44892-44896	Step	_	
201-207	44897-44909	Facilitation	_	
201-208	44910-44912	in	_	
201-209	44913-44930	cocaine-dependent	_	
201-210	44931-44942	individuals	_	
201-211	44943-44953	maintained	_	
201-212	44954-44956	on	_	
201-213	44957-44966	methadone	_	
201-214	44966-44967	:	_	
201-215	44968-44969	a	_	
201-216	44970-44980	randomized	_	
201-217	44981-44999	placebo-controlled	_	
201-218	45000-45005	trial	_	
201-219	45006-45007	A	_	
201-220	45008-45015	general	_	
201-221	45016-45022	system	_	
201-222	45023-45026	for	_	
201-223	45027-45037	evaluating	_	
201-224	45038-45047	therapist	_	
201-225	45048-45057	adherence	_	
201-226	45058-45061	and	_	
201-227	45062-45072	competence	_	
201-228	45073-45075	in	_	
201-229	45076-45089	psychotherapy	_	
201-230	45090-45098	research	_	
201-231	45099-45101	in	_	
201-232	45102-45105	the	_	
201-233	45106-45116	addictions	_	
201-234	45117-45124	Imaging	_	
201-235	45125-45128	the	_	
201-236	45129-45139	developing	_	
201-237	45140-45145	brain	_	
201-238	45145-45146	:	_	
201-239	45147-45151	what	_	
201-240	45152-45156	have	_	
201-241	45157-45159	we	_	
201-242	45160-45167	learned	_	
201-243	45168-45173	about	_	
201-244	45174-45183	cognitive	_	
201-245	45184-45195	development	_	
201-246	45195-45196	?	_	

#Text=Error processing in current and former cocaine users
#Text=Brain mechanisms of Change in Addictions Treatment: Models, Methods, and Emerging Findings
#Text=The neurobiology of cognitive control in successful cocaine abstinence
#Text=Substrates of neuropsychological functioning in stimulant dependence: a review of functional neuroimaging research
#Text=Gender differences in clinical outcomes for cocaine dependence: Randomized clinical trials of behavioral therapy and disulfiram
#Text=A preliminary study of the neural effects of behavioral therapy for substance use disorders
#Text=A meta-analytic review of psychosocial interventions for substance use disorders
#Text=Neural network activation during a stop-signal task discriminates cocaine-dependent from non-drug-abusing men
#Text=The neurobiology of successful abstinence
#Text=The role of cognitive control in cocaine dependence
#Text=Acute effects of cocaine on the neurobiology of cognitive control
#Text=Cue-induced cocaine craving: neuroanatomical specificity for drug users and drug stimuli
#Text=Neurocognitive insights into substance abuse
#Text=mechanisms of disulfiram-induced cocaine abstinence: antabuse and cocaine relapse
#Text=Disulfiram versus placebo for cocaine dependence in buprenorphine-maintained subjects: a preliminary trial
#Text=The effect of practice on a sustained attention task in cocaine abusers
#Text=Dysfunction of the prefrontal cortex in addiction: neuroimaging findings and clinical implications
#Text=Neurophysiological effects of modafinil on cue-exposure in cocaine dependence: a randomized placebo-controlled cross-over study using pharmacological fMRI
#Text=Executive dysfunction in cocaine addiction: evidence for discordant frontal, cingulate, and cerebellar activity
#Text=National Institute of Mental Health clinical trials: new opportunities, new expectations
#Text=The effects of methylphenidate on cognitive control in active methamphetamine dependence using functional magnetic resonance imaging
#Text=The efficacy of disulfiram for the treatment of alcohol use disorder
#Text=Differentiation of disulfiram effects on central catecholamines and hepatic ethanol metabolism
#Text=Cingulate hypoactivity in cocaine users during a GO-NOGO task as revealed by event-related functional magnetic resonance imaging
#Text=Cannabis abstinence during treatment and one-year follow-up: relationship to neural activity in men
#Text=Prefrontal-striatal pathway underlies cognitive regulation of craving
#Text=Pharmacogenetic randomized trial for cocaine abuse: disulfiram and dopamine beta-hydroxylase
#Text=Increased error-related thalamic activity during early compared to late cocaine abstinence
#Text=Boundary conditions of methamphetamine craving
#Text=Error processing and gender-shared and -specific neural predictors of relapse in cocaine dependence
#Text=Individual differences in anterior cingulate activation associated with attentional bias predict cocaine use after treatment
#Text=Error-related brain activity predicts cocaine use after treatment at 3-month follow-up
#Text=Hyperactivation of the cognitive control network in cocaine use disorders during a multisensory Stroop task
#Text=The Fifth Edition of the Addiction Severity Index
#Text=Neuroscience of inhibition for addiction medicine: from prediction of initiation to prediction of relapse
#Text=Functional, structural, and emotional correlates of impaired insight in cocaine addiction
#Text=Enhanced midbrain response at 6-month follow-up in cocaine addiction, association with reduced drug-related choice
#Text=The contributions of cognitive neuroscience and neuroimaging to understanding mechanisms of behavior change in addiction
#Text=
#Text=Disulfiram for the treatment of cocaine dependence
#Text=Disulfiram treatment for cocaine dependence in methadone-maintained opioid addicts
#Text=A comprehensive guide to the application of contingency management procedures in clinical settings
#Text=Randomized trial of contingent prizes versus vouchers in cocaine-using methadone patients
#Text=Give them prizes, and they will come: contingency management for treatment of alcohol dependence
#Text=Effect of prize-based incentives on outcomes in stimulant abusers in outpatient psychosocial treatment programs: a national drug abuse treatment clinical trials network study
#Text=Contingency management interventions: from research to practice
#Text=Neuroscience of behavioral and pharmacological treatments for addictions
#Text=Reliability of the Timeline Followback for cocaine, cannabis, and cigarette use
#Text=
#Text=
#Text=Pharmacogenetic randomized trial for cocaine abuse: disulfiram and alpha1A–adrenoceptor gene variation
#Text=Timeline followback: A technique for assessing self-reported alcohol consumption
#Text=Cognitive enhancement as a treatment for drug addictions
#Text=Neural systems for error monitoring: recent findings and theoretical perspectives
#Text=Practice-induced changes of brain function during visual attention: a parametric fMRI study at 4 Tesla
#Text=Disulfiram and diethyldithiocarbamate intoxication affects the storage and release of striatal dopamine
#Text=Drug-related decrease in neuropsychological functions of abstinent drug users
#Text=Functional brain networks associated with cognitive control, cocaine dependence, and treatment outcome
#Text=Cognitive interventions for addiction medicine: Understanding the underlying neurobiological mechanisms
#Text=Reduced Stroop-related Activity at Post-Treatment vs.
202-1	45197-45202	Error	_	
202-2	45203-45213	processing	_	
202-3	45214-45216	in	_	
202-4	45217-45224	current	_	
202-5	45225-45228	and	_	
202-6	45229-45235	former	_	
202-7	45236-45243	cocaine	_	
202-8	45244-45249	users	_	
202-9	45250-45255	Brain	_	
202-10	45256-45266	mechanisms	_	
202-11	45267-45269	of	_	
202-12	45270-45276	Change	_	
202-13	45277-45279	in	_	
202-14	45280-45290	Addictions	_	
202-15	45291-45300	Treatment	_	
202-16	45300-45301	:	_	
202-17	45302-45308	Models	_	
202-18	45308-45309	,	_	
202-19	45310-45317	Methods	_	
202-20	45317-45318	,	_	
202-21	45319-45322	and	_	
202-22	45323-45331	Emerging	_	
202-23	45332-45340	Findings	_	
202-24	45341-45344	The	_	
202-25	45345-45357	neurobiology	_	
202-26	45358-45360	of	_	
202-27	45361-45370	cognitive	_	
202-28	45371-45378	control	_	
202-29	45379-45381	in	_	
202-30	45382-45392	successful	_	
202-31	45393-45400	cocaine	_	
202-32	45401-45411	abstinence	_	
202-33	45412-45422	Substrates	_	
202-34	45423-45425	of	_	
202-35	45426-45444	neuropsychological	_	
202-36	45445-45456	functioning	_	
202-37	45457-45459	in	_	
202-38	45460-45469	stimulant	_	
202-39	45470-45480	dependence	_	
202-40	45480-45481	:	_	
202-41	45482-45483	a	_	
202-42	45484-45490	review	_	
202-43	45491-45493	of	_	
202-44	45494-45504	functional	_	
202-45	45505-45517	neuroimaging	_	
202-46	45518-45526	research	_	
202-47	45527-45533	Gender	_	
202-48	45534-45545	differences	_	
202-49	45546-45548	in	_	
202-50	45549-45557	clinical	_	
202-51	45558-45566	outcomes	_	
202-52	45567-45570	for	_	
202-53	45571-45578	cocaine	_	
202-54	45579-45589	dependence	_	
202-55	45589-45590	:	_	
202-56	45591-45601	Randomized	_	
202-57	45602-45610	clinical	_	
202-58	45611-45617	trials	_	
202-59	45618-45620	of	_	
202-60	45621-45631	behavioral	_	
202-61	45632-45639	therapy	_	
202-62	45640-45643	and	_	
202-63	45644-45654	disulfiram	_	
202-64	45655-45656	A	_	
202-65	45657-45668	preliminary	_	
202-66	45669-45674	study	_	
202-67	45675-45677	of	_	
202-68	45678-45681	the	_	
202-69	45682-45688	neural	_	
202-70	45689-45696	effects	_	
202-71	45697-45699	of	_	
202-72	45700-45710	behavioral	_	
202-73	45711-45718	therapy	_	
202-74	45719-45722	for	_	
202-75	45723-45732	substance	_	
202-76	45733-45736	use	_	
202-77	45737-45746	disorders	_	
202-78	45747-45748	A	_	
202-79	45749-45762	meta-analytic	_	
202-80	45763-45769	review	_	
202-81	45770-45772	of	_	
202-82	45773-45785	psychosocial	_	
202-83	45786-45799	interventions	_	
202-84	45800-45803	for	_	
202-85	45804-45813	substance	_	
202-86	45814-45817	use	_	
202-87	45818-45827	disorders	_	
202-88	45828-45834	Neural	_	
202-89	45835-45842	network	_	
202-90	45843-45853	activation	_	
202-91	45854-45860	during	_	
202-92	45861-45862	a	_	
202-93	45863-45874	stop-signal	_	
202-94	45875-45879	task	_	
202-95	45880-45893	discriminates	_	
202-96	45894-45911	cocaine-dependent	_	
202-97	45912-45916	from	_	
202-98	45917-45933	non-drug-abusing	_	
202-99	45934-45937	men	_	
202-100	45938-45941	The	_	
202-101	45942-45954	neurobiology	_	
202-102	45955-45957	of	_	
202-103	45958-45968	successful	_	
202-104	45969-45979	abstinence	_	
202-105	45980-45983	The	_	
202-106	45984-45988	role	_	
202-107	45989-45991	of	_	
202-108	45992-46001	cognitive	_	
202-109	46002-46009	control	_	
202-110	46010-46012	in	_	
202-111	46013-46020	cocaine	_	
202-112	46021-46031	dependence	_	
202-113	46032-46037	Acute	_	
202-114	46038-46045	effects	_	
202-115	46046-46048	of	_	
202-116	46049-46056	cocaine	_	
202-117	46057-46059	on	_	
202-118	46060-46063	the	_	
202-119	46064-46076	neurobiology	_	
202-120	46077-46079	of	_	
202-121	46080-46089	cognitive	_	
202-122	46090-46097	control	_	
202-123	46098-46109	Cue-induced	_	
202-124	46110-46117	cocaine	_	
202-125	46118-46125	craving	_	
202-126	46125-46126	:	_	
202-127	46127-46142	neuroanatomical	_	
202-128	46143-46154	specificity	_	
202-129	46155-46158	for	_	
202-130	46159-46163	drug	_	
202-131	46164-46169	users	_	
202-132	46170-46173	and	_	
202-133	46174-46178	drug	_	
202-134	46179-46186	stimuli	_	
202-135	46187-46201	Neurocognitive	_	
202-136	46202-46210	insights	_	
202-137	46211-46215	into	_	
202-138	46216-46225	substance	_	
202-139	46226-46231	abuse	_	
202-140	46232-46242	mechanisms	_	
202-141	46243-46245	of	_	
202-142	46246-46264	disulfiram-induced	_	
202-143	46265-46272	cocaine	_	
202-144	46273-46283	abstinence	_	
202-145	46283-46284	:	_	
202-146	46285-46293	antabuse	_	
202-147	46294-46297	and	_	
202-148	46298-46305	cocaine	_	
202-149	46306-46313	relapse	_	
202-150	46314-46324	Disulfiram	_	
202-151	46325-46331	versus	_	
202-152	46332-46339	placebo	_	
202-153	46340-46343	for	_	
202-154	46344-46351	cocaine	_	
202-155	46352-46362	dependence	_	
202-156	46363-46365	in	_	
202-157	46366-46390	buprenorphine-maintained	_	
202-158	46391-46399	subjects	_	
202-159	46399-46400	:	_	
202-160	46401-46402	a	_	
202-161	46403-46414	preliminary	_	
202-162	46415-46420	trial	_	
202-163	46421-46424	The	_	
202-164	46425-46431	effect	_	
202-165	46432-46434	of	_	
202-166	46435-46443	practice	_	
202-167	46444-46446	on	_	
202-168	46447-46448	a	_	
202-169	46449-46458	sustained	_	
202-170	46459-46468	attention	_	
202-171	46469-46473	task	_	
202-172	46474-46476	in	_	
202-173	46477-46484	cocaine	_	
202-174	46485-46492	abusers	_	
202-175	46493-46504	Dysfunction	_	
202-176	46505-46507	of	_	
202-177	46508-46511	the	_	
202-178	46512-46522	prefrontal	_	
202-179	46523-46529	cortex	_	
202-180	46530-46532	in	_	
202-181	46533-46542	addiction	_	
202-182	46542-46543	:	_	
202-183	46544-46556	neuroimaging	_	
202-184	46557-46565	findings	_	
202-185	46566-46569	and	_	
202-186	46570-46578	clinical	_	
202-187	46579-46591	implications	_	
202-188	46592-46610	Neurophysiological	_	
202-189	46611-46618	effects	_	
202-190	46619-46621	of	_	
202-191	46622-46631	modafinil	_	
202-192	46632-46634	on	_	
202-193	46635-46647	cue-exposure	_	
202-194	46648-46650	in	_	
202-195	46651-46658	cocaine	_	
202-196	46659-46669	dependence	_	
202-197	46669-46670	:	_	
202-198	46671-46672	a	_	
202-199	46673-46683	randomized	_	
202-200	46684-46702	placebo-controlled	_	
202-201	46703-46713	cross-over	_	
202-202	46714-46719	study	_	
202-203	46720-46725	using	_	
202-204	46726-46741	pharmacological	_	
202-205	46742-46746	fMRI	_	
202-206	46747-46756	Executive	_	
202-207	46757-46768	dysfunction	_	
202-208	46769-46771	in	_	
202-209	46772-46779	cocaine	_	
202-210	46780-46789	addiction	_	
202-211	46789-46790	:	_	
202-212	46791-46799	evidence	_	
202-213	46800-46803	for	_	
202-214	46804-46814	discordant	_	
202-215	46815-46822	frontal	_	
202-216	46822-46823	,	_	
202-217	46824-46833	cingulate	_	
202-218	46833-46834	,	_	
202-219	46835-46838	and	_	
202-220	46839-46849	cerebellar	_	
202-221	46850-46858	activity	_	
202-222	46859-46867	National	_	
202-223	46868-46877	Institute	_	
202-224	46878-46880	of	_	
202-225	46881-46887	Mental	_	
202-226	46888-46894	Health	_	
202-227	46895-46903	clinical	_	
202-228	46904-46910	trials	_	
202-229	46910-46911	:	_	
202-230	46912-46915	new	_	
202-231	46916-46929	opportunities	_	
202-232	46929-46930	,	_	
202-233	46931-46934	new	_	
202-234	46935-46947	expectations	_	
202-235	46948-46951	The	_	
202-236	46952-46959	effects	_	
202-237	46960-46962	of	_	
202-238	46963-46978	methylphenidate	_	
202-239	46979-46981	on	_	
202-240	46982-46991	cognitive	_	
202-241	46992-46999	control	_	
202-242	47000-47002	in	_	
202-243	47003-47009	active	_	
202-244	47010-47025	methamphetamine	_	
202-245	47026-47036	dependence	_	
202-246	47037-47042	using	_	
202-247	47043-47053	functional	_	
202-248	47054-47062	magnetic	_	
202-249	47063-47072	resonance	_	
202-250	47073-47080	imaging	_	
202-251	47081-47084	The	_	
202-252	47085-47093	efficacy	_	
202-253	47094-47096	of	_	
202-254	47097-47107	disulfiram	_	
202-255	47108-47111	for	_	
202-256	47112-47115	the	_	
202-257	47116-47125	treatment	_	
202-258	47126-47128	of	_	
202-259	47129-47136	alcohol	_	
202-260	47137-47140	use	_	
202-261	47141-47149	disorder	_	
202-262	47150-47165	Differentiation	_	
202-263	47166-47168	of	_	
202-264	47169-47179	disulfiram	_	
202-265	47180-47187	effects	_	
202-266	47188-47190	on	_	
202-267	47191-47198	central	_	
202-268	47199-47213	catecholamines	_	
202-269	47214-47217	and	_	
202-270	47218-47225	hepatic	_	
202-271	47226-47233	ethanol	_	
202-272	47234-47244	metabolism	_	
202-273	47245-47254	Cingulate	_	
202-274	47255-47267	hypoactivity	_	
202-275	47268-47270	in	_	
202-276	47271-47278	cocaine	_	
202-277	47279-47284	users	_	
202-278	47285-47291	during	_	
202-279	47292-47293	a	_	
202-280	47294-47301	GO-NOGO	_	
202-281	47302-47306	task	_	
202-282	47307-47309	as	_	
202-283	47310-47318	revealed	_	
202-284	47319-47321	by	_	
202-285	47322-47335	event-related	_	
202-286	47336-47346	functional	_	
202-287	47347-47355	magnetic	_	
202-288	47356-47365	resonance	_	
202-289	47366-47373	imaging	_	
202-290	47374-47382	Cannabis	_	
202-291	47383-47393	abstinence	_	
202-292	47394-47400	during	_	
202-293	47401-47410	treatment	_	
202-294	47411-47414	and	_	
202-295	47415-47423	one-year	_	
202-296	47424-47433	follow-up	_	
202-297	47433-47434	:	_	
202-298	47435-47447	relationship	_	
202-299	47448-47450	to	_	
202-300	47451-47457	neural	_	
202-301	47458-47466	activity	_	
202-302	47467-47469	in	_	
202-303	47470-47473	men	_	
202-304	47474-47493	Prefrontal-striatal	_	
202-305	47494-47501	pathway	_	
202-306	47502-47511	underlies	_	
202-307	47512-47521	cognitive	_	
202-308	47522-47532	regulation	_	
202-309	47533-47535	of	_	
202-310	47536-47543	craving	_	
202-311	47544-47559	Pharmacogenetic	_	
202-312	47560-47570	randomized	_	
202-313	47571-47576	trial	_	
202-314	47577-47580	for	_	
202-315	47581-47588	cocaine	_	
202-316	47589-47594	abuse	_	
202-317	47594-47595	:	_	
202-318	47596-47606	disulfiram	_	
202-319	47607-47610	and	_	
202-320	47611-47619	dopamine	_	
202-321	47620-47636	beta-hydroxylase	_	
202-322	47637-47646	Increased	_	
202-323	47647-47660	error-related	_	
202-324	47661-47669	thalamic	_	
202-325	47670-47678	activity	_	
202-326	47679-47685	during	_	
202-327	47686-47691	early	_	
202-328	47692-47700	compared	_	
202-329	47701-47703	to	_	
202-330	47704-47708	late	_	
202-331	47709-47716	cocaine	_	
202-332	47717-47727	abstinence	_	
202-333	47728-47736	Boundary	_	
202-334	47737-47747	conditions	_	
202-335	47748-47750	of	_	
202-336	47751-47766	methamphetamine	_	
202-337	47767-47774	craving	_	
202-338	47775-47780	Error	_	
202-339	47781-47791	processing	_	
202-340	47792-47795	and	_	
202-341	47796-47809	gender-shared	_	
202-342	47810-47813	and	_	
202-343	47814-47815	-	_	
202-344	47815-47823	specific	_	
202-345	47824-47830	neural	_	
202-346	47831-47841	predictors	_	
202-347	47842-47844	of	_	
202-348	47845-47852	relapse	_	
202-349	47853-47855	in	_	
202-350	47856-47863	cocaine	_	
202-351	47864-47874	dependence	_	
202-352	47875-47885	Individual	_	
202-353	47886-47897	differences	_	
202-354	47898-47900	in	_	
202-355	47901-47909	anterior	_	
202-356	47910-47919	cingulate	_	
202-357	47920-47930	activation	_	
202-358	47931-47941	associated	_	
202-359	47942-47946	with	_	
202-360	47947-47958	attentional	_	
202-361	47959-47963	bias	_	
202-362	47964-47971	predict	_	
202-363	47972-47979	cocaine	_	
202-364	47980-47983	use	_	
202-365	47984-47989	after	_	
202-366	47990-47999	treatment	_	
202-367	48000-48013	Error-related	_	
202-368	48014-48019	brain	_	
202-369	48020-48028	activity	_	
202-370	48029-48037	predicts	_	
202-371	48038-48045	cocaine	_	
202-372	48046-48049	use	_	
202-373	48050-48055	after	_	
202-374	48056-48065	treatment	_	
202-375	48066-48068	at	_	
202-376	48069-48070	3	_	
202-377	48070-48071	-	_	
202-378	48071-48076	month	_	
202-379	48077-48086	follow-up	_	
202-380	48087-48102	Hyperactivation	_	
202-381	48103-48105	of	_	
202-382	48106-48109	the	_	
202-383	48110-48119	cognitive	_	
202-384	48120-48127	control	_	
202-385	48128-48135	network	_	
202-386	48136-48138	in	_	
202-387	48139-48146	cocaine	_	
202-388	48147-48150	use	_	
202-389	48151-48160	disorders	_	
202-390	48161-48167	during	_	
202-391	48168-48169	a	_	
202-392	48170-48182	multisensory	_	
202-393	48183-48189	Stroop	_	
202-394	48190-48194	task	_	
202-395	48195-48198	The	_	
202-396	48199-48204	Fifth	_	
202-397	48205-48212	Edition	_	
202-398	48213-48215	of	_	
202-399	48216-48219	the	_	
202-400	48220-48229	Addiction	_	
202-401	48230-48238	Severity	_	
202-402	48239-48244	Index	_	
202-403	48245-48257	Neuroscience	_	
202-404	48258-48260	of	_	
202-405	48261-48271	inhibition	_	
202-406	48272-48275	for	_	
202-407	48276-48285	addiction	_	
202-408	48286-48294	medicine	_	
202-409	48294-48295	:	_	
202-410	48296-48300	from	_	
202-411	48301-48311	prediction	_	
202-412	48312-48314	of	_	
202-413	48315-48325	initiation	_	
202-414	48326-48328	to	_	
202-415	48329-48339	prediction	_	
202-416	48340-48342	of	_	
202-417	48343-48350	relapse	_	
202-418	48351-48361	Functional	_	
202-419	48361-48362	,	_	
202-420	48363-48373	structural	_	
202-421	48373-48374	,	_	
202-422	48375-48378	and	_	
202-423	48379-48388	emotional	_	
202-424	48389-48399	correlates	_	
202-425	48400-48402	of	_	
202-426	48403-48411	impaired	_	
202-427	48412-48419	insight	_	
202-428	48420-48422	in	_	
202-429	48423-48430	cocaine	_	
202-430	48431-48440	addiction	_	
202-431	48441-48449	Enhanced	_	
202-432	48450-48458	midbrain	_	
202-433	48459-48467	response	_	
202-434	48468-48470	at	_	
202-435	48471-48472	6	_	
202-436	48472-48473	-	_	
202-437	48473-48478	month	_	
202-438	48479-48488	follow-up	_	
202-439	48489-48491	in	_	
202-440	48492-48499	cocaine	_	
202-441	48500-48509	addiction	_	
202-442	48509-48510	,	_	
202-443	48511-48522	association	_	
202-444	48523-48527	with	_	
202-445	48528-48535	reduced	_	
202-446	48536-48548	drug-related	_	
202-447	48549-48555	choice	_	
202-448	48556-48559	The	_	
202-449	48560-48573	contributions	_	
202-450	48574-48576	of	_	
202-451	48577-48586	cognitive	_	
202-452	48587-48599	neuroscience	_	
202-453	48600-48603	and	_	
202-454	48604-48616	neuroimaging	_	
202-455	48617-48619	to	_	
202-456	48620-48633	understanding	_	
202-457	48634-48644	mechanisms	_	
202-458	48645-48647	of	_	
202-459	48648-48656	behavior	_	
202-460	48657-48663	change	_	
202-461	48664-48666	in	_	
202-462	48667-48676	addiction	_	
202-463	48678-48688	Disulfiram	_	
202-464	48689-48692	for	_	
202-465	48693-48696	the	_	
202-466	48697-48706	treatment	_	
202-467	48707-48709	of	_	
202-468	48710-48717	cocaine	_	
202-469	48718-48728	dependence	_	
202-470	48729-48739	Disulfiram	_	
202-471	48740-48749	treatment	_	
202-472	48750-48753	for	_	
202-473	48754-48761	cocaine	_	
202-474	48762-48772	dependence	_	
202-475	48773-48775	in	_	
202-476	48776-48796	methadone-maintained	_	
202-477	48797-48803	opioid	_	
202-478	48804-48811	addicts	_	
202-479	48812-48813	A	_	
202-480	48814-48827	comprehensive	_	
202-481	48828-48833	guide	_	
202-482	48834-48836	to	_	
202-483	48837-48840	the	_	
202-484	48841-48852	application	_	
202-485	48853-48855	of	_	
202-486	48856-48867	contingency	_	
202-487	48868-48878	management	_	
202-488	48879-48889	procedures	_	
202-489	48890-48892	in	_	
202-490	48893-48901	clinical	_	
202-491	48902-48910	settings	_	
202-492	48911-48921	Randomized	_	
202-493	48922-48927	trial	_	
202-494	48928-48930	of	_	
202-495	48931-48941	contingent	_	
202-496	48942-48948	prizes	_	
202-497	48949-48955	versus	_	
202-498	48956-48964	vouchers	_	
202-499	48965-48967	in	_	
202-500	48968-48981	cocaine-using	_	
202-501	48982-48991	methadone	_	
202-502	48992-49000	patients	_	
202-503	49001-49005	Give	_	
202-504	49006-49010	them	_	
202-505	49011-49017	prizes	_	
202-506	49017-49018	,	_	
202-507	49019-49022	and	_	
202-508	49023-49027	they	_	
202-509	49028-49032	will	_	
202-510	49033-49037	come	_	
202-511	49037-49038	:	_	
202-512	49039-49050	contingency	_	
202-513	49051-49061	management	_	
202-514	49062-49065	for	_	
202-515	49066-49075	treatment	_	
202-516	49076-49078	of	_	
202-517	49079-49086	alcohol	_	
202-518	49087-49097	dependence	_	
202-519	49098-49104	Effect	_	
202-520	49105-49107	of	_	
202-521	49108-49119	prize-based	_	
202-522	49120-49130	incentives	_	
202-523	49131-49133	on	_	
202-524	49134-49142	outcomes	_	
202-525	49143-49145	in	_	
202-526	49146-49155	stimulant	_	
202-527	49156-49163	abusers	_	
202-528	49164-49166	in	_	
202-529	49167-49177	outpatient	_	
202-530	49178-49190	psychosocial	_	
202-531	49191-49200	treatment	_	
202-532	49201-49209	programs	_	
202-533	49209-49210	:	_	
202-534	49211-49212	a	_	
202-535	49213-49221	national	_	
202-536	49222-49226	drug	_	
202-537	49227-49232	abuse	_	
202-538	49233-49242	treatment	_	
202-539	49243-49251	clinical	_	
202-540	49252-49258	trials	_	
202-541	49259-49266	network	_	
202-542	49267-49272	study	_	
202-543	49273-49284	Contingency	_	
202-544	49285-49295	management	_	
202-545	49296-49309	interventions	_	
202-546	49309-49310	:	_	
202-547	49311-49315	from	_	
202-548	49316-49324	research	_	
202-549	49325-49327	to	_	
202-550	49328-49336	practice	_	
202-551	49337-49349	Neuroscience	_	
202-552	49350-49352	of	_	
202-553	49353-49363	behavioral	_	
202-554	49364-49367	and	_	
202-555	49368-49383	pharmacological	_	
202-556	49384-49394	treatments	_	
202-557	49395-49398	for	_	
202-558	49399-49409	addictions	_	
202-559	49410-49421	Reliability	_	
202-560	49422-49424	of	_	
202-561	49425-49428	the	_	
202-562	49429-49437	Timeline	_	
202-563	49438-49448	Followback	_	
202-564	49449-49452	for	_	
202-565	49453-49460	cocaine	_	
202-566	49460-49461	,	_	
202-567	49462-49470	cannabis	_	
202-568	49470-49471	,	_	
202-569	49472-49475	and	_	
202-570	49476-49485	cigarette	_	
202-571	49486-49489	use	_	
202-572	49492-49507	Pharmacogenetic	_	
202-573	49508-49518	randomized	_	
202-574	49519-49524	trial	_	
202-575	49525-49528	for	_	
202-576	49529-49536	cocaine	_	
202-577	49537-49542	abuse	_	
202-578	49542-49543	:	_	
202-579	49544-49554	disulfiram	_	
202-580	49555-49558	and	_	
202-581	49559-49579	alpha1A–adrenoceptor	_	
202-582	49580-49584	gene	_	
202-583	49585-49594	variation	_	
202-584	49595-49603	Timeline	_	
202-585	49604-49614	followback	_	
202-586	49614-49615	:	_	
202-587	49616-49617	A	_	
202-588	49618-49627	technique	_	
202-589	49628-49631	for	_	
202-590	49632-49641	assessing	_	
202-591	49642-49655	self-reported	_	
202-592	49656-49663	alcohol	_	
202-593	49664-49675	consumption	_	
202-594	49676-49685	Cognitive	_	
202-595	49686-49697	enhancement	_	
202-596	49698-49700	as	_	
202-597	49701-49702	a	_	
202-598	49703-49712	treatment	_	
202-599	49713-49716	for	_	
202-600	49717-49721	drug	_	
202-601	49722-49732	addictions	_	
202-602	49733-49739	Neural	_	
202-603	49740-49747	systems	_	
202-604	49748-49751	for	_	
202-605	49752-49757	error	_	
202-606	49758-49768	monitoring	_	
202-607	49768-49769	:	_	
202-608	49770-49776	recent	_	
202-609	49777-49785	findings	_	
202-610	49786-49789	and	_	
202-611	49790-49801	theoretical	_	
202-612	49802-49814	perspectives	_	
202-613	49815-49831	Practice-induced	_	
202-614	49832-49839	changes	_	
202-615	49840-49842	of	_	
202-616	49843-49848	brain	_	
202-617	49849-49857	function	_	
202-618	49858-49864	during	_	
202-619	49865-49871	visual	_	
202-620	49872-49881	attention	_	
202-621	49881-49882	:	_	
202-622	49883-49884	a	_	
202-623	49885-49895	parametric	_	
202-624	49896-49900	fMRI	_	
202-625	49901-49906	study	_	
202-626	49907-49909	at	_	
202-627	49910-49911	4	_	
202-628	49912-49917	Tesla	_	
202-629	49918-49928	Disulfiram	_	
202-630	49929-49932	and	_	
202-631	49933-49955	diethyldithiocarbamate	_	
202-632	49956-49968	intoxication	_	
202-633	49969-49976	affects	_	
202-634	49977-49980	the	_	
202-635	49981-49988	storage	_	
202-636	49989-49992	and	_	
202-637	49993-50000	release	_	
202-638	50001-50003	of	_	
202-639	50004-50012	striatal	_	
202-640	50013-50021	dopamine	_	
202-641	50022-50034	Drug-related	_	
202-642	50035-50043	decrease	_	
202-643	50044-50046	in	_	
202-644	50047-50065	neuropsychological	_	
202-645	50066-50075	functions	_	
202-646	50076-50078	of	_	
202-647	50079-50088	abstinent	_	
202-648	50089-50093	drug	_	
202-649	50094-50099	users	_	
202-650	50100-50110	Functional	_	
202-651	50111-50116	brain	_	
202-652	50117-50125	networks	_	
202-653	50126-50136	associated	_	
202-654	50137-50141	with	_	
202-655	50142-50151	cognitive	_	
202-656	50152-50159	control	_	
202-657	50159-50160	,	_	
202-658	50161-50168	cocaine	_	
202-659	50169-50179	dependence	_	
202-660	50179-50180	,	_	
202-661	50181-50184	and	_	
202-662	50185-50194	treatment	_	
202-663	50195-50202	outcome	_	
202-664	50203-50212	Cognitive	_	
202-665	50213-50226	interventions	_	
202-666	50227-50230	for	_	
202-667	50231-50240	addiction	_	
202-668	50241-50249	medicine	_	
202-669	50249-50250	:	_	
202-670	50251-50264	Understanding	_	
202-671	50265-50268	the	_	
202-672	50269-50279	underlying	_	
202-673	50280-50295	neurobiological	_	
202-674	50296-50306	mechanisms	_	
202-675	50307-50314	Reduced	_	
202-676	50315-50329	Stroop-related	_	
202-677	50330-50338	Activity	_	
202-678	50339-50341	at	_	
202-679	50342-50356	Post-Treatment	_	
202-680	50357-50359	vs	_	
202-681	50359-50360	.	_	

#Text=Beginning-of-Treatment
#Text=A.
203-1	50361-50383	Beginning-of-Treatment	_	
203-2	50384-50385	A	_	
203-3	50385-50386	.	_	

#Text=Changes in Stroop effect-related activity (incongruent>congruent trials) at post-treatment versus beginning-of-treatment in the sample overall (N=26).
204-1	50387-50394	Changes	_	
204-2	50395-50397	in	_	
204-3	50398-50404	Stroop	_	
204-4	50405-50419	effect-related	_	
204-5	50420-50428	activity	_	
204-6	50429-50430	(	_	
204-7	50430-50441	incongruent	_	
204-8	50441-50442	>	_	
204-9	50442-50451	congruent	_	
204-10	50452-50458	trials	_	
204-11	50458-50459	)	_	
204-12	50460-50462	at	_	
204-13	50463-50477	post-treatment	_	
204-14	50478-50484	versus	_	
204-15	50485-50507	beginning-of-treatment	_	
204-16	50508-50510	in	_	
204-17	50511-50514	the	_	
204-18	50515-50521	sample	_	
204-19	50522-50529	overall	_	
204-20	50530-50531	(	_	
204-21	50531-50532	N	_	
204-22	50532-50533	=	_	
204-23	50533-50535	26	_	
204-24	50535-50536	)	_	
204-25	50536-50537	.	_	

#Text=Blue indicates regions with lower Stroop-related BOLD signal at post-treatment relative to beginning-of-treatment. fMRI results are family-wise-error-corrected for multiple comparisons at pFWE<.05.
205-1	50538-50542	Blue	_	
205-2	50543-50552	indicates	_	
205-3	50553-50560	regions	_	
205-4	50561-50565	with	_	
205-5	50566-50571	lower	_	
205-6	50572-50586	Stroop-related	_	
205-7	50587-50591	BOLD	_	
205-8	50592-50598	signal	_	
205-9	50599-50601	at	_	
205-10	50602-50616	post-treatment	_	
205-11	50617-50625	relative	_	
205-12	50626-50628	to	_	
205-13	50629-50651	beginning-of-treatment	_	
205-14	50651-50652	.	_	
205-15	50653-50657	fMRI	_	
205-16	50658-50665	results	_	
205-17	50666-50669	are	_	
205-18	50670-50697	family-wise-error-corrected	_	
205-19	50698-50701	for	_	
205-20	50702-50710	multiple	_	
205-21	50711-50722	comparisons	_	
205-22	50723-50725	at	_	
205-23	50726-50730	pFWE	_	
205-24	50730-50731	<	_	
205-25	50731-50734	.05	_	
205-26	50734-50735	.	_	

#Text=For additional details see Table 3A.
206-1	50736-50739	For	_	
206-2	50740-50750	additional	_	
206-3	50751-50758	details	_	
206-4	50759-50762	see	_	
206-5	50763-50768	Table	_	
206-6	50769-50771	3A	_	
206-7	50771-50772	.	_	

#Text=For full results, see Supplementary Figure 2.
207-1	50773-50776	For	_	
207-2	50777-50781	full	_	
207-3	50782-50789	results	_	
207-4	50789-50790	,	_	
207-5	50791-50794	see	_	
207-6	50795-50808	Supplementary	_	
207-7	50809-50815	Figure	_	
207-8	50816-50817	2	_	
207-9	50817-50818	.	_	

#Text=B.
208-1	50819-50820	B	_	
208-2	50820-50821	.	_	

#Text=The mean extracted betas from significant clusters (significant clusters shown in section A, in full Supplementary Figure 2 and reported in Table 3A).
209-1	50822-50825	The	_	
209-2	50826-50830	mean	_	
209-3	50831-50840	extracted	_	
209-4	50841-50846	betas	_	
209-5	50847-50851	from	_	
209-6	50852-50863	significant	_	
209-7	50864-50872	clusters	_	
209-8	50873-50874	(	_	
209-9	50874-50885	significant	_	
209-10	50886-50894	clusters	_	
209-11	50895-50900	shown	_	
209-12	50901-50903	in	_	
209-13	50904-50911	section	_	
209-14	50912-50913	A	_	
209-15	50913-50914	,	_	
209-16	50915-50917	in	_	
209-17	50918-50922	full	_	
209-18	50923-50936	Supplementary	_	
209-19	50937-50943	Figure	_	
209-20	50944-50945	2	_	
209-21	50946-50949	and	_	
209-22	50950-50958	reported	_	
209-23	50959-50961	in	_	
209-24	50962-50967	Table	_	
209-25	50968-50970	3A	_	
209-26	50970-50971	)	_	
209-27	50971-50972	.	_	

#Text=Mean betas are presented for each trial type (incongruent, congruent) and time point (beginning-of-treatment, post-treatment), relative to all unmodeled baseline.
210-1	50973-50977	Mean	_	
210-2	50978-50983	betas	_	
210-3	50984-50987	are	_	
210-4	50988-50997	presented	_	
210-5	50998-51001	for	_	
210-6	51002-51006	each	_	
210-7	51007-51012	trial	_	
210-8	51013-51017	type	_	
210-9	51018-51019	(	_	
210-10	51019-51030	incongruent	_	
210-11	51030-51031	,	_	
210-12	51032-51041	congruent	_	
210-13	51041-51042	)	_	
210-14	51043-51046	and	_	
210-15	51047-51051	time	_	
210-16	51052-51057	point	_	
210-17	51058-51059	(	_	
210-18	51059-51081	beginning-of-treatment	_	
210-19	51081-51082	,	_	
210-20	51083-51097	post-treatment	_	
210-21	51097-51098	)	_	
210-22	51098-51099	,	_	
210-23	51100-51108	relative	_	
210-24	51109-51111	to	_	
210-25	51112-51115	all	_	
210-26	51116-51125	unmodeled	_	
210-27	51126-51134	baseline	_	
210-28	51134-51135	.	_	

#Text=L= left, R= right.
211-1	51136-51137	L	_	
211-2	51137-51138	=	_	
211-3	51139-51143	left	_	
211-4	51143-51144	,	_	
211-5	51145-51146	R	_	
211-6	51146-51147	=	_	
211-7	51148-51153	right	_	
211-8	51153-51154	.	_	

#Text=Bars are in following order: Congruent (Beginning-of-Treatment), Incongruent (Beginning-of-Treatment), Congruent (Post-Treatment), Incongruent (Post-Treatment).
212-1	51155-51159	Bars	_	
212-2	51160-51163	are	_	
212-3	51164-51166	in	_	
212-4	51167-51176	following	_	
212-5	51177-51182	order	_	
212-6	51182-51183	:	_	
212-7	51184-51193	Congruent	_	
212-8	51194-51195	(	_	
212-9	51195-51217	Beginning-of-Treatment	_	
212-10	51217-51218	)	_	
212-11	51218-51219	,	_	
212-12	51220-51231	Incongruent	_	
212-13	51232-51233	(	_	
212-14	51233-51255	Beginning-of-Treatment	_	
212-15	51255-51256	)	_	
212-16	51256-51257	,	_	
212-17	51258-51267	Congruent	_	
212-18	51268-51269	(	_	
212-19	51269-51283	Post-Treatment	_	
212-20	51283-51284	)	_	
212-21	51284-51285	,	_	
212-22	51286-51297	Incongruent	_	
212-23	51298-51299	(	_	
212-24	51299-51313	Post-Treatment	_	
212-25	51313-51314	)	_	
212-26	51314-51315	.	_	

#Text=Fill color indicates trial type (white= congruent; grey= incongruent).
213-1	51316-51320	Fill	_	
213-2	51321-51326	color	_	
213-3	51327-51336	indicates	_	
213-4	51337-51342	trial	_	
213-5	51343-51347	type	_	
213-6	51348-51349	(	_	
213-7	51349-51354	white	_	
213-8	51354-51355	=	_	
213-9	51356-51365	congruent	_	
213-10	51365-51366	;	_	
213-11	51367-51371	grey	_	
213-12	51371-51372	=	_	
213-13	51373-51384	incongruent	_	
213-14	51384-51385	)	_	
213-15	51385-51386	.	_	

#Text=Border color indicates time point (black=Beginning-of-Treatment; red= Post-Treatment).
214-1	51387-51393	Border	_	
214-2	51394-51399	color	_	
214-3	51400-51409	indicates	_	
214-4	51410-51414	time	_	
214-5	51415-51420	point	_	
214-6	51421-51422	(	_	
214-7	51422-51427	black	_	
214-8	51427-51428	=	_	
214-9	51428-51450	Beginning-of-Treatment	_	
214-10	51450-51451	;	_	
214-11	51452-51455	red	_	
214-12	51455-51456	=	_	
214-13	51457-51471	Post-Treatment	_	
214-14	51471-51472	)	_	
214-15	51472-51473	.	_	

#Text=Error bars represent +/− 1 SEM.
215-1	51474-51479	Error	_	
215-2	51480-51484	bars	_	
215-3	51485-51494	represent	_	
215-4	51495-51496	+	_	
215-5	51496-51497	/	_	
215-6	51497-51498	−	_	
215-7	51499-51500	1	_	
215-8	51501-51504	SEM	_	
215-9	51504-51505	.	_	

#Text=Correlation between Change in Stroop effect and Treatment Engagement and Outcome
#Text=Rank-order whole brain correlations between change in Stroop effect-related activity at post-treatment versus beginning-of-treatment ((post incongruent- post congruent)-(pre incongruent- pre congruent)) and (A) number of cognitive behavioral therapy (CBT) sessions attended (N=26); (B) number of contingency management (CM) prizes received, within group randomized to CM (N=14); (C) percent days of self-reported days of cocaine abstinence during treatment.
216-1	51506-51517	Correlation	_	
216-2	51518-51525	between	_	
216-3	51526-51532	Change	_	
216-4	51533-51535	in	_	
216-5	51536-51542	Stroop	_	
216-6	51543-51549	effect	_	
216-7	51550-51553	and	_	
216-8	51554-51563	Treatment	_	
216-9	51564-51574	Engagement	_	
216-10	51575-51578	and	_	
216-11	51579-51586	Outcome	_	
216-12	51587-51597	Rank-order	_	
216-13	51598-51603	whole	_	
216-14	51604-51609	brain	_	
216-15	51610-51622	correlations	_	
216-16	51623-51630	between	_	
216-17	51631-51637	change	_	
216-18	51638-51640	in	_	
216-19	51641-51647	Stroop	_	
216-20	51648-51662	effect-related	_	
216-21	51663-51671	activity	_	
216-22	51672-51674	at	_	
216-23	51675-51689	post-treatment	_	
216-24	51690-51696	versus	_	
216-25	51697-51719	beginning-of-treatment	_	
216-26	51720-51721	(	_	
216-27	51721-51722	(	_	
216-28	51722-51726	post	_	
216-29	51727-51738	incongruent	_	
216-30	51738-51739	-	_	
216-31	51740-51744	post	_	
216-32	51745-51754	congruent	_	
216-33	51754-51755	)	_	
216-34	51755-51756	-	_	
216-35	51756-51757	(	_	
216-36	51757-51760	pre	_	
216-37	51761-51772	incongruent	_	
216-38	51772-51773	-	_	
216-39	51774-51777	pre	_	
216-40	51778-51787	congruent	_	
216-41	51787-51788	)	_	
216-42	51788-51789	)	_	
216-43	51790-51793	and	_	
216-44	51794-51795	(	_	
216-45	51795-51796	A	_	
216-46	51796-51797	)	_	
216-47	51798-51804	number	_	
216-48	51805-51807	of	_	
216-49	51808-51817	cognitive	_	
216-50	51818-51828	behavioral	_	
216-51	51829-51836	therapy	_	
216-52	51837-51838	(	_	
216-53	51838-51841	CBT	_	
216-54	51841-51842	)	_	
216-55	51843-51851	sessions	_	
216-56	51852-51860	attended	_	
216-57	51861-51862	(	_	
216-58	51862-51863	N	_	
216-59	51863-51864	=	_	
216-60	51864-51866	26	_	
216-61	51866-51867	)	_	
216-62	51867-51868	;	_	
216-63	51869-51870	(	_	
216-64	51870-51871	B	_	
216-65	51871-51872	)	_	
216-66	51873-51879	number	_	
216-67	51880-51882	of	_	
216-68	51883-51894	contingency	_	
216-69	51895-51905	management	_	
216-70	51906-51907	(	_	
216-71	51907-51909	CM	_	
216-72	51909-51910	)	_	
216-73	51911-51917	prizes	_	
216-74	51918-51926	received	_	
216-75	51926-51927	,	_	
216-76	51928-51934	within	_	
216-77	51935-51940	group	_	
216-78	51941-51951	randomized	_	
216-79	51952-51954	to	_	
216-80	51955-51957	CM	_	
216-81	51958-51959	(	_	
216-82	51959-51960	N	_	
216-83	51960-51961	=	_	
216-84	51961-51963	14	_	
216-85	51963-51964	)	_	
216-86	51964-51965	;	_	
216-87	51966-51967	(	_	
216-88	51967-51968	C	_	
216-89	51968-51969	)	_	
216-90	51970-51977	percent	_	
216-91	51978-51982	days	_	
216-92	51983-51985	of	_	
216-93	51986-51999	self-reported	_	
216-94	52000-52004	days	_	
216-95	52005-52007	of	_	
216-96	52008-52015	cocaine	_	
216-97	52016-52026	abstinence	_	
216-98	52027-52033	during	_	
216-99	52034-52043	treatment	_	
216-100	52043-52044	.	_	

#Text=Blue regions indicate inverse correlations showing lower Stroop-related activity at post- vs. beginning-of-treatment associated with more treatment engagement.
217-1	52045-52049	Blue	_	
217-2	52050-52057	regions	_	
217-3	52058-52066	indicate	_	
217-4	52067-52074	inverse	_	
217-5	52075-52087	correlations	_	
217-6	52088-52095	showing	_	
217-7	52096-52101	lower	_	
217-8	52102-52116	Stroop-related	_	
217-9	52117-52125	activity	_	
217-10	52126-52128	at	_	
217-11	52129-52133	post	_	
217-12	52133-52134	-	_	
217-13	52135-52137	vs	_	
217-14	52137-52138	.	_	
217-15	52139-52161	beginning-of-treatment	_	
217-16	52162-52172	associated	_	
217-17	52173-52177	with	_	
217-18	52178-52182	more	_	
217-19	52183-52192	treatment	_	
217-20	52193-52203	engagement	_	
217-21	52203-52204	.	_	

#Text=Red regions indicate positive correlations showing higher Stroop-related activity at post- versus beginning-of-treatment associated with more cocaine abstinence.
218-1	52205-52208	Red	_	
218-2	52209-52216	regions	_	
218-3	52217-52225	indicate	_	
218-4	52226-52234	positive	_	
218-5	52235-52247	correlations	_	
218-6	52248-52255	showing	_	
218-7	52256-52262	higher	_	
218-8	52263-52277	Stroop-related	_	
218-9	52278-52286	activity	_	
218-10	52287-52289	at	_	
218-11	52290-52294	post	_	
218-12	52294-52295	-	_	
218-13	52296-52302	versus	_	
218-14	52303-52325	beginning-of-treatment	_	
218-15	52326-52336	associated	_	
218-16	52337-52341	with	_	
218-17	52342-52346	more	_	
218-18	52347-52354	cocaine	_	
218-19	52355-52365	abstinence	_	
218-20	52365-52366	.	_	

#Text=Scatter plots show extracted rank order correlations from each significant cluster (see Table 3B). fMRI results are family-wise-error-corrected for multiple comparisons at pFWE<.05.
219-1	52367-52374	Scatter	_	
219-2	52375-52380	plots	_	
219-3	52381-52385	show	_	
219-4	52386-52395	extracted	_	
219-5	52396-52400	rank	_	
219-6	52401-52406	order	_	
219-7	52407-52419	correlations	_	
219-8	52420-52424	from	_	
219-9	52425-52429	each	_	
219-10	52430-52441	significant	_	
219-11	52442-52449	cluster	_	
219-12	52450-52451	(	_	
219-13	52451-52454	see	_	
219-14	52455-52460	Table	_	
219-15	52461-52463	3B	_	
219-16	52463-52464	)	_	
219-17	52464-52465	.	_	
219-18	52466-52470	fMRI	_	
219-19	52471-52478	results	_	
219-20	52479-52482	are	_	
219-21	52483-52510	family-wise-error-corrected	_	
219-22	52511-52514	for	_	
219-23	52515-52523	multiple	_	
219-24	52524-52535	comparisons	_	
219-25	52536-52538	at	_	
219-26	52539-52543	pFWE	_	
219-27	52543-52544	<	_	
219-28	52544-52547	.05	_	
219-29	52547-52548	.	_	

#Text=For full sliceout of results, see Supplementary Figure 3.
220-1	52549-52552	For	_	
220-2	52553-52557	full	_	
220-3	52558-52566	sliceout	_	
220-4	52567-52569	of	_	
220-5	52570-52577	results	_	
220-6	52577-52578	,	_	
220-7	52579-52582	see	_	
220-8	52583-52596	Supplementary	_	
220-9	52597-52603	Figure	_	
220-10	52604-52605	3	_	
220-11	52605-52606	.	_	

#Text=Definition of Treatment Engagement Variables
#Text=Treatment Component\tTreatment Engagement Variable\tOperational Definition of Treatment Variable\t \tCBT Exposure\tCBT Sessions\tNumber of CBT sessions attended during the 12-week treatment protocol.
221-1	52607-52617	Definition	_	
221-2	52618-52620	of	_	
221-3	52621-52630	Treatment	_	
221-4	52631-52641	Engagement	_	
221-5	52642-52651	Variables	_	
221-6	52652-52661	Treatment	_	
221-7	52662-52671	Component	_	
221-8	52672-52681	Treatment	_	
221-9	52682-52692	Engagement	_	
221-10	52693-52701	Variable	_	
221-11	52702-52713	Operational	_	
221-12	52714-52724	Definition	_	
221-13	52725-52727	of	_	
221-14	52728-52737	Treatment	_	
221-15	52738-52746	Variable	_	
221-16	52749-52752	CBT	_	
221-17	52753-52761	Exposure	_	
221-18	52762-52765	CBT	_	
221-19	52766-52774	Sessions	_	
221-20	52775-52781	Number	_	
221-21	52782-52784	of	_	
221-22	52785-52788	CBT	_	
221-23	52789-52797	sessions	_	
221-24	52798-52806	attended	_	
221-25	52807-52813	during	_	
221-26	52814-52817	the	_	
221-27	52818-52820	12	_	
221-28	52820-52821	-	_	
221-29	52821-52825	week	_	
221-30	52826-52835	treatment	_	
221-31	52836-52844	protocol	_	
221-32	52844-52845	.	_	

#Text=All subjects were invited to attend one 50-min CBT sessions per week during the 12 week protocol (i.e., total of up to 12 CBT sessions).
222-1	52846-52849	All	_	
222-2	52850-52858	subjects	_	
222-3	52859-52863	were	_	
222-4	52864-52871	invited	_	
222-5	52872-52874	to	_	
222-6	52875-52881	attend	_	
222-7	52882-52885	one	_	
222-8	52886-52888	50	_	
222-9	52888-52889	-	_	
222-10	52889-52892	min	_	
222-11	52893-52896	CBT	_	
222-12	52897-52905	sessions	_	
222-13	52906-52909	per	_	
222-14	52910-52914	week	_	
222-15	52915-52921	during	_	
222-16	52922-52925	the	_	
222-17	52926-52928	12	_	
222-18	52929-52933	week	_	
222-19	52934-52942	protocol	_	
222-20	52943-52944	(	_	
222-21	52944-52947	i.e	_	
222-22	52947-52948	.	_	
222-23	52948-52949	,	_	
222-24	52950-52955	total	_	
222-25	52956-52958	of	_	
222-26	52959-52961	up	_	
222-27	52962-52964	to	_	
222-28	52965-52967	12	_	
222-29	52968-52971	CBT	_	
222-30	52972-52980	sessions	_	
222-31	52980-52981	)	_	
222-32	52981-52982	.	_	

#Text=CBT sessions were held individually with a clinician trained in CBT.
223-1	52983-52986	CBT	_	
223-2	52987-52995	sessions	_	
223-3	52996-53000	were	_	
223-4	53001-53005	held	_	
223-5	53006-53018	individually	_	
223-6	53019-53023	with	_	
223-7	53024-53025	a	_	
223-8	53026-53035	clinician	_	
223-9	53036-53043	trained	_	
223-10	53044-53046	in	_	
223-11	53047-53050	CBT	_	
223-12	53050-53051	.	_	

#Text=Subjects could still remain active in the RCT if they failed to attend CBT sessions, so CBT sessions are not fully predicted by the number of weeks in treatment.
224-1	53052-53060	Subjects	_	
224-2	53061-53066	could	_	
224-3	53067-53072	still	_	
224-4	53073-53079	remain	_	
224-5	53080-53086	active	_	
224-6	53087-53089	in	_	
224-7	53090-53093	the	_	
224-8	53094-53097	RCT	_	
224-9	53098-53100	if	_	
224-10	53101-53105	they	_	
224-11	53106-53112	failed	_	
224-12	53113-53115	to	_	
224-13	53116-53122	attend	_	
224-14	53123-53126	CBT	_	
224-15	53127-53135	sessions	_	
224-16	53135-53136	,	_	
224-17	53137-53139	so	_	
224-18	53140-53143	CBT	_	
224-19	53144-53152	sessions	_	
224-20	53153-53156	are	_	
224-21	53157-53160	not	_	
224-22	53161-53166	fully	_	
224-23	53167-53176	predicted	_	
224-24	53177-53179	by	_	
224-25	53180-53183	the	_	
224-26	53184-53190	number	_	
224-27	53191-53193	of	_	
224-28	53194-53199	weeks	_	
224-29	53200-53202	in	_	
224-30	53203-53212	treatment	_	
224-31	53212-53213	.	_	

#Text=CM Exposure\tCM Prizes\tNumber of CM prizes drawn during the RCT protocol, within the group randomized to CM treatment.
225-1	53216-53218	CM	_	
225-2	53219-53227	Exposure	_	
225-3	53228-53230	CM	_	
225-4	53231-53237	Prizes	_	
225-5	53238-53244	Number	_	
225-6	53245-53247	of	_	
225-7	53248-53250	CM	_	
225-8	53251-53257	prizes	_	
225-9	53258-53263	drawn	_	
225-10	53264-53270	during	_	
225-11	53271-53274	the	_	
225-12	53275-53278	RCT	_	
225-13	53279-53287	protocol	_	
225-14	53287-53288	,	_	
225-15	53289-53295	within	_	
225-16	53296-53299	the	_	
225-17	53300-53305	group	_	
225-18	53306-53316	randomized	_	
225-19	53317-53319	to	_	
225-20	53320-53322	CM	_	
225-21	53323-53332	treatment	_	
225-22	53332-53333	.	_	

#Text=Prizes were awarded for submission of urines as scheduled (thrice weekly) that were negative for cocaine and in-person observed administration of study pills as scheduled (thrice weekly).
226-1	53334-53340	Prizes	_	
226-2	53341-53345	were	_	
226-3	53346-53353	awarded	_	
226-4	53354-53357	for	_	
226-5	53358-53368	submission	_	
226-6	53369-53371	of	_	
226-7	53372-53378	urines	_	
226-8	53379-53381	as	_	
226-9	53382-53391	scheduled	_	
226-10	53392-53393	(	_	
226-11	53393-53399	thrice	_	
226-12	53400-53406	weekly	_	
226-13	53406-53407	)	_	
226-14	53408-53412	that	_	
226-15	53413-53417	were	_	
226-16	53418-53426	negative	_	
226-17	53427-53430	for	_	
226-18	53431-53438	cocaine	_	
226-19	53439-53442	and	_	
226-20	53443-53452	in-person	_	
226-21	53453-53461	observed	_	
226-22	53462-53476	administration	_	
226-23	53477-53479	of	_	
226-24	53480-53485	study	_	
226-25	53486-53491	pills	_	
226-26	53492-53494	as	_	
226-27	53495-53504	scheduled	_	
226-28	53505-53506	(	_	
226-29	53506-53512	thrice	_	
226-30	53513-53519	weekly	_	
226-31	53519-53520	)	_	
226-32	53520-53521	.	_	

#Text=The number of prize draws increased for consecutive cocaine-negative urines and pill adherences and decreased following failure to provide a scheduled cocaine-negative urine sample (see Methods and Supplemental Materials for details).
227-1	53522-53525	The	_	
227-2	53526-53532	number	_	
227-3	53533-53535	of	_	
227-4	53536-53541	prize	_	
227-5	53542-53547	draws	_	
227-6	53548-53557	increased	_	
227-7	53558-53561	for	_	
227-8	53562-53573	consecutive	_	
227-9	53574-53590	cocaine-negative	_	
227-10	53591-53597	urines	_	
227-11	53598-53601	and	_	
227-12	53602-53606	pill	_	
227-13	53607-53617	adherences	_	
227-14	53618-53621	and	_	
227-15	53622-53631	decreased	_	
227-16	53632-53641	following	_	
227-17	53642-53649	failure	_	
227-18	53650-53652	to	_	
227-19	53653-53660	provide	_	
227-20	53661-53662	a	_	
227-21	53663-53672	scheduled	_	
227-22	53673-53689	cocaine-negative	_	
227-23	53690-53695	urine	_	
227-24	53696-53702	sample	_	
227-25	53703-53704	(	_	
227-26	53704-53707	see	_	
227-27	53708-53715	Methods	_	
227-28	53716-53719	and	_	
227-29	53720-53732	Supplemental	_	
227-30	53733-53742	Materials	_	
227-31	53743-53746	for	_	
227-32	53747-53754	details	_	
227-33	53754-53755	)	_	
227-34	53755-53756	.	_	

#Text=Disulfiram Exposure\tDisulfiram Medication Days\tNumber of days of observed (during in person visit days) or self-reported (during take-home pill days) adherence to the medication protocol, within individuals randomized to disulfiram.
228-1	53759-53769	Disulfiram	_	
228-2	53770-53778	Exposure	_	
228-3	53779-53789	Disulfiram	_	
228-4	53790-53800	Medication	_	
228-5	53801-53805	Days	_	
228-6	53806-53812	Number	_	
228-7	53813-53815	of	_	
228-8	53816-53820	days	_	
228-9	53821-53823	of	_	
228-10	53824-53832	observed	_	
228-11	53833-53834	(	_	
228-12	53834-53840	during	_	
228-13	53841-53843	in	_	
228-14	53844-53850	person	_	
228-15	53851-53856	visit	_	
228-16	53857-53861	days	_	
228-17	53861-53862	)	_	
228-18	53863-53865	or	_	
228-19	53866-53879	self-reported	_	
228-20	53880-53881	(	_	
228-21	53881-53887	during	_	
228-22	53888-53897	take-home	_	
228-23	53898-53902	pill	_	
228-24	53903-53907	days	_	
228-25	53907-53908	)	_	
228-26	53909-53918	adherence	_	
228-27	53919-53921	to	_	
228-28	53922-53925	the	_	
228-29	53926-53936	medication	_	
228-30	53937-53945	protocol	_	
228-31	53945-53946	,	_	
228-32	53947-53953	within	_	
228-33	53954-53965	individuals	_	
228-34	53966-53976	randomized	_	
228-35	53977-53979	to	_	
228-36	53980-53990	disulfiram	_	
228-37	53990-53991	.	_	

#Text=During thrice-weekly sessions, subjects were observed taking their assigned pills and were given take-home doses of medications and asked to self-report their adherence to prior take-home medication days since last appointment.
229-1	53992-53998	During	_	
229-2	53999-54012	thrice-weekly	_	
229-3	54013-54021	sessions	_	
229-4	54021-54022	,	_	
229-5	54023-54031	subjects	_	
229-6	54032-54036	were	_	
229-7	54037-54045	observed	_	
229-8	54046-54052	taking	_	
229-9	54053-54058	their	_	
229-10	54059-54067	assigned	_	
229-11	54068-54073	pills	_	
229-12	54074-54077	and	_	
229-13	54078-54082	were	_	
229-14	54083-54088	given	_	
229-15	54089-54098	take-home	_	
229-16	54099-54104	doses	_	
229-17	54105-54107	of	_	
229-18	54108-54119	medications	_	
229-19	54120-54123	and	_	
229-20	54124-54129	asked	_	
229-21	54130-54132	to	_	
229-22	54133-54144	self-report	_	
229-23	54145-54150	their	_	
229-24	54151-54160	adherence	_	
229-25	54161-54163	to	_	
229-26	54164-54169	prior	_	
229-27	54170-54179	take-home	_	
229-28	54180-54190	medication	_	
229-29	54191-54195	days	_	
229-30	54196-54201	since	_	
229-31	54202-54206	last	_	
229-32	54207-54218	appointment	_	
229-33	54218-54219	.	_	

#Text=Note.
230-1	54223-54227	Note	_	
230-2	54227-54228	.	_	

#Text=CBT: Cognitive Behavioral Therapy; CM: Contingency Management; RCT: Randomized Clinical Trial.
231-1	54229-54232	CBT	_	
231-2	54232-54233	:	_	
231-3	54234-54243	Cognitive	_	
231-4	54244-54254	Behavioral	_	
231-5	54255-54262	Therapy	_	
231-6	54262-54263	;	_	
231-7	54264-54266	CM	_	
231-8	54266-54267	:	_	
231-9	54268-54279	Contingency	_	
231-10	54280-54290	Management	_	
231-11	54290-54291	;	_	
231-12	54292-54295	RCT	_	
231-13	54295-54296	:	_	
231-14	54297-54307	Randomized	_	
231-15	54308-54316	Clinical	_	
231-16	54317-54322	Trial	_	
231-17	54322-54323	.	_	

#Text=Baseline demographic, psychiatric, and substance-use characteristics and Stroop behavior by treatment group
#Text=\tTotal Sample(n=26)\tContingency Management (n=14)\tNo Contingency Management (n=12)\tStatistics (F(p))\t \t\t\t \t\tPlacebo (n=10)\tDisulfiram (n=4)\tPlacebo (n=6)\tDisulfiram (n=6)\tCM Status\tDisulfiram Status\tCM Status × Disulfiram Status\t \t\t \tDemographics\t\t\t\t\t\t\t\t\t \tSex, N (%) Female\t10 (38.5)\t3 (30.0)\t3 (75.0)\t2 (33.3)\t2 (33.3)\t0.02 (0.89)\t0.00 (1.00)\t1.14 (0.29)\t \tAge\t40.27 (7.55)\t41.00 (6.90)\t42.00 (2.94)\t38.33 (11.26)\t39.83 (7.71)\t0.54 (0.47)\t0.15 (0.71)\t0.01 (0.94)\t \tRace, N (%)\t\t\t\t\t\t\t\t\t \t  Caucasian\t10 (38.5)\t2 (20.0)\t2 (50.0)\t3 (50.0)\t3 (50.0)\t\t\t\t \t  African-American\t12 (46.2)\t6 (60.0)\t2 (50.0)\t2 (33.3)\t2 (33.3)\t\t\t\t \t  Hispanic\t2 (7.7)\t0 (0.0)\t0 (0.0)\t1 (16.7)\t1 (16.7)\t\t\t\t \t  Multiracial/Other\t2 (7.7)\t2 (20.0)\t0 (0.0)\t0 (0.0)\t0 (0.0)\t\t\t\t \tEstimated IQ (SILS)\t97.80 (10.77)\t98.33 (10.33)\t93.25 (8.77)\t96.33 (13.84)\t101.50 (10.60)\t0.30 (0.59)\t0.02 (0.88)\t2.12 (0.16)\t \tNumber of months incarcerated, lifetime\t25.38 (52.88)\t37.20 (65.94)\t3.00 (6.00)\t5.83 (11.94)\t40.17 (67.75)\t0.02 (0.90)\t0.00 (0.99)\t2.40 (0.14)\t \tOther Lifetime Psychiatric Diagnoses, N(%)\t\t\t\t\t\t\t\t\t \tAlcohol-Use Disorder\t16 (61.5)\t5 (50.0)\t3 (75.0)\t4 (66.7)\t6 (100.0)\t0.42 (0.52)\t0.00 (1.00)\t0.00 (1.00)\t \tMajor Depression\t7 (26.9)\t7 (70.0)\t0 (0.0)\t1 (16.7)\t3 (50.0)\t0.35 (0.56)\t1.39 (0.24)\t0.00 (1.00)\t \tAnxiety Disorder\t0(0.0)\t0 (0.0)\t0 (0.0)\t0 (0.0)\t0 (0.0)\t0.00 (1.00)\t0.00 (1.00)\t0.00 (1.00)\t \tAntisocial-Personality Disorder\t2 (7.7)\t0 (0.0)\t0 (0.0)\t0 (0.0)\t2 (33.3)\t0.00 (1.00)\t0.00 (1.00)\t0.00 (1.00)\t \tDays of Use in Month Prior to Treatment1\t\t\t\t\t\t\t\t\t \tCocaine\t14.88 (7.80)\t13.50 (7.69)\t17.50 (8.81)\t16.83 (8.95)\t13.50 (7.40)\t0.01 (0.92)\t0.01 (0.92)\t1.20 (2.90)\t \tAlcohol\t7.35 (8.38)\t5.80 (7.22)\t14.25 (11.90)\t6.67 (9.75)\t6.00 (5.62)\t1.15 (0.30)\t1.28 (0.27)\t1.75 (0.20)\t \tCannabis\t2.12 (5.55)\t0.40 (0.97)\t7.00 (14.00)\t2.67 (2.66)\t1.17 (1.17)\t0.64 (0.43)\t1.31 (0.26)\t3.31 (0.08)\t \tCigarettes\t20.73 (11.89)\t18.80 (13.21)\t21.00 (14.00)\t23.33 (11.43)\t21.17 (11.36)\t0.21 (0.66)\t0.00 (1.00)\t0.18 (0.68)\t \tLifetime Years of Regular Use\t\t\t\t\t\t\t\t\t \tCocaine\t9.31 (6.18)\t7.60 (4.25)\t10.75 (6.99)\t9.33 (8.89)\t11.17 (6.18)\t0.17 (0.69)\t089 (0.36)\t0.06 (0.81)\t \tAlcohol\t8.69 (9.01)\t3.90 (4.95)\t9.00 (8.60)\t13.67 (11.60)\t11.50 (9.85)\t3.02 (0.10)\t0.17 (0.68)\t1.01 (0.31)\t \tCannabis\t5.81 (7.38)\t2.30 (3.37)\t1.50 (2.38)\t7.17 (6.37)\t13.17 (10.05)\t10.65 (0.004)\t1.05 (0.32)\t1.80 (0.19)\t \tTreatment Engagement\t\t\t\t\t\t\t\t\t \tDays in Treatment\t59.77 (30.22)\t44.60 (29.14)\t80.50 (7.00)\t49.67 (38.51)\t81.33 (6.53)\t0.07 (0.79)\t9.54 (0.005)\t0.04 (0.85)\t \tNumber of CBT Sessions Attended\t6.73 (4.28)\t5.20 (4.24)\t8.25 (2.87)\t6.17 (5.42)\t8.83 (3.55)\t0.20 (0.66)\t2.66 (0.12)\t0.01 (0.91)\t \tNumber of Days of Disulfiram Doses Taken\tN/A\tN/A\t39.70 (25.81)\tN/A\t45.00 (34.18)\t0.13 (0.73)\tN/A\tN/A\t \tNumber of CM Prizes Drawn\tN/A\t82.30 (88.87)\t120.50 (84.03)\tN/A\tN/A\tN/A\t0.54 (0.48)\tN/A\t \tTreatment Outcome\t\t\t\t\t\t\t\t\t \t% Days Self-reported Abstinence Within Treatment Period\t81.50 (22.50)\t92.62 (7.48)\t59.23 (45.00)\t76.39 (19.39)\t82.94 (12.73)\t0.19 (0.66)\t2.50 (0.13)\t5.54 (0.03)\t \t% Urines Negative for Cocaine Within Treatment Period\t44.87 (39.78)\t67.74 (34.19)\t35.64 (45.24)\t16.50 (27.53)\t41.29 (41.55)\t2.30 (0.14)\t0.06 (0.81)\t3.58 (0.07)\t \tStroop Task Behavior2\t\t\t\t\t\t\t\t\t \tBeginning-of-Treatment\t\t\t\t\t\t\t\t\t \tMean Congruent Trial RT (ms)\t508.88 (124.40)\t537.27 (120.59)\t436.51 (125.42)\t506.07 (121.09)\t521.59 (157.83)\t.\t.\t.
232-1	54324-54332	Baseline	_	
232-2	54333-54344	demographic	_	
232-3	54344-54345	,	_	
232-4	54346-54357	psychiatric	_	
232-5	54357-54358	,	_	
232-6	54359-54362	and	_	
232-7	54363-54376	substance-use	_	
232-8	54377-54392	characteristics	_	
232-9	54393-54396	and	_	
232-10	54397-54403	Stroop	_	
232-11	54404-54412	behavior	_	
232-12	54413-54415	by	_	
232-13	54416-54425	treatment	_	
232-14	54426-54431	group	_	
232-15	54433-54438	Total	_	
232-16	54439-54445	Sample	_	
232-17	54445-54446	(	_	
232-18	54446-54447	n	_	
232-19	54447-54448	=	_	
232-20	54448-54450	26	_	
232-21	54450-54451	)	_	
232-22	54452-54463	Contingency	_	
232-23	54464-54474	Management	_	
232-24	54475-54476	(	_	
232-25	54476-54477	n	_	
232-26	54477-54478	=	_	
232-27	54478-54480	14	_	
232-28	54480-54481	)	_	
232-29	54482-54484	No	_	
232-30	54485-54496	Contingency	_	
232-31	54497-54507	Management	_	
232-32	54508-54509	(	_	
232-33	54509-54510	n	_	
232-34	54510-54511	=	_	
232-35	54511-54513	12	_	
232-36	54513-54514	)	_	
232-37	54515-54525	Statistics	_	
232-38	54526-54527	(	_	
232-39	54527-54528	F	_	
232-40	54528-54529	(	_	
232-41	54529-54530	p	_	
232-42	54530-54531	)	_	
232-43	54531-54532	)	_	
232-44	54540-54547	Placebo	_	
232-45	54548-54549	(	_	
232-46	54549-54550	n	_	
232-47	54550-54551	=	_	
232-48	54551-54553	10	_	
232-49	54553-54554	)	_	
232-50	54555-54565	Disulfiram	_	
232-51	54566-54567	(	_	
232-52	54567-54568	n	_	
232-53	54568-54569	=	_	
232-54	54569-54570	4	_	
232-55	54570-54571	)	_	
232-56	54572-54579	Placebo	_	
232-57	54580-54581	(	_	
232-58	54581-54582	n	_	
232-59	54582-54583	=	_	
232-60	54583-54584	6	_	
232-61	54584-54585	)	_	
232-62	54586-54596	Disulfiram	_	
232-63	54597-54598	(	_	
232-64	54598-54599	n	_	
232-65	54599-54600	=	_	
232-66	54600-54601	6	_	
232-67	54601-54602	)	_	
232-68	54603-54605	CM	_	
232-69	54606-54612	Status	_	
232-70	54613-54623	Disulfiram	_	
232-71	54624-54630	Status	_	
232-72	54631-54633	CM	_	
232-73	54634-54640	Status	_	
232-74	54641-54642	×	_	
232-75	54643-54653	Disulfiram	_	
232-76	54654-54660	Status	_	
232-77	54666-54678	Demographics	_	
232-78	54689-54692	Sex	_	
232-79	54692-54693	,	_	
232-80	54694-54695	N	_	
232-81	54696-54697	(	_	
232-82	54697-54698	%	_	
232-83	54698-54699	)	_	
232-84	54700-54706	Female	_	
232-85	54707-54709	10	_	
232-86	54710-54711	(	_	
232-87	54711-54715	38.5	_	
232-88	54715-54716	)	_	
232-89	54717-54718	3	_	
232-90	54719-54720	(	_	
232-91	54720-54724	30.0	_	
232-92	54724-54725	)	_	
232-93	54726-54727	3	_	
232-94	54728-54729	(	_	
232-95	54729-54733	75.0	_	
232-96	54733-54734	)	_	
232-97	54735-54736	2	_	
232-98	54737-54738	(	_	
232-99	54738-54742	33.3	_	
232-100	54742-54743	)	_	
232-101	54744-54745	2	_	
232-102	54746-54747	(	_	
232-103	54747-54751	33.3	_	
232-104	54751-54752	)	_	
232-105	54753-54757	0.02	_	
232-106	54758-54759	(	_	
232-107	54759-54763	0.89	_	
232-108	54763-54764	)	_	
232-109	54765-54769	0.00	_	
232-110	54770-54771	(	_	
232-111	54771-54775	1.00	_	
232-112	54775-54776	)	_	
232-113	54777-54781	1.14	_	
232-114	54782-54783	(	_	
232-115	54783-54787	0.29	_	
232-116	54787-54788	)	_	
232-117	54791-54794	Age	_	
232-118	54795-54800	40.27	_	
232-119	54801-54802	(	_	
232-120	54802-54806	7.55	_	
232-121	54806-54807	)	_	
232-122	54808-54813	41.00	_	
232-123	54814-54815	(	_	
232-124	54815-54819	6.90	_	
232-125	54819-54820	)	_	
232-126	54821-54826	42.00	_	
232-127	54827-54828	(	_	
232-128	54828-54832	2.94	_	
232-129	54832-54833	)	_	
232-130	54834-54839	38.33	_	
232-131	54840-54841	(	_	
232-132	54841-54846	11.26	_	
232-133	54846-54847	)	_	
232-134	54848-54853	39.83	_	
232-135	54854-54855	(	_	
232-136	54855-54859	7.71	_	
232-137	54859-54860	)	_	
232-138	54861-54865	0.54	_	
232-139	54866-54867	(	_	
232-140	54867-54871	0.47	_	
232-141	54871-54872	)	_	
232-142	54873-54877	0.15	_	
232-143	54878-54879	(	_	
232-144	54879-54883	0.71	_	
232-145	54883-54884	)	_	
232-146	54885-54889	0.01	_	
232-147	54890-54891	(	_	
232-148	54891-54895	0.94	_	
232-149	54895-54896	)	_	
232-150	54899-54903	Race	_	
232-151	54903-54904	,	_	
232-152	54905-54906	N	_	
232-153	54907-54908	(	_	
232-154	54908-54909	%	_	
232-155	54909-54910	)	_	
232-156	54921-54923	  	_	
232-157	54923-54932	Caucasian	_	
232-158	54933-54935	10	_	
232-159	54936-54937	(	_	
232-160	54937-54941	38.5	_	
232-161	54941-54942	)	_	
232-162	54943-54944	2	_	
232-163	54945-54946	(	_	
232-164	54946-54950	20.0	_	
232-165	54950-54951	)	_	
232-166	54952-54953	2	_	
232-167	54954-54955	(	_	
232-168	54955-54959	50.0	_	
232-169	54959-54960	)	_	
232-170	54961-54962	3	_	
232-171	54963-54964	(	_	
232-172	54964-54968	50.0	_	
232-173	54968-54969	)	_	
232-174	54970-54971	3	_	
232-175	54972-54973	(	_	
232-176	54973-54977	50.0	_	
232-177	54977-54978	)	_	
232-178	54984-54986	  	_	
232-179	54986-55002	African-American	_	
232-180	55003-55005	12	_	
232-181	55006-55007	(	_	
232-182	55007-55011	46.2	_	
232-183	55011-55012	)	_	
232-184	55013-55014	6	_	
232-185	55015-55016	(	_	
232-186	55016-55020	60.0	_	
232-187	55020-55021	)	_	
232-188	55022-55023	2	_	
232-189	55024-55025	(	_	
232-190	55025-55029	50.0	_	
232-191	55029-55030	)	_	
232-192	55031-55032	2	_	
232-193	55033-55034	(	_	
232-194	55034-55038	33.3	_	
232-195	55038-55039	)	_	
232-196	55040-55041	2	_	
232-197	55042-55043	(	_	
232-198	55043-55047	33.3	_	
232-199	55047-55048	)	_	
232-200	55054-55056	  	_	
232-201	55056-55064	Hispanic	_	
232-202	55065-55066	2	_	
232-203	55067-55068	(	_	
232-204	55068-55071	7.7	_	
232-205	55071-55072	)	_	
232-206	55073-55074	0	_	
232-207	55075-55076	(	_	
232-208	55076-55079	0.0	_	
232-209	55079-55080	)	_	
232-210	55081-55082	0	_	
232-211	55083-55084	(	_	
232-212	55084-55087	0.0	_	
232-213	55087-55088	)	_	
232-214	55089-55090	1	_	
232-215	55091-55092	(	_	
232-216	55092-55096	16.7	_	
232-217	55096-55097	)	_	
232-218	55098-55099	1	_	
232-219	55100-55101	(	_	
232-220	55101-55105	16.7	_	
232-221	55105-55106	)	_	
232-222	55112-55114	  	_	
232-223	55114-55125	Multiracial	_	
232-224	55125-55126	/	_	
232-225	55126-55131	Other	_	
232-226	55132-55133	2	_	
232-227	55134-55135	(	_	
232-228	55135-55138	7.7	_	
232-229	55138-55139	)	_	
232-230	55140-55141	2	_	
232-231	55142-55143	(	_	
232-232	55143-55147	20.0	_	
232-233	55147-55148	)	_	
232-234	55149-55150	0	_	
232-235	55151-55152	(	_	
232-236	55152-55155	0.0	_	
232-237	55155-55156	)	_	
232-238	55157-55158	0	_	
232-239	55159-55160	(	_	
232-240	55160-55163	0.0	_	
232-241	55163-55164	)	_	
232-242	55165-55166	0	_	
232-243	55167-55168	(	_	
232-244	55168-55171	0.0	_	
232-245	55171-55172	)	_	
232-246	55178-55187	Estimated	_	
232-247	55188-55190	IQ	_	
232-248	55191-55192	(	_	
232-249	55192-55196	SILS	_	
232-250	55196-55197	)	_	
232-251	55198-55203	97.80	_	
232-252	55204-55205	(	_	
232-253	55205-55210	10.77	_	
232-254	55210-55211	)	_	
232-255	55212-55217	98.33	_	
232-256	55218-55219	(	_	
232-257	55219-55224	10.33	_	
232-258	55224-55225	)	_	
232-259	55226-55231	93.25	_	
232-260	55232-55233	(	_	
232-261	55233-55237	8.77	_	
232-262	55237-55238	)	_	
232-263	55239-55244	96.33	_	
232-264	55245-55246	(	_	
232-265	55246-55251	13.84	_	
232-266	55251-55252	)	_	
232-267	55253-55259	101.50	_	
232-268	55260-55261	(	_	
232-269	55261-55266	10.60	_	
232-270	55266-55267	)	_	
232-271	55268-55272	0.30	_	
232-272	55273-55274	(	_	
232-273	55274-55278	0.59	_	
232-274	55278-55279	)	_	
232-275	55280-55284	0.02	_	
232-276	55285-55286	(	_	
232-277	55286-55290	0.88	_	
232-278	55290-55291	)	_	
232-279	55292-55296	2.12	_	
232-280	55297-55298	(	_	
232-281	55298-55302	0.16	_	
232-282	55302-55303	)	_	
232-283	55306-55312	Number	_	
232-284	55313-55315	of	_	
232-285	55316-55322	months	_	
232-286	55323-55335	incarcerated	_	
232-287	55335-55336	,	_	
232-288	55337-55345	lifetime	_	
232-289	55346-55351	25.38	_	
232-290	55352-55353	(	_	
232-291	55353-55358	52.88	_	
232-292	55358-55359	)	_	
232-293	55360-55365	37.20	_	
232-294	55366-55367	(	_	
232-295	55367-55372	65.94	_	
232-296	55372-55373	)	_	
232-297	55374-55378	3.00	_	
232-298	55379-55380	(	_	
232-299	55380-55384	6.00	_	
232-300	55384-55385	)	_	
232-301	55386-55390	5.83	_	
232-302	55391-55392	(	_	
232-303	55392-55397	11.94	_	
232-304	55397-55398	)	_	
232-305	55399-55404	40.17	_	
232-306	55405-55406	(	_	
232-307	55406-55411	67.75	_	
232-308	55411-55412	)	_	
232-309	55413-55417	0.02	_	
232-310	55418-55419	(	_	
232-311	55419-55423	0.90	_	
232-312	55423-55424	)	_	
232-313	55425-55429	0.00	_	
232-314	55430-55431	(	_	
232-315	55431-55435	0.99	_	
232-316	55435-55436	)	_	
232-317	55437-55441	2.40	_	
232-318	55442-55443	(	_	
232-319	55443-55447	0.14	_	
232-320	55447-55448	)	_	
232-321	55451-55456	Other	_	
232-322	55457-55465	Lifetime	_	
232-323	55466-55477	Psychiatric	_	
232-324	55478-55487	Diagnoses	_	
232-325	55487-55488	,	_	
232-326	55489-55490	N	_	
232-327	55490-55491	(	_	
232-328	55491-55492	%	_	
232-329	55492-55493	)	_	
232-330	55504-55515	Alcohol-Use	_	
232-331	55516-55524	Disorder	_	
232-332	55525-55527	16	_	
232-333	55528-55529	(	_	
232-334	55529-55533	61.5	_	
232-335	55533-55534	)	_	
232-336	55535-55536	5	_	
232-337	55537-55538	(	_	
232-338	55538-55542	50.0	_	
232-339	55542-55543	)	_	
232-340	55544-55545	3	_	
232-341	55546-55547	(	_	
232-342	55547-55551	75.0	_	
232-343	55551-55552	)	_	
232-344	55553-55554	4	_	
232-345	55555-55556	(	_	
232-346	55556-55560	66.7	_	
232-347	55560-55561	)	_	
232-348	55562-55563	6	_	
232-349	55564-55565	(	_	
232-350	55565-55570	100.0	_	
232-351	55570-55571	)	_	
232-352	55572-55576	0.42	_	
232-353	55577-55578	(	_	
232-354	55578-55582	0.52	_	
232-355	55582-55583	)	_	
232-356	55584-55588	0.00	_	
232-357	55589-55590	(	_	
232-358	55590-55594	1.00	_	
232-359	55594-55595	)	_	
232-360	55596-55600	0.00	_	
232-361	55601-55602	(	_	
232-362	55602-55606	1.00	_	
232-363	55606-55607	)	_	
232-364	55610-55615	Major	_	
232-365	55616-55626	Depression	_	
232-366	55627-55628	7	_	
232-367	55629-55630	(	_	
232-368	55630-55634	26.9	_	
232-369	55634-55635	)	_	
232-370	55636-55637	7	_	
232-371	55638-55639	(	_	
232-372	55639-55643	70.0	_	
232-373	55643-55644	)	_	
232-374	55645-55646	0	_	
232-375	55647-55648	(	_	
232-376	55648-55651	0.0	_	
232-377	55651-55652	)	_	
232-378	55653-55654	1	_	
232-379	55655-55656	(	_	
232-380	55656-55660	16.7	_	
232-381	55660-55661	)	_	
232-382	55662-55663	3	_	
232-383	55664-55665	(	_	
232-384	55665-55669	50.0	_	
232-385	55669-55670	)	_	
232-386	55671-55675	0.35	_	
232-387	55676-55677	(	_	
232-388	55677-55681	0.56	_	
232-389	55681-55682	)	_	
232-390	55683-55687	1.39	_	
232-391	55688-55689	(	_	
232-392	55689-55693	0.24	_	
232-393	55693-55694	)	_	
232-394	55695-55699	0.00	_	
232-395	55700-55701	(	_	
232-396	55701-55705	1.00	_	
232-397	55705-55706	)	_	
232-398	55709-55716	Anxiety	_	
232-399	55717-55725	Disorder	_	
232-400	55726-55727	0	_	
232-401	55727-55728	(	_	
232-402	55728-55731	0.0	_	
232-403	55731-55732	)	_	
232-404	55733-55734	0	_	
232-405	55735-55736	(	_	
232-406	55736-55739	0.0	_	
232-407	55739-55740	)	_	
232-408	55741-55742	0	_	
232-409	55743-55744	(	_	
232-410	55744-55747	0.0	_	
232-411	55747-55748	)	_	
232-412	55749-55750	0	_	
232-413	55751-55752	(	_	
232-414	55752-55755	0.0	_	
232-415	55755-55756	)	_	
232-416	55757-55758	0	_	
232-417	55759-55760	(	_	
232-418	55760-55763	0.0	_	
232-419	55763-55764	)	_	
232-420	55765-55769	0.00	_	
232-421	55770-55771	(	_	
232-422	55771-55775	1.00	_	
232-423	55775-55776	)	_	
232-424	55777-55781	0.00	_	
232-425	55782-55783	(	_	
232-426	55783-55787	1.00	_	
232-427	55787-55788	)	_	
232-428	55789-55793	0.00	_	
232-429	55794-55795	(	_	
232-430	55795-55799	1.00	_	
232-431	55799-55800	)	_	
232-432	55803-55825	Antisocial-Personality	_	
232-433	55826-55834	Disorder	_	
232-434	55835-55836	2	_	
232-435	55837-55838	(	_	
232-436	55838-55841	7.7	_	
232-437	55841-55842	)	_	
232-438	55843-55844	0	_	
232-439	55845-55846	(	_	
232-440	55846-55849	0.0	_	
232-441	55849-55850	)	_	
232-442	55851-55852	0	_	
232-443	55853-55854	(	_	
232-444	55854-55857	0.0	_	
232-445	55857-55858	)	_	
232-446	55859-55860	0	_	
232-447	55861-55862	(	_	
232-448	55862-55865	0.0	_	
232-449	55865-55866	)	_	
232-450	55867-55868	2	_	
232-451	55869-55870	(	_	
232-452	55870-55874	33.3	_	
232-453	55874-55875	)	_	
232-454	55876-55880	0.00	_	
232-455	55881-55882	(	_	
232-456	55882-55886	1.00	_	
232-457	55886-55887	)	_	
232-458	55888-55892	0.00	_	
232-459	55893-55894	(	_	
232-460	55894-55898	1.00	_	
232-461	55898-55899	)	_	
232-462	55900-55904	0.00	_	
232-463	55905-55906	(	_	
232-464	55906-55910	1.00	_	
232-465	55910-55911	)	_	
232-466	55914-55918	Days	_	
232-467	55919-55921	of	_	
232-468	55922-55925	Use	_	
232-469	55926-55928	in	_	
232-470	55929-55934	Month	_	
232-471	55935-55940	Prior	_	
232-472	55941-55943	to	_	
232-473	55944-55954	Treatment1	_	
232-474	55965-55972	Cocaine	_	
232-475	55973-55978	14.88	_	
232-476	55979-55980	(	_	
232-477	55980-55984	7.80	_	
232-478	55984-55985	)	_	
232-479	55986-55991	13.50	_	
232-480	55992-55993	(	_	
232-481	55993-55997	7.69	_	
232-482	55997-55998	)	_	
232-483	55999-56004	17.50	_	
232-484	56005-56006	(	_	
232-485	56006-56010	8.81	_	
232-486	56010-56011	)	_	
232-487	56012-56017	16.83	_	
232-488	56018-56019	(	_	
232-489	56019-56023	8.95	_	
232-490	56023-56024	)	_	
232-491	56025-56030	13.50	_	
232-492	56031-56032	(	_	
232-493	56032-56036	7.40	_	
232-494	56036-56037	)	_	
232-495	56038-56042	0.01	_	
232-496	56043-56044	(	_	
232-497	56044-56048	0.92	_	
232-498	56048-56049	)	_	
232-499	56050-56054	0.01	_	
232-500	56055-56056	(	_	
232-501	56056-56060	0.92	_	
232-502	56060-56061	)	_	
232-503	56062-56066	1.20	_	
232-504	56067-56068	(	_	
232-505	56068-56072	2.90	_	
232-506	56072-56073	)	_	
232-507	56076-56083	Alcohol	_	
232-508	56084-56088	7.35	_	
232-509	56089-56090	(	_	
232-510	56090-56094	8.38	_	
232-511	56094-56095	)	_	
232-512	56096-56100	5.80	_	
232-513	56101-56102	(	_	
232-514	56102-56106	7.22	_	
232-515	56106-56107	)	_	
232-516	56108-56113	14.25	_	
232-517	56114-56115	(	_	
232-518	56115-56120	11.90	_	
232-519	56120-56121	)	_	
232-520	56122-56126	6.67	_	
232-521	56127-56128	(	_	
232-522	56128-56132	9.75	_	
232-523	56132-56133	)	_	
232-524	56134-56138	6.00	_	
232-525	56139-56140	(	_	
232-526	56140-56144	5.62	_	
232-527	56144-56145	)	_	
232-528	56146-56150	1.15	_	
232-529	56151-56152	(	_	
232-530	56152-56156	0.30	_	
232-531	56156-56157	)	_	
232-532	56158-56162	1.28	_	
232-533	56163-56164	(	_	
232-534	56164-56168	0.27	_	
232-535	56168-56169	)	_	
232-536	56170-56174	1.75	_	
232-537	56175-56176	(	_	
232-538	56176-56180	0.20	_	
232-539	56180-56181	)	_	
232-540	56184-56192	Cannabis	_	
232-541	56193-56197	2.12	_	
232-542	56198-56199	(	_	
232-543	56199-56203	5.55	_	
232-544	56203-56204	)	_	
232-545	56205-56209	0.40	_	
232-546	56210-56211	(	_	
232-547	56211-56215	0.97	_	
232-548	56215-56216	)	_	
232-549	56217-56221	7.00	_	
232-550	56222-56223	(	_	
232-551	56223-56228	14.00	_	
232-552	56228-56229	)	_	
232-553	56230-56234	2.67	_	
232-554	56235-56236	(	_	
232-555	56236-56240	2.66	_	
232-556	56240-56241	)	_	
232-557	56242-56246	1.17	_	
232-558	56247-56248	(	_	
232-559	56248-56252	1.17	_	
232-560	56252-56253	)	_	
232-561	56254-56258	0.64	_	
232-562	56259-56260	(	_	
232-563	56260-56264	0.43	_	
232-564	56264-56265	)	_	
232-565	56266-56270	1.31	_	
232-566	56271-56272	(	_	
232-567	56272-56276	0.26	_	
232-568	56276-56277	)	_	
232-569	56278-56282	3.31	_	
232-570	56283-56284	(	_	
232-571	56284-56288	0.08	_	
232-572	56288-56289	)	_	
232-573	56292-56302	Cigarettes	_	
232-574	56303-56308	20.73	_	
232-575	56309-56310	(	_	
232-576	56310-56315	11.89	_	
232-577	56315-56316	)	_	
232-578	56317-56322	18.80	_	
232-579	56323-56324	(	_	
232-580	56324-56329	13.21	_	
232-581	56329-56330	)	_	
232-582	56331-56336	21.00	_	
232-583	56337-56338	(	_	
232-584	56338-56343	14.00	_	
232-585	56343-56344	)	_	
232-586	56345-56350	23.33	_	
232-587	56351-56352	(	_	
232-588	56352-56357	11.43	_	
232-589	56357-56358	)	_	
232-590	56359-56364	21.17	_	
232-591	56365-56366	(	_	
232-592	56366-56371	11.36	_	
232-593	56371-56372	)	_	
232-594	56373-56377	0.21	_	
232-595	56378-56379	(	_	
232-596	56379-56383	0.66	_	
232-597	56383-56384	)	_	
232-598	56385-56389	0.00	_	
232-599	56390-56391	(	_	
232-600	56391-56395	1.00	_	
232-601	56395-56396	)	_	
232-602	56397-56401	0.18	_	
232-603	56402-56403	(	_	
232-604	56403-56407	0.68	_	
232-605	56407-56408	)	_	
232-606	56411-56419	Lifetime	_	
232-607	56420-56425	Years	_	
232-608	56426-56428	of	_	
232-609	56429-56436	Regular	_	
232-610	56437-56440	Use	_	
232-611	56451-56458	Cocaine	_	
232-612	56459-56463	9.31	_	
232-613	56464-56465	(	_	
232-614	56465-56469	6.18	_	
232-615	56469-56470	)	_	
232-616	56471-56475	7.60	_	
232-617	56476-56477	(	_	
232-618	56477-56481	4.25	_	
232-619	56481-56482	)	_	
232-620	56483-56488	10.75	_	
232-621	56489-56490	(	_	
232-622	56490-56494	6.99	_	
232-623	56494-56495	)	_	
232-624	56496-56500	9.33	_	
232-625	56501-56502	(	_	
232-626	56502-56506	8.89	_	
232-627	56506-56507	)	_	
232-628	56508-56513	11.17	_	
232-629	56514-56515	(	_	
232-630	56515-56519	6.18	_	
232-631	56519-56520	)	_	
232-632	56521-56525	0.17	_	
232-633	56526-56527	(	_	
232-634	56527-56531	0.69	_	
232-635	56531-56532	)	_	
232-636	56533-56536	089	_	
232-637	56537-56538	(	_	
232-638	56538-56542	0.36	_	
232-639	56542-56543	)	_	
232-640	56544-56548	0.06	_	
232-641	56549-56550	(	_	
232-642	56550-56554	0.81	_	
232-643	56554-56555	)	_	
232-644	56558-56565	Alcohol	_	
232-645	56566-56570	8.69	_	
232-646	56571-56572	(	_	
232-647	56572-56576	9.01	_	
232-648	56576-56577	)	_	
232-649	56578-56582	3.90	_	
232-650	56583-56584	(	_	
232-651	56584-56588	4.95	_	
232-652	56588-56589	)	_	
232-653	56590-56594	9.00	_	
232-654	56595-56596	(	_	
232-655	56596-56600	8.60	_	
232-656	56600-56601	)	_	
232-657	56602-56607	13.67	_	
232-658	56608-56609	(	_	
232-659	56609-56614	11.60	_	
232-660	56614-56615	)	_	
232-661	56616-56621	11.50	_	
232-662	56622-56623	(	_	
232-663	56623-56627	9.85	_	
232-664	56627-56628	)	_	
232-665	56629-56633	3.02	_	
232-666	56634-56635	(	_	
232-667	56635-56639	0.10	_	
232-668	56639-56640	)	_	
232-669	56641-56645	0.17	_	
232-670	56646-56647	(	_	
232-671	56647-56651	0.68	_	
232-672	56651-56652	)	_	
232-673	56653-56657	1.01	_	
232-674	56658-56659	(	_	
232-675	56659-56663	0.31	_	
232-676	56663-56664	)	_	
232-677	56667-56675	Cannabis	_	
232-678	56676-56680	5.81	_	
232-679	56681-56682	(	_	
232-680	56682-56686	7.38	_	
232-681	56686-56687	)	_	
232-682	56688-56692	2.30	_	
232-683	56693-56694	(	_	
232-684	56694-56698	3.37	_	
232-685	56698-56699	)	_	
232-686	56700-56704	1.50	_	
232-687	56705-56706	(	_	
232-688	56706-56710	2.38	_	
232-689	56710-56711	)	_	
232-690	56712-56716	7.17	_	
232-691	56717-56718	(	_	
232-692	56718-56722	6.37	_	
232-693	56722-56723	)	_	
232-694	56724-56729	13.17	_	
232-695	56730-56731	(	_	
232-696	56731-56736	10.05	_	
232-697	56736-56737	)	_	
232-698	56738-56743	10.65	_	
232-699	56744-56745	(	_	
232-700	56745-56750	0.004	_	
232-701	56750-56751	)	_	
232-702	56752-56756	1.05	_	
232-703	56757-56758	(	_	
232-704	56758-56762	0.32	_	
232-705	56762-56763	)	_	
232-706	56764-56768	1.80	_	
232-707	56769-56770	(	_	
232-708	56770-56774	0.19	_	
232-709	56774-56775	)	_	
232-710	56778-56787	Treatment	_	
232-711	56788-56798	Engagement	_	
232-712	56809-56813	Days	_	
232-713	56814-56816	in	_	
232-714	56817-56826	Treatment	_	
232-715	56827-56832	59.77	_	
232-716	56833-56834	(	_	
232-717	56834-56839	30.22	_	
232-718	56839-56840	)	_	
232-719	56841-56846	44.60	_	
232-720	56847-56848	(	_	
232-721	56848-56853	29.14	_	
232-722	56853-56854	)	_	
232-723	56855-56860	80.50	_	
232-724	56861-56862	(	_	
232-725	56862-56866	7.00	_	
232-726	56866-56867	)	_	
232-727	56868-56873	49.67	_	
232-728	56874-56875	(	_	
232-729	56875-56880	38.51	_	
232-730	56880-56881	)	_	
232-731	56882-56887	81.33	_	
232-732	56888-56889	(	_	
232-733	56889-56893	6.53	_	
232-734	56893-56894	)	_	
232-735	56895-56899	0.07	_	
232-736	56900-56901	(	_	
232-737	56901-56905	0.79	_	
232-738	56905-56906	)	_	
232-739	56907-56911	9.54	_	
232-740	56912-56913	(	_	
232-741	56913-56918	0.005	_	
232-742	56918-56919	)	_	
232-743	56920-56924	0.04	_	
232-744	56925-56926	(	_	
232-745	56926-56930	0.85	_	
232-746	56930-56931	)	_	
232-747	56934-56940	Number	_	
232-748	56941-56943	of	_	
232-749	56944-56947	CBT	_	
232-750	56948-56956	Sessions	_	
232-751	56957-56965	Attended	_	
232-752	56966-56970	6.73	_	
232-753	56971-56972	(	_	
232-754	56972-56976	4.28	_	
232-755	56976-56977	)	_	
232-756	56978-56982	5.20	_	
232-757	56983-56984	(	_	
232-758	56984-56988	4.24	_	
232-759	56988-56989	)	_	
232-760	56990-56994	8.25	_	
232-761	56995-56996	(	_	
232-762	56996-57000	2.87	_	
232-763	57000-57001	)	_	
232-764	57002-57006	6.17	_	
232-765	57007-57008	(	_	
232-766	57008-57012	5.42	_	
232-767	57012-57013	)	_	
232-768	57014-57018	8.83	_	
232-769	57019-57020	(	_	
232-770	57020-57024	3.55	_	
232-771	57024-57025	)	_	
232-772	57026-57030	0.20	_	
232-773	57031-57032	(	_	
232-774	57032-57036	0.66	_	
232-775	57036-57037	)	_	
232-776	57038-57042	2.66	_	
232-777	57043-57044	(	_	
232-778	57044-57048	0.12	_	
232-779	57048-57049	)	_	
232-780	57050-57054	0.01	_	
232-781	57055-57056	(	_	
232-782	57056-57060	0.91	_	
232-783	57060-57061	)	_	
232-784	57064-57070	Number	_	
232-785	57071-57073	of	_	
232-786	57074-57078	Days	_	
232-787	57079-57081	of	_	
232-788	57082-57092	Disulfiram	_	
232-789	57093-57098	Doses	_	
232-790	57099-57104	Taken	_	
232-791	57105-57106	N	_	
232-792	57106-57107	/	_	
232-793	57107-57108	A	_	
232-794	57109-57110	N	_	
232-795	57110-57111	/	_	
232-796	57111-57112	A	_	
232-797	57113-57118	39.70	_	
232-798	57119-57120	(	_	
232-799	57120-57125	25.81	_	
232-800	57125-57126	)	_	
232-801	57127-57128	N	_	
232-802	57128-57129	/	_	
232-803	57129-57130	A	_	
232-804	57131-57136	45.00	_	
232-805	57137-57138	(	_	
232-806	57138-57143	34.18	_	
232-807	57143-57144	)	_	
232-808	57145-57149	0.13	_	
232-809	57150-57151	(	_	
232-810	57151-57155	0.73	_	
232-811	57155-57156	)	_	
232-812	57157-57158	N	_	
232-813	57158-57159	/	_	
232-814	57159-57160	A	_	
232-815	57161-57162	N	_	
232-816	57162-57163	/	_	
232-817	57163-57164	A	_	
232-818	57167-57173	Number	_	
232-819	57174-57176	of	_	
232-820	57177-57179	CM	_	
232-821	57180-57186	Prizes	_	
232-822	57187-57192	Drawn	_	
232-823	57193-57194	N	_	
232-824	57194-57195	/	_	
232-825	57195-57196	A	_	
232-826	57197-57202	82.30	_	
232-827	57203-57204	(	_	
232-828	57204-57209	88.87	_	
232-829	57209-57210	)	_	
232-830	57211-57217	120.50	_	
232-831	57218-57219	(	_	
232-832	57219-57224	84.03	_	
232-833	57224-57225	)	_	
232-834	57226-57227	N	_	
232-835	57227-57228	/	_	
232-836	57228-57229	A	_	
232-837	57230-57231	N	_	
232-838	57231-57232	/	_	
232-839	57232-57233	A	_	
232-840	57234-57235	N	_	
232-841	57235-57236	/	_	
232-842	57236-57237	A	_	
232-843	57238-57242	0.54	_	
232-844	57243-57244	(	_	
232-845	57244-57248	0.48	_	
232-846	57248-57249	)	_	
232-847	57250-57251	N	_	
232-848	57251-57252	/	_	
232-849	57252-57253	A	_	
232-850	57256-57265	Treatment	_	
232-851	57266-57273	Outcome	_	
232-852	57284-57285	%	_	
232-853	57286-57290	Days	_	
232-854	57291-57304	Self-reported	_	
232-855	57305-57315	Abstinence	_	
232-856	57316-57322	Within	_	
232-857	57323-57332	Treatment	_	
232-858	57333-57339	Period	_	
232-859	57340-57345	81.50	_	
232-860	57346-57347	(	_	
232-861	57347-57352	22.50	_	
232-862	57352-57353	)	_	
232-863	57354-57359	92.62	_	
232-864	57360-57361	(	_	
232-865	57361-57365	7.48	_	
232-866	57365-57366	)	_	
232-867	57367-57372	59.23	_	
232-868	57373-57374	(	_	
232-869	57374-57379	45.00	_	
232-870	57379-57380	)	_	
232-871	57381-57386	76.39	_	
232-872	57387-57388	(	_	
232-873	57388-57393	19.39	_	
232-874	57393-57394	)	_	
232-875	57395-57400	82.94	_	
232-876	57401-57402	(	_	
232-877	57402-57407	12.73	_	
232-878	57407-57408	)	_	
232-879	57409-57413	0.19	_	
232-880	57414-57415	(	_	
232-881	57415-57419	0.66	_	
232-882	57419-57420	)	_	
232-883	57421-57425	2.50	_	
232-884	57426-57427	(	_	
232-885	57427-57431	0.13	_	
232-886	57431-57432	)	_	
232-887	57433-57437	5.54	_	
232-888	57438-57439	(	_	
232-889	57439-57443	0.03	_	
232-890	57443-57444	)	_	
232-891	57447-57448	%	_	
232-892	57449-57455	Urines	_	
232-893	57456-57464	Negative	_	
232-894	57465-57468	for	_	
232-895	57469-57476	Cocaine	_	
232-896	57477-57483	Within	_	
232-897	57484-57493	Treatment	_	
232-898	57494-57500	Period	_	
232-899	57501-57506	44.87	_	
232-900	57507-57508	(	_	
232-901	57508-57513	39.78	_	
232-902	57513-57514	)	_	
232-903	57515-57520	67.74	_	
232-904	57521-57522	(	_	
232-905	57522-57527	34.19	_	
232-906	57527-57528	)	_	
232-907	57529-57534	35.64	_	
232-908	57535-57536	(	_	
232-909	57536-57541	45.24	_	
232-910	57541-57542	)	_	
232-911	57543-57548	16.50	_	
232-912	57549-57550	(	_	
232-913	57550-57555	27.53	_	
232-914	57555-57556	)	_	
232-915	57557-57562	41.29	_	
232-916	57563-57564	(	_	
232-917	57564-57569	41.55	_	
232-918	57569-57570	)	_	
232-919	57571-57575	2.30	_	
232-920	57576-57577	(	_	
232-921	57577-57581	0.14	_	
232-922	57581-57582	)	_	
232-923	57583-57587	0.06	_	
232-924	57588-57589	(	_	
232-925	57589-57593	0.81	_	
232-926	57593-57594	)	_	
232-927	57595-57599	3.58	_	
232-928	57600-57601	(	_	
232-929	57601-57605	0.07	_	
232-930	57605-57606	)	_	
232-931	57609-57615	Stroop	_	
232-932	57616-57620	Task	_	
232-933	57621-57630	Behavior2	_	
232-934	57641-57663	Beginning-of-Treatment	_	
232-935	57674-57678	Mean	_	
232-936	57679-57688	Congruent	_	
232-937	57689-57694	Trial	_	
232-938	57695-57697	RT	_	
232-939	57698-57699	(	_	
232-940	57699-57701	ms	_	
232-941	57701-57702	)	_	
232-942	57703-57709	508.88	_	
232-943	57710-57711	(	_	
232-944	57711-57717	124.40	_	
232-945	57717-57718	)	_	
232-946	57719-57725	537.27	_	
232-947	57726-57727	(	_	
232-948	57727-57733	120.59	_	
232-949	57733-57734	)	_	
232-950	57735-57741	436.51	_	
232-951	57742-57743	(	_	
232-952	57743-57749	125.42	_	
232-953	57749-57750	)	_	
232-954	57751-57757	506.07	_	
232-955	57758-57759	(	_	
232-956	57759-57765	121.09	_	
232-957	57765-57766	)	_	
232-958	57767-57773	521.59	_	
232-959	57774-57775	(	_	
232-960	57775-57781	157.83	_	
232-961	57781-57782	)	_	
232-962	57783-57784	.	_	
232-963	57785-57786	.	_	
232-964	57787-57788	.	_	

#Text=Mean Incongruent Trial RT (ms)\t637.30 (208.80)\t691.27 (209.99)\t574.74 (221.48)\t597.74 (187.61)\t642.76 (304.05)\t.\t.\t.
233-1	57791-57795	Mean	_	
233-2	57796-57807	Incongruent	_	
233-3	57808-57813	Trial	_	
233-4	57814-57816	RT	_	
233-5	57817-57818	(	_	
233-6	57818-57820	ms	_	
233-7	57820-57821	)	_	
233-8	57822-57828	637.30	_	
233-9	57829-57830	(	_	
233-10	57830-57836	208.80	_	
233-11	57836-57837	)	_	
233-12	57838-57844	691.27	_	
233-13	57845-57846	(	_	
233-14	57846-57852	209.99	_	
233-15	57852-57853	)	_	
233-16	57854-57860	574.74	_	
233-17	57861-57862	(	_	
233-18	57862-57868	221.48	_	
233-19	57868-57869	)	_	
233-20	57870-57876	597.74	_	
233-21	57877-57878	(	_	
233-22	57878-57884	187.61	_	
233-23	57884-57885	)	_	
233-24	57886-57892	642.76	_	
233-25	57893-57894	(	_	
233-26	57894-57900	304.05	_	
233-27	57900-57901	)	_	
233-28	57902-57903	.	_	
233-29	57904-57905	.	_	
233-30	57906-57907	.	_	

#Text=Percent Incongruent Errors\t22.58 (19.64)\t28.14 (26.12)\t15.71 (16.41)\t23.33 (19.24)\t17.14 (5.71)\t.\t.\t.
234-1	57910-57917	Percent	_	
234-2	57918-57929	Incongruent	_	
234-3	57930-57936	Errors	_	
234-4	57937-57942	22.58	_	
234-5	57943-57944	(	_	
234-6	57944-57949	19.64	_	
234-7	57949-57950	)	_	
234-8	57951-57956	28.14	_	
234-9	57957-57958	(	_	
234-10	57958-57963	26.12	_	
234-11	57963-57964	)	_	
234-12	57965-57970	15.71	_	
234-13	57971-57972	(	_	
234-14	57972-57977	16.41	_	
234-15	57977-57978	)	_	
234-16	57979-57984	23.33	_	
234-17	57985-57986	(	_	
234-18	57986-57991	19.24	_	
234-19	57991-57992	)	_	
234-20	57993-57998	17.14	_	
234-21	57999-58000	(	_	
234-22	58000-58004	5.71	_	
234-23	58004-58005	)	_	
234-24	58006-58007	.	_	
234-25	58008-58009	.	_	
234-26	58010-58011	.	_	

#Text=Post-Treatment\t\t\t\t\t\t\t\t\t \tMean Congruent Trial RT (ms)\t517.27 (132.25)\t477.15 (113.64)\t463.05 (53.16)\t560.90 (137.53)\t577.23 (177.49)\t.\t.\t.
235-1	58014-58028	Post-Treatment	_	
235-2	58039-58043	Mean	_	
235-3	58044-58053	Congruent	_	
235-4	58054-58059	Trial	_	
235-5	58060-58062	RT	_	
235-6	58063-58064	(	_	
235-7	58064-58066	ms	_	
235-8	58066-58067	)	_	
235-9	58068-58074	517.27	_	
235-10	58075-58076	(	_	
235-11	58076-58082	132.25	_	
235-12	58082-58083	)	_	
235-13	58084-58090	477.15	_	
235-14	58091-58092	(	_	
235-15	58092-58098	113.64	_	
235-16	58098-58099	)	_	
235-17	58100-58106	463.05	_	
235-18	58107-58108	(	_	
235-19	58108-58113	53.16	_	
235-20	58113-58114	)	_	
235-21	58115-58121	560.90	_	
235-22	58122-58123	(	_	
235-23	58123-58129	137.53	_	
235-24	58129-58130	)	_	
235-25	58131-58137	577.23	_	
235-26	58138-58139	(	_	
235-27	58139-58145	177.49	_	
235-28	58145-58146	)	_	
235-29	58147-58148	.	_	
235-30	58149-58150	.	_	
235-31	58151-58152	.	_	

#Text=Mean Incongruent Trial RT (ms)\t639.87 (211.44)\t593.14 (210.29)\t547.90 (116.71)\t701.69 (240.86)\t719.79 (241.08)\t.\t.\t.
236-1	58155-58159	Mean	_	
236-2	58160-58171	Incongruent	_	
236-3	58172-58177	Trial	_	
236-4	58178-58180	RT	_	
236-5	58181-58182	(	_	
236-6	58182-58184	ms	_	
236-7	58184-58185	)	_	
236-8	58186-58192	639.87	_	
236-9	58193-58194	(	_	
236-10	58194-58200	211.44	_	
236-11	58200-58201	)	_	
236-12	58202-58208	593.14	_	
236-13	58209-58210	(	_	
236-14	58210-58216	210.29	_	
236-15	58216-58217	)	_	
236-16	58218-58224	547.90	_	
236-17	58225-58226	(	_	
236-18	58226-58232	116.71	_	
236-19	58232-58233	)	_	
236-20	58234-58240	701.69	_	
236-21	58241-58242	(	_	
236-22	58242-58248	240.86	_	
236-23	58248-58249	)	_	
236-24	58250-58256	719.79	_	
236-25	58257-58258	(	_	
236-26	58258-58264	241.08	_	
236-27	58264-58265	)	_	
236-28	58266-58267	.	_	
236-29	58268-58269	.	_	
236-30	58270-58271	.	_	

#Text=Percent Incongruent Errors\t23.10 (23.02)\t30.21 (33.00)\t15.00 (15.36)\t18.57 (8.62)\t21.19 (17.06)\t.\t.\t.
237-1	58274-58281	Percent	_	
237-2	58282-58293	Incongruent	_	
237-3	58294-58300	Errors	_	
237-4	58301-58306	23.10	_	
237-5	58307-58308	(	_	
237-6	58308-58313	23.02	_	
237-7	58313-58314	)	_	
237-8	58315-58320	30.21	_	
237-9	58321-58322	(	_	
237-10	58322-58327	33.00	_	
237-11	58327-58328	)	_	
237-12	58329-58334	15.00	_	
237-13	58335-58336	(	_	
237-14	58336-58341	15.36	_	
237-15	58341-58342	)	_	
237-16	58343-58348	18.57	_	
237-17	58349-58350	(	_	
237-18	58350-58354	8.62	_	
237-19	58354-58355	)	_	
237-20	58356-58361	21.19	_	
237-21	58362-58363	(	_	
237-22	58363-58368	17.06	_	
237-23	58368-58369	)	_	
237-24	58370-58371	.	_	
237-25	58372-58373	.	_	
237-26	58374-58375	.	_	

#Text=Results are reported as mean (SD) unless otherwise noted, in which case it is reported as N (percent)
#Text=SILS=Shipley Institute of Living Scale; RT= response time; ms =milliseconds
#Text=Days of use in month prior to treatment was out of a possible total of 28 days (i.e., past four weeks)
#Text=Stroop Task Behavior analysed with mixed model ANOVAs including session (beginning-of-treatment, post-treatment) and trial type (incongruent, congruent) as within-subject factors and medication (disulfiram, placebo) and CM (CM, no-CM) conditions as between-subject factors (Trial type (F=58.99, p<.001); no other significant main or interactive effects).
238-1	58379-58386	Results	_	
238-2	58387-58390	are	_	
238-3	58391-58399	reported	_	
238-4	58400-58402	as	_	
238-5	58403-58407	mean	_	
238-6	58408-58409	(	_	
238-7	58409-58411	SD	_	
238-8	58411-58412	)	_	
238-9	58413-58419	unless	_	
238-10	58420-58429	otherwise	_	
238-11	58430-58435	noted	_	
238-12	58435-58436	,	_	
238-13	58437-58439	in	_	
238-14	58440-58445	which	_	
238-15	58446-58450	case	_	
238-16	58451-58453	it	_	
238-17	58454-58456	is	_	
238-18	58457-58465	reported	_	
238-19	58466-58468	as	_	
238-20	58469-58470	N	_	
238-21	58471-58472	(	_	
238-22	58472-58479	percent	_	
238-23	58479-58480	)	_	
238-24	58481-58485	SILS	_	
238-25	58485-58486	=	_	
238-26	58486-58493	Shipley	_	
238-27	58494-58503	Institute	_	
238-28	58504-58506	of	_	
238-29	58507-58513	Living	_	
238-30	58514-58519	Scale	_	
238-31	58519-58520	;	_	
238-32	58521-58523	RT	_	
238-33	58523-58524	=	_	
238-34	58525-58533	response	_	
238-35	58534-58538	time	_	
238-36	58538-58539	;	_	
238-37	58540-58542	ms	_	
238-38	58543-58544	=	_	
238-39	58544-58556	milliseconds	_	
238-40	58557-58561	Days	_	
238-41	58562-58564	of	_	
238-42	58565-58568	use	_	
238-43	58569-58571	in	_	
238-44	58572-58577	month	_	
238-45	58578-58583	prior	_	
238-46	58584-58586	to	_	
238-47	58587-58596	treatment	_	
238-48	58597-58600	was	_	
238-49	58601-58604	out	_	
238-50	58605-58607	of	_	
238-51	58608-58609	a	_	
238-52	58610-58618	possible	_	
238-53	58619-58624	total	_	
238-54	58625-58627	of	_	
238-55	58628-58630	28	_	
238-56	58631-58635	days	_	
238-57	58636-58637	(	_	
238-58	58637-58640	i.e	_	
238-59	58640-58641	.	_	
238-60	58641-58642	,	_	
238-61	58643-58647	past	_	
238-62	58648-58652	four	_	
238-63	58653-58658	weeks	_	
238-64	58658-58659	)	_	
238-65	58660-58666	Stroop	_	
238-66	58667-58671	Task	_	
238-67	58672-58680	Behavior	_	
238-68	58681-58689	analysed	_	
238-69	58690-58694	with	_	
238-70	58695-58700	mixed	_	
238-71	58701-58706	model	_	
238-72	58707-58713	ANOVAs	_	
238-73	58714-58723	including	_	
238-74	58724-58731	session	_	
238-75	58732-58733	(	_	
238-76	58733-58755	beginning-of-treatment	_	
238-77	58755-58756	,	_	
238-78	58757-58771	post-treatment	_	
238-79	58771-58772	)	_	
238-80	58773-58776	and	_	
238-81	58777-58782	trial	_	
238-82	58783-58787	type	_	
238-83	58788-58789	(	_	
238-84	58789-58800	incongruent	_	
238-85	58800-58801	,	_	
238-86	58802-58811	congruent	_	
238-87	58811-58812	)	_	
238-88	58813-58815	as	_	
238-89	58816-58830	within-subject	_	
238-90	58831-58838	factors	_	
238-91	58839-58842	and	_	
238-92	58843-58853	medication	_	
238-93	58854-58855	(	_	
238-94	58855-58865	disulfiram	_	
238-95	58865-58866	,	_	
238-96	58867-58874	placebo	_	
238-97	58874-58875	)	_	
238-98	58876-58879	and	_	
238-99	58880-58882	CM	_	
238-100	58883-58884	(	_	
238-101	58884-58886	CM	_	
238-102	58886-58887	,	_	
238-103	58888-58893	no-CM	_	
238-104	58893-58894	)	_	
238-105	58895-58905	conditions	_	
238-106	58906-58908	as	_	
238-107	58909-58924	between-subject	_	
238-108	58925-58932	factors	_	
238-109	58933-58934	(	_	
238-110	58934-58939	Trial	_	
238-111	58940-58944	type	_	
238-112	58945-58946	(	_	
238-113	58946-58947	F	_	
238-114	58947-58948	=	_	
238-115	58948-58953	58.99	_	
238-116	58953-58954	,	_	
238-117	58955-58956	p	_	
238-118	58956-58957	<	_	
238-119	58957-58961	.001	_	
238-120	58961-58962	)	_	
238-121	58962-58963	;	_	
238-122	58964-58966	no	_	
238-123	58967-58972	other	_	
238-124	58973-58984	significant	_	
238-125	58985-58989	main	_	
238-126	58990-58992	or	_	
238-127	58993-59004	interactive	_	
238-128	59005-59012	effects	_	
238-129	59012-59013	)	_	
238-130	59013-59014	.	_	

#Text=Stroop errors on incongruent trials were analyzed with mixed-model ANOVAs including session as a within-subject factor and medication and CM conditions as between-subject factors (no significant main or interactive effects).
#Text=fMRI Stroop Changes At Post-Treatment vs.
239-1	59015-59021	Stroop	_	
239-2	59022-59028	errors	_	
239-3	59029-59031	on	_	
239-4	59032-59043	incongruent	_	
239-5	59044-59050	trials	_	
239-6	59051-59055	were	_	
239-7	59056-59064	analyzed	_	
239-8	59065-59069	with	_	
239-9	59070-59081	mixed-model	_	
239-10	59082-59088	ANOVAs	_	
239-11	59089-59098	including	_	
239-12	59099-59106	session	_	
239-13	59107-59109	as	_	
239-14	59110-59111	a	_	
239-15	59112-59126	within-subject	_	
239-16	59127-59133	factor	_	
239-17	59134-59137	and	_	
239-18	59138-59148	medication	_	
239-19	59149-59152	and	_	
239-20	59153-59155	CM	_	
239-21	59156-59166	conditions	_	
239-22	59167-59169	as	_	
239-23	59170-59185	between-subject	_	
239-24	59186-59193	factors	_	
239-25	59194-59195	(	_	
239-26	59195-59197	no	_	
239-27	59198-59209	significant	_	
239-28	59210-59214	main	_	
239-29	59215-59217	or	_	
239-30	59218-59229	interactive	_	
239-31	59230-59237	effects	_	
239-32	59237-59238	)	_	
239-33	59238-59239	.	_	
239-34	59240-59244	fMRI	_	
239-35	59245-59251	Stroop	_	
239-36	59252-59259	Changes	_	
239-37	59260-59262	At	_	
239-38	59263-59277	Post-Treatment	_	
239-39	59278-59280	vs	_	
239-40	59280-59281	.	_	

#Text=Beginning-of-Treatment and Associations With Treatment Components
#Text=\t\t\tPeak Coordinates\t\tStatistics (t-value)\t \tCluster Label (Peak)\tRegions of Activation\tR/L\tx\ty\tz\tk\tMaximum Voxel\tCluster Mean\t \tA.
240-1	59282-59304	Beginning-of-Treatment	_	
240-2	59305-59308	and	_	
240-3	59309-59321	Associations	_	
240-4	59322-59326	With	_	
240-5	59327-59336	Treatment	_	
240-6	59337-59347	Components	_	
240-7	59351-59355	Peak	_	
240-8	59356-59367	Coordinates	_	
240-9	59369-59379	Statistics	_	
240-10	59380-59381	(	_	
240-11	59381-59388	t-value	_	
240-12	59388-59389	)	_	
240-13	59392-59399	Cluster	_	
240-14	59400-59405	Label	_	
240-15	59406-59407	(	_	
240-16	59407-59411	Peak	_	
240-17	59411-59412	)	_	
240-18	59413-59420	Regions	_	
240-19	59421-59423	of	_	
240-20	59424-59434	Activation	_	
240-21	59435-59436	R	_	
240-22	59436-59437	/	_	
240-23	59437-59438	L	_	
240-24	59439-59440	x	_	
240-25	59441-59442	y	_	
240-26	59443-59444	z	_	
240-27	59445-59446	k	_	
240-28	59447-59454	Maximum	_	
240-29	59455-59460	Voxel	_	
240-30	59461-59468	Cluster	_	
240-31	59469-59473	Mean	_	
240-32	59476-59477	A	_	
240-33	59477-59478	.	_	

#Text=Change in fMRI Stroop Effect at Post-Treatment vs.
241-1	59479-59485	Change	_	
241-2	59486-59488	in	_	
241-3	59489-59493	fMRI	_	
241-4	59494-59500	Stroop	_	
241-5	59501-59507	Effect	_	
241-6	59508-59510	at	_	
241-7	59511-59525	Post-Treatment	_	
241-8	59526-59528	vs	_	
241-9	59528-59529	.	_	

#Text=Beginning-of-Treatment (Trial Type (Inc, Con) × Session (Post, Beginning)) (N=26)\t \tCulmen\tL Culmen, L Parahippocampal Gyrus\tL\t−9\t−36\t−9\t188\t−5.45\t−3.29\t \t\tL Precuneus, L Lingual Gyrus, L Posterior\tL\t−9\t−60\t24\t\t\t\t \tPrecuneus\tCingulate\t\t\t\t\t269\t−5.05\t−3.29\t \tCingulate Gyrus\tR/L Cingulate Gyrus\tR\t9\t9\t42\t144\t−4.63\t−3.30\t \tPostcentral Gyrus\tR Postcentral Gyrus, R Precentral Gyrus\tR\t39\t−18\t33\t83\t−4.57\t−3.14\t \t\tL Angular Gyrus, L Middle Temporal Gyrus, L\t\t\t\t\t\t\t\t \tAngular Gyrus\tSuperior Temporal Gyrus\tL\t−33\t−75\t36\t77\t−4.52\t−3.27\t \tThalamus\tL and R Thalamus, R Caudate\tL\t−3\t0\t0\t139\t−4.51\t−3.20\t \tHippocampus\tR Hippocampus, R Amygdala, R Parahippocampal\tR\t30\t−21\t−15\t109\t−4.28\t−3.23\t \tPrecentral Gyrus\tR Precentral Gyrus\tR\t60\t6\t3\t96\t−3.99\t−3.14\t \tB.
242-1	59530-59552	Beginning-of-Treatment	_	
242-2	59553-59554	(	_	
242-3	59554-59559	Trial	_	
242-4	59560-59564	Type	_	
242-5	59565-59566	(	_	
242-6	59566-59569	Inc	_	
242-7	59569-59570	,	_	
242-8	59571-59574	Con	_	
242-9	59574-59575	)	_	
242-10	59576-59577	×	_	
242-11	59578-59585	Session	_	
242-12	59586-59587	(	_	
242-13	59587-59591	Post	_	
242-14	59591-59592	,	_	
242-15	59593-59602	Beginning	_	
242-16	59602-59603	)	_	
242-17	59603-59604	)	_	
242-18	59605-59606	(	_	
242-19	59606-59607	N	_	
242-20	59607-59608	=	_	
242-21	59608-59610	26	_	
242-22	59610-59611	)	_	
242-23	59614-59620	Culmen	_	
242-24	59621-59622	L	_	
242-25	59623-59629	Culmen	_	
242-26	59629-59630	,	_	
242-27	59631-59632	L	_	
242-28	59633-59648	Parahippocampal	_	
242-29	59649-59654	Gyrus	_	
242-30	59655-59656	L	_	
242-31	59657-59658	−	_	
242-32	59658-59659	9	_	
242-33	59660-59661	−	_	
242-34	59661-59663	36	_	
242-35	59664-59665	−	_	
242-36	59665-59666	9	_	
242-37	59667-59670	188	_	
242-38	59671-59672	−	_	
242-39	59672-59676	5.45	_	
242-40	59677-59678	−	_	
242-41	59678-59682	3.29	_	
242-42	59686-59687	L	_	
242-43	59688-59697	Precuneus	_	
242-44	59697-59698	,	_	
242-45	59699-59700	L	_	
242-46	59701-59708	Lingual	_	
242-47	59709-59714	Gyrus	_	
242-48	59714-59715	,	_	
242-49	59716-59717	L	_	
242-50	59718-59727	Posterior	_	
242-51	59728-59729	L	_	
242-52	59730-59731	−	_	
242-53	59731-59732	9	_	
242-54	59733-59734	−	_	
242-55	59734-59736	60	_	
242-56	59737-59739	24	_	
242-57	59745-59754	Precuneus	_	
242-58	59755-59764	Cingulate	_	
242-59	59769-59772	269	_	
242-60	59773-59774	−	_	
242-61	59774-59778	5.05	_	
242-62	59779-59780	−	_	
242-63	59780-59784	3.29	_	
242-64	59787-59796	Cingulate	_	
242-65	59797-59802	Gyrus	_	
242-66	59803-59804	R	_	
242-67	59804-59805	/	_	
242-68	59805-59806	L	_	
242-69	59807-59816	Cingulate	_	
242-70	59817-59822	Gyrus	_	
242-71	59823-59824	R	_	
242-72	59825-59826	9	_	
242-73	59827-59828	9	_	
242-74	59829-59831	42	_	
242-75	59832-59835	144	_	
242-76	59836-59837	−	_	
242-77	59837-59841	4.63	_	
242-78	59842-59843	−	_	
242-79	59843-59847	3.30	_	
242-80	59850-59861	Postcentral	_	
242-81	59862-59867	Gyrus	_	
242-82	59868-59869	R	_	
242-83	59870-59881	Postcentral	_	
242-84	59882-59887	Gyrus	_	
242-85	59887-59888	,	_	
242-86	59889-59890	R	_	
242-87	59891-59901	Precentral	_	
242-88	59902-59907	Gyrus	_	
242-89	59908-59909	R	_	
242-90	59910-59912	39	_	
242-91	59913-59914	−	_	
242-92	59914-59916	18	_	
242-93	59917-59919	33	_	
242-94	59920-59922	83	_	
242-95	59923-59924	−	_	
242-96	59924-59928	4.57	_	
242-97	59929-59930	−	_	
242-98	59930-59934	3.14	_	
242-99	59938-59939	L	_	
242-100	59940-59947	Angular	_	
242-101	59948-59953	Gyrus	_	
242-102	59953-59954	,	_	
242-103	59955-59956	L	_	
242-104	59957-59963	Middle	_	
242-105	59964-59972	Temporal	_	
242-106	59973-59978	Gyrus	_	
242-107	59978-59979	,	_	
242-108	59980-59981	L	_	
242-109	59991-59998	Angular	_	
242-110	59999-60004	Gyrus	_	
242-111	60005-60013	Superior	_	
242-112	60014-60022	Temporal	_	
242-113	60023-60028	Gyrus	_	
242-114	60029-60030	L	_	
242-115	60031-60032	−	_	
242-116	60032-60034	33	_	
242-117	60035-60036	−	_	
242-118	60036-60038	75	_	
242-119	60039-60041	36	_	
242-120	60042-60044	77	_	
242-121	60045-60046	−	_	
242-122	60046-60050	4.52	_	
242-123	60051-60052	−	_	
242-124	60052-60056	3.27	_	
242-125	60059-60067	Thalamus	_	
242-126	60068-60069	L	_	
242-127	60070-60073	and	_	
242-128	60074-60075	R	_	
242-129	60076-60084	Thalamus	_	
242-130	60084-60085	,	_	
242-131	60086-60087	R	_	
242-132	60088-60095	Caudate	_	
242-133	60096-60097	L	_	
242-134	60098-60099	−	_	
242-135	60099-60100	3	_	
242-136	60101-60102	0	_	
242-137	60103-60104	0	_	
242-138	60105-60108	139	_	
242-139	60109-60110	−	_	
242-140	60110-60114	4.51	_	
242-141	60115-60116	−	_	
242-142	60116-60120	3.20	_	
242-143	60123-60134	Hippocampus	_	
242-144	60135-60136	R	_	
242-145	60137-60148	Hippocampus	_	
242-146	60148-60149	,	_	
242-147	60150-60151	R	_	
242-148	60152-60160	Amygdala	_	
242-149	60160-60161	,	_	
242-150	60162-60163	R	_	
242-151	60164-60179	Parahippocampal	_	
242-152	60180-60181	R	_	
242-153	60182-60184	30	_	
242-154	60185-60186	−	_	
242-155	60186-60188	21	_	
242-156	60189-60190	−	_	
242-157	60190-60192	15	_	
242-158	60193-60196	109	_	
242-159	60197-60198	−	_	
242-160	60198-60202	4.28	_	
242-161	60203-60204	−	_	
242-162	60204-60208	3.23	_	
242-163	60211-60221	Precentral	_	
242-164	60222-60227	Gyrus	_	
242-165	60228-60229	R	_	
242-166	60230-60240	Precentral	_	
242-167	60241-60246	Gyrus	_	
242-168	60247-60248	R	_	
242-169	60249-60251	60	_	
242-170	60252-60253	6	_	
242-171	60254-60255	3	_	
242-172	60256-60258	96	_	
242-173	60259-60260	−	_	
242-174	60260-60264	3.99	_	
242-175	60265-60266	−	_	
242-176	60266-60270	3.14	_	
242-177	60273-60274	B	_	
242-178	60274-60275	.	_	

#Text=Whole Brain Correlations between ‘Change in fMRI Stroop Effect’ and Treatment Engagement and Outcome\t \ti.
243-1	60276-60281	Whole	_	
243-2	60282-60287	Brain	_	
243-3	60288-60300	Correlations	_	
243-4	60301-60308	between	_	
243-5	60309-60310	‘	_	
243-6	60310-60316	Change	_	
243-7	60317-60319	in	_	
243-8	60320-60324	fMRI	_	
243-9	60325-60331	Stroop	_	
243-10	60332-60338	Effect	_	
243-11	60338-60339	’	_	
243-12	60340-60343	and	_	
243-13	60344-60353	Treatment	_	
243-14	60354-60364	Engagement	_	
243-15	60365-60368	and	_	
243-16	60369-60376	Outcome	_	
243-17	60379-60380	i	_	
243-18	60380-60381	.	_	

#Text=Correlation between ‘Change in fMRI Stroop Effect’ and Number of CBT Sessions (N=26)\t \tPrecentral Gyrus\tL Precentral Gyrus\tL\t118\t−36\t−15\t48\t−0.75\t−0.55\t \tInferior Parietal Lobule\tR Inferior Parietal Lobule\tR\t74\t33\t−36\t39\t−0.73\t−0.56\t \tMiddle Frontal Gyrus\tL Middle Frontal Gyrus\tL\t61\t−42\t33\t27\t−0.72\t−0.57\t \tMedial Frontal Gyrus\tR Medial Frontal Gyrus, L/R Precentral Gyrus, L/R\tR\t194\t6\t−15\t69\t−0.70\t−0.55\t \tii.
244-1	60382-60393	Correlation	_	
244-2	60394-60401	between	_	
244-3	60402-60403	‘	_	
244-4	60403-60409	Change	_	
244-5	60410-60412	in	_	
244-6	60413-60417	fMRI	_	
244-7	60418-60424	Stroop	_	
244-8	60425-60431	Effect	_	
244-9	60431-60432	’	_	
244-10	60433-60436	and	_	
244-11	60437-60443	Number	_	
244-12	60444-60446	of	_	
244-13	60447-60450	CBT	_	
244-14	60451-60459	Sessions	_	
244-15	60460-60461	(	_	
244-16	60461-60462	N	_	
244-17	60462-60463	=	_	
244-18	60463-60465	26	_	
244-19	60465-60466	)	_	
244-20	60469-60479	Precentral	_	
244-21	60480-60485	Gyrus	_	
244-22	60486-60487	L	_	
244-23	60488-60498	Precentral	_	
244-24	60499-60504	Gyrus	_	
244-25	60505-60506	L	_	
244-26	60507-60510	118	_	
244-27	60511-60512	−	_	
244-28	60512-60514	36	_	
244-29	60515-60516	−	_	
244-30	60516-60518	15	_	
244-31	60519-60521	48	_	
244-32	60522-60523	−	_	
244-33	60523-60527	0.75	_	
244-34	60528-60529	−	_	
244-35	60529-60533	0.55	_	
244-36	60536-60544	Inferior	_	
244-37	60545-60553	Parietal	_	
244-38	60554-60560	Lobule	_	
244-39	60561-60562	R	_	
244-40	60563-60571	Inferior	_	
244-41	60572-60580	Parietal	_	
244-42	60581-60587	Lobule	_	
244-43	60588-60589	R	_	
244-44	60590-60592	74	_	
244-45	60593-60595	33	_	
244-46	60596-60597	−	_	
244-47	60597-60599	36	_	
244-48	60600-60602	39	_	
244-49	60603-60604	−	_	
244-50	60604-60608	0.73	_	
244-51	60609-60610	−	_	
244-52	60610-60614	0.56	_	
244-53	60617-60623	Middle	_	
244-54	60624-60631	Frontal	_	
244-55	60632-60637	Gyrus	_	
244-56	60638-60639	L	_	
244-57	60640-60646	Middle	_	
244-58	60647-60654	Frontal	_	
244-59	60655-60660	Gyrus	_	
244-60	60661-60662	L	_	
244-61	60663-60665	61	_	
244-62	60666-60667	−	_	
244-63	60667-60669	42	_	
244-64	60670-60672	33	_	
244-65	60673-60675	27	_	
244-66	60676-60677	−	_	
244-67	60677-60681	0.72	_	
244-68	60682-60683	−	_	
244-69	60683-60687	0.57	_	
244-70	60690-60696	Medial	_	
244-71	60697-60704	Frontal	_	
244-72	60705-60710	Gyrus	_	
244-73	60711-60712	R	_	
244-74	60713-60719	Medial	_	
244-75	60720-60727	Frontal	_	
244-76	60728-60733	Gyrus	_	
244-77	60733-60734	,	_	
244-78	60735-60736	L	_	
244-79	60736-60737	/	_	
244-80	60737-60738	R	_	
244-81	60739-60749	Precentral	_	
244-82	60750-60755	Gyrus	_	
244-83	60755-60756	,	_	
244-84	60757-60758	L	_	
244-85	60758-60759	/	_	
244-86	60759-60760	R	_	
244-87	60761-60762	R	_	
244-88	60763-60766	194	_	
244-89	60767-60768	6	_	
244-90	60769-60770	−	_	
244-91	60770-60772	15	_	
244-92	60773-60775	69	_	
244-93	60776-60777	−	_	
244-94	60777-60781	0.70	_	
244-95	60782-60783	−	_	
244-96	60783-60787	0.55	_	
244-97	60790-60792	ii	_	
244-98	60792-60793	.	_	

#Text=Correlation ‘Change in fMRI Stroop Effect’ and Total Number of Contingency Management Prizes (within CM Group, N=14)\t \tPostcentral\tR Postcentral\tR\t51\t45\t−18\t39\t−0.93\t−0.73\t \tPostcentral\tL Postcentral, L Precentral Gyrus\tL\t58\t−33\t−24\t45\t−0.91\t−0.73\t \tiii.
245-1	60794-60805	Correlation	_	
245-2	60806-60807	‘	_	
245-3	60807-60813	Change	_	
245-4	60814-60816	in	_	
245-5	60817-60821	fMRI	_	
245-6	60822-60828	Stroop	_	
245-7	60829-60835	Effect	_	
245-8	60835-60836	’	_	
245-9	60837-60840	and	_	
245-10	60841-60846	Total	_	
245-11	60847-60853	Number	_	
245-12	60854-60856	of	_	
245-13	60857-60868	Contingency	_	
245-14	60869-60879	Management	_	
245-15	60880-60886	Prizes	_	
245-16	60887-60888	(	_	
245-17	60888-60894	within	_	
245-18	60895-60897	CM	_	
245-19	60898-60903	Group	_	
245-20	60903-60904	,	_	
245-21	60905-60906	N	_	
245-22	60906-60907	=	_	
245-23	60907-60909	14	_	
245-24	60909-60910	)	_	
245-25	60913-60924	Postcentral	_	
245-26	60925-60926	R	_	
245-27	60927-60938	Postcentral	_	
245-28	60939-60940	R	_	
245-29	60941-60943	51	_	
245-30	60944-60946	45	_	
245-31	60947-60948	−	_	
245-32	60948-60950	18	_	
245-33	60951-60953	39	_	
245-34	60954-60955	−	_	
245-35	60955-60959	0.93	_	
245-36	60960-60961	−	_	
245-37	60961-60965	0.73	_	
245-38	60968-60979	Postcentral	_	
245-39	60980-60981	L	_	
245-40	60982-60993	Postcentral	_	
245-41	60993-60994	,	_	
245-42	60995-60996	L	_	
245-43	60997-61007	Precentral	_	
245-44	61008-61013	Gyrus	_	
245-45	61014-61015	L	_	
245-46	61016-61018	58	_	
245-47	61019-61020	−	_	
245-48	61020-61022	33	_	
245-49	61023-61024	−	_	
245-50	61024-61026	24	_	
245-51	61027-61029	45	_	
245-52	61030-61031	−	_	
245-53	61031-61035	0.91	_	
245-54	61036-61037	−	_	
245-55	61037-61041	0.73	_	
245-56	61044-61047	iii	_	
245-57	61047-61048	.	_	

#Text=Correlation between ‘Change in fMRI Stroop Effect’ and Number of Days of Disulfiram Treatment Taken (N=10)\t \tNo Significant Clusters\t \tiv.
246-1	61049-61060	Correlation	_	
246-2	61061-61068	between	_	
246-3	61069-61070	‘	_	
246-4	61070-61076	Change	_	
246-5	61077-61079	in	_	
246-6	61080-61084	fMRI	_	
246-7	61085-61091	Stroop	_	
246-8	61092-61098	Effect	_	
246-9	61098-61099	’	_	
246-10	61100-61103	and	_	
246-11	61104-61110	Number	_	
246-12	61111-61113	of	_	
246-13	61114-61118	Days	_	
246-14	61119-61121	of	_	
246-15	61122-61132	Disulfiram	_	
246-16	61133-61142	Treatment	_	
246-17	61143-61148	Taken	_	
246-18	61149-61150	(	_	
246-19	61150-61151	N	_	
246-20	61151-61152	=	_	
246-21	61152-61154	10	_	
246-22	61154-61155	)	_	
246-23	61158-61160	No	_	
246-24	61161-61172	Significant	_	
246-25	61173-61181	Clusters	_	
246-26	61184-61186	iv	_	
246-27	61186-61187	.	_	

#Text=Correlation between ‘Change in fMRI Stroop Effect’ and Percent Days Cocaine Abstinent During Treatment Period (N=26)\t \tSuperior Temporal Gyrus\tR Superior Temporal Gyrus, R Transverse Temporal\tR\t63\t−12\t12\t72\t0.72\t0.55\t \t
#Text=Note.
247-1	61188-61199	Correlation	_	
247-2	61200-61207	between	_	
247-3	61208-61209	‘	_	
247-4	61209-61215	Change	_	
247-5	61216-61218	in	_	
247-6	61219-61223	fMRI	_	
247-7	61224-61230	Stroop	_	
247-8	61231-61237	Effect	_	
247-9	61237-61238	’	_	
247-10	61239-61242	and	_	
247-11	61243-61250	Percent	_	
247-12	61251-61255	Days	_	
247-13	61256-61263	Cocaine	_	
247-14	61264-61273	Abstinent	_	
247-15	61274-61280	During	_	
247-16	61281-61290	Treatment	_	
247-17	61291-61297	Period	_	
247-18	61298-61299	(	_	
247-19	61299-61300	N	_	
247-20	61300-61301	=	_	
247-21	61301-61303	26	_	
247-22	61303-61304	)	_	
247-23	61307-61315	Superior	_	
247-24	61316-61324	Temporal	_	
247-25	61325-61330	Gyrus	_	
247-26	61331-61332	R	_	
247-27	61333-61341	Superior	_	
247-28	61342-61350	Temporal	_	
247-29	61351-61356	Gyrus	_	
247-30	61356-61357	,	_	
247-31	61358-61359	R	_	
247-32	61360-61370	Transverse	_	
247-33	61371-61379	Temporal	_	
247-34	61380-61381	R	_	
247-35	61382-61384	63	_	
247-36	61385-61386	−	_	
247-37	61386-61388	12	_	
247-38	61389-61391	12	_	
247-39	61392-61394	72	_	
247-40	61395-61399	0.72	_	
247-41	61400-61404	0.55	_	
247-42	61408-61412	Note	_	
247-43	61412-61413	.	_	

#Text=All results presented survive family wise error correction for multiple comparisons at the whole brain level to two-tailed pFWE<.05.
248-1	61414-61417	All	_	
248-2	61418-61425	results	_	
248-3	61426-61435	presented	_	
248-4	61436-61443	survive	_	
248-5	61444-61450	family	_	
248-6	61451-61455	wise	_	
248-7	61456-61461	error	_	
248-8	61462-61472	correction	_	
248-9	61473-61476	for	_	
248-10	61477-61485	multiple	_	
248-11	61486-61497	comparisons	_	
248-12	61498-61500	at	_	
248-13	61501-61504	the	_	
248-14	61505-61510	whole	_	
248-15	61511-61516	brain	_	
248-16	61517-61522	level	_	
248-17	61523-61525	to	_	
248-18	61526-61536	two-tailed	_	
248-19	61537-61541	pFWE	_	
248-20	61541-61542	<	_	
248-21	61542-61545	.05	_	
248-22	61545-61546	.	_	

#Text=Section A shows clusters that survived corrections for mutliple comparisons that showed a change in ‘Stroop effect’ related activity in the sample overall at post-treatment versus beginning-of-treatment (N=26).
249-1	61547-61554	Section	_	
249-2	61555-61556	A	_	
249-3	61557-61562	shows	_	
249-4	61563-61571	clusters	_	
249-5	61572-61576	that	_	
249-6	61577-61585	survived	_	
249-7	61586-61597	corrections	_	
249-8	61598-61601	for	_	
249-9	61602-61610	mutliple	_	
249-10	61611-61622	comparisons	_	
249-11	61623-61627	that	_	
249-12	61628-61634	showed	_	
249-13	61635-61636	a	_	
249-14	61637-61643	change	_	
249-15	61644-61646	in	_	
249-16	61647-61648	‘	_	
249-17	61648-61654	Stroop	_	
249-18	61655-61661	effect	_	
249-19	61661-61662	’	_	
249-20	61663-61670	related	_	
249-21	61671-61679	activity	_	
249-22	61680-61682	in	_	
249-23	61683-61686	the	_	
249-24	61687-61693	sample	_	
249-25	61694-61701	overall	_	
249-26	61702-61704	at	_	
249-27	61705-61719	post-treatment	_	
249-28	61720-61726	versus	_	
249-29	61727-61749	beginning-of-treatment	_	
249-30	61750-61751	(	_	
249-31	61751-61752	N	_	
249-32	61752-61753	=	_	
249-33	61753-61755	26	_	
249-34	61755-61756	)	_	
249-35	61756-61757	.	_	

#Text=Section B shows clusters that survived corrections for multiple comparisons from separate whole-brain rank-order non-parametric correlations with the change in Stroop effect contrast and measures of treatment engagement (i.
250-1	61758-61765	Section	_	
250-2	61766-61767	B	_	
250-3	61768-61773	shows	_	
250-4	61774-61782	clusters	_	
250-5	61783-61787	that	_	
250-6	61788-61796	survived	_	
250-7	61797-61808	corrections	_	
250-8	61809-61812	for	_	
250-9	61813-61821	multiple	_	
250-10	61822-61833	comparisons	_	
250-11	61834-61838	from	_	
250-12	61839-61847	separate	_	
250-13	61848-61859	whole-brain	_	
250-14	61860-61870	rank-order	_	
250-15	61871-61885	non-parametric	_	
250-16	61886-61898	correlations	_	
250-17	61899-61903	with	_	
250-18	61904-61907	the	_	
250-19	61908-61914	change	_	
250-20	61915-61917	in	_	
250-21	61918-61924	Stroop	_	
250-22	61925-61931	effect	_	
250-23	61932-61940	contrast	_	
250-24	61941-61944	and	_	
250-25	61945-61953	measures	_	
250-26	61954-61956	of	_	
250-27	61957-61966	treatment	_	
250-28	61967-61977	engagement	_	
250-29	61978-61979	(	_	
250-30	61979-61980	i	_	
250-31	61980-61981	.	_	

#Text=Number of Cognitive Behavioral Therapy (CBT) Sessions (N=26); ii.
251-1	61982-61988	Number	_	
251-2	61989-61991	of	_	
251-3	61992-62001	Cognitive	_	
251-4	62002-62012	Behavioral	_	
251-5	62013-62020	Therapy	_	
251-6	62021-62022	(	_	
251-7	62022-62025	CBT	_	
251-8	62025-62026	)	_	
251-9	62027-62035	Sessions	_	
251-10	62036-62037	(	_	
251-11	62037-62038	N	_	
251-12	62038-62039	=	_	
251-13	62039-62041	26	_	
251-14	62041-62042	)	_	
251-15	62042-62043	;	_	
251-16	62044-62046	ii	_	
251-17	62046-62047	.	_	

#Text=Total Number of Contingency Management (CM) Prizes within those randomized to CM (N=14); iii.
252-1	62048-62053	Total	_	
252-2	62054-62060	Number	_	
252-3	62061-62063	of	_	
252-4	62064-62075	Contingency	_	
252-5	62076-62086	Management	_	
252-6	62087-62088	(	_	
252-7	62088-62090	CM	_	
252-8	62090-62091	)	_	
252-9	62092-62098	Prizes	_	
252-10	62099-62105	within	_	
252-11	62106-62111	those	_	
252-12	62112-62122	randomized	_	
252-13	62123-62125	to	_	
252-14	62126-62128	CM	_	
252-15	62129-62130	(	_	
252-16	62130-62131	N	_	
252-17	62131-62132	=	_	
252-18	62132-62134	14	_	
252-19	62134-62135	)	_	
252-20	62135-62136	;	_	
252-21	62137-62140	iii	_	
252-22	62140-62141	.	_	

#Text=Number of Days of Disulfiram Treatment Taken within those randomized to medication (N=10)); and within-treatment cocaine use (iv.
253-1	62142-62148	Number	_	
253-2	62149-62151	of	_	
253-3	62152-62156	Days	_	
253-4	62157-62159	of	_	
253-5	62160-62170	Disulfiram	_	
253-6	62171-62180	Treatment	_	
253-7	62181-62186	Taken	_	
253-8	62187-62193	within	_	
253-9	62194-62199	those	_	
253-10	62200-62210	randomized	_	
253-11	62211-62213	to	_	
253-12	62214-62224	medication	_	
253-13	62225-62226	(	_	
253-14	62226-62227	N	_	
253-15	62227-62228	=	_	
253-16	62228-62230	10	_	
253-17	62230-62231	)	_	
253-18	62231-62232	)	_	
253-19	62232-62233	;	_	
253-20	62234-62237	and	_	
253-21	62238-62254	within-treatment	_	
253-22	62255-62262	cocaine	_	
253-23	62263-62266	use	_	
253-24	62267-62268	(	_	
253-25	62268-62270	iv	_	
253-26	62270-62271	.	_	

#Text=Percent Days Cocaine Abstinent During the Treatment Period (N=26)).
254-1	62272-62279	Percent	_	
254-2	62280-62284	Days	_	
254-3	62285-62292	Cocaine	_	
254-4	62293-62302	Abstinent	_	
254-5	62303-62309	During	_	
254-6	62310-62313	the	_	
254-7	62314-62323	Treatment	_	
254-8	62324-62330	Period	_	
254-9	62331-62332	(	_	
254-10	62332-62333	N	_	
254-11	62333-62334	=	_	
254-12	62334-62336	26	_	
254-13	62336-62337	)	_	
254-14	62337-62338	)	_	
254-15	62338-62339	.	_	

#Text=Abbreviations: Inc= incongruent trials, Con=congruent trials, Beginning= beginning-of-treatment, Post=post-treatment, R=right, L=left, k=cluster size (in voxels), CM=contingency management; CBT= cognitive behavioral therapy.
255-1	62340-62353	Abbreviations	_	
255-2	62353-62354	:	_	
255-3	62355-62358	Inc	_	
255-4	62358-62359	=	_	
255-5	62360-62371	incongruent	_	
255-6	62372-62378	trials	_	
255-7	62378-62379	,	_	
255-8	62380-62383	Con	_	
255-9	62383-62384	=	_	
255-10	62384-62393	congruent	_	
255-11	62394-62400	trials	_	
255-12	62400-62401	,	_	
255-13	62402-62411	Beginning	_	
255-14	62411-62412	=	_	
255-15	62413-62435	beginning-of-treatment	_	
255-16	62435-62436	,	_	
255-17	62437-62441	Post	_	
255-18	62441-62442	=	_	
255-19	62442-62456	post-treatment	_	
255-20	62456-62457	,	_	
255-21	62458-62459	R	_	
255-22	62459-62460	=	_	
255-23	62460-62465	right	_	
255-24	62465-62466	,	_	
255-25	62467-62468	L	_	
255-26	62468-62469	=	_	
255-27	62469-62473	left	_	
255-28	62473-62474	,	_	
255-29	62475-62476	k	_	
255-30	62476-62477	=	_	
255-31	62477-62484	cluster	_	
255-32	62485-62489	size	_	
255-33	62490-62491	(	_	
255-34	62491-62493	in	_	
255-35	62494-62500	voxels	_	
255-36	62500-62501	)	_	
255-37	62501-62502	,	_	
255-38	62503-62505	CM	_	
255-39	62505-62506	=	_	
255-40	62506-62517	contingency	_	
255-41	62518-62528	management	_	
255-42	62528-62529	;	_	
255-43	62530-62533	CBT	_	
255-44	62533-62534	=	_	
255-45	62535-62544	cognitive	_	
255-46	62545-62555	behavioral	_	
255-47	62556-62563	therapy	_	
255-48	62563-62564	.	_	

#Text=The figures which correspond to the these results are as follows: For section A, see Figure 1A, extracted cluster means in Figure 1B, and “whole-brain” slice-out images in Supplemental Figure 2 (as well as full slice-out images for the beginning of treatment Stroop effect and post-treatment Stroop effect contrasts separately in Supplemental Figure 1).
256-1	62565-62568	The	_	
256-2	62569-62576	figures	_	
256-3	62577-62582	which	_	
256-4	62583-62593	correspond	_	
256-5	62594-62596	to	_	
256-6	62597-62600	the	_	
256-7	62601-62606	these	_	
256-8	62607-62614	results	_	
256-9	62615-62618	are	_	
256-10	62619-62621	as	_	
256-11	62622-62629	follows	_	
256-12	62629-62630	:	_	
256-13	62631-62634	For	_	
256-14	62635-62642	section	_	
256-15	62643-62644	A	_	
256-16	62644-62645	,	_	
256-17	62646-62649	see	_	
256-18	62650-62656	Figure	_	
256-19	62657-62659	1A	_	
256-20	62659-62660	,	_	
256-21	62661-62670	extracted	_	
256-22	62671-62678	cluster	_	
256-23	62679-62684	means	_	
256-24	62685-62687	in	_	
256-25	62688-62694	Figure	_	
256-26	62695-62697	1B	_	
256-27	62697-62698	,	_	
256-28	62699-62702	and	_	
256-29	62703-62704	“	_	
256-30	62704-62715	whole-brain	_	
256-31	62715-62716	”	_	
256-32	62717-62726	slice-out	_	
256-33	62727-62733	images	_	
256-34	62734-62736	in	_	
256-35	62737-62749	Supplemental	_	
256-36	62750-62756	Figure	_	
256-37	62757-62758	2	_	
256-38	62759-62760	(	_	
256-39	62760-62762	as	_	
256-40	62763-62767	well	_	
256-41	62768-62770	as	_	
256-42	62771-62775	full	_	
256-43	62776-62785	slice-out	_	
256-44	62786-62792	images	_	
256-45	62793-62796	for	_	
256-46	62797-62800	the	_	
256-47	62801-62810	beginning	_	
256-48	62811-62813	of	_	
256-49	62814-62823	treatment	_	
256-50	62824-62830	Stroop	_	
256-51	62831-62837	effect	_	
256-52	62838-62841	and	_	
256-53	62842-62856	post-treatment	_	
256-54	62857-62863	Stroop	_	
256-55	62864-62870	effect	_	
256-56	62871-62880	contrasts	_	
256-57	62881-62891	separately	_	
256-58	62892-62894	in	_	
256-59	62895-62907	Supplemental	_	
256-60	62908-62914	Figure	_	
256-61	62915-62916	1	_	
256-62	62916-62917	)	_	
256-63	62917-62918	.	_	

#Text=For section B, see Figure 2 and “whole-brain” slice-out images in Supplemental Figure 3.
257-1	62919-62922	For	_	
257-2	62923-62930	section	_	
257-3	62931-62932	B	_	
257-4	62932-62933	,	_	
257-5	62934-62937	see	_	
257-6	62938-62944	Figure	_	
257-7	62945-62946	2	_	
257-8	62947-62950	and	_	
257-9	62951-62952	“	_	
257-10	62952-62963	whole-brain	_	
257-11	62963-62964	”	_	
257-12	62965-62974	slice-out	_	
257-13	62975-62981	images	_	
257-14	62982-62984	in	_	
257-15	62985-62997	Supplemental	_	
257-16	62998-63004	Figure	_	
257-17	63005-63006	3	_	
257-18	63006-63007	.	_	
